Compounds > fluoxetine
Page last updated: 2024-10-27

fluoxetine and Depression, Involutional

fluoxetine has been researched along with Depression, Involutional in 699 studies

Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.

Depression, Involutional: Form of depression in those MIDDLE AGE with feelings of ANXIETY.

Research Excerpts

ExcerptRelevanceReference
"Severity of anxiety does not appear to influence the antidepressant response to fluoxetine during acute treatment of major depressive disorder (MDD)."10.21Long-term treatment outcomes of depression with associated anxiety: efficacy of continuation treatment with fluoxetine. ( Fava, M; Joliat, MJ; Michelson, D; Miner, CM; Schmidt, ME; Trapp, NJ; Zhang, S, 2004)
" Fluoxetine is one of the main first-line medications used for depression, and it is hypothesized that it participates in the decrease of pro-inflammatory cytokines."9.22Fluoxetine modulates the pro-inflammatory process of IL-6, IL-1β and TNF-α levels in individuals with depression: a systematic review and meta-analysis. ( García-García, ML; Genis-Mendoza, AD; González-Castro, TB; Juárez-Rojop, IE; López-Nárvaez, ML; Martinez-Magaña, JJ; Ramos-Méndez, MÁ; Ruiz-Quiñones, JA; Saucedo-Osti, AS; Tovilla-Zárate, CA; Villar-Soto, M, 2022)
" This open-label study evaluated the efficacy and safety of modafinil treatment initiated with an SSRI in patients with MDD and fatigue."9.11Adjunctive modafinil at initiation of treatment with a selective serotonin reuptake inhibitor enhances the degree and onset of therapeutic effects in patients with major depressive disorder and fatigue. ( Glass, SJ; Hassman, HA; McManus, FC; Ninan, PT, 2004)
"Low-dose cotherapy of fluoxetine with clonazepam was safe and accelerated response over 21 days of treatment, decreasing anxiety and sleep disturbance as symptoms and partially suppressed them as SSRI side-effects; it also modestly reduced core symptoms of low mood and loss of interest."9.09Short-term cotherapy with clonazepam and fluoxetine: anxiety, sleep disturbance and core symptoms of depression. ( Glaudin, V; Londborg, PD; Painter, JR; Smith, WT, 2000)
"83 weeks) in patients with unipolar depression (studies=4, n=187; monotherapy vs lithium=1, augmentation of antidepressants vs placebo=3) or bipolar depression (studies=14, n=1965; monotherapy vs placebo=5, monotherapy vs lithium or olanzapine+fluoxetine=2, augmentation of antidepressants vs placebo=1, augmentation of mood stabilizers vs placebo=3, augmentation of mood stabilizers vs trancylpromine, citalopram, or inositol=3) were meta-analyzed."8.93Lamotrigine compared to placebo and other agents with antidepressant activity in patients with unipolar and bipolar depression: a comprehensive meta-analysis of efficacy and safety outcomes in short-term trials. ( Anghelescu, IG; Correll, CU; Gao, K; Normann, C; Reis, C; Schaffer, A; Solmi, M; van der Loos, ML; Veronese, N; Zaninotto, L, 2016)
"This meta-analysis assessed aggression and/or hostility-related events in children and adolescents treated with fluoxetine (n = 376) compared with placebo (n = 255)."8.84Meta-analysis of aggression and/or hostility-related events in children and adolescents treated with fluoxetine compared with placebo. ( Allen, AJ; Caldwell, C; Nilsson, M; Plewes, J; Tauscher-Wisniewski, S, 2007)
"The aim of the study was to determine whether baseline pain was associated with discernible clinical features and treatment outcomes for patients with major depressive disorder (MDD) receiving 6-week fluoxetine treatment."7.81Pain Affects Clinical Patterns and Treatment Outcomes for Patients With Major Depressive Disorder Taking Fluoxetine. ( Lin, CH; Lin, HS; Wang, FC, 2015)
"Following zuclopenthixol acuphase administration, dangerous extra-pyramidal side effects were observed, including severe laryngeal dystonia necessitating emergency medical treatment."7.76Severe laryngeal dystonia in a patient receiving zuclopenthixol "Acuphase" and fluoxetine. ( Bennett, L; Davies, S; Hood, S; Orr, K, 2010)
"Blood from pregnant women taking fluoxetine (n = 9), during pregnancy was sampled in the third trimester and at delivery (maternal and cord venous blood), and from the infants 48 h after delivery."7.73Stereoselective disposition of fluoxetine and norfluoxetine during pregnancy and breast-feeding. ( Fitzgerald, C; Grunau, RE; Kent, N; Kim, J; Misri, S; Oberlander, TF; Riggs, KW; Rurak, DW, 2006)
"Effective treatment of depression is a key target for suicide prevention strategies."7.01Trajectories of change in depression symptoms and suicidal ideation over the course of evidence-based treatment for depression: Secondary analysis of a randomised controlled trial of cognitive behavioural therapy plus fluoxetine in young people. ( Berk, M; Chanen, A; Cotton, S; Davey, CG; Dean, O; Hetrick, S; Madsen, T; McGorry, PD; Witt, K, 2021)
"Medication is commonly used to treat youth depression, but whether medication should be added to cognitive behavioural therapy (CBT) as first-line treatment is unclear."6.90The addition of fluoxetine to cognitive behavioural therapy for youth depression (YoDA-C): a randomised, double-blind, placebo-controlled, multicentre clinical trial. ( Amminger, GP; Berk, M; Catania, L; Chanen, AM; Cotton, SM; Davey, CG; Dean, OM; Harrison, BJ; Hetrick, SE; Kazantzis, N; Kerr, M; Koutsogiannis, J; McGorry, PD; Mullen, E; Parker, AG; Phelan, M; Quinn, AL; Ratheesh, A; Rice, S; Weller, A, 2019)
"Fluoxetine was not different from placebo in Greene Climacteric Scale."6.80Individualized homeopathic treatment and fluoxetine for moderate to severe depression in peri- and postmenopausal women (HOMDEP-MENOP study): a randomized, double-dummy, double-blind, placebo-controlled trial. ( Aguilar-Faisal, L; Asbun-Bojalil, J; Llanes-González, L; Macías-Cortés, Edel C, 2015)
"Fluoxetine (FLX) has been one of the most widely studied selective serotonin reuptake inhibitors in adolescents."6.79Plasma fluoxetine concentrations and clinical improvement in an adolescent sample diagnosed with major depressive disorder, obsessive-compulsive disorder, or generalized anxiety disorder. ( Arnaiz, JA; Blázquez, A; Gassó, P; Lafuente, A; Lázaro, L; Mas, S; Méndez, I; Plana, MT; Torra, M, 2014)
"Adolescent major depressive disorder (MDD) is a life-threatening brain disease with limited interventions."6.76Open-label adjunctive creatine for female adolescents with SSRI-resistant major depressive disorder: a 31-phosphorus magnetic resonance spectroscopy study. ( Fiedler, KK; Hellem, TL; Jeong, EK; Kondo, DG; Renshaw, PF; Shi, X; Sung, YH, 2011)
"Discontinuation syndrome is associated with a rostral anterior cingulate Cho/Cre metabolite ratio decrease that may reflect dynamics of rostral anterior cingulate function."6.71Selective serotonin reuptake inhibitor discontinuation syndrome is associated with a rostral anterior cingulate choline metabolite decrease: a proton magnetic resonance spectroscopic imaging study. ( Cohen, BM; Frederick, Bd; Hennen, J; Henry, ME; Kaufman, MJ; Renshaw, PF; Schmidt, ME; Stoddard, EP; Villafuerte, RA, 2003)
"The incidence of treatment-emergent nausea during 6-month continuation of duloxetine treatment (80 mg/d, 2."6.71Incidence and duration of antidepressant-induced nausea: duloxetine compared with paroxetine and fluoxetine. ( Greist, J; Mallinckrodt, CH; McNamara, RK; Raskin, J; Rayamajhi, JN, 2004)
"Treatment with olanzapine may impact a patient's weight; thus, long-term weight gain and potential predictors (e."6.71Long-term weight gain in patients treated with open-label olanzapine in combination with fluoxetine for major depressive disorder. ( Andersen, SW; Clemow, DB; Corya, SA, 2005)
"Severity of anxiety does not appear to influence the antidepressant response to fluoxetine during acute treatment of major depressive disorder (MDD)."6.21Long-term treatment outcomes of depression with associated anxiety: efficacy of continuation treatment with fluoxetine. ( Fava, M; Joliat, MJ; Michelson, D; Miner, CM; Schmidt, ME; Trapp, NJ; Zhang, S, 2004)
" Fluoxetine is one of the main first-line medications used for depression, and it is hypothesized that it participates in the decrease of pro-inflammatory cytokines."5.22Fluoxetine modulates the pro-inflammatory process of IL-6, IL-1β and TNF-α levels in individuals with depression: a systematic review and meta-analysis. ( García-García, ML; Genis-Mendoza, AD; González-Castro, TB; Juárez-Rojop, IE; López-Nárvaez, ML; Martinez-Magaña, JJ; Ramos-Méndez, MÁ; Ruiz-Quiñones, JA; Saucedo-Osti, AS; Tovilla-Zárate, CA; Villar-Soto, M, 2022)
"Saffron is a tolerable and efficacious treatment for fluoxetine-related erectile dysfunction."5.16Effect of saffron on fluoxetine-induced sexual impairment in men: randomized double-blind placebo-controlled trial. ( Akhondzadeh, S; Ashrafi, M; Jamshidi, A; Modabbernia, A; Nasehi, AA; Raisi, F; Saroukhani, S; Sohrabi, H; Tabrizi, M, 2012)
" This study aimed to establish the effects of fluoxetine and sertraline treatments on thyroid function and thyroid autoimmunity in patients with major depression and primary hypothyroidism and in patients with major depression and normal thyroid function."5.14Effects of selective serotonin reuptake inhibitors on thyroid function in depressed patients with primary hypothyroidism or normal thyroid function. ( Bahls, SC; Boeving, A; de Carvalho, GA; Graf, H, 2009)
"The objective of this study was to assess the relationship between early changes in anxiety/somatization symptoms and treatment outcome among major depressive disorder patients during a 12-week trial of fluoxetine."5.14Anxious depression and early changes in the HAMD-17 anxiety-somatization factor items and antidepressant treatment outcome. ( Alpert, J; Baer, L; Bitran, S; Chuzi, S; Clain, AJ; Dording, C; Farabaugh, AH; Fava, M; McGrath, PJ; Mischoulon, D; Papakostas, GI; Witte, J, 2010)
"This study compared the acute phase (12-week) efficacy of fluoxetine versus placebo for the treatment of the depressive symptoms and the cannabis use of adolescents and young adults with comorbid major depression (MDD) and a cannabis use disorder (CUD) (cannabis dependence or cannabis abuse)."5.14Double-blind fluoxetine trial in comorbid MDD-CUD youth and young adults. ( Brown, SJ; Bukstein, OG; Chung, TA; Clark, DB; Cornelius, JR; Daley, DC; Douaihy, AB; Wood, DS, 2010)
"To add to the limited data on the clinical pharmacology of antidepressants during pregnancy, we examined the dose-corrected chiral and racemic levels (level/dose) of fluoxetine (FLX) and norfluoxetine (NorFLX) during pregnancy and early postpartum."5.14Disposition of chiral and racemic fluoxetine and norfluoxetine across childbearing. ( Helsel, JC; Luther, JF; Perel, JM; Sit, D; Wisner, KL; Wisniewski, SR, 2010)
" Following maprotiline treatment, the body weight and BMI were significantly increased (P=0."5.12Comparisons of glucose-insulin homeostasis following maprotiline and fluoxetine treatment in depressed males. ( Chen, YC; Chou, CH; Hung, YJ; Perng, CH; Shen, YC; Yeh, CB, 2007)
" We compare the effects of 2 combined therapies, fluoxetine and interpersonal therapy (IPT) or fluoxetine and cognitive therapy (CT), on major depression in patients with borderline personality disorder (BPD)."5.12Combined therapy of major depression with concomitant borderline personality disorder: comparison of interpersonal and cognitive psychotherapy. ( Bellino, S; Bogetto, F; Rinaldi, C; Zizza, M, 2007)
" This open-label study evaluated the efficacy and safety of modafinil treatment initiated with an SSRI in patients with MDD and fatigue."5.11Adjunctive modafinil at initiation of treatment with a selective serotonin reuptake inhibitor enhances the degree and onset of therapeutic effects in patients with major depressive disorder and fatigue. ( Glass, SJ; Hassman, HA; McManus, FC; Ninan, PT, 2004)
" This is the first report aimed at studying the beneficial therapeutic effects of fluoxetine alone on anxiety dimension in first episode drug naive patients suffering from DSM-IV major depression (MDD) and double depression (DD)."5.10Fluoxetine alone in the treatment of first episode anxious-depression: an open clinical trial. ( Caltagirone, C; Pasini, A; Spalletta, G, 2002)
"Low-dose cotherapy of fluoxetine with clonazepam was safe and accelerated response over 21 days of treatment, decreasing anxiety and sleep disturbance as symptoms and partially suppressed them as SSRI side-effects; it also modestly reduced core symptoms of low mood and loss of interest."5.09Short-term cotherapy with clonazepam and fluoxetine: anxiety, sleep disturbance and core symptoms of depression. ( Glaudin, V; Londborg, PD; Painter, JR; Smith, WT, 2000)
"This study assessed the effect of fluoxetine 20 mg/day on weight loss in older patients treated for major depression in a multicenter, double-blind placebo-controlled, 6-week clinical trial."5.08Fluoxetine in medically stable, depressed geriatric patients: effects on weight. ( Beasley, CM; Goldstein, DJ; Hamilton, SH; Masica, DN, 1997)
"83 weeks) in patients with unipolar depression (studies=4, n=187; monotherapy vs lithium=1, augmentation of antidepressants vs placebo=3) or bipolar depression (studies=14, n=1965; monotherapy vs placebo=5, monotherapy vs lithium or olanzapine+fluoxetine=2, augmentation of antidepressants vs placebo=1, augmentation of mood stabilizers vs placebo=3, augmentation of mood stabilizers vs trancylpromine, citalopram, or inositol=3) were meta-analyzed."4.93Lamotrigine compared to placebo and other agents with antidepressant activity in patients with unipolar and bipolar depression: a comprehensive meta-analysis of efficacy and safety outcomes in short-term trials. ( Anghelescu, IG; Correll, CU; Gao, K; Normann, C; Reis, C; Schaffer, A; Solmi, M; van der Loos, ML; Veronese, N; Zaninotto, L, 2016)
"This meta-analysis assessed aggression and/or hostility-related events in children and adolescents treated with fluoxetine (n = 376) compared with placebo (n = 255)."4.84Meta-analysis of aggression and/or hostility-related events in children and adolescents treated with fluoxetine compared with placebo. ( Allen, AJ; Caldwell, C; Nilsson, M; Plewes, J; Tauscher-Wisniewski, S, 2007)
"We report here the case of a patient with fluoxetine and selegiline induced serotonin syndrome, which presented as encephalopathy, generalized myoclonias, fever, stiffness and sweating, complicated with acute renal failure, rhabdomyolysis and disseminated intravascular coagulation findings."4.81[Serotonin syndrome: report of a fatal case and review of the literature]. ( Bilbao Garay, J; Castilla Castellano, V; Dhimes Tejada, P; Mesa Plaza, N, 2002)
"We conclude that oral G115® significantly potentiates the antidepressant-like effect of fluoxetine in the FST in the absence of potentially confounding effects on locomotion and anxiety."4.02Standardised ginseng extract G115® potentiates the antidepressant-like properties of fluoxetine in the forced swim test. ( MacDonald, DS; Tasker, RA; Terstege, DJ, 2021)
"Electroconvulsive therapy was superior to fluoxetine in resolving suicidal ideation during acute treatment."3.96Electroconvulsive Therapy Versus Fluoxetine in Suicidal Resolution for Patients With Major Depressive Disorder. ( Chen, CC; Huang, CJ; Lin, CH, 2020)
"A 21-year-old female with a history of generalized anxiety disorder and major depression presented with increased depressive symptoms over several months while taking fluoxetine 20 mg daily."3.96A Case Report of Serotonin Syndrome in a Patient on Selective Serotonin Reuptake Inhibitor (SSRI) Monotherapy. ( Blake, CS; Hudd, TR; Nguyen, TT; Rimola-Dejesus, Y; Zaiken, K, 2020)
"In this item-based, patient-level, post-hoc analysis, we pooled data from all completed, acute-phase, placebo-controlled, industry-sponsored, HDRS-based trials of the SSRIs citalopram, paroxetine, or sertraline in adult major depression."3.91Influence of baseline severity on the effects of SSRIs in depression: an item-based, patient-level post-hoc analysis. ( Eriksson, E; Hieronymus, F; Lisinski, A; Nilsson, S, 2019)
" We carried out a study to compare the behavioural effects of fluoxetine (FLX) in a model of depression in two mice strains: C57BL6/J and BALB/c."3.85Fluoxetine induces paradoxical effects in C57BL6/J mice: comparison with BALB/c mice. ( Belzung, C; Brizard, B; Gosselin, T; Hommet, C; Le Guisquet, AM; Minier, F, 2017)
"We measured [(3)H]AF-DX 384 binding in BA 46 and BA 24 from subjects with bipolar disorders (n = 14), major depressive disorders (n = 19), as well as age- and sex-matched controls (n = 19) and the CNS of rats treated with fluoxetine or imipramine."3.83Changes in Muscarinic M2 Receptor Levels in the Cortex of Subjects with Bipolar Disorder and Major Depressive Disorder and in Rats after Treatment with Mood Stabilisers and Antidepressants. ( Dean, B; Gibbons, AS; Jeon, WJ; Scarr, E, 2016)
" Subsequently, density of [(3)H]LY341495 binding was measured in BA24(anterior cingulate cortex), BA17(visual cortex) and BA46(dorsolateral prefrontal cortex) from subjects with MDD, Bipolar Disorder(BPD), Schizophrenia(SCZ), and controls, as well as rats treated with imipramine (20mg/kg), fluoxetine (10mg/kg), or vehicle."3.83Lower [3H]LY341495 binding to mGlu2/3 receptors in the anterior cingulate of subjects with major depressive disorder but not bipolar disorder or schizophrenia. ( Dean, B; Gibbons, A; Hopper, S; McOmish, CE; Pavey, G; Scarr, E; Udawela, M, 2016)
"The aim of the study was to determine whether baseline pain was associated with discernible clinical features and treatment outcomes for patients with major depressive disorder (MDD) receiving 6-week fluoxetine treatment."3.81Pain Affects Clinical Patterns and Treatment Outcomes for Patients With Major Depressive Disorder Taking Fluoxetine. ( Lin, CH; Lin, HS; Wang, FC, 2015)
" In situ [3H]ketanserin binding and autoradiography was used to measure levels of HTR2A in Brodmann's area (BA) 46 and 24 from people with major depressive disorders (MDD, n = 16), bipolar disorders (BD, n = 14) and healthy controls (n = 14) as well as the central nervous system (CNS) of rats (20 per treatment arm) treated for 10 or 28 d with fluoxetine (10 mg/kg/d) or imipramine (20 mg/kg/d)."3.80Lower cortical serotonin 2A receptors in major depressive disorder, suicide and in rats after administration of imipramine. ( Dean, B; Everall, I; Gibbons, A; Jeon, WJ; Scarr, E; Seo, MS; Tawadros, N, 2014)
" We aimed to investigate the relationships among body weight, body mass index (BMI=kg/m(2)), change in a depression rating scale, and change in a functional scale with fluoxetine treatment for hospitalized patients with major depressive disorder (MDD)."3.80Both body weight and BMI predicts improvement in symptom and functioning for patients with major depressive disorder. ( Chen, CC; Lin, CH; McIntyre, RS; Wong, J, 2014)
" Anhedonia, brain BDNF and circulating corticosterone levels, considered endophenotypes of depression, were investigated."3.79Antidepressant treatment outcome depends on the quality of the living environment: a pre-clinical investigation in mice. ( Alleva, E; Branchi, I; Capoccia, S; Cirulli, F; D'Andrea, I; Poggini, S; Santarelli, S, 2013)
"The objective of this study was to investigate the effects of depression relief and pain relief on the improvement in daily functioning and quality of life (QOL) for depressed patients receiving a 6-week treatment of fluoxetine."3.79Relief of depression and pain improves daily functioning and quality of life in patients with major depressive disorder. ( Chen, CC; Chen, MC; Lin, CH; Yen, YC, 2013)
"Following zuclopenthixol acuphase administration, dangerous extra-pyramidal side effects were observed, including severe laryngeal dystonia necessitating emergency medical treatment."3.76Severe laryngeal dystonia in a patient receiving zuclopenthixol "Acuphase" and fluoxetine. ( Bennett, L; Davies, S; Hood, S; Orr, K, 2010)
"Anxiety disorders alone did not predict response or remission, but the total number of co-morbid illnesses was associated with remission in depressed children and adolescents treated with fluoxetine."3.76Anxiety as a predictor of treatment outcome in children and adolescents with depression. ( Cheung, A; Emslie, G; Kiss, A; Levitt, A; Mayes, T; Michalak, E; Schaffer, A, 2010)
"Our work suggests that the combination of the number of comorbid anxiety disorders, an attentional variable, and two planning variables makes it possible to correctly classify 82% of the depressed patients who responded to the treatment with fluoxetine, and 74% of the patients who did not respond to that treatment."3.76The role of clinical variables, neuropsychological performance and SLC6A4 and COMT gene polymorphisms on the prediction of early response to fluoxetine in major depressive disorder. ( Avilés Reyes, R; Camarena, B; Carrillo-Guerrero, MY; Cortés-Penagos, C; Cruz, D; Genis, A; Guàrdia-Olmos, J; Gudayol-Ferré, E; Hernández, S; Herrera-Abarca, JE; Herrera-Guzmán, I; Martínez-Medina, P, 2010)
" We report a case with no previous history of bipolar disorder, whereas developed full-blown psychotic manic symptoms soon after switch from fluoxetine to mirtazapine."3.75Antidepressant-associated mania: soon after switch from fluoxetine to mirtazapine in an elderly woman with mixed depressive features. ( Liang, KY; Liao, SC; Liu, CC, 2009)
"Blood from pregnant women taking fluoxetine (n = 9), during pregnancy was sampled in the third trimester and at delivery (maternal and cord venous blood), and from the infants 48 h after delivery."3.73Stereoselective disposition of fluoxetine and norfluoxetine during pregnancy and breast-feeding. ( Fitzgerald, C; Grunau, RE; Kent, N; Kim, J; Misri, S; Oberlander, TF; Riggs, KW; Rurak, DW, 2006)
"The purpose of this study was to examine the relationship between the degree of anxiety or somatic symptoms present before treatment with the subsequent diagnosis of treatment-related adverse events (TRAEs) in patients with major depressive disorder (MDD) enrolled in an 8-week open trial of fluoxetine (20 mg)."3.72Anxiety and somatic symptoms as predictors of treatment-related adverse events in major depressive disorder. ( Alpert, JE; Fava, M; Hughes, ME; Nierenberg, AA; Papakostas, GI; Petersen, T, 2004)
"One hundred and twenty-nine children, 2 to 8 years old, with idiopathic autistic spectrum disorder diagnosed by standard instruments (Childhood Austim Ratings Scale and Autism Diagnostic Observation Schedule) were treated with fluoxetine (0."3.71Fluoxetine response in children with autistic spectrum disorders: correlation with familial major affective disorder and intellectual achievement. ( Burch, S; DeLong, GR; Ritch, CR, 2002)
"Adolescent major depressive disorder (MDD) is associated with disrupted processing of emotional stimuli and difficulties in cognitive reappraisal."3.30Acute neural effects of fluoxetine on emotional regulation in depressed adolescents. ( Capitão, LP; Chapman, R; Cowen, PJ; Filippini, N; Harmer, CJ; James, A; Murphy, SE; Wright, L, 2023)
"Adolescent major depressive disorder (MDD) is a prevalent mental health problem with low treatment success rates."3.30Sequenced treatment alternatives to relieve adolescent depression (STAR-AD): a multicentre open-label randomized controlled trial protocol. ( Chen, F; Gan, X; He, Y; Huang, Y; Lei, T; Li, J; Li, X; Liu, R; Ouyang, X; Teng, T; Wang, T; Xie, Y; Zhou, X, 2023)
"Adults with major depressive disorder (MDD) often experience reduced quality of life (QOL)."3.01Quality of life after response to acute-phase cognitive therapy for recurrent depression. ( Jarrett, RB; Jha, MK; Minhajuddin, A; Thase, ME; Vittengl, JR, 2021)
"Effective treatment of depression is a key target for suicide prevention strategies."3.01Trajectories of change in depression symptoms and suicidal ideation over the course of evidence-based treatment for depression: Secondary analysis of a randomised controlled trial of cognitive behavioural therapy plus fluoxetine in young people. ( Berk, M; Chanen, A; Cotton, S; Davey, CG; Dean, O; Hetrick, S; Madsen, T; McGorry, PD; Witt, K, 2021)
"fluoxetine in the treatment of postmenopausal MDD."3.01Venlafaxine vs. fluoxetine in postmenopausal women with major depressive disorder: an 8-week, randomized, single-blind, active-controlled study. ( Boyce, P; Chen, R; Feng, L; Hu, Y; Shi, H; Wang, G; Wang, X; Xiao, L; Yang, R; Zhou, J; Zhu, X, 2021)
"Treatment with fluoxetine over 8 weeks led to reductions in cognitive distortions, with decreased negative and increased positive affect in adolescents with MDD."2.90Changes in cognitive distortions and affectivity levels in adolescent depression after acute phase fluoxetine treatment. ( Stevanovic, D; Zalsman, G, 2019)
" This will be the first clinical attempt of the intravenous administration of ATP and PCr combined with orally administered fluoxetine in MDD."2.90Intravenous administration of adenosine triphosphate and phosphocreatine combined with fluoxetine in major depressive disorder: protocol for a randomized, double-blind, placebo-controlled pilot study. ( Cao, X; Chen, Y; Gao, T; Ou, CQ; Shen, X; Tan, S; Zang, W; Zhao, L, 2019)
"Medication is commonly used to treat youth depression, but whether medication should be added to cognitive behavioural therapy (CBT) as first-line treatment is unclear."2.90The addition of fluoxetine to cognitive behavioural therapy for youth depression (YoDA-C): a randomised, double-blind, placebo-controlled, multicentre clinical trial. ( Amminger, GP; Berk, M; Catania, L; Chanen, AM; Cotton, SM; Davey, CG; Dean, OM; Harrison, BJ; Hetrick, SE; Kazantzis, N; Kerr, M; Koutsogiannis, J; McGorry, PD; Mullen, E; Parker, AG; Phelan, M; Quinn, AL; Ratheesh, A; Rice, S; Weller, A, 2019)
"Fluoxetine treatment was associated with an improvement in depressive symptomology and HRQOL."2.84Factors related to the improvement in quality of life for depressed inpatients treated with fluoxetine. ( Lin, CH; Lu, MJ; Wang, FC; Yang, WC, 2017)
"Thirty adults with major depressive disorder received 8 weeks of fluoxetine 20-40 mgs and were randomized to 8h TIB or 6h TIB for the first 2 weeks."2.84Relationships between circadian measures, depression, and response to antidepressant treatment: A preliminary investigation. ( Armitage, R; Bertram, H; Burgess, HJ; Dopp, R; Hoffmann, R; Huntley, ED; Mooney, A; Swanson, LM; Todd Arnedt, J; Zollars, J, 2017)
"However, the presence of recurrent major depressive disorder and multiple psychiatric comorbidities is associated with poorer functioning trajectories, offering targets for maintenance treatment or secondary prevention."2.82Trajectories of Functioning Into Emerging Adulthood Following Treatment for Adolescent Depression. ( Albano, AM; Curry, JF; Feldhaus, C; Henry, DB; Jacobs, RH; Langenecker, SA; Peters, AT; Reinecke, MA; Silva, SG, 2016)
"To prevent recurrence (i."2.82Quantifying and qualifying the preventive effects of acute-phase cognitive therapy: Pathways to personalizing care. ( Clark, LA; Jarrett, RB; Minhajuddin, A; Thase, ME; Vittengl, JR, 2016)
"The crocin group (n=20) was given one selective serotonin reuptake inhibitor (SSRI) drug (fluoxetine 20mg/day or sertraline 50mg/day or citalopram 20mg/day) plus crocin tablets (30mg/day; 15mg BID) and placebo group (n=20) was administered one SSRI (fluoxetine 20mg/day or sertraline 50mg/day or citalopram 20mg/day) plus placebo (two placebo tablets per day) for 4 weeks."2.80Crocin, the main active saffron constituent, as an adjunctive treatment in major depressive disorder: a randomized, double-blind, placebo-controlled, pilot clinical trial. ( Hassanpour Moghadam, M; Mohajeri, SA; Sajadi Tabassi, SA; Talaei, A, 2015)
"Fluoxetine was not different from placebo in Greene Climacteric Scale."2.80Individualized homeopathic treatment and fluoxetine for moderate to severe depression in peri- and postmenopausal women (HOMDEP-MENOP study): a randomized, double-dummy, double-blind, placebo-controlled trial. ( Aguilar-Faisal, L; Asbun-Bojalil, J; Llanes-González, L; Macías-Cortés, Edel C, 2015)
"Most adults with Major Depressive Disorder (MDD) will not experience a remission with the first antidepressant trial."2.80A rest-activity biomarker to predict response to SSRIs in major depressive disorder. ( McCall, WV, 2015)
"Simvastatin-treated patients experienced significantly more reductions in HDRS scores compared to the placebo group by the end of the trial (p=0."2.80Simvastatin as an adjuvant therapy to fluoxetine in patients with moderate to severe major depression: A double-blind placebo-controlled trial. ( Akhondzadeh, S; Farokhnia, M; Gougol, A; Iranpour, N; Raheb, S; Salimi, S; Yekehtaz, H; Zareh-Mohammadi, N, 2015)
" Safety measures included treatment-emergent adverse events (TEAEs), the Columbia-Suicide Severity Rating Scale, vital signs, electrocardiograms, laboratory samples, and growth (height and weight) assessments."2.80Acute and longer-term safety results from a pooled analysis of duloxetine studies for the treatment of children and adolescents with major depressive disorder. ( Bangs, ME; Emslie, GJ; March, JS; Pangallo, BA; Prakash, A; Wells, TG; Zhang, Q, 2015)
"After patients with major depressive disorder (MDD) respond to acute-phase cognitive therapy (CT), continuation-phase treatments may be applied to improve long-term outcomes."2.80Predictors of longitudinal outcomes after unstable response to acute-phase cognitive therapy for major depressive disorder. ( Clark, LA; Jarrett, RB; Thase, ME; Vittengl, JR, 2015)
" Both the antidepressants were found to be safe and well tolerated."2.80Comparison of efficacy, safety and brain derived neurotrophic factor (BDNF) levels in patients of major depressive disorder, treated with fluoxetine and desvenlafaxine. ( Bhatia, MS; Ghosh, R; Gupta, LK; Gupta, R; Tripathi, AK, 2015)
"Youth (aged 8-17 years) with major depressive disorder (MDD) were treated with fluoxetine for 6 weeks."2.80Continued Effectiveness of Relapse Prevention Cognitive-Behavioral Therapy Following Fluoxetine Treatment in Youth With Major Depressive Disorder. ( Emslie, GJ; Foxwell, AA; Jones, JM; Kennard, BD; King, J; Mayes, TL; Moore, J; Nakonezny, PA, 2015)
" This study provides first clinical evidence that curcumin may be used as an effective and safe modality for treatment in patients with MDD without concurrent suicidal ideation or other psychotic disorders."2.79Efficacy and safety of curcumin in major depressive disorder: a randomized controlled trial. ( Goel, A; Panchal, B; Patel, T; Sanmukhani, J; Satodia, V; Tiwari, D; Tripathi, CB; Trivedi, J, 2014)
" Tolerability and safety evaluations were based on emergent adverse events."2.79Comparable efficacy and safety of 8 weeks treatment with agomelatine 25-50mg or fluoxetine 20-40mg in Asian out-patients with major depressive disorder. ( Crutel, VS; Fones Soon Leng, C; Huang, YS; Kim, YS; Shu, L; Sulaiman, AH, 2014)
"Fluoxetine (FLX) has been one of the most widely studied selective serotonin reuptake inhibitors in adolescents."2.79Plasma fluoxetine concentrations and clinical improvement in an adolescent sample diagnosed with major depressive disorder, obsessive-compulsive disorder, or generalized anxiety disorder. ( Arnaiz, JA; Blázquez, A; Gassó, P; Lafuente, A; Lázaro, L; Mas, S; Méndez, I; Plana, MT; Torra, M, 2014)
" There were no significant differences between patients treated with OFC and fluoxetine in extrapyramidal symptoms or serious adverse events."2.79Efficacy and safety of olanzapine/fluoxetine combination vs fluoxetine monotherapy following successful combination therapy of treatment-resistant major depressive disorder. ( Brunner, E; Landry, J; Osuntokun, O; Thase, ME; Tohen, M, 2014)
" Measures included: Children's Depression Rating Scale-Revised (CDRS-R), treatment-emergent adverse events (TEAEs), and Columbia-Suicide Severity Rating Scale (C-SSRS)."2.79A double-blind efficacy and safety study of duloxetine flexible dosing in children and adolescents with major depressive disorder. ( Atkinson, SD; Bangs, ME; Emslie, GJ; March, JS; Pangallo, BA; Prakash, A; Zhang, Q, 2014)
" Measures included: Children's Depression Rating Scale-Revised (CDRS-R), treatment-emergent adverse events (TEAEs), and Columbia-Suicide Severity Rating Scale (C-SSRS)."2.79A double-blind efficacy and safety study of duloxetine fixed doses in children and adolescents with major depressive disorder. ( Bangs, ME; Emslie, GJ; March, JS; Pangallo, BA; Prakash, A; Zhang, Q, 2014)
"One hundred and three patients of major depressive disorders were observed."2.79Effects of olanzapine-fluoxetine combination treatment of major depressive disorders on the quality of life during acute treatment period. ( Gu, S; Guo, J; Luo, H; Qu, W; Tang, Q, 2014)
"Though encouraging evidence exists for the use of folic acid as an augmenting agent to antidepressants, evidence regarding its optimal dosage is lacking."2.78A randomized double-blind comparison of fluoxetine augmentation by high and low dosage folic acid in patients with depressive episodes. ( Kumar, CN; Pandey, RS; Venkatasubramanian, R, 2013)
"Adult outpatients with recurrent major depressive disorder were randomly assigned to receive venlafaxine extended release (ER; 75-300 mg/day) or fluoxetine (20-60 mg/day)."2.78Sexual functioning in patients with recurrent major depressive disorder enrolled in the PREVENT study. ( Dorries, KM; Dunner, DL; Gelenberg, AJ; Ninan, PT; Pedersen, R; Rothschild, AJ, 2013)
"Patients suffering from major depressive disorder (MDD) have been reported to have substantial long-lasting limitations in multiple domains of health-related quality of life (HRQoL)."2.78Health-related quality of life and symptom severity in Chinese patients with major depressive disorder. ( Cao, Y; Li, W; Luo, X; Malison, RT; Shen, J; Zhang, Y, 2013)
"A total of 523 adults with recurrent major depressive disorder began acute phase CT, of which 241 higher-risk responders were randomized and 181 subsequently entered the follow-up."2.78Preventing depressive relapse and recurrence in higher-risk cognitive therapy responders: a randomized trial of continuation phase cognitive therapy, fluoxetine, or matched pill placebo. ( Friedman, ES; Gershenfeld, H; Jarrett, RB; Minhajuddin, A; Thase, ME, 2013)
"Twenty-one patients with major depressive disorder and without other Axis I or Axis II diagnoses were scanned before treatment and 2 and 6 months into treatment at the university's functional magnetic resonance imaging facility."2.78Increased prefrontal cortex activity during negative emotion regulation as a predictor of depression symptom severity trajectory over 6 months. ( Davidson, RJ; Heller, AS; Johnstone, T; Kalin, NH; Kolden, GG; Peterson, MJ, 2013)
" High inter-individual variability in serum concentrations of the active moiety of FLX at each dosage level was observed and no relationship between serum concentration and clinical outcome was found."2.77Therapeutic drug monitoring of children and adolescents treated with fluoxetine. ( Burger, R; Egberts, K; Fegert, JM; Gerlach, M; Kliegl, K; Koelch, M; Ludolph, AG; Mehler-Wex, C; Pfalzer, AK; Rothenhöfer, S; Stingl, J; Taurines, R, 2012)
"There are limited data on the impact of insomnia in response to acute treatment, which is particularly relevant with serotonin-selective reuptake inhibitors, given their tendency to worsen sleep architecture."2.77Insomnia moderates outcome of serotonin-selective reuptake inhibitor treatment in depressed youth. ( Croarkin, P; Emslie, GJ; Hughes, C; Kennard, BD; Mayes, TL; Nakonezny, PA; Tao, R; Zhu, L, 2012)
"Fluoxetine treatment decreased activations in all three regions, as compared with the repeat scans of healthy comparison subjects."2.77Brain activity in adolescent major depressive disorder before and after fluoxetine treatment. ( Calley, CS; Emslie, GJ; Hart, J; Kennard, BD; Lu, H; Mayes, TL; Nakonezny, PA; Tamminga, CA; Tao, R, 2012)
"Eighty-nine adults with Major Depressive Disorder (MDD), characterized as antidepressant-experienced or antidepressant-naive, received one week of single-blind placebo treatment prior to eight weeks of randomized treatment with medication (fluoxetine or venlafaxine; n = 47) or placebo (n = 42) in one of three similar placebo-controlled trials."2.77Does prior antidepressant treatment of major depression impact brain function during current treatment? ( Cook, IA; Hunter, AM; Leuchter, AF, 2012)
"35 patients with DSM IV-defined major depressive disorder of mild or moderate severity were randomized to receive either short-term psychodynamic psychotherapy or fluoxetine treatment for 16 weeks."2.76Personality traits and recovery from major depressive disorder. ( Hietala, J; Kajander, J; Karlsson, H; Kronström, K; Markkula, J; Rasi-Hakala, H; Salminen, JK; Vahlberg, T, 2011)
"Sex predicted recurrence (57."2.76Recovery and recurrence following treatment for adolescent major depression. ( Albano, AM; Becker-Weidman, E; Burns, B; Curry, J; Emslie, G; Feeny, N; Ginsburg, G; Jacobs, R; Kastelic, E; Kennard, B; Kirchner, J; Kratochvil, C; Lavanier, S; March, J; May, D; Mayes, T; Reinecke, M; Rohde, P; Silva, S; Simons, A; Walkup, J; Weller, E; Wells, K, 2011)
"Patients with major depressive disorder (MDD) and significant anxiety are less responsive to antidepressants than those without anxiety."2.76A post hoc analysis of the effect of nightly administration of eszopiclone and a selective serotonin reuptake inhibitor in patients with insomnia and anxious depression. ( Fava, M; Huang, H; Iosifescu, DV; Mischoulon, D; Schaefer, K; Wessel, TC; Wilson, A, 2011)
"Many patients with major depressive disorder (MDD) who achieve full remission after antidepressant treatment still have residual depressive symptoms."2.76Residual symptoms after remission of major depressive disorder with fluoxetine and risk of relapse. ( Baer, L; Clain, A; Iovieno, N; Nierenberg, AA; van Nieuwenhuizen, A, 2011)
"In treatment trials for major depressive disorder (MDD), early symptom improvement is predictive of eventual clinical response."2.76Rostral anterior cingulate cortex activity and early symptom improvement during treatment for major depressive disorder. ( Cook, IA; Hunter, AM; Korb, AS; Leuchter, AF, 2011)
"Adolescent major depressive disorder (MDD) is a life-threatening brain disease with limited interventions."2.76Open-label adjunctive creatine for female adolescents with SSRI-resistant major depressive disorder: a 31-phosphorus magnetic resonance spectroscopy study. ( Fiedler, KK; Hellem, TL; Jeong, EK; Kondo, DG; Renshaw, PF; Shi, X; Sung, YH, 2011)
"The goal of treating major depressive disorder is to achieve remission."2.76Predictors of fluoxetine remission for hospitalized patients with major depressive disorder. ( Chen, CC; Juo, SH; Lane, HY; Lin, CH; Yen, CF, 2011)
" Blood samples were collected for pharmacokinetic analysis of ADTs."2.75The pharmacokinetics of standard antidepressants with aripiprazole as adjunctive therapy: studies in healthy subjects and in patients with major depressive disorder. ( Balch, AH; Berman, RM; Boulton, DW; Mallikaarjun, S; Patel, CG; Reeves, RA; Royzman, K, 2010)
"Relapse of major depressive disorder (MDD) is a common clinical problem."2.75Type of residual symptom and risk of relapse during the continuation/maintenance phase treatment of major depressive disorder with the selective serotonin reuptake inhibitor fluoxetine. ( Baer, L; Chen, Y; Chuzi, S; Clain, A; Fava, M; Johnson, D; McGrath, PJ; Papakostas, GI; Sinicropi-Yao, L; Stewart, JW; Yang, H, 2010)
"Individuals with Major Depressive Disorder (MDD) vary regarding the rate, magnitude and stability of symptom changes during antidepressant treatment."2.75Antidepressant response trajectories and quantitative electroencephalography (QEEG) biomarkers in major depressive disorder. ( Cook, IA; Hunter, AM; Leuchter, AF; Muthén, BO, 2010)
"Sixty-nine patients diagnosed with major depressive disorder (MDD) according to DSM-IV and 36 healthy controls are included in the study."2.75Effects of venlafaxine and fluoxetine on lymphocyte subsets in patients with major depressive disorder: a flow cytometric analysis. ( Başterzi, AD; Buturak, V; Cimen, B; Eskandari, G; Taşdelen, B; Tot Acar, S; Yazici, A; Yazici, K, 2010)
"Personality disorders are neither particularly stable nor treatment resistant."2.75Personality disorders improve in patients treated for major depression. ( Frampton, CM; Joyce, PR; Mulder, RT, 2010)
"Anxious depression, defined as major depressive disorder (MDD) accompanied by high levels of anxiety, seems to be both common and difficult to treat, with antidepressant monotherapy often yielding modest results."2.75Fluoxetine-clonazepam cotherapy for anxious depression: an exploratory, post-hoc analysis of a randomized, double blind study. ( Ameral, VE; Baer, L; Brintz, C; Clain, A; Fava, M; Glaudin, V; Londborg, PD; Painter, JR; Papakostas, GI; Smith, WT, 2010)
"Patients with major depressive disorder (MDD) took fluoxetine (20 mg/day) for 6 weeks."2.75Association of BDNF Val66Met polymorphism with both baseline HRQOL scores and improvement in HRQOL scores in Chinese major depressive patients treated with fluoxetine. ( Feng, XL; Hu, J; Li, HC; Li, KQ; Li, M; Liu, P; Liu, Y; Liu, ZC; Tao, M; Wang, BY; Wang, Y; Wei, J; Xu, XP; Ye, DQ; Yu, X; Zang, TH; Zhang, KR; Zou, YF, 2010)
"Seventy-two major depressive disorder (MDD) subjects were treated with fluoxetine 20 mg (n = 13), venlafaxine 150 mg (n = 24), or placebo (n = 35) under double-blind conditions."2.75Brain functional changes (QEEG cordance) and worsening suicidal ideation and mood symptoms during antidepressant treatment. ( Abrams, M; Cook, IA; Hunter, AM; Leuchter, AF, 2010)
"A link between insomnia and suicide has not been previously examined in the setting of a clinical trial."2.75Insomnia severity is an indicator of suicidal ideation during a depression clinical trial. ( Blocker, JN; Boggs, N; D'Agostino, R; Kimball, J; Lasater, B; McCall, WV; Rosenquist, PB, 2010)
"60 depressed, insomniac outpatients."2.75Treatment of insomnia in depressed insomniacs: effects on health-related quality of life, objective and self-reported sleep, and depression. ( Blocker, JN; Boggs, N; D'Agostino, R; Haskett, R; Kimball, J; Krystal, A; Lasater, B; McCall, WV; McDonald, WM; Rosenquist, PB, 2010)
"Adolescents with major depressive disorder (N=439) were randomly assigned to receive an initial 12 weeks of treatment with fluoxetine, cognitive-behavioral therapy (CBT), combination treatment with fluoxetine and CBT, or clinical management with placebo; those assigned to placebo received open active treatment as clinically indicated after 12 weeks of placebo."2.74Assessment of safety and long-term outcomes of initial treatment with placebo in TADS. ( Curry, JF; Emslie, GJ; Hughes, JL; Kennard, BD; Kratochvil, CJ; March, JS; Mayes, TL; Reinecke, MA; Rohde, P; Silva, SG; Vitiello, B, 2009)
"The authors sought to identify predictors of self-harm adverse events in treatment-resistant, depressed adolescents during the first 12 weeks of treatment."2.74Predictors of spontaneous and systematically assessed suicidal adverse events in the treatment of SSRI-resistant depression in adolescents (TORDIA) study. ( Asarnow, J; Birmaher, B; Brent, DA; Clarke, GN; Debar, LL; Emslie, GJ; Iyengar, S; Keller, MB; Kennard, B; Leonard, H; Mayes, TL; McCracken, JT; Onorato, M; Porta, G; Ritz, L; Ryan, ND; Spirito, A; Strober, M; Suddath, R; Vitiello, B; Zelazny, J, 2009)
"Fluoxetine was well tolerated in this treatment population."2.74Double-blind placebo-controlled trial of fluoxetine in adolescents with comorbid major depression and an alcohol use disorder. ( Bukstein, OG; Clark, DB; Cornelius, JR; Douaihy, A; Kirisci, L; Wood, DS, 2009)
"95 outpatients with major depressive disorder were treated for 6 weeks with EA, fluoxetine or placebo."2.74Imbalance between pro- and anti-inflammatory cytokines, and between Th1 and Th2 cytokines in depressed patients: the effect of electroacupuncture or fluoxetine treatment. ( Halbreich, U; Han, C; Leonard, BE; Luo, H; Song, C, 2009)
"Fifty-one patients with major depressive disorder (DSM-IV) of mild or moderate severity were recruited through occupational health services providing primary health care."2.73Short-term psychodynamic psychotherapy and fluoxetine in major depressive disorder: a randomized comparative study. ( Aalto, S; Hietala, J; Kajander, J; Karlsson, H; Markkula, J; Rasi-Hakala, H; Salminen, JK; Toikka, T, 2008)
" Quetiapine was flexibly dosed starting at 25 mg to a maximum of 100 mg daily."2.73A randomized, double-blind, and placebo-controlled trial of quetiapine augmentation of fluoxetine in major depressive disorder. ( Fava, M; Garakani, A; Hirschowitz, J; Marcus, S; Martinez, JM; Rickels, K; Weaver, J, 2008)
" Adverse effects and other clinical features associated with the emergence of suicidality, defined using item 3 of the Hamilton Depression Rating Scale, were examined using Cox regression models."2.73Treatment-associated suicidal ideation and adverse effects in an open, multicenter trial of fluoxetine for major depressive episodes. ( Amsterdam, J; Beasley, CM; Cusin, C; Fava, M; Perlis, RH; Quitkin, F; Rosenbaum, JF; Shear, D; Strong, RE; Tamura, RN; Wines, JD, 2007)
"Melatonin rhythms were similar between depressed patients and matched healthy controls."2.73Effect of fluoxetine on circadian rhythm of melatonin in patients with major depressive disorder. ( Bao, AM; Liu, YJ; Tan, ZL; Zhao, GQ; Zhou, JN, 2007)
"Insomnia and major depressive disorder (MDD) may coexist."2.73Evaluation of eszopiclone discontinuation after cotherapy with fluoxetine for insomnia with coexisting depression. ( Caron, J; Fava, M; Krystal, A; McCall, WV; Roth, T; Rubens, R; Wessel, T; Wilson, P, 2007)
"Sixty outpatients with a diagnosis of major depressive disorder based on DSM-IV criteria and a score >or=15 in the 17-item Hamilton Depression Rating Scale (HDRS) were randomly allocated to receive daily either 1000 mg EPA or 20 mg fluoxetine, or their combination for 8 weeks."2.73Comparison of therapeutic effects of omega-3 fatty acid eicosapentaenoic acid and fluoxetine, separately and in combination, in major depressive disorder. ( Amini, H; Djazayery, A; Hosseini, M; Jalali, M; Jazayeri, S; Keshavarz, SA; Peet, M; Tehrani-Doost, M, 2008)
"Aripiprazole is an effective and safe adjunctive therapy as demonstrated in this short-term study for patients who are nonresponsive to standard ADT."2.73The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. ( Berman, RM; Carson, WH; Fava, M; Hennicken, D; Marcus, RN; McQuade, RD; Simon, JS; Thase, ME; Trivedi, MH, 2008)
"Major depressive disorders have a significant impact on children and adolescents, including on educational and vocational outcomes, interpersonal relationships, and physical and mental health and well-being."2.72New generation antidepressants for depression in children and adolescents: a network meta-analysis. ( Badcock, PB; Bailey, AP; Cox, GR; Hetrick, SE; McKenzie, JE; Meader, N; Merry, SN; Moller, CI; Sharma, V, 2021)
"Patients with major depressive disorder or dysthymic disorder achieved similar clinical improvement in both treatment groups (mean MADRS ratings decrease in major depressive disorder from baseline to 6 months of 18."2.72Effectiveness and cost-effectiveness of antidepressant treatment in primary health care: a six-month randomised study comparing fluoxetine to imipramine. ( Caramés, E; Gabarron, E; Garcia-Bayo, I; Haro, JM; Peñarrubia-Maria, MT; Pinto-Meza, A; Serrano-Blanco, A; Soler-Vila, M, 2006)
"Risk factors such as borderline personality disorder and childhood abuse experiences were systematically assessed, and patients were genotyped for polymorphisms of GNbeta3."2.72Genetic, developmental and personality correlates of self-mutilation in depressed patients. ( Joyce, PR; Kennedy, MA; Luty, SE; McKenzie, JM; Miller, AL; Mulder, RT; Sullivan, PF, 2006)
"Unawareness of impairment (anosognosia) is a phenomenon associated with right hemisphere lesions."2.72Response of emotional unawareness after stroke to antidepressant treatment. ( Bria, P; Caltagirone, C; Ripa, A; Robinson, RG; Spalletta, G, 2006)
"Treatment with fluoxetine is less likely to lead to remission of MDD in patients with stable PDs."2.72Problem-solving ability and comorbid personality disorders in depressed outpatients. ( Farabaugh, A; Fava, M; Harley, R; Papakostas, GI; Petersen, T; Scalia, M, 2006)
"Hyperprolactinemia was defined as a serum prolactin level greater than 16."2.72Serum prolactin levels among outpatients with major depressive disorder during the acute phase of treatment with fluoxetine. ( Fava, M; Hilliker, SE; Klibanski, A; Miller, KK; Papakostas, GI; Petersen, T; Sklarsky, KG, 2006)
"Five hundred seventy persons with major depressive disorder were treated with fluoxetine for 12 weeks and their pattern of response was determined."2.72Predictors of relapse in a prospective study of fluoxetine treatment of major depression. ( Alpert, JE; Chen, Y; Cheng, J; Fava, M; McGrath, PJ; Nierenberg, AA; Petkova, E; Quitkin, FM; Stewart, JW, 2006)
"Fluoxetine was superior to CBT on the CGAS (p < ."2.72Functioning and quality of life in the Treatment for Adolescents with Depression Study (TADS). ( Casat, C; Kratochvil, C; March, J; Pathak, S; Reinecke, M; Robins, M; Rohde, P; Silva, S; Simons, A; Vitiello, B; Walkup, J; Waslick, B; Weller, E; Wells, K, 2006)
"Safety assessments included adverse events (AEs) collected by spontaneous report, as well as systematic measures for specific physical and psychiatric symptoms."2.72Treatment for Adolescents with Depression Study (TADS): safety results. ( Casat, C; Emslie, G; Kratochvil, C; March, J; Mayes, T; McNulty, S; Pathak, S; Posner, K; Rohde, P; Silva, S; Vitiello, B; Walkup, J; Waslick, B; Weller, E, 2006)
"Up to 50% of patients with major depressive disorder (MDD) fail to respond to an antidepressant trial, with most taking a selective serotonin reuptake inhibitor (SSRI) as an initial treatment."2.71Switching to bupropion in fluoxetine-resistant major depressive disorder. ( Fava, M; Mahal, Y; McGrath, P; Papakostas, GI; Petersen, T; Quitkin, F; Stewart, J, 2003)
" Safety was evaluated by recording spontaneously reported adverse events."2.71Switching to reboxetine: an efficacy and safety study in patients with major depressive disorder unresponsive to fluoxetine. ( Fava, M; McGrath, PJ; Sheu, WP, 2003)
"Discontinuation syndrome is associated with a rostral anterior cingulate Cho/Cre metabolite ratio decrease that may reflect dynamics of rostral anterior cingulate function."2.71Selective serotonin reuptake inhibitor discontinuation syndrome is associated with a rostral anterior cingulate choline metabolite decrease: a proton magnetic resonance spectroscopic imaging study. ( Cohen, BM; Frederick, Bd; Hennen, J; Henry, ME; Kaufman, MJ; Renshaw, PF; Schmidt, ME; Stoddard, EP; Villafuerte, RA, 2003)
"Fluoxetine was associated with some adverse events in 46."2.71Fluoxetine once every third day in the treatment of major depressive disorder. ( Onder, E; Tural, U, 2003)
"Forty-two outpatients with DSM-IV major depressive disorder who had an insufficient response to an adequate trial of an SSRI (fluoxetine, paroxetine, or sertraline) were randomly assigned to pindolol, 2."2.71Pindolol augmentation in depressed patients resistant to selective serotonin reuptake inhibitors: a double-blind, randomized, controlled trial. ( Anand, A; Berman, RM; Charney, DS; Lynch-Colonese, K; Perry, EB; Sanacora, G, 2004)
"The yohimbine dose was titrated based on blood pressure changes over the treatment period, in a blind-preserving manner."2.71Addition of the alpha2-antagonist yohimbine to fluoxetine: effects on rate of antidepressant response. ( Berman, RM; Cappiello, A; Charney, DS; Fasula, D; Gueorguieva, R; Kugaya, A; Liu, N; Oren, DA; Sanacora, G, 2004)
"Sixty nondiabetic patients with major depressive disorder (based on Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria) entered this randomized, double-blind study."2.71Comparing the effects of 8-week treatment with fluoxetine and imipramine on fasting blood glucose of patients with major depressive disorder. ( Dashti-Khavidaki, S; Ghaeli, P; Kamkar, MZ; Mesbahi, M; Sadeghi, M; Shahsavand, E, 2004)
"Fifty-one subjects with major depressive disorder (MDD) were enrolled in a 1-week single blind placebo lead-in, followed by an 8-week, double-blind placebo-controlled treatment with either fluoxetine or venlafaxine."2.71Predictors of improved mood over time in clinical trials for major depression. ( Azen, SP; Chou, CP; James Gauderman, W; Leuchter, AF; Marie-Mitchell, A, 2004)
"Fluoxetine alone is a superior treatment to CBT alone (P =."2.71Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial. ( Burns, B; Curry, J; Domino, M; Fairbank, J; March, J; McNulty, S; Petrycki, S; Severe, J; Silva, S; Vitiello, B; Wells, K, 2004)
"Reboxetine is a novel selective noradrenaline reuptake inhibitor."2.71Reboxetine induces similar sleep-EEG changes like SSRI's in patients with depression. ( Held, K; Kuenzel, HE; Murck, H; Steiger, A; Ziegenbein, M, 2004)
"Fluoxetine was not different from placebo."2.71Hypericum extract in patients with MDD and reversed vegetative signs: re-analysis from data of a double-blind, randomized trial of hypericum extract, fluoxetine, and placebo. ( Alpert, J; Fava, M; Mannel, M; Mischoulon, D; Murck, H; Nierenberg, AA; Otto, MW; Rosenbaum, JF; Zajecka, J, 2005)
"The incidence of treatment-emergent nausea during 6-month continuation of duloxetine treatment (80 mg/d, 2."2.71Incidence and duration of antidepressant-induced nausea: duloxetine compared with paroxetine and fluoxetine. ( Greist, J; Mallinckrodt, CH; McNamara, RK; Raskin, J; Rayamajhi, JN, 2004)
"Fluoxetine-treated patients gained statistically significantly less height (fluoxetine: 1."2.71Safety of subchronic treatment with fluoxetine for major depressive disorder in children and adolescents. ( Brown, EB; Heiligenstein, JH; Joliat, MJ; Miner, CM; Nilsson, M, 2004)
"Phenytoin was the first non-sedative anticonvulsant introduced and is still the anticonvulsant most widely used worldwide in neurology."2.71Controlled double-blind trial of phenytoin vs. fluoxetine in major depressive disorder. ( Belmaker, RH; Bersudsky, Y; Nemets, B, 2005)
" All adverse events which developed during the study period were recorded."2.71Comparison of efficacy and safety of milnacipran and fluoxetine in Korean patients with major depression. ( Chee, IS; Choe, BM; Ham, BJ; Jung, HY; Kee, BS; Kim, JB; Lee, C; Lee, MS; Oh, BH; Oh, KS; Paik, IH; Yeon, BK, 2005)
"Treatment with olanzapine may impact a patient's weight; thus, long-term weight gain and potential predictors (e."2.71Long-term weight gain in patients treated with open-label olanzapine in combination with fluoxetine for major depressive disorder. ( Andersen, SW; Clemow, DB; Corya, SA, 2005)
"We identified 101 outpatients with major depressive disorder (52 men and 49 women; mean age, 41."2.70Double-blind study of high-dose fluoxetine versus lithium or desipramine augmentation of fluoxetine in partial responders and nonresponders to fluoxetine. ( Alpert, J; Baer, L; Fava, M; Lagomasino, I; Nierenberg, A; Rosenbaum, JF; Sonawalla, S; Tedlow, J; Worthington, J, 2002)
"Patients with major depressive disorder remain at risk for relapse following remission and often continue to experience subthreshold symptoms."2.70Effects of adding cognitive therapy to fluoxetine dose increase on risk of relapse and residual depressive symptoms in continuation treatment of major depressive disorder. ( Alpert, JE; Buchin, J; Fava, M; Matthews, JD; Nierenberg, AA; Pava, J; Perlis, RH; Sickinger, AH, 2002)
"Patients (N = 284) with DSM-IV major depressive disorder were randomly assigned in a double-blind fashion to fluoxetine, paroxetine, or sertraline for 10 to 16 weeks of treatment."2.70Acute efficacy of fluoxetine versus sertraline and paroxetine in major depressive disorder including effects of baseline insomnia. ( Fava, M; Gonzales, JS; Hoog, SL; Judge, RA; Kopp, JB; Nilsson, ME, 2002)
" This raises the important question of whether once-weekly enteric-coated fluoxetine, 90 mg, is effective for maintenance of response in patients whose depressive symptoms have responded to daily dosing with selective serotonin reuptake inhibitors (SSRIs) such as citalopram, paroxetine, or sertraline."2.70Switching patients from daily citalopram, paroxetine, or sertraline to once-weekly fluoxetine in the maintenance of response for depression. ( Brown, EB; Gonzales, JS; Miner, CM; Munir, R, 2002)
"Paroxetine appears to produce an earlier improvement in agitation and psychic anxiety symptoms compared with fluoxetine."2.69A Canadian multicenter, double-blind study of paroxetine and fluoxetine in major depressive disorder. ( Bakish, D; Beauclair, L; Bélanger, MC; Chouinard, G; Manchanda, R; Morris, P; O'Neill, MC; Ravindran, A; Reesal, R; Remick, R; Saxena, B; Vasavan Nair, NP, 1999)
"Relapse was defined as a 50% increase in HDRS with total < or = 17."2.69Tryptophan-depletion challenge in depressed patients treated with desipramine or fluoxetine: implications for the role of serotonin in the mechanism of antidepressant action. ( Charney, DS; Delgado, PL; Heninger, GR; Krystal, JH; Licinio, J; Miller, HL; Moreno, FA; Salomon, RM, 1999)
" No cases of serotonin syndrome occurred, and the combination was well tolerated, although the 4 g per day dosage of tryptophan produced daytime drowsiness."2.69Preliminary randomized double-blind placebo-controlled trial of tryptophan combined with fluoxetine to treat major depressive disorder: antidepressant and hypnotic effects. ( Driver, HS; Jindal, R; Kennedy, SH; Levitan, RD; Shapiro, CM; Shen, JH, 2000)
" The present study was designed to clarify the relationship between dosage and treatment response in major depressive disorder."2.53Systematic Review and Meta-Analysis: Dose-Response Relationship of Selective Serotonin Reuptake Inhibitors in Major Depressive Disorder. ( Bloch, MH; Freemantle, N; Jakubovski, E; Taylor, MJ; Varigonda, AL, 2016)
"Major depressive disorder is one of the most common mental disorders in children and adolescents."2.53Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis. ( Cipriani, A; Coghill, D; Cohen, D; Cuijpers, P; Del Giovane, C; Hazell, P; Hetrick, SE; Leucht, S; Liu, L; Liu, Y; Michael, KD; Pu, J; Qin, B; Ravindran, AV; Whittington, C; Xie, P; Yang, L; Zhang, Y; Zhou, X, 2016)
" In this article, we report the evidence that contributed to the implementation of pharmacokinetic pharmacogenetic guidelines for antidepressants primarily metabolized by CYP2D6 and CYP2C19."2.53Pharmacokinetic Pharmacogenetic Prescribing Guidelines for Antidepressants: A Template for Psychiatric Precision Medicine. ( Black, JL; Elliott, MA; Frye, MA; Nassan, M; Nicholson, WT; Rohrer Vitek, CR, 2016)
"At any one time, major depressive disorder (MDD) affects 4 - 6% of adolescents."2.46Pharmacotherapy of major depressive disorder in adolescents. ( Brovedani, P; Liboni, F; Masi, G, 2010)
"Mirtazapine-treated patients had a 74% higher likelihood of achieving remission during the first 2 weeks of therapy compared with patients treated with SSRIs."2.46Remission with mirtazapine and selective serotonin reuptake inhibitors: a meta-analysis of individual patient data from 15 controlled trials of acute phase treatment of major depression. ( Nierenberg, AA; Schutte, AJ; Simmons, JH; Thase, ME; van Oers, HJ; Vrijland, P, 2010)
" A secondary analysis of dose-response relationships indicated that this advantage was not attributable to the studies using higher doses of duloxetine."2.44Efficacy of duloxetine and selective serotonin reuptake inhibitors: comparisons as assessed by remission rates in patients with major depressive disorder. ( Detke, MJ; Ossanna, MJ; Pritchett, YL; Swindle, RW; Thase, ME; Xu, J, 2007)
"Fluoxetine treatment did not result in greater worsening but was associated with greater improvement and faster resolution of ideation (P < or = 0."2.44Fluoxetine and adult suicidality revisited: an updated meta-analysis using expanded data sources from placebo-controlled trials. ( Acharya, N; Ball, SG; Beasley, CM; Nilsson, ME; Plewes, J; Polzer, J; Tauscher-Wisniewski, S, 2007)
"Major depressive disorder is a common, chronic, recurring, and disabling illness in children and adolescents."2.43Major depressive disorder in children and adolescents: clinical trial design and antidepressant efficacy. ( Emslie, GJ; Ryan, ND; Wagner, KD, 2005)
"Adolescents with major depressive disorder (MDD), their families and clinicians experience significant challenges when weighing the potential risks versus benefits of available choices in the treatment of MDD."2.43Comparative efficacy of cognitive behavioral therapy, fluoxetine, and their combination in depressed adolescents: initial lessons from the treatment for adolescents with depression study. ( Kratochvil, CJ; March, JS; Pathak, S; Rogers, GM; Silva, S; Vitiello, B; Weller, EB, 2005)
"Sixteen trials studied patients with major depressive disorder, and the remaining 8 studied obsessive-compulsive disorder (n = 4), generalized anxiety disorder (n = 2), attention-deficit/hyperactivity disorder (n = 1), and social anxiety disorder (n = 1)."2.43Suicidality in pediatric patients treated with antidepressant drugs. ( Hammad, TA; Laughren, T; Racoosin, J, 2006)
"Fluoxetine was not statistically different in either tolerability or efficacy when compared with duloxetine."2.43Duloxetine compared with fluoxetine and venlafaxine: use of meta-regression analysis for indirect comparisons. ( Eckert, L; Lançon, C, 2006)
"The patient also had untreated Polycystic Ovarian Syndrome (PCOS)."2.41Common treatment of polycystic ovarian syndrome and major depressive disorder: case report and review. ( Bauer, M; Carter, MS; Elman, S; Korenman, SG; Love, M; Rasgon, NL, 2002)
" The rate of discontinuation due to adverse effects with reboxetine was not significantly different from that observed with placebo in short-term studies."2.41Reboxetine: tolerability and safety profile in patients with major depression. ( Tanum, L, 2000)
" It is also suggested that positron emission tomography may be used to define therapeutic dosing early on in the process of clinical evaluation of new treatment strategies."2.41Pindolol augmentation of antidepressant treatment: recent contributions from brain imaging studies. ( Broft, A; Laruelle, M; Martinez, D, 2000)
" Spontaneously reported treatment-emergent adverse events, reasons for discontinuation, and events leading to discontinuation were compared between groups."2.41Adverse events and treatment discontinuations in clinical trials of fluoxetine in major depressive disorder: an updated meta-analysis. ( Beasley, CM; Gonzales, JS; Koke, SC; Nilsson, ME, 2000)
"Pharmacotherapy for major depressive disorder (MDD) typically consists of trial-and-error and clinician preference approaches, where patients often fail one or more antidepressants before finding an optimal regimen."1.91Case Report: Performing a Medication Safety Review Assisted by Pharmacogenomics to Explain a Prescribing Cascade Resulting in a Patient Fall. ( Amin, NS; Arwood, MJ; Cambridge, MD; Michaud, V; Russell, J; Toro-Pagán, NMD; Turgeon, J, 2023)
"Antidepressants are the first-line treatment for major depressive disorder, but if patients don't respond adequately, brain stimulation therapy may be needed as second-line treatment."1.91Right-side frontal-central cortical hyperactivation before the treatment predicts outcomes of antidepressant and electroconvulsive therapy responsivity in major depressive disorder. ( Lin, CH; Tsai, HJ; Tsai, SJ; Yang, AC; Yang, WC, 2023)
"Fluoxetine (Flx) has been widely used to treat MDD, but its mechanisms of action remain elusive."1.91Chronic fluoxetine treatment in socially-isolated rats modulates the prefrontal cortex synaptoproteome. ( Bernardi, RE; Filipović, D; Novak, B; Turck, CW; Xiao, J; Yan, Y, 2023)
"Our study included 101 patients with major depressive disorder and alcohol use disorder (average age: 41."1.62Impact of CYP2D6 Polymorphism on Equilibrium Concentration of Fluoxetine in Patients Diagnosed With Major Depressive Disorder and Comorbid Alcohol Use Disorders. ( Bryun, EA; Grishina, EA; Pankratenko, EP; Petukhov, AE; Ryzhikova, KA; Shipitsyn, VV; Skryabin, VY; Sychev, DA; Torrado, MV; Zastrozhin, MS, 2021)
"Fluoxetine was continued for a total of 12 weeks."1.62Higher dose weekly fluoxetine in hemodialysis patients: A case series report. ( Dolata, J; Figueroa, M; Gunzler, D; Huml, A; Kauffman, KM; Pencak, J; Sajatovic, M; Sehgal, AR, 2021)
"The synaptogenic hypothesis of major depressive disorder implies that preventing the onset of depressive-like behavior also prevents the loss of hippocampal spine synapses."1.62Stress Resilience is Associated with Hippocampal Synaptoprotection in the Female Rat Learned Helplessness Paradigm. ( Baka, J; Csakvari, E; Dobos, N; Duman, RS; Farkas, T; Hajszan, T; Huzian, O; Leranth, C; Siklos, L, 2021)
"Rates of major depressive disorder (MDD) increase with living at altitude."1.62Sex-Based Impact of Creatine Supplementation on Depressive Symptoms, Brain Serotonin and SSRI Efficacy in an Animal Model of Treatment-Resistant Depression. ( Brown, J; Ettaro, R; Hoffman, MD; Kanekar, S; Lynch, C; Ombach, HJ; Renshaw, PF; Sheth, CS, 2021)
"placebo in adolescents with major depressive disorder."1.56Neural effects of a single dose of fluoxetine on resting-state functional connectivity in adolescent depression. ( Capitão, LP; Chapman, R; Cowen, PJ; Filippini, N; Harmer, CJ; James, A; Murphy, SE; Wright, L, 2020)
"The etiology of major depressive disorder (MDD), the leading cause of worldwide disability, is unknown."1.51Activating newborn neurons suppresses depression and anxiety-like behaviors. ( Contractor, A; Dunlop, SR; Kessler, JA; Peng, CY; Tunc-Ozcan, E; Zhu, Y, 2019)
"The prevalence of juvenile major depressive disorder has resulted in a parallel increase in the prescription rates of fluoxetine (FLX) within this age group."1.51Adolescent fluoxetine history impairs spatial memory in adult male, but not female, C57BL/6 mice. ( Alipio, JB; Castillo, SA; Flores-Ramirez, FJ; Garcia-Carachure, I; Iñiguez, SD; Lira, O; Parise, LF; Preciado-Piña, J; Rodriguez, M; Themman, A, 2019)
"The burden of major depressive disorder includes suffering due to symptom severity, functional impairment, and quality of life deficits."1.48ECT Has Greater Efficacy Than Fluoxetine in Alleviating the Burden of Illness for Patients with Major Depressive Disorder: A Taiwanese Pooled Analysis. ( Chen, CC; Huang, CJ; Lin, CH, 2018)
"Vortioxetine is a novel antidepressant capable of improving depressive and cognitive symptoms associated with major depressive disorder (MDD)."1.48Effects of vortioxetine and fluoxetine on the level of Brain Derived Neurotrophic Factors (BDNF) in the hippocampus of chronic unpredictable mild stress-induced depressive rats. ( Ho, CS; Ho, RC; Lu, Y; McIntyre, RS; Wang, W, 2018)
"Women with major depressive disorder during pregnancy often use selective serotonin reuptake inhibitors (SSRIs) antidepressants."1.46Prenatal fluoxetine modifies the behavioral and hormonal responses to stress in male mice: role for glucocorticoid insensitivity. ( Avitsur, R, 2017)
" However, while the chronic administration of the SSRIs escitalopram or fluoxetine elicited a progressive increased in the firing rate of 5-HT neurons in 5-HT2A(+/+) mice, it failed to do so in 5-HT2A(-/-) mutants."1.43Genetic dysfunction of serotonin 2A receptor hampers response to antidepressant drugs: A translational approach. ( Becquemont, L; Colle, R; Corruble, E; Dahan, L; David, D; Gardier, AM; Guiard, BP; Guilloux, JP; Nguyen, HT; Petit, AC; Qesseveur, G; Robert, P; Rotenberg, S; Seif, I; Verstuyft, C, 2016)
"(DSM-IV) criteria for major depressive disorder (MDD) or anxiety disorders participated in study."1.43The Relationship Between Plasma Cytokine Levels and Response to Selective Serotonin Reuptake Inhibitor Treatment in Children and Adolescents with Depression and/or Anxiety Disorders. ( Amitai, M; Apter, A; Carmel, M; Chen, A; Eilat, T; Fennig, S; Michaelovsky, E; Orpaz, N; Taler, M; Weizman, A; Yablonski, M, 2016)
"Adolescents with major depressive disorder (MDD) were found to have deficits in executive function, attention, and memory."1.43Neurocognitive Changes in Selective Serotonin Reuptake Inhibitors-Treated Adolescents with Depression. ( Brent, D; Maalouf, FT; Shehab, AA, 2016)
"Only 30% of major depressive disorder (MDD) patients achieve complete remission with a serotonergic antidepressant (selective serotonin reuptake inhibitor)."1.43Evaluation of interleukin-6 and serotonin as biomarkers to predict response to fluoxetine. ( Manoharan, A; Muthuramalingam, A; Paul, A; Rajkumar, RP; Shewade, DG; Sundaram, R, 2016)
"Up to 30-40 % of the major depressive disorder patients do not respond sufficiently to antidepressant treatment."1.43Serotonin transporter gene (SLC6A4) polymorphisms are associated with response to fluoxetine in south Indian major depressive disorder patients. ( Adithan, S; Manoharan, A; Rajkumar, RP; Shewade, DG, 2016)
" We calculated the ratio of the mean doses for each study and weighted it by the total sample size to find the weighted mean ratio for each drug, which was then used to define the drug׳s dosage equivalent to fluoxetine 40mg/d."1.42Dose equivalents of antidepressants: Evidence-based recommendations from randomized controlled trials. ( Barbui, C; Cipriani, A; Furukawa, TA; Hayasaka, Y; Leucht, S; Magni, LR; Ogawa, Y; Purgato, M; Takeshima, N, 2015)
" On the basis of these data, novel dosing strategies were developed for five antidepressants to mimic the pharmacological profile of the antidepressant with the longest half-life, fluoxetine."1.42The role of 5-HT1A receptors in mediating acute negative effects of antidepressants: implications in pediatric depression. ( Cao, YJ; Hendrix, CW; Kaplin, AI; Rahn, KA, 2015)
"Ketamine is an anesthetic with antidepressant properties."1.42The positive effect on ketamine as a priming adjuvant in antidepressant treatment. ( Dalla, C; Ferreira, C; Kokras, N; Melo, A; Pêgo, JM; Sousa, N; Ventura-Silva, AP, 2015)
"Fluoxetine treatment significantly reduced glucose stimulated insulin secretion (GSIS)."1.40Fluoxetine-induced pancreatic beta cell dysfunction: New insight into the benefits of folic acid in the treatment of depression. ( De Long, NE; Hardy, DB; Holloway, AC; Hyslop, JR; Raha, S, 2014)
"Treatment with fluoxetine/olanzapine demonstrated similar biomarkers of response to monotherapeutic strategies."1.39Neural response to emotional stimuli associated with successful antidepressant treatment and behavioral activation. ( Downar, J; Giacobbe, P; Kennedy, SH; Konarski, JZ; McIntyre, RS; Rizvi, SJ; Salomons, TV, 2013)
" Animal studies indicate that 5-HT1A receptor expression may be reduced by long-term administration of corticosterone."1.39Chronic effects of corticosterone on GIRK1-3 subunits and 5-HT1A receptor expression in rat brain and their reversal by concurrent fluoxetine treatment. ( Cortés, R; García del Caño, G; Mengod, G; Montaña, M; Saenz del Burgo, L; Sallés, J, 2013)
" Moderate to high dosing was the only significant associated factor for FSD (odds ratio = 4."1.38Female sexual dysfunction in patients treated with antidepressant-comparison between escitalopram and fluoxetine. ( Asmidar, D; Guan, NC; Hod, R; Sidi, H, 2012)
"73) and moderate to high dosage of antidepressant (adjusted OR = 4."1.38Hypoactive sexual desire among depressed female patients treated with selective serotonin reuptake inhibitors: a comparison between escitalopram and fluoxetine. ( Asmidar, D; Guan, NC; Hod, R; Jaafar, NR; Sidi, H, 2012)
"Treatments (fluoxetine 10 mg/kg; NaCl 0."1.38Fluoxetine effect on aortic nitric oxide-dependent vasorelaxation in the unpredictable chronic mild stress model of depression in mice. ( Belzung, C; Camus, V; Freslon, JL; Isingrini, E; Machet, MC, 2012)
"Five patients in their first episode of major depressive disorder (MDD) on a single SSRI underwent [(123)I]5-I-A85380- SPECT neuroimaging prior to stopping their medication and again 6 weeks following medication cessation."1.36SSRI antidepressants do not confound single photon emission computed tomography (SPECT) imaging studies using the alpha4beta2 nicotinic acetylcholine receptor [123I]5-I-A85380 ligand: in vivo and in vitro evidence. ( Cavanagh, J; Dewar, D; Patterson, J; Pimlott, S; Wyper, D, 2010)
"Fluoxetine was the most commonly prescribed drug followed by TCAs."1.36Adherence to antidepressant therapy for major depressive patients in a psychiatric hospital in Thailand. ( Bertram, M; Burgess, P; Chaiyakunapruk, N; Prukkanone, B; Vos, T, 2010)
"Fluoxetine is the treatment of first choice."1.35[A place for SSRIs in the treatment of severely depressed children and adolescents]. ( Buitelaar, JK; Roobol, TH, 2008)
"A decision-tree model for the treatment of major depressive disorder was constructed using a Delphi panel."1.35Cost effectiveness of venlafaxine compared with generic fluoxetine or generic amitriptyline in major depressive disorder in the UK. ( Burslem, K; Greenstreet, L; Knight, C; Lenox-Smith, A, 2009)
"All patients had a diagnosis of major depressive disorder as defined by DSM-III or DSM-IV criteria."1.35An integrated analysis of olanzapine/fluoxetine combination in clinical trials of treatment-resistant depression. ( Campbell, GM; Case, M; Corya, SA; Henley, DB; Osuntokun, O; Thase, ME; Trivedi, MH; Watson, SB, 2009)
"Seventy seven patients with major depressive disorder (MDD), divided into two groups were included in the study."1.35Oxidative stress parameters after combined fluoxetine and acetylsalicylic acid therapy in depressive patients. ( Bieńkiewicz, M; Gałecka, E; Gałecki, P; Szemraj, J; Zboralski, K, 2009)
"Patients who met the criteria for major depressive disorder were treated for 6 weeks with fluoxetine, paroxetine or citalopram."1.355-HTR1A, 5-HTR2A, 5-HTR6, TPH1 and TPH2 polymorphisms and major depression. ( Huhtala, H; Illi, A; Kampman, O; Lehtimäki, T; Leinonen, E; Mononen, N; Poutanen, O; Setälä-Soikkeli, E; Viikki, M, 2009)
"Patients with major depressive disorder (DSM-IV) who showed favorable treatment response to venlafaxine (mean +/- SD dose = 116."1.35Time to rehospitalization in patients with major depressive disorder taking venlafaxine or fluoxetine. ( Chen, MC; Lane, HY; Lin, CH; Lin, CY; Lin, KS, 2008)
"The most common withdrawal symptoms among those with cannabis dependence were craving (82%), irritability (76%), restlessness (58%), anxiety (55%), and depression (52%)."1.35Cannabis withdrawal is common among treatment-seeking adolescents with cannabis dependence and major depression, and is associated with rapid relapse to dependence. ( Chung, T; Clark, DB; Cornelius, JR; Martin, C; Wood, DS, 2008)
"Salivary serotonin in patients with major depressive disorder showed clear circadian rhythm."1.34Circadian rhythm of salivary serotonin in patients with major depressive disorder. ( Bao, AM; Liu, YJ; Tan, ZL; Tao, M; Zhou, JN, 2007)
" In this study, we investigated plasma concentrations of norepinephrine, epinephrine and dopamine after acute and chronic administration of fluoxetine in depressive patients."1.33Plasma catecholamine levels after fluoxetine treatment in depressive patients. ( Auteri, A; Blardi, P; Castrogiovanni, P; de Lalla, A; Dell'Erba, A; Iapichino, S, 2005)
"Although adverse events are a key factor in compliance, their evolution during treatment with antidepressants is poorly documented."1.33What happens with adverse events during 6 months of treatment with selective serotonin reuptake inhibitors? ( Albert, A; De Bruyckere, K; Demyttenaere, K; Dewé, W; Mesters, P; Sangeleer, M, 2005)
"Patients with major depressive disorder showed pronounced psychomotor retardation in the visuomotor tasks."1.33[Psychomotor retardation in depression assessed by visuomotor tasks. Overview and achievements of ten years' research]. ( Hulstijn, W; Pier, MP; Sabbe, BG; van Hoof, JJ, 2006)
"Of 60 AIDS patients, 32 patients had received highly active antiretroviral therapy and received subsequent assessment of lymphocyte cell counts 1 month later."1.33Lymphocyte subsets and viral load in male AIDS patients with major depression: naturalistic study. ( Huang, TL; Leu, HS; Liu, JW, 2006)
"In addition, major depressive disorder (MDD) patients were found to have significantly higher plasma nitrate concentrations than normal subjects, an index of NO production, in comparison to normal subjects."1.32Association analysis for neuronal nitric oxide synthase gene polymorphism with major depression and fluoxetine response. ( Chen, TJ; Hong, CJ; Liou, YJ; Tsai, SJ; Wang, YC; Yu, YW, 2003)
" Treatment-emergent adverse effects were assessed at each study visit."1.32Serotonin transporter polymorphisms and adverse effects with fluoxetine treatment. ( Fava, M; Lamon-Fava, S; Lin, KM; Mischoulon, D; Perlis, RH; Rosenbaum, JF; Smoller, JW; Wan, YJ, 2003)
"For fluoxetine-treated patients, the odds ratio for completing therapy relative to tricyclic antidepressant-treated patients dropped from 3."1.31A retrospective analysis of the revocation of prior authorization restrictions and the use of antidepressant medications for treating major depressive disorder. ( Croghan, TW; McCombs, JS; Shi, L; Stimmel, GL, 2002)
" However, there is no data on the dosage of selective serotonin uptake inhibitors (SSRIs) required to maintain symptom resolution in women treated for major depression during pregnancy."1.31Dose of selective serotonin uptake inhibitors across pregnancy: clinical implications. ( Hostetter, A; Llewellyn, A; McLaughlin, E; Stowe, ZN; Strader, JR, 2000)
" Fluvoxamine brain elimination half-life (79 +/- 24 hours; n = 4) was significantly shorter than that of CF-norfluoxetine (382 +/- 48 hours; n = 2)."1.31Brain pharmacokinetics and tissue distribution in vivo of fluvoxamine and fluoxetine by fluorine magnetic resonance spectroscopy. ( Bolo, NR; Hodé, Y; Lainé, E; Macher, JP; Nédélec, JF; Wagner, G, 2000)
"A continuing challenge in the treatment of depression is how to determine whether an effective drug has been selected for a particular patient, given that individuals will respond to some antidepressants but not others."1.31Prefrontal changes and treatment response prediction in depression. ( Cook, IA; Leuchter, AF, 2001)
"Mood disorders are the leading causes of morbidity and mortality in children and adolescence."1.31Mood disorders in children and adolescents: psychopharmacological treatment. ( Emslie, GJ; Mayes, TL, 2001)
"Fluoxetine levels were also detectable in platelets, with a time variation similar to plasma values."1.31Serotonin and fluoxetine levels in plasma and platelets after fluoxetine treatment in depressive patients. ( Auteri, A; Blardi, P; Castrogiovanni, P; De Lalla, A; Dell'Erba, A; Di Muro, A; Iapichino, S; Leo, A, 2002)
"Patients meeting DSM-IV criteria for major depressive disorder (MDD) entered randomized, controlled medication trials."1.30Defense mechanisms and personality in depression. ( Blanco, C; Mullen, LS; Roose, SP; Vaughan, R; Vaughan, SC, 1999)

Research

Studies (699)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's22 (3.15)18.2507
2000's320 (45.78)29.6817
2010's288 (41.20)24.3611
2020's69 (9.87)2.80

Authors

AuthorsStudies
Li, Z2
Cai, G1
Fang, F1
Li, W4
Fan, M1
Lian, J1
Qiu, Y1
Xu, X1
Lv, X1
Li, Y3
Zheng, R1
Wang, Y6
Zhang, G1
Liu, Z2
Huang, Z1
Zhang, L1
Zastrozhin, MS1
Skryabin, VY1
Petukhov, AE1
Pankratenko, EP1
Grishina, EA1
Ryzhikova, KA1
Torrado, MV1
Shipitsyn, VV1
Bryun, EA1
Sychev, DA1
Li, VW1
Morton, E2
Michalak, EE4
Tam, EM4
Levitt, AJ3
Levitan, RD5
Cheung, A3
Morehouse, R4
Ramasubbu, R4
Yatham, LN4
Lam, RW4
García-García, ML1
Tovilla-Zárate, CA1
Villar-Soto, M1
Juárez-Rojop, IE1
González-Castro, TB1
Genis-Mendoza, AD1
Ramos-Méndez, MÁ1
López-Nárvaez, ML1
Saucedo-Osti, AS1
Ruiz-Quiñones, JA1
Martinez-Magaña, JJ1
Ayyash, A1
Holloway, AC2
Findling, RL2
DelBello, MP1
Zuddas, A1
Emslie, GJ24
Ettrup, A1
Petersen, ML1
Schmidt, SN1
Rosen, M1
Fang, Y2
Ding, X1
Zhang, Y7
Cai, L1
Ge, Y1
Ma, K1
Xu, R1
Li, S2
Song, M1
Zhu, H1
Liu, J3
Ding, J1
Lu, M1
Hu, G1
Athreya, AP1
Vande Voort, JL1
Shekunov, J1
Rackley, SJ1
Leffler, JM1
McKean, AJ1
Romanowicz, M1
Kennard, BD17
Mayes, T9
Trivedi, M2
Wang, L1
Weinshilboum, RM1
Bobo, WV2
Croarkin, PE5
Teng, T2
Zhang, Z1
Yin, B1
Guo, T1
Wang, X5
Hu, J3
Ran, X1
Dai, Q1
Zhou, X3
Liang, L1
Wang, H2
Hu, Y2
Bian, H1
Xiao, L2
Wang, G3
Capitão, LP3
Chapman, R3
Filippini, N2
Wright, L2
Murphy, SE4
James, A3
Cowen, PJ3
Harmer, CJ3
Hermanns, T1
Graf-Boxhorn, S1
Poeck, B1
Strauss, R1
Filipović, D4
Novak, B2
Xiao, J2
Yan, Y3
Yeoh, K1
Turck, CW3
Jang, DY1
Yang, B1
You, MJ1
Rim, C1
Kim, HJ1
Sung, S1
Kwon, MS1
de Melo Martins, GM1
Petersen, BD1
Rübensam, G1
da Silva, JMK1
Gaspary, KV1
Wiprich, MT1
Altenhofen, S1
Bonan, CD1
Gaber, A1
Alsanie, WF1
Alhomrani, M1
Alamri, AS1
Alyami, H1
Shakya, S1
Habeeballah, H1
Alkhatabi, HA1
Felimban, RI1
Alamri, A1
Alhabeeb, AA1
Raafat, BM1
Refat, MS1
Kishi, T1
Ikuta, T1
Sakuma, K1
Okuya, M1
Hatano, M1
Matsuda, Y1
Iwata, N1
Park, DI1
Horn, A1
Golub, M1
Tsujii, T1
Sakurai, H1
Takeuchi, H1
Suzuki, T1
Mimura, M1
Uchida, H1
Costina, V2
Findeisen, P2
Inta, D2
Amada, N1
Hirose, T1
Suzuki, M1
Kakumoto, Y1
Futamura, T3
Maeda, K1
Kikuchi, T1
Russell, J1
Arwood, MJ1
Toro-Pagán, NMD1
Amin, NS1
Cambridge, MD1
Turgeon, J1
Michaud, V1
Nichols, AL1
Blumenfeld, Z1
Luebbert, L1
Knox, HJ1
Muthusamy, AK1
Marvin, JS1
Kim, CH1
Grant, SN1
Walton, DP1
Cohen, BN1
Hammar, R1
Looger, L1
Artursson, P1
Dougherty, DA1
Lester, HA1
Li, L2
Ma, S2
Wang, J1
Chen, Y5
Wang, F2
Zheng, M1
Zhang, K1
Miao, S1
Shi, X2
Tsai, HJ1
Yang, WC2
Tsai, SJ13
Lin, CH16
Yang, AC1
Doan, J1
Defaix, C1
Mendez-David, I1
Gardier, AM2
Colle, R2
Corruble, E3
McGowan, JC1
David, DJ1
Guilloux, JP2
Tritschler, L1
Bernardi, RE1
Rao, Y1
Yang, R2
Zhao, J1
Cao, Q1
Madjid, N1
Lidell, V1
Nordvall, G1
Lindskog, M1
Ögren, SO1
Forsell, P1
Sandin, J1
Almeida, OP1
Orrico-Sanchez, A1
Guiard, BP2
Manta, S1
Callebert, J1
Launay, JM3
Louis, F1
Paccard, A1
Gruszczynski, C1
Betancur, C1
Vialou, V1
Gautron, S1
Wilson, GC1
Keitsch, S1
Soddemann, M1
Wilker, B1
Edwards, MJ1
Gulbins, E2
He, Y1
Gan, X1
Li, X1
Wang, T1
Li, J3
Lei, T1
Huang, Y1
Liu, R1
Chen, F1
Xie, Y1
Ouyang, X1
Fricke, HP1
Krajco, CJ1
Perry, MJ1
Desorcy-Scherer, KM1
Wake, LA1
Charles, JF1
Hernandez, LL1
Yan, T1
Goldman, RD1
Tunc-Ozcan, E1
Peng, CY1
Zhu, Y1
Dunlop, SR1
Contractor, A1
Kessler, JA1
Zimmerman, M1
Balling, C1
Chelminski, I1
Dalrymple, K1
Chen, C1
Shan, W1
Boland, EM1
Vittengl, JR14
Clark, LA11
Thase, ME29
Jarrett, RB18
Becerril-Villanueva, E2
Pérez-Sánchez, G2
Alvarez-Herrera, S2
Girón-Pérez, MI1
Arreola, R2
Cruz-Fuentes, C2
Palacios, L2
de la Peña, FR1
Pavón, L2
Levy, R1
Mathai, M1
Chatterjee, P1
Ongeri, L1
Njuguna, S1
Onyango, D1
Akena, D2
Rota, G1
Otieno, A1
Neylan, TC1
Lukwata, H1
Kahn, JG1
Cohen, CR1
Bukusi, D1
Aarons, GA1
Burger, R2
Blum, K1
Nahum-Shani, I1
McCulloch, CE1
Meffert, SM1
Amitai, M3
Taler, M3
Ben-Baruch, R2
Lebow, M2
Rotkopf, R1
Apter, A4
Fennig, S3
Weizman, A3
Chen, A3
Kertys, M1
Krivosova, M1
Ondrejka, I1
Hrtanek, I1
Tonhajzerova, I1
Mokry, J1
Liao, XM1
Su, YA1
Yu, X4
Si, TM1
Gutsmiedl, K1
Krause, M1
Bighelli, I1
Schneider-Thoma, J1
Leucht, S3
Bondar, J1
Caye, A1
Chekroud, AM2
Kieling, C1
Chen, CC9
Huang, CJ4
Kauffman, KM1
Dolata, J1
Figueroa, M1
Gunzler, D1
Huml, A1
Pencak, J1
Sehgal, AR1
Sajatovic, M1
Lorenzo-Luaces, L1
Rodriguez-Quintana, N1
Riley, TN1
Weisz, JR1
Almeida, IB1
Gomes, IA1
Shanmugam, S1
de Moura, TR1
Magalhães, LS1
de Aquino, LAG1
de Souza Araújo, AA1
Oliveira, PD1
Santos, MRV1
Xue, SS1
Zhou, CH1
Xue, F1
Liu, L2
Cai, YH1
Luo, JF1
Tan, QR2
Wang, HN1
Peng, ZW1
Zhang, H1
Li, K1
Zhao, Y1
Sun, J1
Lin, G1
Martin, V1
Mathieu, L1
Diaz, J1
Salman, H1
Alterio, J1
Chevarin, C1
Lanfumey, L1
Hamon, M1
Austin, MC1
Darmon, M1
Stockmeier, CA2
Masson, J1
Levitt, A2
Suresh, V1
Mills, JA2
Strawn, JR3
Stutzman, S1
Atluru, A1
Gunlicks-Stoessel, M2
Klimes-Dougan, B2
VanZomeren, A1
Jha, MK1
Minhajuddin, A4
Coulombe, J1
Moodie, EEM1
Shortreed, SM1
Renoux, C1
Gonçalves, CL1
Abelaira, HM1
Rosa, T1
de Moura, AB1
Veron, DC1
Borba, LA1
Botelho, MEM1
Goldim, MP1
Garbossa, L1
Fileti, ME1
Petronilho, F1
Ignácio, ZM1
Quevedo, J2
Réus, GZ1
Taylor, R1
Bodoukhin, N1
Botros, M1
Luca, L1
Gergues, MM1
Yohn, CN1
Bharadia, A1
Levinstein, MR1
Samuels, BA1
Terstege, DJ1
MacDonald, DS1
Tasker, RA1
Huzian, O1
Baka, J1
Csakvari, E1
Dobos, N1
Leranth, C1
Siklos, L1
Duman, RS2
Farkas, T1
Hajszan, T1
Witt, K1
Madsen, T1
Berk, M5
Dean, O1
Chanen, A1
McGorry, PD3
Cotton, S1
Davey, CG3
Hetrick, S1
Zhou, J1
Feng, L1
Zhu, X1
Shi, H1
Chen, R1
Boyce, P1
Hetrick, SE4
McKenzie, JE1
Bailey, AP1
Sharma, V2
Moller, CI1
Badcock, PB1
Cox, GR1
Merry, SN1
Meader, N1
O'Dor, SL1
Washburn, J1
Howard, KR2
Reinecke, MA12
Qiu, W1
Go, KA1
Lamers, Y1
Galea, LAM1
Kanekar, S1
Ettaro, R1
Hoffman, MD1
Ombach, HJ1
Brown, J1
Lynch, C1
Sheth, CS1
Renshaw, PF6
Anna Clark, L1
Avitsur, R1
Gosselin, T1
Le Guisquet, AM1
Brizard, B1
Hommet, C1
Minier, F1
Belzung, C2
Çetin, B1
Ergelen, M1
Nouraei, H1
Firouzabadi, N2
Mandegary, A1
Zomorrodian, K1
Bahramali, E2
Shayesteh, MRH1
Ansari, S1
Ma, M2
Ren, Q2
Fujita, Y1
Yang, C2
Dong, C5
Ohgi, Y2
Hashimoto, K2
Gupta, K1
Gupta, R2
Bhatia, MS2
Tripathi, AK2
Gupta, LK2
Holl, K1
He, H1
Wedemeyer, M1
Clopton, L1
Wert, S1
Meckes, JK1
Cheng, R1
Kastner, A1
Palmer, AA1
Redei, EE1
Solberg Woods, LC1
Wang, FC2
Lu, MJ2
Dold, M1
Bartova, L1
Rupprecht, R2
Kasper, S4
Hales, CA1
Houghton, CJ1
Robinson, ESJ1
Weihs, KL2
Murphy, W1
Abbas, R1
Chiles, D2
England, RD1
Ramaker, S2
Wajsbrot, DB2
Stewart, RM2
Wong, JWY2
Runions, KC2
Rao, P2
Moore, JK2
Davies, SR1
von Ungern-Sternberg, BS1
Sommerfield, D1
Zepf, FD2
Dong, L1
Xu, L1
Lv, Y1
Liu, H2
Xu, F1
Wu, J1
Zheng, Q1
Chang, HH4
Chen, PS4
Cheng, YW1
Wang, TY1
Yang, YK4
Lu, RB4
Lu, Y2
Ho, CS1
McIntyre, RS4
Wang, W2
Ho, RC1
Aguilar-Valles, A1
Haji, N1
De Gregorio, D1
Matta-Camacho, E1
Eslamizade, MJ1
Popic, J1
Cao, R1
Rummel, C1
Tanti, A1
Wiebe, S1
Nuñez, N1
Comai, S1
Nadon, R1
Luheshi, G1
Mechawar, N1
Turecki, G1
Lacaille, JC1
Gobbi, G1
Sonenberg, N1
Gassó, P4
Blázquez, A4
Rodríguez, N2
Boloc, D2
Torres, T1
Mas, S4
Lafuente, A4
Lázaro, L4
Hood, SD1
Foster, S2
Mohler-Kuo, M2
Smits, JAJ1
Lewis, CP1
Camsari, DD1
Sonmez, AI1
Nandakumar, AL1
Gresbrink, MA1
Daskalakis, ZJ1
Stevanovic, D1
Zalsman, G2
Rodrigues, FTS1
de Souza, MRM1
Lima, CNC1
da Silva, FER1
Costa, DVDS1
Dos Santos, CC1
Miyajima, F1
de Sousa, FCF1
Vasconcelos, SMM1
Barichello, T1
Maes, M3
de Lucena, DF1
Macedo, D1
Lin, HS2
Chou, LS2
Tang, SH1
Narasimha, VL1
Basavaraju, R1
Mangalore, S1
Mehta, UM1
Cao, X1
Zang, W1
Tan, S1
Ou, CQ1
Shen, X1
Gao, T1
Zhao, L1
Martínez-Levy, G1
Hernández-Gutiérrez, ME1
Velasco-Velásquez, MA1
de la Peña, F1
Harvey, CJ1
Scott, K1
Lewis, CC3
Marti, CN1
Flores-Ramirez, FJ1
Parise, LF1
Alipio, JB1
Garcia-Carachure, I1
Castillo, SA1
Rodriguez, M1
Themman, A1
Lira, O1
Preciado-Piña, J1
Iñiguez, SD1
Tay, L1
Hothorn, T1
Seibold, H1
Chappell, P1
Wei, YB1
McCarthy, M1
Ren, H1
Carrillo-Roa, T1
Shekhtman, T1
DeModena, A1
Liu, JJ1
Leckband, SG1
Mors, O1
Rietschel, M1
Henigsberg, N1
Cattaneo, A1
Binder, EB1
Aitchison, KJ1
Kelsoe, JR1
Waldron, EM1
Hudd, TR1
Blake, CS1
Rimola-Dejesus, Y1
Nguyen, TT1
Zaiken, K1
Park, C1
Eckshtain, D1
Lee, S1
Reigstad, K1
Mufson, L1
Weisz, J1
Lu, Q1
Mouri, A1
Yang, Y1
Kunisawa, K1
Teshigawara, T1
Hirakawa, M1
Mori, Y1
Yamamoto, Y1
Libo, Z1
Nabeshima, T1
Saito, K1
Hieronymus, F1
Lisinski, A1
Nilsson, S1
Eriksson, E1
Chanen, AM2
Cotton, SM2
Ratheesh, A2
Amminger, GP2
Koutsogiannis, J1
Phelan, M2
Mullen, E1
Harrison, BJ2
Rice, S1
Parker, AG2
Dean, OM2
Weller, A1
Kerr, M1
Quinn, AL1
Catania, L1
Kazantzis, N1
Demyttenaere, K2
Hale, A2
Quera-Salva, MA1
Picarel-Blanchot, F1
Venkatasubramanian, R1
Kumar, CN1
Pandey, RS1
Amr, M1
El-Mogy, A1
Shams, T1
Vieira, K1
Lakhan, SE1
Gelenberg, AJ1
Dunner, DL2
Rothschild, AJ5
Pedersen, R5
Dorries, KM1
Ninan, PT4
Ranjbar, E1
Shams, J1
Sabetkasaei, M1
M-Shirazi, M1
Rashidkhani, B1
Mostafavi, A1
Bornak, E1
Nasrollahzadeh, J1
Branchi, I2
Santarelli, S1
Capoccia, S1
Poggini, S2
D'Andrea, I1
Cirulli, F2
Alleva, E1
Chi, MH3
Lee, IH2
Tsai, HC1
Gean, PW3
Shahsavand-Ananloo, E1
Berenji, F1
Sadeghniiat, K1
Alimadadi, A1
Zahiroddin, AR1
Tabatabaee, M1
Abbasi-Asl, M1
Ghaeli, P3
Nardi, B1
Francesconi, G1
Catena-Dell'osso, M1
Bellantuono, C1
Gudayol-Ferré, E4
Guàrdia-Olmos, J4
Peró-Cebollero, M2
Herrera-Guzmán, I3
Camarena, B3
Cortés-Penagos, C3
Herrera-Abarca, JE3
Martínez-Medina, P3
Sanmukhani, J1
Satodia, V1
Trivedi, J1
Patel, T1
Tiwari, D1
Panchal, B1
Goel, A1
Tripathi, CB1
Cao, Y2
Shen, J2
Malison, RT2
Luo, X2
Cullen, KR2
Westlund, MK1
LaRiviere, LL1
Rizvi, SJ1
Salomons, TV1
Konarski, JZ1
Downar, J1
Giacobbe, P1
Kennedy, SH3
Yen, YC1
Chen, MC4
Gershenfeld, H1
Friedman, ES5
Quilty, LC4
Robinson, JJ1
Rolland, JP3
Fruyt, FD1
Rouillon, F2
Bagby, RM4
Bastos, AG1
Guimarães, LS1
Trentini, CM1
Ghanizadeh, A4
Hedayati, A1
Yu, L1
Xie, J1
Chen, J4
Wei, Q1
Miller, MC1
Heller, AS3
Johnstone, T3
Peterson, MJ3
Kolden, GG3
Kalin, NH3
Davidson, RJ3
Tuman, TC1
Demir, N1
Topal, Z1
Tuman, BA1
Tufan, EA1
Kornstein, SG5
Pedersen, RD1
Holland, PJ1
Nemeroff, CB3
Trivedi, MH7
Keller, MB5
Kong, L1
Wu, F1
Tang, Y1
Ren, L1
Kong, D1
Liu, Y4
Xu, K1
Asbun-Bojalil, J2
Lira-Islas, Y1
Reyes-Ponce, C1
Dean, B3
Tawadros, N1
Seo, MS1
Jeon, WJ2
Everall, I1
Scarr, E3
Gibbons, A2
Shu, L2
Sulaiman, AH1
Huang, YS1
Fones Soon Leng, C1
Crutel, VS1
Kim, YS1
Brenner, SL1
Burns, BJ3
Curry, JF8
Silva, SG16
Kratochvil, CJ13
Domino, ME3
Weck, F1
Plana, MT3
Méndez, I1
Torra, M1
Arnaiz, JA2
Wong, J2
Shorter, E1
Brunner, E1
Tohen, M2
Osuntokun, O3
Landry, J1
Atkinson, SD1
Prakash, A5
Zhang, Q3
Pangallo, BA3
Bangs, ME3
March, JS20
Dembo, JS1
Philip, NS1
Mayes, TL15
Nakonezny, PA7
Jones, JM3
Foxwell, AA2
King, J2
Cristancho, MA1
Rutherford, BR1
Wall, MM1
Glass, A1
Stewart, JW7
De Long, NE1
Hyslop, JR1
Raha, S1
Hardy, DB1
Qu, W1
Gu, S1
Luo, H3
Tang, Q1
Guo, J1
Thibodeau, MA1
De Fruyt, F3
De Bolle, M2
Ventura-Juncá, R1
Symon, A1
López, P1
Fiedler, JL1
Rojas, G1
Heskia, C1
Lara, P1
Marín, F1
Guajardo, V1
Araya, AV1
Sasso, J1
Herrera, L1
Isa, A1
Bernstein, I1
Kennard, B9
Emslie, G12
Wong, ML5
Flores, DL2
Ehrhart-Bornstein, M2
Bornstein, S2
Arcos-Burgos, M2
Licinio, J6
Birmaher, B7
Kerr, MJ1
Yuen, K1
Schäfer, MR1
Piskulic, D1
Harrigan, S1
Mackinnon, AJ1
Citrome, L1
Chen, JX1
Yao, LH1
Xu, BB1
Qian, K1
Wang, HL1
Liu, ZC3
Wang, XP1
Wang, GH1
Talaei, A1
Hassanpour Moghadam, M1
Sajadi Tabassi, SA1
Mohajeri, SA1
Wagner, GJ1
Ngo, VK1
Nakasujja, N1
Aunon, F1
Musisi, S1
Purgato, M2
Gastaldon, C1
Papola, D1
Magni, LR2
Rossi, G1
Barbui, C3
Peselow, ED1
Tobia, G1
Karamians, R1
Pizano, D1
IsHak, WW1
Pehrson, AL1
Sanchez, C1
Wang, R1
Schoenfeld, DA1
Hoeppner, B1
Evins, AE1
Macías-Cortés, Edel C1
Llanes-González, L1
Aguilar-Faisal, L1
McCall, WV5
Hong, J1
Novick, D1
Montgomery, W1
Moneta, MV1
Dueñas, H1
Peng, X1
Haro, JM2
Yucel, A1
Yucel, N1
Ozcan, H1
Gulec, M1
Aydin, A1
Uher, R1
Ripke, S1
Müller-Myhsok, B1
Lewis, CM1
Perlis, RH6
Gougol, A1
Zareh-Mohammadi, N1
Raheb, S1
Farokhnia, M1
Salimi, S1
Iranpour, N1
Yekehtaz, H1
Akhondzadeh, S6
Almeida Montes, LG1
Prado Alcántara, H1
Portillo Cedeño, BA1
Hernández García, AO1
Fuentes Rojas, PE1
Heimberg, RG1
Vitiello, B26
Hayasaka, Y1
Ogawa, Y1
Takeshima, N1
Cipriani, A3
Furukawa, TA1
Rahn, KA1
Cao, YJ1
Hendrix, CW1
Kaplin, AI1
Wells, TG1
Melo, A1
Kokras, N1
Dalla, C1
Ferreira, C1
Ventura-Silva, AP1
Sousa, N1
Pêgo, JM1
Smagula, SF1
Meng, H1
Cao, W1
Qiu, T1
Brown, GK1
Borman, PD2
Gibbons, AS1
Ghosh, R1
McOmish, CE1
Pavey, G1
Hopper, S1
Udawela, M1
Jakubovski, E1
Varigonda, AL1
Freemantle, N1
Taylor, MJ1
Bloch, MH1
Peters, AT1
Jacobs, RH3
Feldhaus, C1
Henry, DB1
Albano, AM4
Langenecker, SA1
Cheung, AH1
Moore, J1
Sahraian, A1
Jelodar, S1
Javid, Z1
Mowla, A3
Ahmadzadeh, L1
Alboni, S1
van Dijk, RM1
Milior, G1
Perrotta, M1
Drenth, T1
Brunello, N1
Wolfer, DP1
Limatola, C1
Amrein, I1
Maggi, L1
Qesseveur, G1
Petit, AC1
Nguyen, HT1
Dahan, L1
Rotenberg, S1
Seif, I1
Robert, P1
David, D2
Verstuyft, C1
Becquemont, L1
Carmel, M1
Michaelovsky, E1
Eilat, T1
Yablonski, M1
Orpaz, N1
Cawkwell, P1
Lawler, A1
Maneta, E1
Coffey, BJ1
Liu, SK1
Shehab, AA1
Brent, D3
Maalouf, FT1
Guo, X1
Li, CS1
Manoharan, A2
Rajkumar, RP2
Shewade, DG2
Sundaram, R1
Muthuramalingam, A1
Paul, A1
Salagre, E1
Fernandes, BS1
Dodd, S1
Brownstein, DJ1
Yavarian, I1
Shayesteh, MR1
Erfani, N1
Shoushtari, AA1
Asadpour, R1
Del Giovane, C1
Qin, B1
Whittington, C1
Coghill, D1
Hazell, P1
Cuijpers, P1
Pu, J1
Cohen, D1
Ravindran, AV2
Michael, KD1
Yang, L1
Xie, P1
Nassan, M1
Nicholson, WT1
Elliott, MA1
Rohrer Vitek, CR1
Black, JL1
Frye, MA2
Taguchi, R1
Shikata, K1
Furuya, Y1
Ino, M1
Shin, K1
Shibata, H1
Adithan, S1
Arnedt, JT1
Swanson, LM2
Dopp, RR1
Bertram, HS1
Mooney, AJ1
Huntley, ED2
Hoffmann, RF1
Armitage, R2
Cui, J1
Yang, K1
Wang, JL1
Li, H1
Eniola, K1
Bacigalupo, A1
Mounsey, A1
Hung, YY1
Lin, CC2
Kang, HY1
Huang, TL2
Das, A1
Maiti, A1
Sinha, S1
DeLucia, V1
Kelsberg, G1
Safranek, S1
Solmi, M1
Veronese, N1
Zaninotto, L1
van der Loos, ML1
Gao, K1
Schaffer, A2
Reis, C1
Normann, C1
Anghelescu, IG1
Correll, CU1
Ordóñez, AE1
Wang, Z3
Liu, X2
Nie, G2
Jorgenson, K1
Sohn, KC1
Huang, R2
Liu, M2
Liu, B2
Kong, J2
Byun, JS1
Liang, Y1
Park, J1
Rhein, C1
Reichel, M1
Kramer, M1
Rotter, A1
Lenz, B1
Mühle, C1
Kornhuber, J1
Zhang, JC1
Yao, W1
Monteagudo, A1
Gueorguieva, R2
Krystal, JH3
Chandradasa, M1
Champika, L1
Burgess, HJ1
Bertram, H1
Mooney, A1
Zollars, J1
Dopp, R1
Hoffmann, R1
Todd Arnedt, J1
Liu, CC2
Liang, KY1
Liao, SC1
Gau, YT1
Hong, CJ10
Liou, YJ7
Yu, YW10
Chen, TJ10
Carvalho, LA1
Gorenstein, C1
Moreno, R1
Pariante, C1
Markus, RP1
Candrian, M2
Schwartz, F3
Farabaugh, A7
Ehlert, U1
Fava, M55
Gorlyn, M1
Keilp, JG1
Grunebaum, MF1
Taylor, BP3
Oquendo, MA1
Bruder, GE2
Mann, JJ5
Preskorn, SH1
Katona, C1
Salminen, JK5
Karlsson, H5
Hietala, J5
Kajander, J5
Aalto, S3
Markkula, J5
Rasi-Hakala, H5
Toikka, T1
Garakani, A1
Martinez, JM1
Marcus, S1
Weaver, J1
Rickels, K1
Hirschowitz, J1
Resler, G1
Lavie, R1
Campos, J1
Mata, S2
Urbina, M4
García, A1
Apitz, R1
Lima, L4
Roobol, TH1
Buitelaar, JK1
Papakostas, GI24
McGrath, P2
Stewart, J2
Charles, D2
Mischoulon, D17
Dording, C3
Fisar, Z1
Kalisová, L1
Paclt, I1
Anders, M1
Vevera, J1
Boulton, DW1
Balch, AH1
Royzman, K1
Patel, CG1
Berman, RM4
Mallikaarjun, S1
Reeves, RA1
Kongsakon, R1
Bunchapattanasakda, C1
Kocsis, JH4
Ahmed, S1
Thase, M1
Dunlop, BW3
Yan, B1
Li, T3
Keller, M4
Pedrelli, P2
Feldman, GC1
Vorono, S1
Petersen, T12
Nightingale-Teresi, J3
Hughes, JL4
Tao, R8
Stewart, SM3
Andeweg, J1
van Grinsven, M1
Sava, FA1
Yates, BT1
Lupu, V1
Szentagotai, A1
Nakonezny, P1
Hughes, C5
Hunter, AM8
Ravikumar, S1
Cook, IA13
Leuchter, AF14
Tonev, S2
Rohde, P13
Reinecke, M8
March, J12
Brent, DA6
Clarke, GN2
Asarnow, J1
Spirito, A2
Ritz, L2
Iyengar, S3
Ryan, ND5
Zelazny, J2
Onorato, M2
Debar, LL1
McCracken, JT2
Strober, M2
Suddath, R2
Leonard, H2
Porta, G4
Sheehan, DV1
Entsuah, R3
Lenox-Smith, A1
Greenstreet, L1
Burslem, K1
Knight, C1
Hou, SJ2
Yen, FC2
Henley, DB2
Case, M4
Watson, SB2
Campbell, GM1
Corya, SA5
Gałecki, P2
Szemraj, J1
Bieńkiewicz, M1
Zboralski, K1
Gałecka, E2
Cornelius, JR6
Bukstein, OG5
Wood, DS4
Kirisci, L1
Douaihy, A2
Clark, DB5
Becker-Weidman, EG1
Martinovich, Z1
Harley, J1
Roberts, R1
Joyce, P1
Mulder, R1
Luty, S1
Frampton, C1
Kennedy, M1
Filho, AS1
Carvalho, DL1
Tumas, V1
Hetem, LA1
Ferrari, MC1
Crippa, JA1
Foster, EM1
Simons, AD4
Small, DM1
Murakami, JL2
High, RR1
Kronström, K2
Vahlberg, T2
Jafari, S1
Raisi, F3
Nasehi, AA3
Ghoreishi, A1
Salehi, B1
Mohebbi-Rasa, S1
Raznahan, M2
Kamalipour, A1
Dording, CM4
Sinicropi-Yao, L2
Papakostas, G1
Matthews, JD4
Nierenberg, AA18
Johnstone, JM1
Luty, SE9
Carter, JD3
Mulder, RT10
Frampton, CM2
Joyce, PR10
Rozzini, L1
Chilovi, BV1
Conti, M1
Bertoletti, E1
Zanetti, M1
Trabucchi, M1
Padovani, A1
Posner, K2
May, DE4
Yang, H1
Chuzi, S2
Johnson, D1
Clain, A5
Baer, L10
McGrath, PJ7
de Carvalho, GA1
Bahls, SC1
Boeving, A1
Graf, H1
Illi, A1
Setälä-Soikkeli, E1
Viikki, M1
Poutanen, O1
Huhtala, H1
Mononen, N1
Lehtimäki, T1
Leinonen, E1
Kampman, O1
Muthén, BO1
Shelton, RC3
Sussman, N1
Chen, ML1
Silva, S13
Curry, J9
Wells, K7
Fairbank, J3
Burns, B5
Domino, M3
Severe, J3
Riedal, K1
Goldman, M1
Feeny, N6
Findling, R1
Stull, S1
Baab, S1
Weller, EB3
Robbins, M1
Weller, RA2
Jessani, N1
Waslick, B4
Sweeney, M2
Dublin, R1
Walkup, J7
Ginsburg, G5
Kastelic, E3
Koo, H1
Kratochvil, C8
May, D4
LaGrone, R1
Vaughan, B1
Hirsch, GS1
Podniesinki, E1
Chu, A1
Reincecke, M1
Leventhal, B1
Rogers, G1
Jacobs, R3
Pathak, S8
Wells, J1
Lavanier, SA1
Danielyan, A1
Simons, A6
Grimm, J1
Frank, S1
Rosenberg, D3
Benazon, N1
Butkus, M1
Bartoi, M1
Song, C1
Halbreich, U2
Han, C1
Leonard, BE1
Gelenberg, A2
Holland, P1
Shelton, R1
Zajecka, JM1
Goldstein, C1
Cavanagh, J1
Patterson, J1
Pimlott, S1
Wyper, D1
Dewar, D1
Başterzi, AD1
Yazici, K1
Buturak, V1
Cimen, B1
Yazici, A1
Eskandari, G1
Tot Acar, S1
Taşdelen, B1
Madaan, V1
Puumala, SE1
Kepley, H1
Ameral, VE2
Brintz, C1
Smith, WT2
Londborg, PD2
Glaudin, V2
Painter, JR2
Hirvonen, J2
Någren, K2
Benazzi, F3
Barraco, A1
Feyissa, AM1
Woolverton, WL1
Miguel-Hidalgo, JJ1
Kyle, PB1
Hasler, G1
Iyo, AH1
Karolewicz, B1
Rohmer, JG1
Blier, P2
Ward, HE1
Tremblay, P1
Laberge, L1
Hébert, C1
Bergeron, R1
Zou, YF2
Liu, P2
Feng, XL2
Wang, BY2
Zang, TH2
Wei, J2
Tao, M3
Li, HC2
Li, KQ2
Li, M3
Zhang, KR2
Ye, DQ2
Xu, XP2
Masi, G1
Liboni, F1
Brovedani, P1
Croxtall, JD1
Scott, LJ1
Hood, S1
Orr, K1
Bennett, L1
Davies, S1
Kingery, JN2
Kepley, HO1
Ginsburg, GS3
Walkup, JT2
Hoyle, RH2
Feeny, NC1
McNulty, S5
Pathak, SM1
Wells, KC1
Robins, M4
Rush, AJ3
Nguyen, LJ1
Reid, MW1
Ninan, P2
Spittlehouse, JK1
Pearson, JF1
McKenzie, JM6
Abrams, M5
Farabaugh, AH4
Bitran, S3
Witte, J2
Alpert, J5
Clain, AJ3
Maneeton, N1
Thongkam, A1
Maneeton, B1
Yu, ZJ1
Mooreville, M1
Jazayeri, S3
Keshavarz, SA2
Tehrani-Doost, M3
Djalali, M1
Hosseini, M3
Amini, H3
Chamari, M1
Djazayery, A3
Amsterdam, JD5
Shults, J2
Blocker, JN2
D'Agostino, R2
Kimball, J2
Boggs, N2
Lasater, B2
Rosenquist, PB2
Vrijland, P1
van Oers, HJ1
Schutte, AJ1
Simmons, JH1
Snedecor, SJ1
Botteman, MF1
Schaefer, K2
Sarocco, P1
Barry, N1
Pickard, AS1
Douaihy, AB1
Chung, TA1
Daley, DC2
Brown, SJ1
Michalak, E1
Kiss, A1
Cruz, D1
Hernández, S1
Genis, A1
Carrillo-Guerrero, MY1
Avilés Reyes, R1
Sit, D2
Perel, JM3
Luther, JF2
Wisniewski, SR2
Helsel, JC2
Wisner, KL2
Lee, SY1
Sonawalla, S2
Johnson, DP1
Goodness, T1
Harley, R4
Goodness, TM1
Haskett, R1
Krystal, A2
McDonald, WM1
Prukkanone, B1
Vos, T1
Burgess, P1
Chaiyakunapruk, N1
Bertram, M1
Fischer, K1
Goetghebeur, E1
Vrijens, B1
White, IR1
Corral, RM1
Mencacci, C1
Ruiz, JS1
Severo, CA1
Gentil, V1
Wang, HC1
Yeh, TL1
Hughes, CW4
Sternweis-Yang, KH1
Byerly, MJ1
Kirchner, J2
Lavanier, S2
Becker-Weidman, E2
Weller, E7
Savitz, JB1
Nugent, AC1
Bogers, W1
Roiser, JP1
Bain, EE1
Neumeister, A1
Zarate, CA1
Manji, HK1
Cannon, DM1
Marrett, S1
Henn, F1
Charney, DS5
Drevets, WC1
Silk, JS1
Forbes, EE1
Whalen, DJ1
Jakubcak, JL1
Thompson, WK1
Axelson, DA1
Dahl, RE1
He, W1
Cai, D1
Lin, L1
Zheng, X1
Bernstein, IH2
Haley, CL1
Sakolsky, DJ1
Wagner, KD5
Asarnow, JR3
Strober, MJ1
Huang, H2
Wilson, A1
Iosifescu, DV6
Wessel, TC1
LaRocca, RA1
Iovieno, N1
van Nieuwenhuizen, A1
Kardeh, E1
Allaman, I1
Fiumelli, H1
Magistretti, PJ1
Martin, JL1
Decuyper, M1
Lane, HY3
Juo, SH2
Yen, CF2
Abolfazli, R1
Ghaleiha, A1
Tabrizi, M2
Golalizadeh, M1
Sidi, H3
Asmidar, D3
Hod, R2
Guan, NC3
Wood, SD1
Kelly, TM2
Salloum, IM3
Korb, AS1
Posternak, MA1
Andjelkovic, M1
Jovanovic, DB1
Zdravkovic, N1
Jankovic, SM1
Kondo, DG1
Sung, YH1
Hellem, TL1
Fiedler, KK1
Jeong, EK1
de la Cerda, P1
Cervelló, E1
Cocca, A1
Viciana, J1
Light, SN2
Greenwald, SD1
Tran, ML1
Miyamoto, KN1
Scorza, MC1
Lladó-Pelfort, L1
Oller, S1
Cortés, R2
Puigdemont, D1
Portella, MJ1
Pérez-Egea, R1
Alvarez, E2
Celada, P1
Pérez, V2
Artigas, F2
Koelch, M1
Pfalzer, AK1
Kliegl, K1
Rothenhöfer, S1
Ludolph, AG1
Fegert, JM1
Mehler-Wex, C1
Stingl, J1
Taurines, R1
Egberts, K1
Gerlach, M1
Jaafar, NR1
Isingrini, E1
Freslon, JL1
Machet, MC1
Camus, V1
Zhang, ZJ1
Ng, R1
Man, SC1
Li, TY1
Wong, W1
Wong, HK1
Chung, KF1
Wong, MT1
Tsang, WK1
Yip, KC1
Ziea, E1
Wong, VT1
Shamseddeen, W1
Clarke, G2
Ryan, N2
Zhu, L1
Croarkin, P1
Calley, CS1
Hart, J1
Lu, H1
Tamminga, CA1
Gibbons, RD4
Brown, CH4
Hur, K4
Davis, J1
McCall, C1
Davis, JM4
Devi, S1
Piwowarska, J1
Chimiak, A1
Matsumoto, H1
Dziklińska, A1
Radziwoń-Zaleska, M1
Szelenberger, W1
Pachecka, J1
Dunlap, L1
Segal, ZV2
Kidner, CL1
Mayer, G1
Faivel, N1
Aviram, S1
Walter, G1
Bloch, Y1
Taneja, C1
Jing, Y1
Baker, RA1
Forbes, RA1
Oster, G1
Modabbernia, A2
Sohrabi, H2
Saroukhani, S2
Jamshidi, A2
Ashrafi, M2
Rico-Villademoros, F1
Saenz del Burgo, L1
Mengod, G1
Montaña, M1
García del Caño, G1
Sallés, J1
Chen, CH2
Cheng, CY3
Chen, SY1
Nian, FS1
Peñas-Lledó, EM1
Trejo, HD1
Dorado, P1
Ortega, A1
Jung, H1
Alonso, E1
Naranjo, ME1
López-López, M1
Llerena, A1
Lamon-Fava, S2
Selhub, J1
Katz, J1
Yeung, AS1
Alpert, JE14
Mouillet-Richard, S1
Baudry, A1
Pietri, M1
Kellermann, O1
Myung, W1
Lim, SW2
Kim, S2
Kim, H2
Chung, JW1
Seo, MY1
Kim, JW2
Carroll, BJ4
Kim, DK2
Khoraminya, N1
Hosseini, A1
Midi, M1
Kanagasundram, S1
Naing, L1
Lin, HY1
Kashani, L1
Mansouri, P1
Andrade, C1
Spielmans, GI1
Jureidini, J1
Healy, D2
Purssey, R1
Siesser, WB1
Sachs, BD1
Ramsey, AJ1
Sotnikova, TD1
Beaulieu, JM1
Zhang, X1
Caron, MG1
Gainetdinov, RR1
Andreoli, V1
Caillard, V1
Deo, RS1
Rybakowski, JK2
Versiani, M1
Nierenberg, A1
Lagomasino, I1
Tedlow, J1
Worthington, J1
Rosenbaum, JF11
Ross, DC1
Quitkin, FM6
Klein, DF2
Levkovitz, Y1
Caftori, R1
Avital, A1
Richter-Levin, G1
Scott, LV2
Dinan, TG2
Davidson, JR2
Meoni, P1
Haudiquet, V1
Cantillon, M1
Hackett, D1
Sonawalla, SB2
Johnson, MW1
Morray, M1
Delgado, ML1
Pingol, MG1
Pava, J1
Buchin, J1
Sickinger, AH1
Brunswick, DJ2
Eichhorn, M1
Eich, P1
Novotny, V1
Faltus, F1
DeLong, GR1
Ritch, CR1
Burch, S1
Rasgon, NL1
Carter, MS1
Elman, S1
Bauer, M1
Love, M1
Korenman, SG1
McCombs, JS1
Shi, L1
Stimmel, GL1
Croghan, TW1
Henry, ME2
Kaufman, MJ2
Hennen, J3
Michelson, D2
Schmidt, ME3
Stoddard, E1
Vukovic, AJ1
Barreira, PJ1
Cohen, BM3
Bottonari, KA1
Polania, LM1
Irvin, R1
Romeo, E1
Pompili, E1
di Michele, F1
Pace, M1
Bernardi, G1
Pasinib, A1
Wang, YC1
Manev, H1
Uz, T1
Manev, R1
Feiger, AD1
Flament, MF1
Boyer, P2
Gillespie, JA1
Mahal, Y1
Quitkin, F3
Dalery, J1
Honig, A1
Agid, O1
Lerer, B1
Sheu, WP1
Detweiler, MB1
Trinkle, DB1
Varley, CK1
Frederick, Bd1
Villafuerte, RA1
Stoddard, EP1
Smoller, JW1
Wan, YJ1
Lin, KM1
Miller, AL3
Rogers, GR1
Kennedy, MA4
Corey-Lisle, PK1
Birnbaum, H1
Greenberg, P1
Marynchenko, M1
Dube, S2
Sullivan, PF3
Cloninger, CR1
Smith, M1
Winokur, A1
DeMartinis, NA1
McNally, DP1
Gary, EM1
Cormier, JL1
Gary, KA1
Chollet, CA1
Andreatini, R1
Tural, U1
Onder, E1
Roberts, RL1
Perry, EB1
Sanacora, G3
Anand, A2
Lynch-Colonese, K1
Cappiello, A2
Oren, DA1
Kugaya, A2
Liu, N1
Fasula, D1
Bolo, NR2
Hodé, Y2
Macher, JP2
Joliat, MJ2
Zhang, S1
Trapp, NJ1
Miner, CM3
Hassman, HA1
Glass, SJ1
McManus, FC1
O'Reardon, JP1
Chopra, MP1
Bergan, A1
Gallop, R1
DeRubeis, RJ1
Crits-Christoph, P1
Hughes, ME1
Olié, JP1
McIntosh, VV1
Carter, FA1
Bulik, CM1
Young, EA2
Altemus, M1
Lopez, JF1
Schatzberg, AF1
DeBattista, C1
Zubieta, JK2
Williamson, DJ2
Tohen, MF1
Schatzberg, A2
Andersen, SW2
Van Campen, LE2
Sanger, TM4
Tollefson, GD2
Shahsavand, E1
Mesbahi, M1
Kamkar, MZ1
Sadeghi, M1
Dashti-Khavidaki, S1
Hamill, SK1
Cassano, P2
Soares, CN2
Cohen, LS2
Lyster, AK1
Morgan, M3
Dunkin, J1
Witte, E2
Montoya, HD1
Marie-Mitchell, A1
Chou, CP1
James Gauderman, W1
Azen, SP1
Pae, CU1
Lee, CU1
Lee, SJ1
Lee, C2
Paik, IH2
Petrycki, S2
Glass, RM1
Denninger, JW1
Tossani, E2
Pava, JA1
Wan, GJ1
Mallick, R1
Casciano, R1
Geissler, EC1
Panish, JM1
Kuenzel, HE1
Murck, H3
Held, K1
Ziegenbein, M1
Steiger, A1
Burns, AM1
Huang, SC1
Chang, JC1
Staley, JK1
Bozkurt, A1
Khan, S1
Van Dyck, CH1
Baldwin, RM1
Seibyl, JP1
Charney, D1
Innis, RB1
Otto, MW2
Zajecka, J2
Mannel, M1
Greist, J1
McNamara, RK1
Mallinckrodt, CH3
Rayamajhi, JN1
Raskin, J1
Möller, HJ1
Rifkin, A1
Rifkin, W1
Antonuccio, D1
Burns, D1
Bridge, JA1
Nilsson, M2
Brown, EB2
Heiligenstein, JH1
Wehmeier, PM1
Kluge, M1
Maras, A1
Riemann, D1
Berger, M1
Kohnen, R1
Dittmann, RW1
Gattaz, WF1
Doggrell, SA1
Wu, SL1
Mascarini, A2
Blardi, P2
de Lalla, A2
Auteri, A2
Iapichino, S2
Dell'Erba, A2
Castrogiovanni, P2
Brambilla, P1
Hotopf, M1
Aghayan, S1
Jalili, SA1
Yahyazadeh, O1
Pakravan-Nejad, M1
Willner, P1
Hale, AS1
Argyropoulos, S1
Dekker, J2
Molenaar, PJ1
Kool, S2
Van Aalst, G1
Peen, J2
de Jonghe, F1
Porter, RJ2
Lebowitz, BD1
Ryan, JL1
Bottiglieri, T1
Cai, W1
Khaoustov, VI1
Xie, Q1
Pan, T1
Le, W1
Yoffe, B1
Nemets, B2
Bersudsky, Y1
Belmaker, RH2
Boggio, PS3
Fregni, F3
Bermpohl, F1
Mansur, CG1
Rosa, M1
Rumi, DO1
Barbosa, ER1
Odebrecht Rosa, M1
Pascual-Leone, A2
Rigonatti, SP3
Marcolin, MA1
Araujo Silva, MT1
Shelton, C1
Padmanabhan, SK1
Vinall, PE1
Lee, TW1
Yang, CW1
Kronenberg, S1
Deliyannides, D1
Davies, CA1
Cyranowski, JM1
Frank, E1
Shear, MK1
Swartz, H1
Fagiolini, A1
Scott, J1
Kupfer, DJ1
Albert, A1
Mesters, P1
Dewé, W1
De Bruyckere, K1
Sangeleer, M1
Brown, SA1
Calarge, C1
Kuperman, S1
Lee, MS1
Ham, BJ1
Kee, BS1
Kim, JB1
Yeon, BK1
Oh, KS1
Oh, BH1
Jung, HY1
Chee, IS1
Choe, BM1
de Swart, H1
Friis Andersen, H1
Manzano, E1
Ortiz, T1
Cusin, C3
Mansfield, PR1
Raven, MK1
Jureidini, JN1
Briggs, SD2
Rogers, GM1
Huang, GJ1
Herbert, J1
Halperin, J1
Ehrlichman, H1
Clemow, DB1
Kim, J3
Riggs, KW1
Misri, S1
Kent, N1
Oberlander, TF1
Grunau, RE1
Fitzgerald, C1
Rurak, DW1
Serrano-Blanco, A1
Gabarron, E1
Garcia-Bayo, I1
Soler-Vila, M1
Caramés, E1
Peñarrubia-Maria, MT1
Pinto-Meza, A1
Gallassi, R1
Di Sarro, R1
Morreale, A1
Amore, M1
Spalletta, G2
Ripa, A1
Bria, P1
Caltagirone, C2
Robinson, RG1
Sackeim, HA1
Roose, SP2
Lavori, PW1
Hammad, TA1
Laughren, T1
Racoosin, J1
Roose, S1
Laske, C1
Stransky, E1
Eschweiler, GW1
Klein, R1
Wittorf, A1
Leyhe, T1
Richartz, E1
Köhler, N1
Bartels, M1
Buchkremer, G1
Schott, K1
Tsao, CW1
Lin, YS1
Bai, CH1
Wu, SR1
Pani, A1
O'Brien, SM1
Williamson, D1
Tollefson, G1
Lee, KM1
Kim, YK1
Shapira, B1
Trachtenberg, A1
Bellino, S2
Zizza, M2
Rinaldi, C2
Bogetto, F2
Scalia, M1
Miller, KK1
Sklarsky, KG2
Hilliker, SE1
Klibanski, A1
Eckert, L1
Lançon, C1
Morgan, ML1
Cookson, J1
Gilaberte, I2
Desaiah, D1
Kajdasz, DK1
Epperson, CN1
Amin, Z1
Naftolin, F1
Czarkowski, KA1
Stiklus, S1
Anderson, GM1
Song, Y1
Zhou, D1
Fan, J1
Cheng, J1
Petkova, E1
Safer, DJ1
Moreno, C1
Roche, AM1
Greenhill, LL1
Pier, MP1
Hulstijn, W2
van Hoof, JJ1
Sabbe, BG1
Guo, Y1
Nilsson, ME4
Heiligenstein, J1
Wilson, MG1
Whelan, F2
Deloukas, P1
Whittaker, P1
Delgado, M1
Cantor, RM1
McCann, SM1
Chang, YH1
Pender, M1
Kennedy, SE1
Koeppe, RA1
Leu, HS1
Liu, JW1
Hughes, J1
Casat, C3
Jensen, PS1
Mao, PX1
Tang, YL1
Jiang, F1
Gu, X1
Qian, M1
Ma, C1
Mitchell, PB1
Cai, ZJ1
Beasley, CM7
Wines, JD1
Tamura, RN1
Shear, D1
Amsterdam, J2
Strong, RE1
Bremner, JD1
Vythilingam, M1
Vermetten, E1
Prospero-Garcia, KA1
Torres-Ruiz, A1
Ramirez-Bermudez, J1
Velazquez-Moctezuma, J1
Arana-Lechuga, Y1
Teran-Perez, G1
Sernyak, MJ1
Rosenheck, RA1
Sharma, A1
Busnello, JV1
Ribeiro, L1
Thakur, S1
Elashoff, RM1
Zhu, F1
Xiao, Z1
Tang, J1
Liu, W1
Wu, Y1
Cao, Z1
Rintelmann, JW2
Carmody, T3
Tan, ZL2
Bao, AM2
Zhao, GQ1
Liu, YJ2
Zhou, JN2
Reimherr, FW2
Łojko, D1
Spring, B1
Doran, N1
Pagoto, S1
McChargue, D1
Cook, JW1
Bailey, K1
Crayton, J1
Hedeker, D1
Peterson, TJ1
Feldman, G1
Fresco, DM1
Graves, L1
Holmes, A1
Bogdan, R1
Bohn, L1
Lury, RA1
Bragulat, V1
Paillère-Martinot, ML1
Artiges, E1
Frouin, V1
Poline, JB1
Martinot, JL1
Chen, YC1
Shen, YC1
Hung, YJ1
Chou, CH1
Yeh, CB1
Perng, CH1
Fraguas, R1
Marci, C1
Bankier, B1
Loh, R1
Dougherty, DD1
Fu, CH3
Williams, SC3
Brammer, MJ2
Suckling, J3
Cleare, AJ2
Walsh, ND3
Mitterschiffthaler, MT3
Andrew, CM1
Pich, EM3
Bullmore, ET2
Fountoulakis, KN1
Samolis, S1
Iacovides, A1
St Kaprinis, G1
Vaishnavi, S1
Connor, K1
Meyers, AL1
Faries, DE1
Detke, MJ3
Van, HL1
Schoevers, RA1
Hendriksen, M1
Lai, AL1
Zhao, YW1
Qi, HY1
Zhang, JS1
Zhang, LS1
Weng, YQ1
Rubens, R1
Wessel, T1
Caron, J1
Wilson, P1
Roth, T1
Mehta, MA1
Kedziora, J1
Florkowski, A1
Edwards, JL1
Kirk, KK1
Midha, CK1
Cardoso, EF1
Martins Maia, F1
Luis Myczkowski, M1
Coracini, K1
Lopes Vieira, A1
Melo, LM1
Sato, JR1
Antonio Marcolin, M1
Cruz, AC1
Reis Barbosa, E1
Amaro, E1
Jain, S1
Carmody, TJ1
Morris, DW1
Coffey, B1
Wieland, N1
Benattia, I1
Demitrack, M1
Sloan, DM1
Gourley, SL1
Wu, FJ1
Kiraly, DD1
Ploski, JE1
Kedves, AT1
Taylor, JR1
Herman, KC1
Ostrander, R1
Arnold, KK1
Yager, J1
Tauscher-Wisniewski, S2
Caldwell, C1
Plewes, J2
Allen, AJ1
Pizzagalli, DA1
Ooi, C1
Bullmore, E1
Pritchett, YL1
Ossanna, MJ1
Swindle, RW1
Xu, J1
Ball, SG1
Polzer, J1
Acharya, N1
Myczkowski, ML1
Otta, E1
Fiquer, JT1
Ribeiro, RB1
Nitsche, MA1
Prentice, ED1
Houston, JP1
Swindle, R1
Rouillon, PF1
Parry, BL1
Jonsson, GW1
Moosa, MY1
Jeenah, FY1
Jalali, M1
Peet, M1
Crawford, CM1
Scalia, MJ1
Lin, KS1
Lin, CY1
Chung, T1
Martin, C1
Abebe, K1
DeBar, L1
McCracken, J1
Melhem, N1
Pearson, JL1
Marcus, RN1
McQuade, RD1
Carson, WH1
Hennicken, D1
Simon, JS1
Tonev, ST1
Mario, J1
Norquist, G1
McGuire, TG1
Essock, SM1
Goodyer, IM1
Dubicka, B1
Wilkinson, P1
Kelvin, R1
Roberts, C1
Byford, S1
Breen, S1
Ford, C1
Barrett, B1
Leech, A1
Rothwell, J1
White, L1
Harrington, R1
Fazzino, F1
Montes, C1
Carreira, I1
Westenberg, H1
Vandoolaeghe, E2
Demedts, P1
Wauters, A1
Neels, H1
Meltzer, HY1
Goldstein, DJ2
Hamilton, SH1
Masica, DN1
Khouzam, HR1
Kissmeyer, P1
Uzunova, V1
Sheline, Y1
Rasmusson, A1
Uzunov, DP1
Costa, E1
Guidotti, A1
Blumenfield, M1
Levy, NB1
Spinowitz, B1
Charytan, C1
Dubey, AK1
Solomon, RJ1
Todd, R1
Goodman, A1
Bergstrom, RF1
Verkerk, R1
Lin, A1
Scharpé, S1
Thomas, P1
Goudemand, M1
Rousseaux, M1
Mentré, F1
Golmard, JL1
Aubin-Brunet, V1
Bouhassira, M1
Jouvent, R1
Chouinard, G1
Saxena, B1
Bélanger, MC1
Ravindran, A1
Bakish, D1
Beauclair, L1
Morris, P1
Vasavan Nair, NP1
Manchanda, R1
Reesal, R1
Remick, R1
O'Neill, MC1
Delgado, PL1
Miller, HL1
Salomon, RM1
Moreno, FA1
Heninger, GR1
Peretti, CS1
Finkel, SI1
Richter, EM1
Clary, CM1
Batzar, E1
Bech, P1
Raabaek Olsen, L1
Jarløv, N1
Hammer, M1
Schütze, T1
Breum, L1
Klimke, A1
Larisch, R1
Janz, A1
Vosberg, H1
Müller-Gärtner, HW1
Gaebel, W1
Garcia-España, F1
Fawcett, J2
Reimherr, F1
Rosenbaum, J1
Beasley, C1
Sabbe, B1
van Hoof, J1
Tuynman-Qua, HG1
Zitman, F1
Sechter, D1
Troy, S1
Paternetti, S1
New, AS1
Woo-Ming, A1
Mitropoulou, V1
Silverman, J1
Reynolds, D1
Schopick, F1
Trestman, RL1
Siever, LJ1
Mullen, LS1
Blanco, C1
Vaughan, SC1
Vaughan, R1
Pillay, SS1
Bonello, CM1
Lafer, BC1
Yurgelun-Todd, D1
Zaharia, MD1
Griffiths, J1
Merali, Z1
Anisman, H1
Flint, AJ1
Rifat, SL1
Hostetter, A1
Stowe, ZN1
Strader, JR1
McLaughlin, E1
Llewellyn, A1
Corrigan, MH1
Denahan, AQ1
Wright, CE1
Ragual, RJ1
Evans, DL1
Lucca, A1
Gentilini, G1
Lopez-Silva, S1
Soldarini, A1
Tanum, L1
Dunkin, JJ1
Kasl-Godley, JE1
Rosenberg-Thompson, S1
Coppen, A1
Bailey, J1
Nédélec, JF1
Lainé, E1
Wagner, G1
Montgomery, SA1
Judge, R2
Shen, JH1
Jindal, R1
Driver, HS1
Shapiro, CM1
Martinez, D1
Broft, A1
Laruelle, M1
Mayberg, HS1
Brannan, SK1
Tekell, JL1
Silva, JA1
Mahurin, RK1
McGinnis, S1
Jerabek, PA1
Plewes, JM1
Kumar, V1
Koke, SC2
Kopp, JB2
Burger, JK1
Spillmann, MK1
Worthington, JJ1
Gonzales, JS3
Puiigdemont, D1
Ferreri, M1
Lavergne, F1
Berlin, I1
Payan, C1
Puech, AJ1
Yohannes, AM1
Connolly, MJ1
Baldwin, RC1
Grunhaus, L1
Hirschman, S1
Dolberg, OT1
Schreiber, S1
Dannon, PN1
Schmitz, JM1
Averill, P1
Stotts, AL1
Moeller, FG1
Rhoades, HM1
Grabowski, J1
Wellington, K1
Perry, CM1
Gregory, RJ1
Jindal, RD1
Wu, WH1
Huo, SJ1
Parow, AM1
Hirashima, F1
Ke, Y1
Moore, CM1
Frederick, Bde B1
Witte, EA1
Entsuah, AR1
Bottonari, K1
Iacoviello, B1
Leo, A1
Di Muro, A1
Hoog, SL1
Judge, RA1
Mallinckrodt, C1
Demitrack, MA1
Munir, R1
Bilbao Garay, J1
Mesa Plaza, N1
Castilla Castellano, V1
Dhimes Tejada, P1
Pasini, A1
Stubbeman, WF1
Rosenberg, S1
Uijtdehaage, SH1

Clinical Trials (95)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Sequenced Treatment Alternatives to Relieve Adolescent Depression (STAR-AD) a Multicentre Open-label Randomized Controlled Trial Protocol[NCT05814640]Phase 1/Phase 2520 participants (Anticipated)Interventional2023-02-20Recruiting
Interventional, Randomised, Double-blind, Placebo-controlled, Active Reference (Fluoxetine), Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 12 to 17 Years, With Major Depressive Disorder (MDD)[NCT02709746]Phase 3784 participants (Actual)Interventional2016-05-31Completed
Assessment of Efficacy and Safety of Anodal Transcranial Direct Current Stimulation (TDCS) in Pediatric and Teenage Patients With Major Depressive Disorder During COVID-19 Pandemics[NCT04780152]Phase 2/Phase 3172 participants (Anticipated)Interventional2021-10-31Recruiting
A Sequential, Multiple Assignment Randomized Trial (SMART) for Non-specialist Treatment of Common Mental Disorders in Kenya: Leveraging the Depression And Primary-care Partnership for Effectiveness-implementation Research (DAPPER) Project[NCT03466346]2,710 participants (Anticipated)Interventional2020-08-31Active, not recruiting
Citalopram Improves Vasomotor and Urogenital Syndromes in Mexican Patients With Post-menopause[NCT05346445]91 participants (Actual)Interventional2021-01-20Completed
A 8-week, Rater-blind, Active-controlled, Randomized Study to Compare the Effectiveness of Venlafaxine With Fluoxetine in the Treatment of Postmenopausal Women With Major Depressive Disorder[NCT01824433]Phase 4189 participants (Actual)Interventional2013-03-07Completed
Model for Early Prediction of Clinical Response in Patients With Major Depression Receiving Fluoxetine[NCT01075529]Phase 4140 participants (Actual)Interventional2007-03-31Completed
Light and Ion Treatment to Enhance Medication Efficacy in Depression[NCT00958204]Phase 3134 participants (Actual)Interventional2009-10-31Completed
Treatment for Adolescents With Depression Study (TADS)[NCT00006286]Phase 3432 participants Interventional1998-09-30Completed
A Randomized Controlled Trial of Sequential Bilateral Accelerated Theta Burst Stimulation in Adolescents With Suicidal Ideation Associated With Major Depressive Disorder[NCT04502758]80 participants (Anticipated)Interventional2022-04-04Recruiting
A Preliminary Clinical Study on the Rapid Antidepressant Effects of Adenosine Triphosphate (ATP) and Phosphocreatine Combinated With Fluoxetine[NCT03138681]Phase 242 participants (Anticipated)Interventional2017-05-03Recruiting
Effects of Nutrients Supplementation in Antidepressant Treated Depressive Disorder Patients[NCT04179006]120 participants (Anticipated)Interventional2019-11-14Recruiting
A Randomized, Single-blind, Placebo-controlled Study to Evaluate the Effects of a Turmeric and Black Cumin Seed Formulation on Cholesterol Levels Among Generally Healthy Participants[NCT03175757]33 participants (Actual)Interventional2017-05-12Completed
Prophylactic Cognitive Therapy for Depression.[NCT00118404]Phase 3523 participants (Actual)Interventional2000-03-31Completed
Non-Invasive Brain Imaging Techniques That Predict Antidepressant Responsiveness and Provide Insights Into the Mechanism of Action of Venlafaxine ER vs. Fluoxetine[NCT00909155]50 participants (Actual)Interventional2002-07-31Completed
An Acute and Continuation Phase Study of the Comparative Efficacy Study of Venlafaxine ER (Effexor® XR) and Fluoxetine (Prozac®) in Achieving and Sustaining Remission (Wellness) in Patients With Recurrent Unipolar Major Depression; Followed by a Long Term[NCT00046020]Phase 41,096 participants (Actual)Interventional2000-08-31Completed
A Double-Blind, Efficacy and Safety Study of Duloxetine Versus Placebo in the Treatment of Children and Adolescents With Major Depressive Disorder[NCT00849901]Phase 3337 participants (Actual)Interventional2009-03-31Completed
A Double-Blind, Efficacy and Safety Study of Duloxetine Versus Placebo in the Treatment of Children and Adolescents With Major Depressive Disorder[NCT00849693]Phase 3463 participants (Actual)Interventional2009-03-31Completed
Narrative Therapy for Treatment-Resistant Obsessive-Compulsive Disorder[NCT04154085]14 participants (Actual)Interventional2021-01-02Completed
Pediatric MDD: Sequential Treatment With Fluoxetine and Relapse Prevention[NCT00612313]144 participants (Actual)Interventional2008-02-29Completed
[NCT00265291]Phase 2700 participants (Actual)Interventional1999-11-30Completed
Role of the Gut Microbiome as Determinant of Depression in Multiple Sclerosis Subjects[NCT05808101]120 participants (Anticipated)Observational2022-01-27Recruiting
Efficacy of Individualized Homeopathic Treatment for Moderate to Severe Depression in Peri- and Postmenopausal Women: a Randomized Placebo-controlled, Double-blind, Double-dummy, Study Protocol[NCT01635218]Phase 2133 participants (Actual)Interventional2012-03-31Completed
Escitalopram and Language Intervention for Subacute Aphasia (ELISA)[NCT03843463]Phase 288 participants (Anticipated)Interventional2021-07-18Recruiting
Can Non-drug Antidepressant Treatments Influence the Way the Human Brain Processes Information?[NCT03688048]50 participants (Actual)Interventional2017-02-20Completed
Feasibility Study of Adjunctive Bright Light Therapy (BLT) for Amelioration of Fatigue in Chinese Cancer Patients Admitted to a Palliative Care Unit[NCT04525924]42 participants (Anticipated)Interventional2020-08-01Recruiting
Effect of Bright Light Therapy on Depression Symptoms in Adult Inpatients With Cystic Fibrosis (CF) and Chronic Obstructive Pulmonary Disease (COPD)[NCT04921332]4 participants (Actual)Interventional2021-09-07Terminated (stopped due to Study was stopped secondary to principal investigator needing to analyze data and present prior to graduating. Target enrollment not able to be reached prior to this.)
Fluoxetine to Reduce Hospitalization From COVID-19 Infection (FloR COVID-19)[NCT04570449]Early Phase 10 participants (Actual)Interventional2020-11-30Withdrawn (stopped due to Study timeline is not feasible)
The Effect of Seven-Day Atorvastatin Administration on Emotional Processing, Reward Processing, and Inflammation in Healthy Volunteers[NCT03966859]50 participants (Actual)Interventional2019-06-19Completed
Development and Evaluation of an Ecological Momentary Assessment (EMA) Baseline Screening System for Therapists Who Treat Youths With Depressive Symptoms[NCT04830527]60 participants (Actual)Interventional2020-11-24Terminated (stopped due to The study was terminated early due to the difficulty in recruiting cases during a pandemic period.)
A Prospective Interventional Trial of Pharmacogenomic-Guided Supportive Care in Hematopoietic Cell Transplantation[NCT04727827]110 participants (Actual)Interventional2021-02-01Completed
Repeated Partial Sleep Deprivation to Augment SSRI Response in Depression[NCT01545843]Phase 268 participants (Actual)Interventional2009-03-31Completed
The BrainDrugs-Epilepsy Study: A Prospective Open-label Cohort Precision Medicine Study in Epilepsy[NCT05450822]550 participants (Anticipated)Observational2022-02-18Recruiting
Randomized Controlled Study on the Effect of Pharmacogenomics on Individualized Precise Treatment of Patients With Depression[NCT05669391]120 participants (Anticipated)Interventional2023-01-01Not yet recruiting
Double-Blind, Placebo-Controlled, Randomized Trial of Adjunctive Lisdexamfetamine Dimesylate in Residual Symptoms of Major Depressive Disorder Partially Responsive to Selective Serotonin or Norepinephrine Reuptake Inhibitor Monotherapy[NCT01148979]Phase 435 participants (Actual)Interventional2010-09-30Completed
A Study of Adjunctive Aripiprazole in Patients With Major Depressive Disorder[NCT00095758]Phase 31,200 participants Interventional2004-09-30Completed
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Aripiprazole as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder.[NCT00095823]Phase 31,200 participants Interventional2004-06-30Completed
Effects of Aripiprazole on the Steady-State Pharmacokinetics of Venlafaxine in Healthy Subjects[NCT00362271]Phase 138 participants Interventional2006-08-31Completed
Effects on Aripiprazole on the Steady-State Pharmacokinetics of Escitalopram in Healthy Subjects[NCT00361790]Phase 125 participants Interventional2006-08-31Completed
Continuation Phase CBT for Youth With MDD[NCT00158301]72 participants (Actual)Interventional2004-09-30Completed
Childhood Depression: Remission and Relapse[NCT00332787]200 participants Interventional2000-06-30Completed
Treatment of SSRI-Resistant Depression in Adolescents (TORDIA)[NCT00018902]Phase 2/Phase 3334 participants (Actual)Interventional2001-01-31Completed
A Preliminary Study of the Efficacy and Safety of Carbamazepine in Severe Liver Disease Due to Alpha-1 Antitrypsin Deficiency[NCT01379469]Phase 220 participants (Actual)Interventional2012-01-31Terminated
Pharmacological Intervention Project (Fluoxetine)[NCT00027378]Phase 250 participants (Actual)Interventional2001-07-31Completed
Randomized Trial of KEEP-P, a Preventive Intervention for Foster Preschoolers[NCT03106636]442 participants (Actual)Interventional2014-05-20Completed
Salicylic Augmentation in Depression[NCT03152409]Phase 274 participants (Anticipated)Interventional2018-11-15Recruiting
Hypnotics in the Treatment of Psychiatric Disorders[NCT00247624]Phase 460 participants (Actual)Interventional2005-10-31Completed
Depression Response to Eszopiclone in Adults With Major Depressive Disorder (DREAMDD): A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 8-Week, Safety & Efficacy Study of Eszopiclone 3 mg Compared to Placebo in Subjects With Insomnia Relate[NCT00368030]Phase 3545 participants (Actual)Interventional2004-01-31Completed
Fluoxetine for Major Depressive Disorder/Cannabis Disorder in Young People[NCT00149643]Phase 270 participants (Actual)Interventional2004-09-30Completed
Antidepressant Use During Pregnancy[NCT00279370]283 participants (Actual)Observational1999-09-30Completed
Using Smartphones to Enhance the Treatment of Childhood Anxiety[NCT02259036]40 participants (Actual)Interventional2014-08-31Completed
The Efficacy of Eszopiclone 3 mg as Adjunctive Therapy in Subjects With Insomnia Related to Generalized Anxiety Disorder.[NCT00235508]Phase 4420 participants (Actual)Interventional2005-06-30Completed
Prozac Treatment of Major Depression: Discontinuation Study[NCT00427128]Phase 4627 participants (Actual)Interventional1995-11-30Completed
Creatine Augmentation in Female & Male Veterans With Selective Serotonin Reuptake Inhibitor-Resistant Major Depressive Disorder[NCT01175616]Phase 40 participants (Actual)Interventional2012-09-30Withdrawn (stopped due to Study withdrawn from ClinicalTrials.gov.)
Adjunctive Creatine Treatment for Adolescent Females With Major Depressive Disorder Who Are Non-Responders to Fluoxetine or Escitalopram: A Magnetic Resonance Spectroscopy Study[NCT00851006]Phase 213 participants (Actual)Interventional2009-04-30Completed
Placebo-Controlled Trial of Creatine Augmentation for Adolescent Females With Treatment-Resistant Major Depressive Disorder: a Magnetic Resonance Spectroscopy Study[NCT02134808]Phase 471 participants (Actual)Interventional2014-11-21Completed
Fluoxetine Versus Fluoxetine Plus DU125530 in Latency of Antidepressant Response Shortening in Major Depressive Disorder[NCT01119430]Phase 250 participants (Actual)Interventional2004-05-31Terminated (stopped due to interim analysis suggested no differences with whole sample)
An Assessor-Blinded, Randomised Controlled Trial of Acupuncture to Prevent Chemobrain in Breast Cancer Patients[NCT02457039]93 participants (Actual)Interventional2015-10-31Completed
A Multisite, Assessor-blinded, Randomized Controlled Trial of Acupuncture for Post-stroke Depression[NCT02644161]91 participants (Actual)Interventional2015-10-31Completed
Transcutaneous Electrical Acupoint Stimulation (TEAS) and Dense Cranial Electroacupuncture Stimulation (DCEAS) for Psychiatric Sequelae and Related Biomarkers in Women Victims of Domestic Violence: a Randomized Controlled Trial[NCT05102253]110 participants (Anticipated)Interventional2022-07-13Recruiting
Combining Acupuncture and Acupressure for Community-dwelling Elderly With Dementia: an Assessor-blinded, Randomized Controlled Trial[NCT04305951]248 participants (Anticipated)Interventional2021-10-05Recruiting
Using Telehealth to Improve Outcomes in Veterans at Risk for Suicide[NCT03724370]180 participants (Anticipated)Interventional2018-12-14Recruiting
Efficacy Of Switching From SSRI to Desvenlafaxine on Cognitive Function In Patients With an Acute Episode of Major Depression[NCT03432221]36 participants (Anticipated)Observational2018-04-03Recruiting
The Effects of Glycine Transport Inhibition on Brain Glycine Concentration[NCT00538070]68 participants (Actual)Interventional2007-08-31Completed
[NCT00229476]Phase 460 participants Interventional2003-12-31Completed
Targeting Adolescent Insomnia to Lessen Overall Risk of Suicidal Behavior[NCT05390918]190 participants (Anticipated)Interventional2022-10-20Recruiting
Study of Web-based Cognitive Behavioral Therapy in Adolescent Depression; Randomized Controlled Trial for Korean Adolescents[NCT02072304]164 participants (Anticipated)Interventional2014-01-31Recruiting
Stepped Approach to Reducing Risk of Suicide in Primary Care[NCT06018285]4,648 participants (Anticipated)Interventional2023-08-08Recruiting
Efficacy and Safety Analyses of Mirtazapine in the Treatment of Malignant Tumor Related Depression: A Phase II, Placebo-controlled, Randomized, Double-blinded Clinical Trial in Advanced Non-small Cell Lung Cancer Patients[NCT02650544]Phase 2236 participants (Anticipated)Interventional2015-12-31Active, not recruiting
Increasing Access to Evidence-based Treatments for Depression: The Development and Evaluation of a Digital Training Platform for Interpersonal Psychotherapy.[NCT04619615]44 participants (Actual)Interventional2020-07-27Active, not recruiting
Medication Treatment Following Neuropsychologic, Dichotic and f-MRI Tests in Depressed Outpatients With Repeat f-MRI Following Treatment[NCT00296777]Phase 428 participants (Actual)Interventional2004-12-31Completed
Genetics of Self-injurious Behaviour[NCT05563324]234 participants (Actual)Observational2014-05-09Completed
Influences on and Prevention of Self-harm Behaviour Among the Most At-risk Adolescents[NCT05765864]400 participants (Anticipated)Observational2023-03-23Recruiting
High-definition Transcranial Direct Current Stimulation (HD-tDCS) as Augmentation Therapy in Late-life Depression (LLD) With Suboptimal Response to Treatment - Double-blinded Randomized Sham-controlled Trial[NCT05322863]58 participants (Anticipated)Interventional2021-02-22Recruiting
Mood Disorder Cohort Research Consortium (MDCRC) in Korea[NCT03088657]500 participants (Anticipated)Observational [Patient Registry]2015-09-30Recruiting
Efficacy of Memantine in the Treatment of Fibromyalgia: a Double-blind Randomized Trial[NCT01653457]Phase 360 participants (Anticipated)Interventional2012-09-30Not yet recruiting
Interaction of Estrogen and Serotonin in Modulating Brain Activation in Menopause[NCT01208324]47 participants (Actual)Interventional2010-03-04Completed
Attachment Based Family Therapy (ABFT) for Suicidal Adolescents[NCT01537419]129 participants (Actual)Interventional2012-03-31Completed
Prospective 24-week Study, Comparing Clinical Outcomes Between Switching Antidepressants and Maintaining the Same Antidepressant in Patients With Major Depressive Disorder Who do Not Show a 20% Reduction in Symptoms at Week 2[NCT00519012]Phase 4200 participants (Anticipated)Interventional2007-08-31Recruiting
Fluoxetine as a Quit Smoking Aid for Depression-Prone Smokers[NCT00018174]Phase 3247 participants (Actual)Interventional1998-02-28Completed
The Study of Olanzapine Plus Fluoxetine in Combination for Treatment-Resistant Depression Without Psychotic Features[NCT00035321]Phase 3600 participants Interventional2002-04-30Completed
Evaluation of Blended Stepped-care Mental Well-being Intervention for Adults: A Randomized Controlled Trial[NCT05395312]402 participants (Anticipated)Interventional2022-07-30Active, not recruiting
Repetitive Transcranial Magnetic Stimulation (rTMS) for Motor and Mood Symptoms of Parkinson's Disease (MASTER-PD), a Multicenter Clinical Trial[NCT01080794]61 participants (Actual)Interventional2010-05-31Completed
A Randomized, Single Blind, Controlled, Longitudinal Study of the Effects of Venlafaxine Hydrochloride Capsules on the Language Function of Stroke Patients With Subcortical Aphasia Using fMRI[NCT03588572]43 participants (Actual)Interventional2018-08-01Completed
Home-based Transcranial Direct Current Stimulation in Postpartum Depression: the Feasibility Study and Pilot Study[NCT05046405]50 participants (Anticipated)Interventional2022-10-02Not yet recruiting
Real-world Data Collection and Real-world Evidence Clinical Demonstration Study of tDCS for the Treatment of Depression in Perinatal Women[NCT06015425]125 participants (Anticipated)Interventional2023-10-01Not yet recruiting
The Use of Electronic Communications-based Automated Technologies to Augment Traditional Mental Health Care[NCT03925038]100 participants (Anticipated)Interventional2019-04-01Recruiting
A Double-Blind, Placebo-Controlled Study of Aripiprazole Adjunctive to Antidepressant Therapy (ADT) Among Outpatients With Major Depressive Disorder Who Have Responded Inadequately to Prior ADT[NCT00683852]Phase 3225 participants (Actual)Interventional2008-09-30Completed
A Phase I Randomized, Double-blinded, Placebo-controlled Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetic of HS-10353 in Chinese Adult Subjects[NCT05195203]Phase 196 participants (Actual)Interventional2021-01-27Completed
Detecting Depression and Bipolar Disorder in Adolescents Using a Biomarker Panel[NCT01957501]75 participants (Actual)Observational2013-07-31Terminated (stopped due to Funding has been terminated for this study.)
Investigating the Efficacy of a Top-Down Approach to Cognitive Remediation in Individuals With Affective Disorders[NCT02502604]58 participants (Actual)Interventional2015-09-30Completed
Assesment of Vitamin B6 Level in Patients With Major Depressive Disorder[NCT05649293]94 participants (Anticipated)Observational2023-04-01Not yet recruiting
"Response Variability in Treatment Resistant Depression - an Ancillary Study to Sequenced Treatment Alternatives to Relieve Depression (STAR*D)"[NCT00375843]Phase 4118 participants (Actual)Interventional2005-01-31Completed
Cerebral Neuroinflammation During Major Depressive Episode: Multicentric Comparative Study.[NCT03314155]60 participants (Anticipated)Interventional2018-12-07Recruiting
Study of Antidepressants in Parkinson's Disease[NCT00086190]Phase 3115 participants (Actual)Interventional2005-06-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

CDRS-R Remission

Remission is defined as a CDRS-R total score <= 28. (NCT02709746)
Timeframe: From Randomization to Week 8

InterventionParticipants (Count of Participants)
Vortioxetine 10 mg/Day21
Vortioxetine 20 mg/Day24
Fluoxetine 20 mg/Day,32
Placebo20

CDRS-R Response

Children Depression Rating Scale - Response: defined as a >= 50% decrease in CDRS-R total score, calculated as (change from baseline [Randomization])/(baseline value - 17). (NCT02709746)
Timeframe: From Randomization to Week 8

InterventionParticipants (Count of Participants)
Vortioxetine 10 mg/Day53
Vortioxetine 20 mg/Day60
Fluoxetine 20 mg/Day,68
Placebo49

CGI-S Remission

Remission defined as CGI-S score of 1 or 2. (NCT02709746)
Timeframe: From Randomization to Week 8

InterventionParticipants (Count of Participants)
Vortioxetine 10 mg/Day26
Vortioxetine 20 mg/Day33
Fluoxetine 20 mg/Day,36
Placebo24

Change General Behaviour Inventory (GBI) Depression Subscale Score Assessed by the Child

The GBI 10-item mania scale is a parent- and subject-rated scale designed to screen for manic symptoms in children and adolescents. The 10 items are rated on a scale from 0 (never or hardly ever) to 3 (very often or almost constantly). The total score ranges from 0 to 30 points, with high scores indicating greater pathology. (NCT02709746)
Timeframe: From randomization to Week 8

Interventionunits on a scale (Least Squares Mean)
Vortioxetine 10 mg/Day-5.48
Vortioxetine 20 mg/Day-5.55
Fluoxetine 20 mg/Day,-6.30
Placebo-6.03

Change in CDRS-R Behaviour Score

Change in Children Depression Rating Scale - Revised (CDRS-R): Behaviour. The CDRS-R has been widely used for the evaluation of children and adolescents with major depressive disorder (MDD). The CDRS-R total score is the sum of the responses to 17 items. Each item is graded on a 5- or 7-point scale. behaviour is one of four subscores defined in the CDRS-R:sum of items 1, 2, 3; score ranges from 3 to 21. The highest possible score indicates the most severe measure of depression. (NCT02709746)
Timeframe: From Randomization to Week 8

Interventionunits on a scale (Least Squares Mean)
Vortioxetine 10 mg/Day-4.32
Vortioxetine 20 mg/Day-4.90
Fluoxetine 20 mg/Day,-5.52
Placebo-4.73

Change in CDRS-R Mood Score

Change in Children Depression Rating Scale - Revised (CDRS-R) Mood. The CDRS-R has been widely used for the evaluation of children and adolescents with major depressive disorder (MDD). The CDRS-R total score is the sum of the responses to 17 items. Each item is graded on a 5- or 7-point scale. Mood is one of four subscores defined in the CDRS-R: sum of items 8, 11, 14, 15; score range 4 to 28. The highest possible score indicates the most severe measure of depression. (NCT02709746)
Timeframe: From randomization to Week 8

Interventionunits on a scale (Least Squares Mean)
Vortioxetine 10 mg/Day-5.05
Vortioxetine 20 mg/Day-5.47
Fluoxetine 20 mg/Day,-6.53
Placebo-5.32

Change in CDRS-R Somatic Score

Change in Children Depression Rating Scale - Revised (CDRS-R): Somatic. The CDRS-R has been widely used for the evaluation of children and adolescents with major depressive disorder (MDD). The CDRS-R total score is the sum of the responses to 17 items. Each item is graded on a 5- or 7-point scale. Somatic is one of four subscores defined in the CDRS-R: sum of items 4, 5, 6, 7, 16, 17; score ranges from 6 to 36. The highest possible score indicates the most severe measure of depression. (NCT02709746)
Timeframe: From Randomization to Week 8

Interventionunits on a scale (Least Squares Mean)
Vortioxetine 10 mg/Day-5.63
Vortioxetine 20 mg/Day-6.03
Fluoxetine 20 mg/Day,-6.79
Placebo-5.78

Change in CDRS-R Subjective Score

Change in Children Depression Rating Scale - Revised (CDRS-R): Subjective. The CDRS-R has been widely used for the evaluation of children and adolescents with major depressive disorder (MDD). The CDRS-R total score is the sum of the responses to 17 items. Each item is graded on a 5- or 7-point scale. Subjective is one of four subscores defined in the CDRS-R: sum of items 9, 10, 12, 13; score ranges from 4 to 28. The highest possible score indicates the most severe measure of depression. (NCT02709746)
Timeframe: From Randomization to Week 8

Interventionunits on a scale (Least Squares Mean)
Vortioxetine 10 mg/Day-2.41
Vortioxetine 20 mg/Day-2.63
Fluoxetine 20 mg/Day,-3.23
Placebo-2.66

Change in CDRS-R Total Score During Treatment (at Week 2)

The CDRS-R is a clinician-rated scale to measure the severity of depression of children and adolescents. The CDRS-R consists of 17 items: 14 items rate verbal observations, and three items rate nonverbal observations (tempo of language, hypoactivity, and nonverbal expression of depressed affect). Depression symptoms are rated on a 5-point scale from 1 to 5 for the verbal observations, and a 7-point scale from 1 to 7 for the nonverbal observations. The total score ranges from 17 (normal) to 113 (severe depression).Children and parents answer separately. Rater judges and selects 'Best'. (NCT02709746)
Timeframe: At week 2

Interventionunits on a scale (Least Squares Mean)
Vortioxetine 10 mg/Day-9.58
Vortioxetine 20 mg/Day-10.15
Fluoxetine 20 mg/Day,-10.34
Placebo-8.83

Change in CDRS-R Total Score During Treatment (at Week 4)

The CDRS-R is a clinician-rated scale to measure the severity of depression of children and adolescents. The CDRS-R consists of 17 items: 14 items rate verbal observations, and three items rate nonverbal observations (tempo of language, hypoactivity, and nonverbal expression of depressed affect). Depression symptoms are rated on a 5-point scale from 1 to 5 for the verbal observations, and a 7-point scale from 1 to 7 for the nonverbal observations. The total score ranges from 17 (normal) to 113 (severe depression). (NCT02709746)
Timeframe: At week 4

Interventionunits on a scale (Least Squares Mean)
Vortioxetine 10 mg/Day-14.32
Vortioxetine 20 mg/Day-15.03
Fluoxetine 20 mg/Day,-16.25
Placebo-13.71

Change in CDRS-R Total Score During Treatment (at Week 6)

The CDRS-R is a clinician-rated scale to measure the severity of depression of children and adolescents. The CDRS-R consists of 17 items: 14 items rate verbal observations, and three items rate nonverbal observations (tempo of language, hypoactivity, and nonverbal expression of depressed affect). Depression symptoms are rated on a 5-point scale from 1 to 5 for the verbal observations, and a 7-point scale from 1 to 7 for the nonverbal observations. The total score ranges from 17 (normal) to 113 (severe depression). (NCT02709746)
Timeframe: At week 6

Interventionunits on a scale (Least Squares Mean)
Vortioxetine 10 mg/Day-15.43
Vortioxetine 20 mg/Day-17.78
Fluoxetine 20 mg/Day,-19.20
Placebo-16.71

Change in Children Depression Rating Scale - Revised (CDRS-R) Total Score After Treatment

The CDRS-R is a clinician-rated scale to measure the severity of depression of children and adolescents. The CDRS-R consists of 17 items: 14 items rate verbal observations, and three items rate nonverbal observations (tempo of language, hypoactivity, and nonverbal expression of depressed affect). Depression symptoms are rated on a 5-point scale from 1 to 5 for the verbal observations, and a 7-point scale from 1 to 7 for the nonverbal observations. The total score ranges from 17 (normal) to 113 (severe depression). (NCT02709746)
Timeframe: From Randomization to Week 8

Interventionunits on a scale (Least Squares Mean)
Vortioxetine 10 mg/Day-17.09
Vortioxetine 20 mg/Day-18.94
Fluoxetine 20 mg/Day,-21.95
Placebo-18.22
Vortioxetine Average (Avg. VOR)-18.01

Change in Children's Global Assessment Scale (CGAS) Score

The Children's Global Assessment Score (CGAS) is a rating scale which measures psychological, social and school functioning for children. The CGAS is a clinician-rated global scale to measure the lowest level of functioning for a child (4 to 16 years) during a specified time period. The CGAS contains behaviourally oriented descriptors at each anchor point that depict behaviours and life situations applicable to a child. The items range in value from 1 (most functionally impaired child) to 100 (the healthiest). A total score above 70 indicates normal function. (NCT02709746)
Timeframe: From Randomization to Week 8

Interventionunits on a scale (Least Squares Mean)
Vortioxetine 10 mg/Day12.24
Vortioxetine 20 mg/Day13.89
Fluoxetine 20 mg/Day,16.43
Placebo14.52

Change in Clinical Global Impression Severity of Illness (CGI-S) Score

The CGI-S provides the clinician's impression of the patient's current state of mental illness. The clinician uses his or her clinical experience of this patient population to rate the severity of the patient's current mental illness on a 7-point scale ranging from 1 (normal - not at all ill) to 7 (among the most extremely ill patients). (NCT02709746)
Timeframe: From Randomization to Week 8

Interventionunits on a scale (Least Squares Mean)
Vortioxetine 10 mg/Day-1.23
Vortioxetine 20 mg/Day-1.38
Fluoxetine 20 mg/Day,-1.59
Placebo-1.21

Change in General Behaviour Inventory (GBI) Depression Sub Scale Score Assessed by the Parents

Using the 10-item depression subscale, assessed by parent (PGBI-10D). Change from randomization to Week 8 in GBI Total Parent/Guardian Version Depression score. GBI is a self-report inventory with 73 items focused on mood-related behaviors including depressive, hypomanic, and biphasic symptoms. One 20-item subscale completed by parent/guardian. Symptoms rated on 4-point Likert scale from 0 (never/hardly ever) to 3 (often/almost constantly). Minimum score 0=better outcome, maximum score 60=worse outcome. (NCT02709746)
Timeframe: From randomization to week 8

Interventionunits on a scale (Least Squares Mean)
Vortioxetine 10 mg/Day-6.23
Vortioxetine 20 mg/Day-6.48
Fluoxetine 20 mg/Day,-8.00
Placebo-6.62

Change in Paediatric Quality of Life Enjoyment and Satisfaction Questionnaire (PQ-LES-Q) Total Scores

PQ-LES-Q total score (items 1 to 14). The PQ-LES-Q is a patient-rated scale designed to assess satisfaction with life. It is an adaptation of the Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q), which is used to measure quality of life in adults. The PQ LES Q consist of 15 items, item 1-14 assess the degree of satisfaction experienced by subjects in various areas of daily functioning (and item 15 allows subjects to summarize their experience in a global rating). Each item is rated on a 5-point scale from 1 (very poor) to 5 (very good). The total score range of item 1-14 (this outcome measurement) is 14 to 70, with higher scores indicating greater satisfaction. (NCT02709746)
Timeframe: From Randomization to Week 8

Interventionunits on a scale (Least Squares Mean)
Vortioxetine 10 mg/Day7.62
Vortioxetine 20 mg/Day7.56
Fluoxetine 20 mg/Day,9.26
Placebo7.06

Change in Pediatric Quality of Life Inventory (PedsQL) Visual Analogue Scales (VAS): Afraid or Scared (Anxiety) Score

The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The patients are asked to mark on the line how they feel. A lower value represents a better outcome. (NCT02709746)
Timeframe: From Randomization to Week 8

Interventionunits on a scale (Least Squares Mean)
Vortioxetine 10 mg/Day-0.47
Vortioxetine 20 mg/Day-0.76
Fluoxetine 20 mg/Day,-0.78
Placebo-0.71

Change in PedsQL Emotional Distress Summary Average Score

The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The patients are asked to mark on the line how they feel. The average emotional distress summary score is the mean of the anxiety, sadness, anger, and worry items. A lower value represents a better outcome. (NCT02709746)
Timeframe: From Randomization to week 8

Interventionunits on a scale (Least Squares Mean)
Vortioxetine 10 mg/Day-0.93
Vortioxetine 20 mg/Day-1.09
Fluoxetine 20 mg/Day,-1.33
Placebo-1.18

Change in PedsQL VAS Total Average Score

The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL™ VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue, and pain using visual analogue scales. The functionality for each domain is measured on a 10cm line with a happy face at one end and a sad face at the other (0-10 points). The patients are asked to mark on the line how they feel. The total score is the average of all 6 items. A lower value represents a better outcome. (NCT02709746)
Timeframe: From Randomization to week 8

Interventionunits on a scale (Least Squares Mean)
Vortioxetine 10 mg/Day-1.00
Vortioxetine 20 mg/Day-1.13
Fluoxetine 20 mg/Day,-1.33
Placebo-1.14

Change in PedsQL VAS: Angry Score

The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The patients are asked to mark on the line how they feel. A lower value represents a better outcome. (NCT02709746)
Timeframe: From Randomization to Week 8

Interventionunits on a scale (Least Squares Mean)
Vortioxetine 10 mg/Day-0.51
Vortioxetine 20 mg/Day-0.70
Fluoxetine 20 mg/Day,-1.01
Placebo-0.59

Change in PedsQL VAS: Pain or Hurt Score

The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The patients are asked to mark on the line how they feel. A lower value represents a better outcome. (NCT02709746)
Timeframe: From Randomization to Week 8

Interventionunits on a scale (Least Squares Mean)
Vortioxetine 10 mg/Day-1.12
Vortioxetine 20 mg/Day-0.97
Fluoxetine 20 mg/Day,-0.83
Placebo-0.76

Change in PedsQL VAS: Sad or Blue (Sadness) Score

The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The patients are asked to mark on the line how they feel. A lower value represents a better outcome. (NCT02709746)
Timeframe: From Randomization to Week 8

Interventionunits on a scale (Least Squares Mean)
Vortioxetine 10 mg/Day-1.90
Vortioxetine 20 mg/Day-1.71
Fluoxetine 20 mg/Day,-2.45
Placebo-2.12

Change in PedsQL VAS: Tired (Fatigue) Score

The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The patients are asked to mark on the line how they feel. A lower value represents a better outcome. (NCT02709746)
Timeframe: From Randomization to week 8

Interventionunits on a scale (Least Squares Mean)
Vortioxetine 10 mg/Day-1.18
Vortioxetine 20 mg/Day-1.40
Fluoxetine 20 mg/Day,-1.55
Placebo-1.27

Change in PedsQL VAS: Worry Score

The PedsQL™ VAS is designed to measure at-that-moment functioning in children and adolescents. The PedsQL VAS consists of 6 domains: anxiety, sadness, anger, worry, fatigue and pain using visual analogue scales. The functionality for each domain is measured on a 10 cm line with a happy face at one end and a sad face at the other (0-10 points). The patients are asked to mark on the line how they feel. A lower value represents a better outcome. (NCT02709746)
Timeframe: From Randomization to Week 8

Interventionunits on a scale (Least Squares Mean)
Vortioxetine 10 mg/Day-0.96
Vortioxetine 20 mg/Day-1.17
Fluoxetine 20 mg/Day,-0.91
Placebo-1.33

Change in PQ-LES-Q Overall Score

PQ-LES-Q overall evaluation score (item 15). The PQ-LES-Q is a patient-rated scale designed to assess satisfaction with life. It is an adaptation of the Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q), which is used to measure quality of life in adults. The PQ-LES-Q consist of 15 items, item 1-14 assess the degree of satisfaction experienced by subjects in various areas of daily functioning and item 15 allows subjects to summarize their experience in a global rating (this outcome measurement). Item 15 is rated on a 5-point scale from 1 (very poor) to 5 (very good). (NCT02709746)
Timeframe: From Randomization to Week 8

Interventionunits on a scale (Least Squares Mean)
Vortioxetine 10 mg/Day0.54
Vortioxetine 20 mg/Day0.43
Fluoxetine 20 mg/Day,0.67
Placebo0.51

Change in Symbol Digit Modalities Test (SDMT)

The Symbol Digit Modalities Test (SDMT) is a cognitive test designed to assess speed of performance requiring visual perception, spatial decision-making and psychomotor skills. The SDMT consists of 110 geometric symbols that the patient has to substitute with a corresponding digit in a 90-second period. Each correct digit is counted, and the total score ranges from 0 (less than normal functioning) to 110 (greater than normal functioning). (NCT02709746)
Timeframe: From Randomization to Week 8

Interventionunits on a scale (Least Squares Mean)
Vortioxetine 10 mg/Day3.75
Vortioxetine 20 mg/Day2.64
Fluoxetine 20 mg/Day,2.69
Placebo2.41

Clinical Global Impression - Global Improvement (CGI-I) Score

The CGI-I provides the clinician's impression of the patient's improvement (or worsening). The clinician assesses the patient's condition relative to a baseline on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). In all cases, the assessment should be made independent of whether the rater believes the improvement is drug-related or not. (NCT02709746)
Timeframe: From Randomization to Week 8

Interventionunits on a scale (Least Squares Mean)
Vortioxetine 10 mg/Day2.81
Vortioxetine 20 mg/Day2.69
Fluoxetine 20 mg/Day,2.50
Placebo2.73

Parent Global Assessment-Global Improvement (PGA) Score

The PGA is a parent-rated variation of the CGI-I to evaluate the severity of the child's symptoms. The PGA reflects assessments of change from Baseline symptoms using a 7 point scale ranging from 1 (very much improved) to 7 (very much worse). (NCT02709746)
Timeframe: From Randomization to Week 8

Interventionunits on a scale (Least Squares Mean)
Vortioxetine 10 mg/Day2.80
Vortioxetine 20 mg/Day2.74
Fluoxetine 20 mg/Day,2.49
Placebo2.72

Depressive Relapse or MDD

"Longitudinal Interval Follow-up Evaluation - Psychiatric Status Rating (LIFE-PSR) of 5 or more (on a scale from 1 to 6 measuring major depressive disorder) for 2 consecutive weeks according to evaluator blinded to randomized assignment~LIFE-PSR Scale:~= No residual symptoms, no current evidence of the disorder.~= Mild symptoms~= Considerably less psychopathology than full criteria with no more than moderate impairment~= Does not meet full criteria but has major symptoms of impairment~= Meets criteria without extreme impairment in functioning~= Meets criteria with extreme impairment in functioning~The relapse rate was estimated using Kaplan-Meier estimates (Kaplan, Meier J Am Stat, 1958, pp.457-481)" (NCT00118404)
Timeframe: Measured at month 8

Intervention% patients who relapsed (Number)
Continuation Phase Fluoxetine18
Continuation Phase Cognitive Therapy18.3
Continuation Phase Pill Placebo32.7

Depressive Relapse/Recurrence or MDD

"Longitudinal Interval Follow-up Evaluation - Psychiatric Status Rating (LIFE-PSR) of 5 or more (on a scale from 1 to 6 measuring MDD) for 2 consecutive weeks according to evaluator blinded to randomized assignment~LIFE-PSR Scale:~= No residual symptoms, no current evidence of the disorder.~= Mild symptoms~= Considerably less psychopathology than full criteria with no more than moderate impairment~= Does not meet full criteria but has major symptoms of impairment~= Meets criteria without extreme impairment in functioning~= Meets criteria with extreme impairment in functioning~Relapse/recurrence rate was estimated using Kaplan-Meier estimates (Kaplan, Meier J Am Stat, 1958, pp.457-481)." (NCT00118404)
Timeframe: Measured at month 32

Intervention% patients who relapsed/recurred (Number)
Continuation Phase Fluoxetine41.1
Continuation Phase Cognitive Therapy45.2
Continuation Phase Pill Placebo56.3

Depressive Relapse/Recurrence or MDD

"Longitudinal Interval Follow-up Evaluation - Psychiatric Status Rating (LIFE-PSR) of 5 or more (on a scale from 1 to 6 measuring MDD) for 2 consecutive weeks according to evaluator blinded to randomized assignment~LIFE-PSR Scale:~= No residual symptoms, no current evidence of the disorder.~= Mild symptoms~= Considerably less psychopathology than full criteria with no more than moderate impairment~= Does not meet full criteria but has major symptoms of impairment~= Meets criteria without extreme impairment in functioning~= Meets criteria with extreme impairment in functioning~Relapse/recurrence rate was estimated using Kaplan-Meier estimates (Kaplan, Meier J Am Stat, 1958, pp.457-481)" (NCT00118404)
Timeframe: Measured at month 20

Intervention% patients who relapsed/recurred (Number)
Continuation Phase Fluoxetine35.1
Continuation Phase Cognitive Therapy35.0
Continuation Phase Pill Placebo42.7

Functional Magnetic Resonance Imaging (fMRI) Response to an Emotional Regulation Task.

"Depressed participants were scanned while viewing a sequence of positive and negative images; they were instructed to enhance or supress their emotional response to the image or to continue to attend. To examine brain function when regulating negative affect, we created contrast maps for each participant at all 3 time points by subtracting the attend condition from the suppress condition in response to negative stimuli. Data from all 3 scan sessions were used to assess treatment-induced change in brain activity when regulating emotion. Analyses examining change using difference scores (end vs. starting points), we subtracted initial HAMD score from final HAMD score. For fMRI analyses, in a voxelwise manner, we subtracted initial negative suppress vs attend from final negative suppress vs attend.~Control subjects were not depressed, repeat scans to assess change were not completed.~Reported results are from BA10, one of our areas of interest." (NCT00909155)
Timeframe: At study entry, 2 months and end of study (6 months)

InterventionfMRI signal change (Mean)
Depressed; Venlafaxine Treatment-0.042666667
Depressed; Fluoxetine Treatment0.0414

Hamilton Depression (HAM-D) and Anxiety (HAM-A) Rating Scales

"Hamilton Depression rating scale is a clinician assessment tool to measure severity of depression symptoms. Minimum score is 0 (no symptoms); maximum score is 52 (severe symptoms of depression).~Hamilton Anxiety rating scale is a clinician assessment tool to measure severity of anxiety symptoms. Minimum score is 0 (no symptoms); maximum score is 56 (severe symptoms of anxiety)." (NCT00909155)
Timeframe: Study entry, 2 months, and at end of study (6 mos)

,,
Interventionunits on a scale (Mean)
HAMD T0HAMA T0HAMD 2monthsHAMA 2monthsHAMD 6monthsHAMA 6months
Control (Non-psychiatric Subjects)1NA1.25NA1.64NA
Currently Depressed Subjects: Fluoxetine21.3615.5710.158.547.335.89
Currently Depressed Subjects: Venlafaxine20.0714.078.867.554.25

Change From Baseline in Children's Depression Rating Scale-Revised (CDRS-R) Total Score at Week 10 Endpoint

CDRS-R Total score measure the presence and severity of depression in children. The scale consists of 17 items scored on a 1-to-5- or 1-to-7-point scale. A rating of 1 indicates normal functioning. Total scores range from 17 to 113. In general, scores below 20 indicate an absence of depression, scores of 20 to 30 indicate borderline depression, and scores of 40 to 60 indicate moderate depression. Least Square (LS) means are adjusted for baseline, pooled investigator, age category, visit, treatment, treatment*visit, age category*visit and baseline*visit. (NCT00849901)
Timeframe: Baseline, Week 10

Interventionunits on a scale (Least Squares Mean)
Duloxetine-24.3
Fluoxetine-23.7
Placebo-24.3

Change From Baseline in Clinical Global Impressions of Severity (CGI-Severity) Scale at Week 10 Endpoint

CGI-Severity evaluates the severity of illness at the time of assessment. The score ranges from 1 (normal, not at all ill) to 7 (among the most extremely ill patients). LS means are adjusted for baseline, pooled investigator, age category, visit, treatment, treatment*visit, age category*visit and baseline*visit. (NCT00849901)
Timeframe: Baseline, Week 10

Interventionunits on a scale (Least Squares Mean)
Duloxetine-1.9
Fluoxetine-1.8
Placebo-1.9

Change From Week 10 in Children's Depression Rating Scale-Revised (CDRS-R) Total Score at Week 36 Endpoint

CDRS-R Total score measure the presence and severity of depression in children. The scale consists of 17 items scored on a 1-to-5- or 1-to-7-point scale. A rating of 1 indicates normal functioning. Total scores range from 17 to 113. In general, scores below 20 indicate an absence of depression, scores of 20 to 30 indicate borderline depression, and scores of 40 to 60 indicate moderate depression. LS means are adjusted for baseline, pooled investigator, age category, visit, age category*visit and baseline*visit. (NCT00849901)
Timeframe: Week 10, Week 36

Interventionunits on a scale (Least Squares Mean)
Duloxetine/Duloxetine-7.2
Fluoxetine/Fluoxetine-9.9
Placebo/Duloxetine-9.6

Change From Week 10 in Clinical Global Impressions of Severity (CGI-Severity) Scale at Week 36 Endpoint

CGI-Severity evaluates the severity of illness at the time of assessment. The score ranges from 1 (normal, not at all ill) to 7 (among the most extremely ill patients). LS means are adjusted for baseline, pooled investigator, age category, visit, age category*visit and baseline*visit. (NCT00849901)
Timeframe: Week 10, Week 36

Interventionunits on a scale (Least Squares Mean)
Duloxetine/Duloxetine-0.6
Fluoxetine/Fluoxetine-1.0
Placebo/Duloxetine-1.1

Change From Baseline in Children's Depression Rating Scale-Revised (CDRS-R) Subscale Score at Week 10 Endpoint

CDRS-R Subscale scores include Mood (Sum of items 8, 11, 14, 15), Somatic (Sum of items 4-7, 16, 17), Subjective (Sum of items 9, 10, 12, 13) and Behavior (Sum of items 1-3). Mood and Subjective subscale scores range from 4 to 28; Somatic subscale scores range from 6 to 36; Behavior subscale scores range from 3 to 21. Higher score indicates greater severity of disease. LS means are adjusted for baseline, pooled investigator, age category, visit, treatment, treatment*visit, age category*visit and baseline*visit. (NCT00849901)
Timeframe: Baseline, Week 10

,,
Interventionunits on a scale (Least Squares Mean)
Mood (N=113, 113, 103)Somatic (N=113, 113, 103)Subjective (N=113, 113, 103)Behavior (N=113, 112, 103)
Duloxetine-7.0-7.7-4.0-5.6
Fluoxetine-7.1-7.6-3.6-5.4
Placebo-7.0-7.7-4.0-5.7

Change From Week 10 in Children's Depression Rating Scale-Revised (CDRS-R) Subscale Score at Week 36 Endpoint

CDRS-R Subscale scores include Mood (Sum of items 8, 11, 14, 15), Somatic (Sum of items 4-7, 16, 17), Subjective (Sum of items 9, 10, 12, 13) and Behavior (Sum of items 1-3). Mood and Subjective subscale scores range from 4 to 28; Somatic subscale scores range from 6 to 36; Behavior subscale scores range from 3 to 21. Higher score indicates greater severity of disease. LS means are adjusted for baseline, pooled investigator, age category, visit, age category*visit and baseline*visit. (NCT00849901)
Timeframe: Week 10, Week 36

,,
Interventionunits on a scale (Least Squares Mean)
MoodSomaticSubjectiveBehavior
Duloxetine/Duloxetine-1.9-2.8-0.3-1.9
Fluoxetine/Fluoxetine-2.5-3.6-1.3-2.8
Placebo/Duloxetine-2.9-3.2-1.2-2.1

Number of Participants With Potentially Clinically Significant Hepatic Laboratory Results Any Time Baseline Through Week 10

Total number of participants with any abnormal post-baseline value, based on all values at scheduled and unscheduled visits. Potentially clinically significant hepatic laboratory results at any time are defined as alanine transaminase (ALT) ≥3 x upper limit of normal (ULN), ALT ≥5 x ULN and ALT ≥10 x ULN, as well as ALT ≥3 x ULN and Total Bilirubin ≥2 x ULN. (NCT00849901)
Timeframe: Baseline through Week 10

,,
Interventionparticipants (Number)
ALT≥3 x ULNALT≥5 x ULNALT≥10 x ULNALT≥3 x ULN and Total Bilirubin≥2 x ULN
Duloxetine0000
Fluoxetine0000
Placebo0000

Number of Participants With Potentially Clinically Significant Hepatic Laboratory Results Any Time Week 10 Through Week 36

Total number of participants with any abnormal post-baseline value, based on all values at scheduled and unscheduled visits. Potentially clinically significant hepatic laboratory results at any time are defined as alanine transaminase (ALT) ≥3 x upper limit of normal (ULN), ALT ≥5 x ULN and ALT ≥10 x ULN, as well as ALT ≥3 x ULN and Total Bilirubin ≥2 x ULN. (NCT00849901)
Timeframe: Week 10 through Week 36

,,
Interventionparticipants (Number)
ALT≥3 x ULNALT≥5 x ULNALT≥10 x ULNALT≥3 x ULN and Total Bilirubin≥2 x ULN
Duloxetine/Duloxetine0000
Fluoxetine/Fluoxetine1100
Placebo/Duloxetine0000

Number of Participants With Suicidal Ideation or Suicidal Behavior Baseline Through Week 10

"Columbia Suicide Rating Scale (C-SSRS) captures occurrence, severity, and frequency of suicide-related thoughts and behaviors. Suicidal behavior: a yes answer to any of 5 suicidal behavior questions: preparatory acts or behavior, aborted attempt, interrupted attempt, actual attempt, and completed suicide. Suicidal ideation: a yes answer to any one of 5 suicidal ideation questions: wish to be dead, and 4 different categories of active suicidal ideation. Treatment Emergent Suicidal Ideation is worsening or new occurrence of events during treatment compared to lead-in baseline (Week -1 - 0)." (NCT00849901)
Timeframe: Baseline through Week 10

,,
Interventionparticipants (Number)
Suicidal IdeationSuicidal BehaviorTreatment Emergent Suicidal Ideation
Duloxetine1608
Fluoxetine1619
Placebo1507

Number of Participants With Suicidal Ideation or Suicidal Behavior Week 10 Through Week 36

"Columbia Suicide Rating Scale (C-SSRS) captures occurrence, severity, and frequency of suicide-related thoughts and behaviors. Suicidal behavior: a yes answer to any of 5 suicidal behavior questions: preparatory acts or behavior, aborted attempt, interrupted attempt, actual attempt, and completed suicide. Suicidal ideation: a yes answer to any one of 5 suicidal ideation questions: wish to be dead, and 4 different categories of active suicidal ideation. Treatment Emergent Suicidal Ideation is worsening or new occurrence of events during treatment compared to lead-in baseline (Week 7-10)." (NCT00849901)
Timeframe: Week 10 through Week 36

,,
Interventionparticipants (Number)
Suicidal IdeationSuicidal BehaviorTreatment Emergent Suicidal Ideation
Duloxetine/Duloxetine1319
Fluoxetine/Fluoxetine13113
Placebo/Duloxetine808

Percentage of Participants With Potentially Clinically Significant (PCS) Changes in Systolic Blood Pressure (BP), Diastolic BP, Pulse, and Weight Any Time Baseline Through Week 10

PCS increase in systolic and diastolic BP was defined as increase of ≥5 millimeter mercury (mm Hg) from baseline (BL) high value to a value above the 95th percentile at post-BL; PCS increase of pulse was defined as >140 and increase of ≥15 from BL high value for age 7-11 and >120 and increase of ≥15 from BL high value for age 12-17; PCS decrease of pulse was defined as <60 and a decrease of ≥25 from BL low value for age 7-11 and <50 and a decrease of ≥15 from BL low value for age 12-17; PCS decrease of weight was defined as decrease of at least 3.5% from BL low value. (NCT00849901)
Timeframe: Baseline through Week 10

,,
Interventionpercentage of participants (Number)
Diastolic BP Increase (N=102, 106, 93)Systolic BP Increase (N=100, 106, 90)Pulse Decrease (N=111, 112, 102)Pulse Increase (N=113, 114, 103)Weight Decrease (N=113, 114, 103)
Duloxetine8.87.00.9012.4
Fluoxetine7.55.70.9011.4
Placebo17.26.71.01.04.9

Percentage of Participants With Potentially Clinically Significant (PCS) Changes in Systolic Blood Pressure (BP), Diastolic BP, Pulse, and Weight Any Time Week 10 Through Week 36

PCS increase in systolic and diastolic BP was defined as increase of ≥ 5mm Hg from baseline (BL) high value to a value above the 95th percentile at post-BL; PCS increase of pulse was defined as >140 and increase of ≥15 from BL high value for age 7-11 and >120 and increase of ≥15 from BL high value for age 12-17; PCS decrease of pulse was defined as <60 and a decrease of ≥25 from BL low value for age 7-11 and <50 and a decrease of ≥15 from BL low value for age 12-17; PCS decrease of weight was defined as decrease of at least 3.5% from BL low value. (NCT00849901)
Timeframe: Week 10 through Week 36

,,
Interventionpercentage of participants (Number)
Diastolic BP Increase (N=65, 76, 61)Systolic BP Increase (N=64, 80, 69)Pulse Decrease (N=78, 84, 82)Pulse Increase (N=81, 91, 84)Weight Decrease (N=81, 91, 85)
Duloxetine/Duloxetine16.912.5006.2
Fluoxetine/Fluoxetine11.812.5003.3
Placebo/Duloxetine4.910.1009.4

Change From Baseline in Children's Depression Rating Scale-Revised (CDRS-R) Total Score at Week 10 Endpoint

CDRS-R Total score measure the presence and severity of depression in children. The scale consists of 17 items scored on a 1-to-5- or 1-to-7-point scale. A rating of 1 indicates normal functioning. Total scores range from 17 to 113. In general, scores below 20 indicate an absence of depression, scores of 20 to 30 indicate borderline depression, and scores of 40 to 60 indicate moderate depression. Least Square (LS) means are adjusted for baseline, pooled investigator, age category, visit, treatment, treatment*visit, age category*visit and baseline*visit. (NCT00849693)
Timeframe: Baseline, Week 10

,
Interventionunits on a scale (Least Squares Mean)
Duloxetine 60mg-23.9
Placebo-21.6
Duloxetine 30mg-24.6
Fluoxetine 20mg-22.6
Placebo-21.6

Change From Baseline in Clinical Global Impressions of Severity (CGI-Severity) Scale at Week 10 Endpoint

CGI-Severity evaluates the severity of illness at the time of assessment. The score ranges from 1 (normal, not at all ill) to 7 (among the most extremely ill patients). LS means are adjusted for baseline, pooled investigator, age category, visit, treatment, treatment*visit, age category*visit and baseline*visit. (NCT00849693)
Timeframe: Baseline, Week 10

Interventionunits on a scale (Least Squares Mean)
Duloxetine 60mg-1.5
Duloxetine 30mg-1.5
Fluoxetine 20mg-1.4
Placebo-1.4

Change From Week 10 in Children's Depression Rating Scale-Revised (CDRS-R) Total Score at Week 36 Endpoint

CDRS-R Total score measure the presence and severity of depression in children. The scale consists of 17 items scored on a 1-to-5- or 1-to-7-point scale. A rating of 1 indicates normal functioning. Total scores range from 17 to 113. In general, scores below 20 indicate an absence of depression, scores of 20 to 30 indicate borderline depression, and scores of 40 to 60 indicate moderate depression. LS means are adjusted for baseline, pooled investigator, age category, visit, age category*visit and baseline*visit. (NCT00849693)
Timeframe: Week 10, Week 36

Interventionunits on a scale (Least Squares Mean)
Duloxetine 60 mg / Duloxetine 60-120 mg-7.8
Duloxetine 30 mg/Duloxetine 60-120 mg-7.4
Fluoxetine 20 mg/Fluoxetine 20-40 mg-10.0
Placebo/Duloxetine 60-120 mg-9.0

Change From Week 10 in Clinical Global Impressions of Severity (CGI-Severity) Scale at Week 36 Endpoint

CGI-Severity evaluates the severity of illness at the time of assessment. The score ranges from 1 (normal, not at all ill) to 7 (among the most extremely ill patients). LS means are adjusted for baseline, pooled investigator, age category, visit, age category*visit and baseline*visit. (NCT00849693)
Timeframe: Week 10, Week 36

Interventionunits on a scale (Least Squares Mean)
Duloxetine 60 mg / Duloxetine 60-120 mg-1.1
Duloxetine 30 mg/Duloxetine 60-120 mg-0.9
Fluoxetine 20 mg/Fluoxetine 20-40 mg-1.3
Placebo/Duloxetine 60-120 mg-1.0

Change From Baseline in Children's Depression Rating Scale-Revised (CDRS-R) Subscale Score at Week 10 Endpoint

CDRS-R Subscale scores include Mood (Sum of items 8, 11, 14, 15), Somatic (Sum of items 4-7, 16, 17), Subjective (Sum of items 9, 10, 12, 13) and Behavior (Sum of items 1-3). Mood and Subjective subscale scores range from 4 to 28; Somatic subscale scores range from 6 to 36; Behavior subscale scores range from 3 to 21. Higher score indicates greater severity of disease. LS means are adjusted for baseline, pooled investigator, age category, visit, treatment, treatment*visit, age category*visit and baseline*visit. (NCT00849693)
Timeframe: Baseline, Week 10

,,,
Interventionunits on a scale (Least Squares Mean)
MoodSomaticSubjectiveBehavior
Duloxetine 30mg-7.2-7.9-4.0-5.6
Duloxetine 60mg-7.1-7.6-3.6-5.8
Fluoxetine 20mg-6.6-7.1-3.5-5.6
Placebo-6.4-6.4-3.6-5.4

Change From Week 10 in Children's Depression Rating Scale-Revised (CDRS-R) Subscale Score at Week 36 Endpoint

CDRS-R Subscale scores include Mood (Sum of items 8, 11, 14, 15), Somatic (Sum of items 4-7, 16, 17), Subjective (Sum of items 9, 10, 12, 13) and Behavior (Sum of items 1-3). Mood and Subjective subscale scores range from 4 to 28; Somatic subscale scores range from 6 to 36; Behavior subscale scores range from 3 to 21. Higher score indicates greater severity of disease. LS means are adjusted for baseline, pooled investigator, age category, visit, age category*visit and baseline*visit. (NCT00849693)
Timeframe: Week 10, Week 36

,,,
Interventionunits on a scale (Least Squares Mean)
MoodSomaticSubjectiveBehavior
Duloxetine 30 mg/Duloxetine 60-120 mg-1.9-2.4-1.3-1.8
Duloxetine 60 mg / Duloxetine 60-120 mg-1.9-2.8-1.2-2.1
Fluoxetine 20 mg/Fluoxetine 20-40 mg-2.4-4.0-1.5-2.7
Placebo/Duloxetine 60-120 mg-2.3-3.2-1.0-2.4

Number of Participants With Potentially Clinically Significant Hepatic Laboratory Results Any Time Baseline Through Week 10

Total number of participants with any abnormal post-baseline value, based on all values at scheduled and unscheduled visits. Potentially clinically significant hepatic laboratory results at any time are defined as alanine transaminase (ALT) ≥3 x upper limit of normal (ULN), ALT ≥5 x ULN and ALT ≥10 x ULN, as well as ALT ≥3 x ULN and Total Bilirubin ≥2 x ULN. (NCT00849693)
Timeframe: Baseline through Week 10

,,,
Interventionparticipants (Number)
ALT≥3 x ULNALT≥5 x ULNALT≥10 x ULNALT≥3 x ULN and Total Bilirubin≥2 x ULN
Duloxetine 30mg0000
Duloxetine 60mg0000
Fluoxetine 20mg0000
Placebo0000

Number of Participants With Potentially Clinically Significant Hepatic Laboratory Results Any Time Week 10 Through Week 36

Total number of participants with any abnormal post-baseline value, based on all values at scheduled and unscheduled visits. Potentially clinically significant hepatic laboratory results at any time are defined as ALT ≥3 x ULN, ALT ≥5 x ULN and ALT ≥10 x ULN, as well as ALT≥3 x ULN and Total Bilirubin ≥2 x ULN. (NCT00849693)
Timeframe: Week 10 through Week 36

,,,
Interventionparticipants (Number)
ALT≥3 x ULNALT≥5 x ULNALT≥10 x ULNALT≥3 x ULN and Total Bilirubin≥2 x ULN
Duloxetine 30 mg/Duloxetine 60-120 mg0000
Duloxetine 60 mg / Duloxetine 60-120 mg0000
Fluoxetine 20 mg/Fluoxetine 20-40 mg0000
Placebo/Duloxetine 60-120 mg0000

Number of Participants With Suicidal Ideation or Suicidal Behavior Baseline Through Week 10

"Columbia Suicide Rating Scale (C-SSRS) captures occurrence, severity, and frequency of suicide-related thoughts and behaviors. Suicidal behavior: a yes answer to any of 5 suicidal behavior questions: preparatory acts or behavior, aborted attempt, interrupted attempt, actual attempt, and completed suicide. Suicidal ideation: a yes answer to any one of 5 suicidal ideation questions: wish to be dead, and 4 different categories of active suicidal ideation. Treatment Emergent Suicidal Ideation is worsening or new occurrence of events during treatment compared to lead-in baseline (Week -1 to 0)." (NCT00849693)
Timeframe: Baseline through Week 10

,,,
Interventionparticipants (Number)
Suicidal IdeationSuicidal BehaviorTreatment Emergent Suicidal Ideation
Duloxetine 30mg1106
Duloxetine 60mg1607
Fluoxetine 20mg1319
Placebo15111

Number of Participants With Suicidal Ideation or Suicidal Behavior Week 10 Through Week 36

"Columbia Suicide Rating Scale (C-SSRS) captures occurrence, severity, and frequency of suicide-related thoughts and behaviors. Suicidal behavior: a yes answer to any of 5 suicidal behavior questions: preparatory acts or behavior, aborted attempt, interrupted attempt, actual attempt, and completed suicide. Suicidal ideation: a yes answer to any one of 5 suicidal ideation questions: wish to be dead, and 4 different categories of active suicidal ideation. Treatment Emergent Suicidal Ideation is worsening or new occurrence of events during treatment compared to lead-in baseline (Week 7-10)." (NCT00849693)
Timeframe: Week 10 through Week 36

,,,
Interventionparticipants (Number)
Suicidal IdeationSuicidal BehaviorTreatment Emergent Suicidal Ideation
Duloxetine 30 mg/Duloxetine 60-120 mg1238
Duloxetine 60 mg / Duloxetine 60-120 mg625
Fluoxetine 20 mg/Fluoxetine 20-40 mg807
Placebo/Duloxetine 60-120 mg816

Percentage of Participants With Potentially Clinically Significant (PCS) Changes in Systolic Blood Pressure (BP), Diastolic BP, Pulse, and Weight Any Time Baseline Through Week 10

PCS increase in systolic and diastolic BP was defined as increase of ≥5 millimeter mercury (mm Hg) from baseline (BL) high value to a value above the 95th percentile at post-BL; PCS increase of pulse was defined as >140 and increase of ≥15 from BL high value for age 7-11 and >120 and increase of ≥15 from BL high value for age 12-17; PCS decrease of pulse was defined as <60 and a decrease of ≥25 from BL low value for age 7-11 and <50 and a decrease of ≥15 from BL low value for age 12-17; PCS decrease of weight was defined as decrease of at least 3.5% from BL low value. (NCT00849693)
Timeframe: Baseline through Week 10

,,,
Interventionpercentage of participants (Number)
Diastolic BP Increase (N=93, 100, 99, 110)Systolic BP Increase (N=88, 95, 93, 98)Pulse Decrease (N=100, 108, 108, 112)Pulse Increase (N=105, 114, 112, 117)Weight Decrease (N=105, 114, 112, 117)
Duloxetine 30mg7.012.6008.8
Duloxetine 60mg11.89.10013.3
Fluoxetine 20mg10.112.90011.6
Placebo4.510.2005.1

Percentage of Participants With Potentially Clinically Significant (PCS) Changes in Systolic Blood Pressure (BP), Diastolic BP, Pulse, and Weight Any Time Week 10 Through Week 36

PCS increase in systolic and diastolic BP was defined as increase of ≥5 mm Hg from baseline (BL) high value to a value above the 95th percentile at post-BL; PCS increase of pulse was defined as >140 and increase of ≥15 from BL high value for age 7-11 and >120 and increase of ≥15 from BL high value for age 12-17; PCS decrease of pulse was defined as <60 and a decrease of ≥25 from BL low value for age 7-11 and <50 and a decrease of ≥15 from BL low value for age 12-17; PCS decrease of weight was defined as decrease of at least 3.5% from BL low value. (NCT00849693)
Timeframe: Week 10 through Week 36

,,,
Interventionpercentage of participants (Number)
Diastolic BP Increase (N=55, 65, 64, 69)Systolic BP Increase (N=53, 62, 57, 57)Pulse Decrease (N=68, 75, 76, 73)Pulse Increase (N=71, 78, 81, 79)Weight Decrease (N=71, 78, 81, 79)
Duloxetine 30 mg/Duloxetine 60-120 mg4.66.5009.0
Duloxetine 60 mg / Duloxetine 60-120 mg14.59.401.42.8
Fluoxetine 20 mg/Fluoxetine 20-40 mg20.37.0003.7
Placebo/Duloxetine 60-120 mg11.610.501.313.9

K-Life (Time Well)

"K-Life interview was conducted at Weeks 6, 12, 18, 24, and 30, with ratings for depressive illness for each week throughout the study.~Ratings definitions: 1=Normal, no residual symptoms; 2=Presence of 1 or more symptosm in no more than mild degree; 3=Considerably less psychopathology than full criteria, but still obvious evidence of disorder with no more than moderate impairment; 4=Does not meet full criteria, but has major symptoms or impairment from the disorder; 5=Meets full criteria, but no extreme impairment; 6=Meets full criteria, and either has prominent psychotic symptoms or extreme impairment.~Time well is defined as each week the depression rating was a 1 or 2. Percent time well was defined as each week the depression rating was a 1 or 2 divided by the total number of weeks in the study.~Statistic: anova" (NCT00612313)
Timeframe: 30 weeks

InterventionWeeks spent well (Mean)
Continued Medication Alone12.8
Continued Medication Plus CBT16.0

Time to Remission

Remission is defined as CDRS-R <=28. Timing of remission is based on clinical assessment using the CDRS-R and K-Life to identify the week at which point the patient remitted. (NCT00612313)
Timeframe: 30 weeks

Interventionweeks (Mean)
Continued Medication Alone13.67
Continued Medication Plus CBT11.33

Relapse

"Relapse was defined as:~1) CDRS-R score >=40 with a history of 2 weeks of clinical deterioration or 2) CDRS-R<40, but with a 2 week history of significant clinical deterioration." (NCT00612313)
Timeframe: Measured at Weeks 12, 18, 24, and 30

,
Interventionprobability of relapse (%) (Number)
Week 12Week 18Week 24Week 30
Continued Medication Alone31020.526.5
Continued Medication Plus CBT13.579

Relapse

"Up through week 30, relapse was defined as:~1) CDRS-R score >=40 with a history of 2 weeks of clinical deterioration or 2) CDRS-R<40, but with a 2 week history of significant clinical deterioration.~From week 31-78, relapse was assessed using the K-Life. Relapse was defined as at least 2 weeks of a K-Life rating of 5 or 6; participants may also be identified as relapsing with a K-Life rating of 4 if the rating was for several weeks and not strictly related to stressful life events." (NCT00612313)
Timeframe: Weeks 52 and 78

,
InterventionProbability of Relapse (%) (Number)
Week 52Week 78
Continued Medication Alone4962
Continued Medication Plus CBT2736

Remission

Remission is defined as CDRS-R <=28 (up through week 30) or at least 8 consecutive weeks of a K-Life rating of 1 or 2. Timing of remission is based on clinical assessment using the CDRS-R and K-Life to identify the week at which point the patient remitted. (NCT00612313)
Timeframe: Weeks 52 and 78

,
InterventionProbability of remission (%) (Number)
Week 52Week 78
Continued Medication Alone8992
Continued Medication Plus CBT9496

Remission

Remission is defined as CDRS-R <=28. (NCT00612313)
Timeframe: Measured at Weeks 12, 18, 24, and 30

,
Interventionprobability of remitting (%) (Number)
Week 12Week 18Week 24Week 30
Continued Medication Alone59718084
Continued Medication Plus CBT68798690

Change From Baseline in 17-item Hamilton Rating Scale for Depression at 6 Weeks.

17-item Hamilton Rating Scale for Depression (HRSD) is a well-known standardized scale used worldwide to assess severity of depression. Score ranges from 0 (no depression) up to 52 (maximum depression severity). A total score in HRSD was assessed at baseline and after six weeks of treatment. For this study the change was calculated as the later time point (total score in 17- HRSD at 6 weeks) minus the earlier time point (total score at baseline). A score < or = 7 is considered normal, 7 - 13 (mild depression), 14 - 24 (moderate to severe depression), > 24 (severe depression). (NCT01635218)
Timeframe: Baseline and 6 weeks

InterventionUnits in Hamilton Scale (Mean)
Individualized Homeopathic Treatment9.9
Fluoxetine11.7
Placebo15

Change From Baseline in Beck Depression Inventory at 6 Weeks.

Beck Depression Inventory (BDI) is a 21-question multiple-choice self-report inventory that assess severity of depression. A total score range was assessed at baseline and after six weeks of treatment. A score 0 (without depression) up to 63 (most severe depression). For this study the change was calculated as the later time point (total score in BDI at 6 weeks) minus the earlier time point (total score in BDI at baseline). A score 0 - 8 is considered normal, 9 - 18 (mild to moderate depression), 19 - 28 (moderate to severe depression), > 29 (severe depression). (NCT01635218)
Timeframe: Baseline and 6 weeks

InterventionUnits in Beck Depression Inventory (Mean)
Individualized Homeopathic Treatment12
Fluoxetine14.2
Placebo15.5

Change From Baseline in Greene´s Scale at 6 Weeks.

Greene Climacteric Scale (GS) is intended to be a standard measure of core climacteric symptoms. For this study a total range was assessed at baseline and after six weeks of treatment. A total score 0 (without climacteric symptoms) up to 63 (most severe climacteric symptoms). The change was calculated as the later time point (total score in GS at 6 weeks) minus the earlier time point (total score at baseline).The scale measures four separate sub-scales (anxiety, depression, somatic symptoms and sexual function). The score of the four sub-scales was summed. A total score of 0 -10 is considered without symptoms, 11 - 29 (mild symptoms), 30 - 49 (moderate symptoms) and > 50 (severe symptoms). (NCT01635218)
Timeframe: Baseline and 6 weeks

InterventionUnits in Green Scale (Mean)
Individualized Homeopathic Treatment18.1
Fluoxetine23.1
Placebo26.8

Remission Rates at 6 Weeks

17-item Hamilton Rating Scale for Depression is a well-known standardized scale used worldwide to assess severity of depression. Score ranges from 0 (no depression) up to 52 (maximum depression severity). A total score in 17-item Hamilton Scale for Depression was assessed for this study. It ranges from 0 (no depression) up to 52 (most severe depression). A score < or = 7 is considered normal, 7 - 13 (mild depression), 14 - 24 (moderate to severe depression), > 24 (severe depression). Remission rate definition: 17-item Hamilton Rating Scale for Depression score < 7 points after 6 weeks of treatment. (NCT01635218)
Timeframe: 6 weeks

Interventionparticipants with a score of < 7 in HS (Number)
Individualized Homeopathic Treatment7
Fluoxetine7
Placebo2

Responder Rates at 6 Weeks.

17-item Hamilton Rating Scale for Depression is a well-known standardized scale used worldwide to assess severity of depression. Score ranges from 0 (no depression) up to 52 (maximum depression severity). A total score in 17-item Hamilton Scale for Depression was assessed for this study. It ranges from 0 (no depression) up to 52 (most severe depression). A score < or = 7 is considered normal, 7 - 13 (mild depression), 14 - 24 (moderate to severe depression), > 24 (severe depression). Responder rate definition: a decrease of 50% or more from baseline score using 17-item Hamilton Rating Scale for Depression after six weeks treatment. (NCT01635218)
Timeframe: 6 weeks

Interventionparticipants with a decrease >50% in HS (Number)
Individualized Homeopathic Treatment24
Fluoxetine19
Placebo5

Change in Pre- and Post-intervention Beck's Depression Inventory II Scores (BDI-II)

Change between pre-intervention and post-intervention self-reported answer totals to the 21 scored items on BDI-II (minimum score obtainable=0 (absent symptoms); maximum score obtainable=63 (most severe symptoms). (NCT04921332)
Timeframe: First at time of admission, second at end of 7 day goal or upon discharge.

Interventionscore on a scale (Mean)
Bright Light Therapy (BLT)8.750

Number of Days Until Completion of Daily Bright Light Therapy (BLT)

The RN will sign a daily log indicating what time therapy was initiated and if therapy was refused. These logs will be collected from patient doors at the end of each week by the principal investigator (PI) in order to measure compliance with completion of therapy on a daily basis. (NCT04921332)
Timeframe: Daily for duration of intervention period (goal/maximum of 7 days).

Interventiondays (Mean)
Bright Light Therapy Compliance (Secondary Outcome)4.5

Hamilton Rating Scale for Depression-17 Item Minus Sleep Items

Total score on a clinician-rated measure of depressive symptoms, minus 3 sleep items Total score range: 0-46. Higher scores represent more severe depression. (NCT01545843)
Timeframe: Post-treatment (8 weeks)

Interventionunits on a scale (Mean)
No Sleep Deprivation6.1
Late Bedtime Sleep Deprivation8.1
Early Risetime Sleep Deprivation6.3

Quick Inventory of Depressive Symptoms (QIDS)

Patient-reported depression symptom severity at post-treatment, total score. Total scores range from 0 to 27. Higher scores represent more severe depression. (NCT01545843)
Timeframe: Post-treatment (8 weeks)

Interventionunits on a scale (Mean)
No Sleep Deprivation5.3
Late Bedtime Sleep Deprivation6.9
Early Risetime Sleep Deprivation6.7

Change in EEG Sleep Measures I: Total Sleep Time

Measurement of EEG activity during sleep using polysomnography: Total Sleep Time is the length of time from sleep onset to final wake up minus any wakefulness during the night. It reflects the total amount of time asleep during the night. (NCT01545843)
Timeframe: Baseline, 2 weeks, 8 weeks

,,
Interventionminutes (Mean)
BaselineWeek 2Week 8
Early Risetime Sleep Deprivation444.040332.909433.333
Late Bedtime Sleep Deprivation439.208337.75428.264
No Sleep Deprivation430.132435.382439.6

Change in EEG Sleep Measures II (Sleep Efficiency)

Measurement of EEG activity during sleep using polysomnography: Sleep efficiency [(total sleep time/time in bed)*100] (NCT01545843)
Timeframe: Baseline, 2 weeks, 8 weeks

,,
Interventionpercent of sleep time (Mean)
BaselineWeek 2Week 8
Early Risetime Sleep Deprivation92.824892.908290.3838
Late Bedtime Sleep Deprivation91.682993.332288.9224
No Sleep Deprivation89.700590.782491.6153

Change in Neurologic Functioning: Reaction Time

Reaction Time is measured using a modified Go/No-go test of inhibitory control (NCT01545843)
Timeframe: 0, 2, 8 weeks

,,
Interventionmilliseconds (Mean)
Week 0 (Baseline)Week 2Week 8
Early Risetime Sleep Deprivation470.2942472.7244500.1197
Late Bedtime Sleep Deprivation528.3513519.8196557.1635
No Sleep Deprivation499.1545493.2579483.7349

Change in Neuropsychological Functioning: Memory

Change in different aspects of thinking (e.g., memory, attention, executive functioning) (NCT01545843)
Timeframe: Baseline, 2 weeks, 8 weeks

,,
Interventionwords (Mean)
BaselineWeek 2Week 8
Early Risetime Sleep Deprivation76.09577.40081.200
Late Bedtime Sleep Deprivation74.93881.52979.733
No Sleep Deprivation77.11876.64773.923

Neurological Function (Emotional Perception)

Emotional Perception is measured based on the percent of faces whose emotions are correctly identified using the Facial Emotion Perception Test (FEPT) (NCT01545843)
Timeframe: 0 weeks, 2 weeks, 8 weeks

,,
Interventionpercentage of emotions accurately ID'ed (Mean)
0 weeks (Baseline)Week 2Week 8
Early Risetime Sleep Deprivation88.8388.7587.74
Late Bedtime Sleep Deprivation86.2488.1589.15
No Sleep Deprivation83.5483.0885.95

Pittsburgh Sleep Quality Index

Self-report measure of sleep quality. The Pittsburgh Sleep Quality Index is a validated scale which measures self-reported sleep quality based on a wide variety of questions (duration, quality, disturbances, medication, etc.) and converts them to a scale which ranges from 0 to 21 where 6 or higher denotes poor sleep quality. (NCT01545843)
Timeframe: Baseline, 2 weeks and 8 weeks post-treatment

,,
Interventionunits on a scale (Mean)
BaselineWeek 2Week 8
Early Risetime Sleep Deprivation6.855.506.33
Late Bedtime Sleep Deprivation8.676.076.23
No Sleep Deprivation6.005.234.86

Change From Baseline in the Dysphoric Apathy/Retardation Sub-factor (MDAR) of Montgomery-Asberg Depression Rating Scale (MADRS) at 4 Weeks.

The Montgomery-Asberg Depression Rating Scale Dysphoric Apathy Retardation subfactor (MDAR) is a 5-item subscale of the clinician-administered 10-item Montgomery-Asberg Depression Rating Scale (MADRS). MDAR score can range from 0-30 with a higher score representing a greater severity of depressive symptoms. (NCT01148979)
Timeframe: Baseline to 4 weeks of treatment

,
Interventionscores on a scale (Mean)
Baseline Mean MDAR scoreWeek 4 Mean MDAR scoreChange from BL in mean MDAR score
Lisdexamfetamine Dimesylate (Vyvanse)13.466.36-7.08
Placebo Adjunct12.579.08-3.49

Alcohol Use Behaviors

Alcohol use behaviors measured by drinks per week. (NCT00027378)
Timeframe: Average number of drinks as recorded on the Timeline Follow-Back (subject-reported) measure daily over the 12-week acute phase.

Interventionstandard drink (14 gr. alcohol) (Mean)
Fluoxetine Plus Treatment As Usual (TAU)1.56
Placebo Plus Treatment as Usual (TAU)1.73

Depressive Symptoms

Beck Depression Inventory (BDI) Scores measured at Weeks 1-4, 6, 8, 10, 12. The BDI is a subject reported measure that has a minimum score of 0 and a maximum score of 63. A better outcome would consist of values near the minimum end of the scale (0) and a worse outcome would consist of values near the maximum end of the scale (63). (NCT00027378)
Timeframe: Average score as measured by participant's report on the Beck Depression Inventory (BDI).

Interventionunits on a scale (Mean)
Fluoxetine Plus Treatment As Usual (TAU)6.79
Placebo Plus Treatment as Usual (TAU)10.46

Caregiver's Perceived Sense of Competency in Parenting Via Self-report Measure Parent Sense of Competency Scale (PSOC)

"The FOI-adapted Parenting Sense of Competence (PSOC) questionnaire is filled out by the caregiver to assess parents' sense of competence and enjoyment of parenting. This is an adapted version of the PSOC (original PSOC has 17 items, Johnston & Mash, 1989), with 18 items and simplified language for lower reading levels.~Items are answered on a 4-point Likert scale ranging from strongly agree to strongly disagree. Nine items (#s 2,3,4,5,8,9,13,15 and 17) are reverse coded so that, for all items, higher scores indicate greater parenting self-esteem.~Total score of parent's perceived sense of competency is calculated by summing up scores of all the 18 items, ranging from 18 to 72." (NCT03106636)
Timeframe: Change from baseline at endpoint (3-4 months post-baseline)

,
Interventionscore on a scale (Mean)
BaselineEndpointChange
KEEP-P49.4251.62.14
KEEP-P+49.8250.150.3

Child Attachment Behaviors Via Caregiver-report Measure Attachment Diary (ADRY)

"The Attachment Diary (ADRY) is a 47-item measure in which caregivers report how the child reacts when hurt, frightened, or separated from the caregiver by placing check marks on a behavior list. All the checked behaviors are coded into three categories, proximity seeking/contact maintenance, avoidance, and resistance, to assess individual differences in child's attachment behaviors. Thus, there are no total scores for the ADRY, only subscale scores for the three categories.~Outcomes include scores for proximity seeking/contact maintenance (range from 0 to 14), scores for avoidance (range from 0 to 18), and scores for resistance (range from 0 to 6), which are generated by counting the number of checked behaviors in corresponding subscales. Higher scores indicate higher levels of behaviors correspondingly." (NCT03106636)
Timeframe: Change from baseline at endpoint (3-4 months post-baseline)

,
Interventionscore on a scale (Mean)
Baseline ProximityEndpoint ProximityChange ProximityBaseline AvoidanceEndpoint AvoidanceChange AvoidanceBaseline ResistanceEndpoint ResistanceChange Resistance
KEEP-P7.537.750.221.841.78-0.030.720.57-0.08
KEEP-P+8.427.87-0.491.952.06-0.040.880.70-0.21

Child Executive Function Via Kansas Reflection-Impulsivity Scale for Preschoolers (KRISP)

"The Kansas Reflection-Impulsivity Scale for Preschoolers (KRISP) presents children with a target picture and 4-6 similar pictures. Children were asked to identify an exact match of the target picture.~Fifteen test trials were administered following a single practice trial. Each item was scored based on the number of incorrect responses, up to 3 errors. Final score is calculated as the number of errors subtracted from the total errors possible (45), ranging from 0 to 45. Higher score indicates better executive functioning." (NCT03106636)
Timeframe: Change from baseline at endpoint (3-4 months post-baseline)

,
Interventionscore on a scale (Mean)
BaselineEndpointChange
KEEP-P35.7637.812.16
KEEP-P+33.5235.83.96

Child Internalizing/Externalizing Symptoms and Total Behavior Score Via Caregiver-report Measure Child Behaviour Checklist (CBCL)

"The Child Behavior Checklist (CBCL) is a 100-item questionnaire to assess emotional and behavioral problems in children. Caregivers are asked to rate how often their child displayed certain behaviors in the past two months on a 3-point Likert scale (0 = Not True, 1 = Somewhat/Sometimes True, 2 = Very True/Often True).~Subscales include: Internalizing symptoms - Emotionally Reactive: 21, 46, 82, 83, 92, 97, 99; Anxious/Depressed: 10, 33, 37, 43, 47, 68, 87, 90; Somatic Complaints: 1, 7, 39, 45, 78, 86, 93; Withdrawn: 2, 4, 12, 19, 23, 62, 67, 70, 71, 98 Externalizing symptoms - Attention Problems: 5, 6, 24, 48, 51, 56, 59, 64, 95; Aggressive Behavior: 8, 14, 15, 16, 17, 18, 20, 22, 27, 28, 29, 35, 40, 42, 44, 53, 58, 66, 69, 74, 81, 84, 85, 88, 96 Raw scores for each subscale were calculated by summing up item scores correspondingly and then normalized to T-scores. The means are anchored to 50, with a standard deviation of 10 points. Higher T score indicates more behavior problems." (NCT03106636)
Timeframe: Change from baseline at endpoint (3-4 months post-baseline)

,
InterventionT-score (Mean)
BaselineEndpointChange
KEEP-P59.657.18-3.24
KEEP-P+61.6557.47-3.76

Child Social-emotional Development Via Caregiver-report Measure Ages and Stages Questionnaire: Social-Emotional (ASQ:SE)

"The Ages and Stages Questionnaires: Social-Emotional Development Screening Tool (ASQ:SE) is a caregiver-report questionnaire about children's social-emotional development.~The ASQ:SE has 29 questions, of which 26 questions are scored from 0-15, the others are open-ended. Therefore the total score (the sum of the 26 item scores) ranges from 0 to 390. Lower scores indicate more pocitive outcomes, i.e. better social-emotional development." (NCT03106636)
Timeframe: Change from baseline at endpoint (3-4 months post-baseline)

,
Interventionscore on a scale (Mean)
BaselineEndpointChange
KEEP-P121.35105-14.33
KEEP-P+125.81119.13-2.39

Dimensional Change Card Sort (DCCS)

The total number of phases passed in the DCCS. A phase was passed if 4/6 trials were correct. Children only proceeded to the next phase if they passed the previous phase. 5 phases total. Higher score indicates better executive functioning. (NCT03106636)
Timeframe: Change from baseline at endpoint (3-4 months post-baseline)

,
Interventionnumber of phases passed (Mean)
BaselineEndpointChange
KEEP-P1.762.120.48
KEEP-P+1.612.050.43

Frequency of Family Routines Via Self-report Measure Family Routines Questionnaire (FRQ)

"The Family Routines Questionnaire (FRQ) is a 28-item measure of the frequency and rated importance of family routines. Scores are calculated based on the how frequent the family's routines are and how important the routines are to them. The frequency of family routines construct was reported in the results.~To rate each endorsed routine by the frequency of its performance by the family, daily performance is assigned a weight of 3, a somewhat less frequency performance of 3-5 times a week is assigned a weight of 2; and an even less frequent performance of l-2 times a week is assigned a weight of 1. The 'almost never' category is taken to mean that the family does not participate in the particular routine, and it is therefore assigned a value of 0 in computing the total inventory score. By summing up frequency scores of all the 28 items, the total frequency score ranges from 0 to 84. Higher scores indicate higher frequency of family routines." (NCT03106636)
Timeframe: Change from baseline at endpoint (3-4 months post-baseline)

,
Interventionscore on a scale (Mean)
BaselineEndpointChange
KEEP-P51.6652.631.37
KEEP-P+50.4352.091.3

Mindful Parenting Via Self-report Measure Interpersonal Mindfulness in Parenting (IEMP)

"The Interpersonal Mindfulness in Parenting (IEMP) scale is a 10-item measure to investigate the quality of interpersonal mindfulness in parenting.~Items are answered on a 5-point Likert scale ranging from never true to always true. Four items (#s 1,5,9, and 10) are reverse coded.~Total score is the sum of all the item scores, ranging from 10 to 50. Higher scores indicate higher quality of Mindful parenting." (NCT03106636)
Timeframe: Change from baseline at endpoint (3-4 months post-baseline)

,
Interventionscore on a scale (Mean)
BaselineEndpointChange
KEEP-P37.8738.80.81
KEEP-P+37.1737.560.69

Observed Level of Child Inhibitory Control Via Bear/Dragon Task

"In the Bear/Dragon Task, children were presented with a nice bear and a mean dragon and instructed to do what the bear says (e.g., touch your nose), but not to do what the dragon says.~Children's compliance was scored on a 4-point scale on 5 bear trials (0 = failure to move; 1 = a wrong movement; 2 = a partial movement; 3 = a full correct movement) and 5 dragon trials (0 = a full commanded movement; 1 = a partial commanded movement; 2 = a flinch or wrong movement; 3 = no movement). Scores of each trial are summed up to produce a total score ranging from 0 to 30. A higher score indicates better inhibitory control." (NCT03106636)
Timeframe: Change from baseline at endpoint (3-4 months post-baseline)

,
Interventiontotal score (Mean)
BaselineEndpointChange
KEEP-P21.5223.61.56
KEEP-P+20.4222.423.24

Observed Level of Child Inhibitory Control Via Delay Choice Paradigm

"In the Delay Choice Paradigm, children were asked to make choices between getting one penny/sticker/treat now or four (or more) to bring home for nine times.~Total score is the total times when the child chooses the bring home option (ranges from 0 to 9). Higher score indicates better ability for child to delay gratification, i.e. better inhibitory control." (NCT03106636)
Timeframe: Change from baseline at endpoint (3-4 months post-baseline)

,
Interventionscore on a scale (Mean)
BaselineEndpointChange
KEEP-P4.865.240.19
KEEP-P+5.554.54-0.89

Observed Level of Child Working Memory Via Spin the Pots Task

"In the Spin the Pots Task, several visually distinct boxes were arranged on a rotating tray (2.5-year -olds: 8 boxes; 3-year-olds: 9 boxes; 3.5 year olds: 10 boxes; 4-year-olds; 11 boxes). Children watched the experimenter hide colourful stickers inside all but two boxes, cover the boxes with a cloth, and rotate a tray for a few seconds to mark the beginning of a search trial. The cloth was removed and children were instructed to select a box to find a sticker. If a sticker was found, children were allowed to keep it. After each search attempt, the tray was covered and rotated again to mark the beginning of the next search trial. The task was completed once children found all hidden stickers or after the allotted number of trials (2.5-year -olds: 12 trials; 3-year-olds: 14 trials; 3.5 year olds: 16 trials; 4-year-olds; 18 trials).~Ratio of stickers found to number of trials ranges from 0 to 1. A higher score indicates better working memory." (NCT03106636)
Timeframe: Change from baseline at endpoint (3-4 months post-baseline)

,
InterventionRatio of stickers found to trials (Mean)
BaselineEndpointChange
KEEP-P0.580.620.05
KEEP-P+0.550.590.06

Observed Level of Developmentally-supportive Parenting Via Observational Measure Parenting Interactions With Children: Checklist of Observations Linked to Outcomes (PICCOLO)

"The Parenting Interactions with Children: Checklist of Observations Linked to Outcomes (PICCOLO) is an observational measure which rates developmentally-supportive parenting across four domains: affection, responsiveness, encouragement, and teaching.~It is a checklist of 29 items reflecting positive parent-child interaction behaviors. Each behavior is rated according to their frequency as 0 (absent, no behavior observed), 1 (barely, minor or emerging behavior) and 2 (clearly, definitive, strong and frequent behavior). Higher scores indicating higher levels of positive parenting.~PICCOLO total score is calculated by summing up scores of all the 29 items, ranging from 0 to 58. " (NCT03106636)
Timeframe: Change from baseline at endpoint (3-4 months post-baseline)

,
Interventionscore on a scale (Mean)
BaselineEndpointChange
KEEP-P42.5842.850.14
KEEP-P+43.3643.08-0.76

Parental Stress Via Caregiver-report Measure Parent Daily Report (PDR)

"The Parent Daily Report (PDR) is a caregiver-report measure assessing child behaviour problems and associated parental stress occurring in the past 24 hours. The measure has several versions. The version used in the present research is the Oregon Social Learning Center Community Programs PDR which has 39 questions with only negative child behaviors, targeting to children from 3 to 6 years.~Caregivers rate each child behavior as 0 = Did Not Occur, 1 = Occurred & Not Stressful, 2 = Occurred & Stressful. The PDR was administered 3 times per wave. For each response, total score of stressful behaviors was calculated by counting the number of behaviors rated as 2 = Occurred & Stressful. Then the three total scores was averaged to get the mean of stressful behaviors (ranges from 0 to 39) as a indicator of parental stress. Higher score indicates higher level of parental stress." (NCT03106636)
Timeframe: Change from baseline at endpoint (3-4 months post-baseline)

,
Interventionscore on a scale (Mean)
BaselineEndpointChange
KEEP-P6.564.48-1.9
KEEP-P+7.264.58-2.8

Parenting Stress Via Self-report Measure Parenting Stress Index IV (PSI-IV) Short Form

"The Parenting Stress Index IV (PSI-IV) Short Form evaluates the magnitude of stress in the parent-child relationship based on the parent's perception of the child's characteristics, the personal characteristics of the parent, and the interaction between the parent and child.~It is a 5-point Likert scale ranging from strongly agree to strongly disagree with 36 items. Item 32 is the only item which is reverse coded. For all the other items, higher scores indicate higher levels of stress.~Total parenting stress score is calculated by summing up scores of all the 36 items, ranging from 36 to 180." (NCT03106636)
Timeframe: Change from baseline at endpoint (3-4 months post-baseline)

,
Interventionscore on a scale (Mean)
BaselineEndpointChange
KEEP-P80.8774.62-5.29
KEEP-P+86.1880.8-5.72

Preschool and Kindergarten Behavior Scales (PKBS)

"Caregivers perception of their child's behaviors via the Preschool and Kindergarten Behavior Scales (PKBS). Items are on a 4-point scale ranging from never to often. Higher scores indicate more behavior problems.~PKBS total score (76 items) sum score ranging between 0-228." (NCT03106636)
Timeframe: Change from baseline at endpoint (3-4 months post-baseline)

,
Interventiontotal score on scale (Mean)
BaselineEndpointChange
KEEP-P55.8650.6-3.44
KEEP-P+54.6352.39-3.09

Silly Animal Categories

Proportion of animals sorted correctly after rule switch. Higher score indicates better executive functioning. (NCT03106636)
Timeframe: Change from baseline at endpoint (3-4 months post-baseline)

,
Interventionproportion correct (Mean)
BaselineEndpointChange
KEEP-P0.640.670.05
KEEP-P+0.610.710.1

Daily Living and Role Functioning (DLRF) Basis-32 Subscale Ratings

"The BASIS 32 psychometric includes several subscales, including daily living and role functioning (DLRF). These subscales are rated from 0-4, with higher scores indicating a greater deal of difficulty in this dimension and lower scores denoting better outcomes. Measured weekly for 9 weeks. Reported as mean of 9 weeks." (NCT00247624)
Timeframe: 9 weeks

Interventionunits on a scale (Mean)
Fluoxetine (FLX) Plus Eszopiclone (ESZ)0.81
FLX Plus Placebo1.2

Insomnia Severity Index (ISI)

The Insomnia Severity Index has seven questions. The seven answers are added up to get a total score, range 0-28. Lower scores represent better outcomes. Total score categories: 0-7 = No clinically significant insomnia, 8-14 = Subthreshold insomnia, 15-21 = Clinical insomnia (moderate severity), 22-28 = Clinical insomnia (severe). (NCT00247624)
Timeframe: 9 weeks

Interventionunits on a scale (Mean)
Fluoxetine (FLX) Plus Eszopiclone (ESZ)21.1
FLX Plus Placebo20.2

Quality of Life Ratings, as Measured by the Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q)

The Q-LES-Q is scored from 0-100, with higher scores better than lower. Measured weekly for 9 weeks. Reported as mean of 9 weeks. (NCT00247624)
Timeframe: 9 weeks

Interventionunits on a scale (Mean)
Fluoxetine (FLX) Plus Eszopiclone (ESZ)50.2
FLX Plus Placebo46.9

Relation to Self/Others (RSO) Basis-32 Subscale Ratings

"The BASIS 32 psychometric includes several subscales, including relation to self and others (RSO). These subscales are rated from 0-4, with higher scores indicating a greater deal of difficulty in this dimension. Measured weekly for 9 weeks. Reported as mean of 9 weeks." (NCT00247624)
Timeframe: 9 weeks

Interventionunits on a scale (Mean)
Fluoxetine (FLX) Plus Eszopiclone (ESZ)0.74
FLX Plus Placebo1.04

Days Per Week of Cannabis Use.

The number days out of the last seven days that cannabis was used. (NCT00149643)
Timeframe: 12 Weeks

InterventionDays of cannabis use per week (Mean)
Fluoxetine3.88
Placebo3.1

Depression Symptoms at Week 12

Average of Beck Depression Inventory (BDI) Scores measured at Weeks 1-4, 6, 8, 10 and 12. The BDI is a subject reported measure that has a minimim score of 0 and a maximum score of 63. A better outcome would consist of values near the minimum end of the scale (0) and a worse outcome would consist of values near the maximum end of the scare (63). Each DSM-IV criteron asses a different depressive symptom. (NCT00149643)
Timeframe: 12 Weeks

InterventionBDI Total (Mean)
Fluoxetine7.79
Placebo7.31

Number of Cannabis Use Disorder Criterion Met at a Particular Time Point.

Criterion used in this study was the number of DSM-IV cannabis use disorder symptoms (criteria) that were met. (NCT00149643)
Timeframe: 12 Weeks

InterventionNumber of DSM-IV criterion (Mean)
Fluoxetine0.59
Placebo0.47

31-phosphorus Magnetic Resonance Spectroscopy Phosphocreatine Metabolite

Phosphocreatine Metabolite is a phosphorylated creatine molecule that plays a role in the production of the energy in the body. Phosphocreatine (PCr) metabolite was quantified by calculating the ratio of PCr over total phosphorus resonance from 31-Phosphorus Magnetic Resonance Spectroscopy. (NCT00851006)
Timeframe: 8 weeks

,
Interventionratio of PCr and total phosphorus (Mean)
BaselineAfter 8 weeks
Healthy Control Group0.15560.1558
Open Label Creatine Treatment0.15130.1610

Mean Children's Depression Rating Scale (CDRS-R) [Reference: Poznanski EO et al. Preliminary Studies of the Reliability and Validity of the Children's Depression Rating Scale. J Am Acad Child Psychiatry. 1984 Mar;23(2):191-7.]

The CDRS-R is a 17-item scale, with items ranging from 1 to 5 or 1 to 7 (possible total score from 17 to 113), rated by a clinician via interviews with the child or parent. Scores ≥40 are indicative of depression, whereas scores ≤28 is often used to define remission (NCT00851006)
Timeframe: 8 weeks

InterventionUnits on a scale (Mean)
BaselineAfter 8 week Creatine treatment
Open Label Creatine Treatment6930.6

Percent Change in BOLD Signal

To replicate and extend our previous behavioral findings of an interaction between estrogen therapy (ET) and tryptophan depletion on verbal memory in a group of early menopausal women randomized to receive ET. Blood-oxygen-level dependent or BOLD signal is the outcome of BOLD imaging, which is a technique used in functional MRI. BOLD signal reflects changes in regional cerebral blood flow which delineate regional activity. A positive BOLD signal marks an increase in regional blood flow, while a negative BOLD signal marks a decrease in regional blood flow. A positive percent change means that between scans the BOLD signal i.e. blood flow in that region has increased, a negative percent change means that the BOLD signal has decreased between scans. (NCT01208324)
Timeframe: 8 weeks

Interventionpercentage of BOLD signal changes (Mean)
High Ace-.43
Low Ace.20

Change in the Evidence of Family Conflict Between Parent and Youth After Intervention Between Intake and End of Treatment

The Self-Report of Family Functioning consists of 10 items selected from a number of well-known family assessment measures (Family Environment Scale, Family Concept Q-Sort, Family Adaptability and Cohesion Scale, and Family Assessment Measure). The scale ranges from 10 to 40, with a score of 10 being representative of no family conflict and a score of 40 being representative of the greatest magnitude of family conflict. Therefore, a decrease in score represents and decrease in self-reported family conflict. (NCT01537419)
Timeframe: 16 weeks (end of treatment)

Interventionunits on a scale (Mean)
Family-Enhanced Non-directive Supportive Therapy-1.058
Attachment-Based Family Therapy-1.2538

Change in the Intensity of Suicidal Ideation Between Intake and End of Treatment

The Suicidal Ideation Questionnaire-JR is a 15-item self-report assessment. It is based on Reynolds' theoretical notion of suicidality forming a continuum ranging from thoughts of death, thoughts of wanting to be dead, general and specific suicidal plans, preparations for carrying out plans, and actual suicide attempts. The scale ranges from 0 to 90, with a score of 0 being representative of no suicidal ideation, and a score of 31 or greater indicating severe suicidal ideation. (NCT01537419)
Timeframe: 16 weeks (end of treatment)

Interventionunits on a scale (Mean)
Family-Enhanced Non-directive Supportive Therapy-27.42
Attachment-Based Family Therapy-31.55

Change in the Severity of Depression Symptoms Between Intake and End of Treatment

Beck Depression Inventory-II. The second edition of the BDI is a widely-used, 21-item self-report instrument designed to assess the severity of depressive symptoms in adults and adolescents. The BDI-II has 21 items and takes approximately 5 minutes to complete. The scale ranges from 0 to 63, with a higher score being representative of a greater clinical magnitude of depression: a total score of 0-13 is considered minimal depression, 14-19 is mild depression, 20-28 is moderate depression, and 29-63 is severe depression. (NCT01537419)
Timeframe: 16 weeks (end of treatment)

Interventionunits on a scale (Mean)
Family-Enhanced Non-directive Supportive Therapy-4.87
Attachment-Based Family Therapy-5.40

The Number All Types of Adverse Events.

To establish the safety and tolerability of rTMS in Parkinson's Disease. (NCT01080794)
Timeframe: Baseline through Month 6

Interventionincidents of an adverse event (Number)
Double rTMS18
M1 Active rTMS + DLPFC Sham rTMS14
DLPFC Active rTMS + M1 Sham rTMS1
Double Sham rTMS1

Apathy Evaluation Scale (AES)

To evaluate apathy in Parkinson's Disease. The AES mean scores were reported for each group at each time point. The AES Score Range is 0-42, where higher the score indicates greater severity of the apathy symptoms. (NCT01080794)
Timeframe: Pre-treatment; Post-treatment 0,1,3, and 6 months.

,,,
Interventionunits on a scale (Mean)
Baseline (Pre-Treatment)Week 1 Post TreatmentMonth 1 Post TreatmentMonth 3 Post TreatmentMonth 6 Post Treatment
DLPFC Active rTMS + M1 Sham rTMS18.718.119.019.315.8
Double rTMS15.616.21716.917.8
Double Sham rTMS16.315.515.016.116.2
M1 Active rTMS + DLPFC Sham rTMS15.916.914.615.112.4

Beck Depression Inventory (BDI-II)

To assess mood symptoms in Parkinson's Disease. The BDI-II mean scores were reported for each group at each time point. The BDI-II Score Range is 0 - 63, where higher the score indicates greater severity of the mood symptoms. (NCT01080794)
Timeframe: Pre-treatment; Post-treatment 0,1,3, and 6 months.

,,,
Interventionunits on a scale (Mean)
Baseline (Pre-Treatment)Week 1 Post TreatmentMonth 1 Post TreatmentMonth 3 Post TreatmentMonth 6 Post Treatment
DLPFC Active rTMS + M1 Sham rTMS21.718.220.219.015.7
Double rTMS23.220.716.417.920.1
Double Sham rTMS18.813.713.114.716.8
M1 Active rTMS + DLPFC Sham rTMS18.516.516.719.116.3

Clinical Anxiety Scale (CAS)

To evaluate anxiety in Parkinson's Disease. The CAS mean scores were reported for each group at each time point. The CAS Score Range is 0 - 100, where higher the score indicates greater severity of the anxiety symptoms. (NCT01080794)
Timeframe: Pre-treatment; Post-treatment 0,1,3, and 6 months.

,,,
Interventionunits on a scale (Mean)
Baseline (Pre-Treatment)Week 1 Post TreatmentMonth 1 Post TreatmentMonth 3 Post TreatmentMonth 6 Post Treatment
DLPFC Active rTMS + M1 Sham rTMS33.427.630.831.424.8
Double rTMS36.334.231.733.133.4
Double Sham rTMS37.532.428.228.535.0
M1 Active rTMS + DLPFC Sham rTMS34.331.030.827.328.1

Global Impression Scales

To assess symptom severity and treatment response in Parkinson's Disease. The CGI mean scores were reported for each group at each time point. The CGI Score Range is 1 - 8, where higher the score indicates greater severity of illness or worsening of illness. (NCT01080794)
Timeframe: Pre-treatment; Post-treatment 0,1,3, and 6 months.

,,,
Interventionunits on a scale (Mean)
Baseline (Pre-Treatment): SeverityWeek 1 Post Treatment: SeverityWeek 1 Post Treatment: ImprovementMonth 1 Post Treatment: SeverityMonth 1 Post Treatment: ImprovementMonth 3 Post Treatment: SeverityMonth 3 Post Treatment: ImprovementMonth 6 Post Treatment: SeverityMonth 6 Post Treatment: Improvement
DLPFC Active rTMS + M1 Sham rTMS4.34.73.54.43.74.43.64.33.7
Double rTMS4.94.83.64.43.54.63.74.23.5
Double Sham rTMS3.63.93.04.13.54.43.64.63.4
M1 Active rTMS + DLPFC Sham rTMS4.74.93.54.83.83.83.45.04.2

Hamilton Depression Scale (HAM-D)

"To evaluate the depressive mood symptoms in PD.~The HAM-D mean scores were reported for each group at each time point. The HAM-D Score Range is 0 - 56, where higher the score indicates greater severity of depressive mood symptoms." (NCT01080794)
Timeframe: Pre-treatment; Post-treatment 0,1,3, and 6 months.

,,,
Interventionunits on a scale (Mean)
Baseline (Pre-Treatment)Week 1 Post-TreatmentMonth 1 Post-TreatmentMonth 3 Post-TreatmentMonth 6 Post-Treatment
DLPFC Active rTMS + M1 Sham rTMS13.89.412.410.410.4
Double rTMS15.211.310.610.710.4
Double Sham rTMS14.19.38.011.110.4
M1 Active rTMS + DLPFC Sham rTMS16.711.210.110.18.6

Montreal Cognitive Assessment (MoCA)

To screen and follow cognitive function in Parkinson's Disease. The MoCA mean scores were reported for each group at each time point. The MoCA Score Range is 0 - 30, where 26-30 indicates normal cognition. (NCT01080794)
Timeframe: pre-treatment; 0,1,3, and 6 months post-treatment

,,,
Interventionunits on a scale (Mean)
Baseline (Pre-Treatment)Week 1 Post TreatmentMonth 1 Post TreatmentMonth 3 Post TreatmentMonth 6 Post Treatment
DLPFC Active rTMS + M1 Sham rTMS27.326.326.826.726.6
Double rTMS28.226.828.826.528.0
Double Sham rTMS26.227.828.724.928.0
M1 Active rTMS + DLPFC Sham rTMS26.627.127.225.327.9

Motor Subscale of the Unified Parkinson's Disease Rating Scale (UPDRS Part III)

"To evaluate the motor symptoms in Parkinson's Disease.~The UPDRS-III mean scores were reported for each group at each time point. The UPDRS-III Score Range is 0 - 56, where higher the score indicates greater severity of the motor symptoms." (NCT01080794)
Timeframe: Pre-treatment; Post-treatment 0,1,3, and 6 months.

,,,
Interventionunits on a scale (Mean)
Baseline (Pre-Treatment)Week 1 Post-TreatmentMonth 1 Post-TreatmentMonth 3 Post-TreatmentMonth 6 Post-Treatment
DLPFC Active rTMS + M1 Sham rTMS32.830.329.331.528.8
Double rTMS32.331.230.129.630.5
Double Sham rTMS28.928.228.628.629.0
M1 Active rTMS + DLPFC Sham rTMS33.127.428.133.230.6

Parkinson's Disease Questionnaire 39 (PDQ-39)

To assess the quality of life (QOL) in Parkinson's Disease. The PDQ-39 mean scores were reported for each group at each time point. The PDQ-39 Score Range is 0 - 156, where higher the score indicates greater impact on quality of life. (NCT01080794)
Timeframe: Pre-treatment; Post-treatment 0,1,3, and 6 months.

,,,
Interventionunits on a scale (Mean)
Baseline (Pre-Treatment)Week 1 Post TreatmentMonth 1 Post TreatmentMonth 3 Post TreatmentMonth 6 Post Treatment
DLPFC Active rTMS + M1 Sham rTMS51.946.849.449.449
Double rTMS57.651.249.951.750.5
Double Sham rTMS55.543.140.943.147.5
M1 Active rTMS + DLPFC Sham rTMS61.560.756.853.148.3

Unified Parkinson's Disease Rating Scale (UPDRS) Parts I, II, and IV

"To assess apathy, cognition, depression, activities of daily living (ADL), quality of life (QOL), and motor symptoms in Parkinson's Disease.~The UPDRS I, II, IV total mean scores were reported for each group at each time point. The UPDRS I, II, IV scores were added together for each patient, with a total score range of 0 - 91, where higher the score indicates greater severity of the symptoms." (NCT01080794)
Timeframe: Pre-treatment; Post-treatment 0,1,3, and 6 months.

,,,
Interventionunits on a scale (Mean)
Baseline (Pre-Treatment)Week 1 Post TreatmentMonth 1 Post TreatmentMonth 3 Post TreatmentMonth 6 Post Treatment
DLPFC Active rTMS + M1 Sham rTMS21.519.319.918.920.2
Double rTMS25.423.321.821.123.8
Double Sham rTMS19.615.516.516.918.8
M1 Active rTMS + DLPFC Sham rTMS26.123.223.023.222.7

A Change of Outcome Measure:Picture Naming Test(PNT)

This test mainly assesses the ability of picture name of participants.we used a program for displaying named pictures on a computer screen (60 photos in total, of which 20 were Chinese celebrity faces). Each image was displayed in 3 seconds, and 1 point was correctly named for an image.The faces of celebrities were selected from the picture database of Chinese celebrities in the State Key Laboratory of Cognitive Neuroscience and Learning at Beijing Normal University.Score fluctuation is 0-60 points, the higher the score, the better the ability of picture name. (NCT03588572)
Timeframe: This is an outcome measure to assess the improvement of language function from onset to 3 months after treatment. Thus, participates will undergo this assessment on the first days (V1), 28±3 days (V2), and 90±3 days (V3) after randomization.

,
Interventionscore on a scale (Mean)
Visitation 1Visitation 2Visitation 3
Controlled Group38.3143.3148.31
Venlafaxine Group39.1946.7552.25

A Change of Outcome Measure:Spontaneous Language Frequency Test(SLFT)

This test mainly assesses spontaneous speech fluency of participants.It requires participants name as many food names as possible within one minute, and each correct one to give one point.The higher the score, the better the language function. (NCT03588572)
Timeframe: This is an outcome measure to assess the improvement of language function from onset to 3 months after treatment. Thus, participates will undergo this assessment on the first days (V1), 28±3 days (V2), and 90±3 days (V3) after randomization.

,
Interventionscore on a scale (Mean)
Visitation 1Visitation 2Visitation 3
Controlled Group5.758.1310.81
Venlafaxine Group5.319.3112.69

A Change of Outcome Measure:the Chinese Version of Western Aphasia Battery(WAB)

The main outcome measure for this scale is Aphasia Quotient(AQ) which mainly tests the ability of spontaneous speech, oral comprehension, repetition, and naming, and reflects the severity of aphasia, and can be used as a reliable indicator to evaluate the improvement and deterioration of aphasia. Score fluctuation is 0-100 points, the normal value is 98.4-100 points, AQ<93.8 can be judged as language dysfunction. (NCT03588572)
Timeframe: This is an outcome measure to assess the improvement of language function from onset to 3 months after treatment. Thus, participates will undergo this assessment on the first days (V1), 28±3 days (V2), and 90±3 days (V3) after randomization.

,
Interventionscore on a scale (Mean)
Visitation 1Visitation 2Visitation 3
Controlled Group78.6083.5188.55
Venlafaxine Group78.1688.2494.23

Follow-up Measurement: Hamilton Anxiety Rating Scale (HAMA)

The Hamilton Anxiety Rating Scale (HAMA) is a widely used and well-validated tool for measuring the severity of a patient's anxiety. The HAMA is composed of 14 items and takes 15-20 minutes to complete the interview and score the results. Each item is scored on a 5-point scale, ranging from 0=not present to 4=severe.HAMA Scoring Instructions:0-8=Normal, 8-13= Possible Anxiety, 14-17 = Mild Anxiety, 18-24 = Moderate Anxiety, 25-30 = Severe Anxiety(i.e.,the higher the score, the greater the likelihood of anxiety). (NCT03588572)
Timeframe: We must determine that the participant is not in anxiety at each follow-up. Thus, participates will undergo this assessment on the first days (V1), 28±3 days (V2), and 90±3 days (V3) after randomization.

,
Interventionscore on a scale (Mean)
Visitation 1Visitation 2Visitation 3
Controlled Group4.634.003.25
Venlafaxine Group4.884.133.56

Follow-up Measurement: Hamilton Depression Rating Scale (HAMD)

The Hamilton Depression Rating Scale (HAMD) has proven useful for many years as a way of determining a patient's level of depression before, during, and after treatment. It generally takes 15-20 minutes to complete the interview and score the results. Eight items are scored on a 5-point scale, ranging from 0 = not present to 4 = severe. Nine items are scored from 0-2. HAMD Scoring Instructions:0-7=Normal, 8-13 = Mild Depression, 14-18 = Moderate Depression, 19-22 = Severe Depression, ≥ 23 = Very Severe Depression(i.e.,Minimum 0 points and maximum 50 points, the higher the score, the greater the likelihood of depression). (NCT03588572)
Timeframe: We must determine that the participant is not in depression at each follow-up. Thus, participates will undergo this assessment on the first days (V1), 28±3 days (V2), and 90±3 days (V3) after randomization.

,
Interventionscore on a scale (Mean)
Visitation 1Visitation 2Visitation 3
Controlled Group5.254.633.88
Venlafaxine Group5.634.944.06

Follow-up Measurement: Mini-Mental State Examination (MMSE)

The Mini-Mental State Examination (MMSE) is a 30-point questionnaire that is used extensively in clinical and research settings to measure cognitive impairment. Administration of the test takes between 5 and 10 minutes. The MMSE test includes simple questions and problems in a number of areas: the time and place of the test, repeating lists of words, arithmetic such as the serial sevens, language use and comprehension, and basic motor skills. Any score greater than or equal to 24 points (out of 30) indicates a normal cognition. Below this, scores can indicate severe (≤9 points), moderate (10-18 points) or mild (19-23 points) cognitive impairment.The raw score may also need to be corrected for educational attainment and age. (NCT03588572)
Timeframe: We must determine that the participant is not in moderate or more cognitive impairment at each follow-up. Thus, participates will undergo this assessment on the first days (V1), 28±3 days (V2), and 90±3 days (V3) after randomization.

,
Interventionscore on a scale (Mean)
Visitation 1Visitation 2Visitation 3
Controlled Group23.8825.0026.19
Venlafaxine Group23.8125.3826.38

MADRS (Montgomery-Asberg Depression Rating Scale) Readmission Rate

MADRS readmission rate is defined as MADRS score<11. The 10-item Montgomery-Asberg Depression Rating Scale (MADRS), which measures depression severity over the past week, was completed by clinicians using an MGH structured interview. Each item is measured on a scale from 0 to 6, and the items are summed to find the total score. The total minimum score is 0 units on a scale and the total maximum score is 60 units on a scale, where higher scores indicate more severe depression. (NCT00683852)
Timeframe: 12 weeks

InterventionParticipants (Count of Participants)
Phase 1 Drug4
Phase 1 Placebo Non-Responders on Drug in Phase 28
Phase I Placebo16
Phase 1 Placebo Non-Responders on Placebo in Phase 24

MADRS (Montgomery-Asberg Depression Rating Scale) Response Rate

The primary outcome was the difference in response rate (decrease in MADRS total score of at least 50%) using the SPCD (sequential parallel comparison design). The 10-item Montgomery-Asberg Depression Rating Scale (MADRS), which measures depression severity over the past week, was completed by clinicians using an MGH structured interview. Each item is measured on a scale from 0 to 6, and the items are summed to find the total score. The total minimum score is 0 units on a scale and the total maximum score is 60 units on a scale, where higher scores indicate more severe depression. (NCT00683852)
Timeframe: 12 weeks

InterventionParticipants (Count of Participants)
Phase 1 Drug10
Phase 1 Placebo Non-Responders on Drug in Phase 211
Phase I Placebo29
Phase 1 Placebo Non-Responders on Placebo in Phase 25

Mean Change in Clinical Global Impression of Severity (CGI-S)

The CGI-S scale was administered by clinicians based on assessment of the patient's clinical status. They measured, based on history and scores on other instruments, depressive severity. It consists of one question scored on a seven-point scale (1 = normal to 7 = among the most severe), so a higher total score indicates greater depressive severity. The minimum score is 1, and the maximum score is 7. (NCT00683852)
Timeframe: Baseline and 12 weeks

Interventionunits on a scale (Mean)
Phase 1 Drug-0.81
Phase 1 Placebo Non-Responders on Drug in Phase 2-0.64
Phase I Placebo-0.84
Phase 1 Placebo Non-Responders on Placebo in Phase 2-0.43

Mean Change in MADRS (Montgomery-Asberg Depression Rating Scale) Score From Baseline to the End of Follow-up

The 10-item Montgomery-Asberg Depression Rating Scale (MADRS), which measures depression severity over the past week, was completed by clinicians using an MGH structured interview. Each item is measured on a scale from 0 to 6, and the items are summed to find the total score. The total minimum score is 0 units on a scale and the total maximum score is 60 units on a scale, where higher scores indicate more severe depression. (NCT00683852)
Timeframe: Baseline and 12 Weeks

Interventionunits on a scale (Mean)
Phase 1 Drug-8.54
Phase 1 Placebo Non-Responders on Drug in Phase 2-5.80
Phase I Placebo-8.09
Phase 1 Placebo Non-Responders on Placebo in Phase 2-3.32

Number of Patients With Treatment Emergent AEs in Two Treatment Groups - People Exclusively on Drug or Placebo Throughout the Study

Differences in the incidence of treatment emergent AEs between the treatment groups were examined and evaluated using descriptive statistics. This analysis compared AEs between the arms that received exclusively drug throughout the study or placebo throughout the study. (NCT00683852)
Timeframe: 12 Weeks

InterventionPatients (Number)
ADAPT Drug/Drug Group39
ADAPT Placebo/Placebo Group60

Number of Patients With Treatment Emergent AEs in Two Treatment Groups - Placebo Non-Responders

Differences in the incidence of treatment emergent AEs between the treatment groups were examined and evaluated using descriptive statistics. This analysis focused on placebo non-responders in phase 1 and presented them by their treatment assignment in phase 2. (NCT00683852)
Timeframe: 12 Weeks

InterventionPatients (Number)
Phase 1 Placebo Non-Responders on Drug in Phase 240
Phase 1 Placebo Non-Responders on Placebo in Phase 244

Treatment Emergent AEs in Two Treatment Groups - Safety Sample

Differences in the incidence of treatment emergent AEs between the treatment groups were examined and evaluated using descriptive statistics. In this analysis, AEs were summarized according to person-phase of occurrence. Each AE was attributed to the person and then to phase 1 or phase 2, depending on the initial date of onset. (NCT00683852)
Timeframe: 12 Weeks

Interventionadverse events (Number)
ADAPT Drug Group58
ADAPT Placebo Group110

Mean Change in Symptom Questionnaire (SQ)

The SQ, a 92-item (yes/no) self-rating questionnaire, includes 4 distress and 4 well-being subscales. There are 68 items for the distress subscales and 24 items for the well-being subscales. Each item has either a Yes/No or True/False answer. For the distress symptom score, add together the following items and score 1 when the answer is Yes/True: 1, 2, 3, 5, 6, 8, 11, 12, 15, 18, 20, 22, 24, 25, 26, 27, 28, 29, 30, 32, 33, 34, 36, 37, 39, 41, 42, 44, 45, 47, 48, 49, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 72, 73, 74, 75, 76, 77, 79, 80, 81, 82, 84, 85, 86, 87, 88, 90, 91, 92. Minimum score is 0 and maximum score is 68. A higher score indicates more distress symptoms. For the well-being subscale score, add together the following items and score 1 when the answer is No/False: 4, 7, 9, 10, 13, 14, 16, 17, 19, 21, 23, 29, 31, 35, 38, 40, 43, 46, 50, 51, 71, 78, 83, 89. Minimum score is 0 and maximum score is 24. A higher score indicates more well-being. (NCT00683852)
Timeframe: Baseline and 12 weeks

,,,
Interventionunits on a scale (Mean)
Sum of 4 subscaled distress scoresSum of 4 subscaled well-being scores
Phase 1 Drug-9.443.71
Phase 1 Placebo Non-Responders on Drug in Phase 2-6.783.34
Phase 1 Placebo Non-Responders on Placebo in Phase 2-4.521.98
Phase I Placebo-9.702.75

Change in Beck Depression Inventory II (BDI-II)

Beck Depression Inventory II ranges from 0-63. Higher score indicates more severe depression. 0-13 minimal depression, 14-19 mild depression, 20-28 moderate depression, 29-63 severe depression. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase

InterventionChange in BDI-II score (Mean)
Paroxetine-9.7
Venlafaxine Extended Release-9.6
Placebo-5.2

Change in Brief Psychiatric Rating Scale (BPRS)

Brief Psychiatric Rating Scale. Maximum score 126. Higher score indicates greater psychiatric difficulties. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase

InterventionChange in BPRS score (Mean)
Paroxetine-9.0
Venlafaxine Extended Release-9.8
Placebo-4.4

Change in Geriatric Depression Rating Scale (GDS)

Geriatric Depression Scale ranges from 0-30. Higher score indicates more severe depression. 0-9 normal, 10-19 mild depression, 20-30 severe depression. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase

InterventionChange in GDS score (Mean)
Paroxetine-6.9
Venlafaxine Extended Release-6.9
Placebo-2.8

Change in Hamilton Depression Rating Scale (HAM-D) Scores

Change in Hamilton Rating Scale for Depression over 12 weeks. Hamilton Depression Rating Scale ranges from 0-50. Higher scores represent more significant depression. Mild depression ranges from 8-13, moderate depression from 14-18, severe 19-22 and very severe any score over 23. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase

InterventionChange in HAM-D score (Mean)
Paroxetine-13.0
Venlafaxine Extended Release-11.0
Placebo-6.8

Change in Montgomery-Asberg Depression Rating Scale (MADRS)

Montgomery-Asberg Depression Rating Scale ranges from 0-60. Higher score indicates more severe depression. 0-6 normal, 7-19 mild depression, 20-34 moderate depression, greater than 34 severe depression. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase

InterventionChange in MADRS score (Mean)
Paroxetine-13.6
Venlafaxine Extended Release-10.9
Placebo-6.6

Change in Parkinson's Disease Questionnaire (PDQ) - 39 - Emotional Well-Being

Parkinson's Disease Questionnaire (PDQ-39) - Emotional Well-Being maximum score 24, minimum score of 0.Lower score indicates a better perceived health status. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase

InterventionChange in PDQ-39 Emotional score (Mean)
Paroxetine-21.4
Venlafaxine Extended Release-20.7
Placebo-10.9

Change in Parkinson's Disease Questionnaire (PDQ) - 39 - Overall

Parkinson's Disease Questionnaire (PDQ-39) Total. Range 0-100. Lower score indicates a better perceived health status. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase

InterventionChange in PDQ-39 score (Mean)
Paroxetine-8.0
Venlafaxine Extended Release-8.4
Placebo-5.3

Change in Pittsburgh Sleep Quality Index (PSQI)

Pittsburgh Sleep Quality Index scores range from 0-21, with higher scores indicating severe sleep difficulties. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase

InterventionChange in PQSI score (Mean)
Paroxetine-2.1
Venlafaxine Extended Release-2.6
Placebo-1.1

Change in Short Form 36 Health Survey - Mental Component Summary

Short Form 36 Health Survey. Range 0-100. Higher score indicates a better perceived quality of life. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase

InterventionChange in SF-36 mental score (Mean)
Paroxetine11.4
Venlafaxine Extended Release9.5
Placebo4.8

Change in Short Form 36 Health Survey - Mental Health

Short Form 36 Health Survey - Mental Health subscale ranges from 0-100. Higher score indicates a better perceived quality of life. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase

InterventionChange in SF-36 Mental Health score (Mean)
Paroxetine16.7
Venlafaxine Extended Release17.4
Placebo9.7

Change in Short Form 36 Health Survey - Role-Emotional

Short Form 36 Health Survey - Emotional subscale ranges from 0-100. Higher score indicates a better perceived quality of life. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase

InterventionChange in SF-36 Role score (Mean)
Paroxetine39.5
Venlafaxine Extended Release26.9
Placebo12.7

Change in Short Form 36 Health Survey - Vitality

Short Form 36 Health Survey - Vitality subscale ranges from 0-100. Higher score indicates a better perceived quality of life. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase

InterventionChange in SF-36 vitality score (Mean)
Paroxetine13.5
Venlafaxine Extended Release9.1
Placebo4.7

Change in Snaith Clinical Anxiety Scale (CAS)

Snaith Clinical Anxiety Scale. Range 0-21. Higher scores indicate increased anxiety. Score greater than 8 indicates clinical anxiety. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase

InterventionChange in CAS score (Mean)
Paroxetine-3.6
Venlafaxine Extended Release-3.2
Placebo-2.4

Change in Unified Parkinson's Disease Rating Scale (UPDRS)

Unified Parkinson's Disease Rating Scale. Higher score indicates more severe Parkinson's disease symptoms. Total maximum = 176. Mental maximum = 52, Activities of Daily Living maximum = 52, Motor maximum = 72. Minimum = 0. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase

InterventionChange in UPDRS score (Mean)
Paroxetine-8.7
Venlafaxine Extended Release-7.0
Placebo-4.3

Change in Unified Parkinson's Disease Rating Scale (UPDRS) - Bulbar

Unified Parkinson's Disease Rating Scale - Bulbar maximum score 24, minimum score of 0. Higher score indicates more severe Parkinson's disease symptoms. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase

InterventionChange in UPDRS-Bulbar score (Mean)
Paroxetine-1.4
Venlafaxine Extended Release-1.4
Placebo-0.5

Change in Unified Parkinson's Disease Rating Scale (UPDRS) - Motor

Unified Parkinson's Disease Rating Scale - Motor has a maximum score of 72, minimum score of 0. Higher score indicates more severe Parkinson's disease symptoms. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase

InterventionChange in UPDRS-motor score (Mean)
Paroxetine-4.3
Venlafaxine Extended Release-2.0
Placebo-1.0

Change in Unified Parkinson's Disease Rating Scale (UPDRS) - Tremor

Unified Parkinson's Disease Rating Scale - Tremor subscale ranges from 0-23. Higher score indicates more severe Parkinson's disease symptoms. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase

InterventionChange in UPDRS-tremor score (Mean)
Paroxetine0.4
Venlafaxine Extended Release0.5
Placebo-0.6

Reviews

63 reviews available for fluoxetine and Depression, Involutional

ArticleYear
Fluoxetine modulates the pro-inflammatory process of IL-6, IL-1β and TNF-α levels in individuals with depression: a systematic review and meta-analysis.
    Psychiatry research, 2022, Volume: 307

    Topics: Cytokines; Depression; Depressive Disorder, Major; Fluoxetine; Humans; Interleukin-1beta; Interleuki

2022
Effect of antidepressants on functioning and quality of life outcomes in children and adolescents with major depressive disorder: a systematic review and meta-analysis.
    Translational psychiatry, 2022, 05-04, Volume: 12, Issue:1

    Topics: Adolescent; Antidepressive Agents; Antidepressive Agents, Second-Generation; Child; Depressive Disor

2022
Antidepressants for the treatment of adults with major depressive disorder in the maintenance phase: a systematic review and network meta-analysis.
    Molecular psychiatry, 2023, Volume: 28, Issue:1

    Topics: Adult; Amitriptyline; Antidepressive Agents; Citalopram; Depressive Disorder, Major; Desvenlafaxine

2023
Efficacy and tolerability of antidepressant drugs in treatment of depression in children and adolescents: a network meta-analysis.
    Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences, 2022, Aug-01, Volume: 51, Issue:4

    Topics: Adolescent; Amitriptyline; Antidepressive Agents; Child; Depression; Depressive Disorder, Major; Dul

2022
Stroke, depression, and self-harm in later life.
    Current opinion in psychiatry, 2023, 09-01, Volume: 36, Issue:5

    Topics: Adult; Antidepressive Agents; Depression; Depressive Disorder, Major; Fluoxetine; Humans; Stroke; Su

2023
Pharmacological and non-pharmacological treatments for major depressive disorder in adults: A systematic review and network meta-analysis.
    Psychiatry research, 2019, Volume: 281

    Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Bupropion; Cognitive Behavioral The

2019
How well do elderly patients with major depressive disorder respond to antidepressants: a systematic review and single-group meta-analysis.
    BMC psychiatry, 2020, 03-04, Volume: 20, Issue:1

    Topics: Aged; Antidepressive Agents; Depressive Disorder, Major; Female; Fluoxetine; Humans; Patients

2020
Inflammatory modulation of fluoxetine use in patients with depression: A systematic review and meta-analysis.
    Cytokine, 2020, Volume: 131

    Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Child; Depressive Disorder, Major

2020
New generation antidepressants for depression in children and adolescents: a network meta-analysis.
    The Cochrane database of systematic reviews, 2021, 05-24, Volume: 5

    Topics: Adolescent; Antidepressive Agents; Bias; Child; Citalopram; Depressive Disorder, Major; Desvenlafaxi

2021
Dose Escalation of Antidepressants in Unipolar Depression: A Meta-Analysis of Double-Blind, Randomized Controlled Trials.
    Psychotherapy and psychosomatics, 2017, Volume: 86, Issue:5

    Topics: Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Drug Administration Schedule

2017
Model-based comparing efficacy of fluoxetine between elderly and non-elderly participants with major depressive disorder.
    Journal of affective disorders, 2018, 03-15, Volume: 229

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Depressive Di

2018
Adolescent depression: clinical features and therapeutic strategies.
    European review for medical and pharmacological sciences, 2013, Volume: 17, Issue:11

    Topics: Adolescent; Cognitive Behavioral Therapy; Depressive Disorder, Major; Fluoxetine; Humans

2013
Comparative efficacies of fluoxetine and paroxetine in major depression across varying acute-phase treatment periods: a meta-analysis.
    Asia-Pacific psychiatry : official journal of the Pacific Rim College of Psychiatrists, 2014, Volume: 6, Issue:4

    Topics: Adult; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Fluoxetine; Humans; Par

2014
Drug safety evaluation of olanzapine/fluoxetine combination.
    Expert opinion on drug safety, 2014, Volume: 13, Issue:8

    Topics: Animals; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Benzodiazepines; Bipolar Di

2014
Treatment of bipolar depression: making sensible decisions.
    CNS spectrums, 2014, Volume: 19 Suppl 1

    Topics: Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; De

2014
Drug dose as mediator of treatment effect in antidepressant drug trials: the case of fluoxetine.
    Acta psychiatrica Scandinavica, 2015, Volume: 131, Issue:6

    Topics: Antidepressive Agents, Second-Generation; Depressive Disorder; Depressive Disorder, Major; Dose-Resp

2015
Altered γ-aminobutyric acid neurotransmission in major depressive disorder: a critical review of the supporting evidence and the influence of serotonergic antidepressants.
    Drug design, development and therapy, 2015, Volume: 9

    Topics: Animals; Antidepressive Agents; Brain; Depressive Disorder, Major; Evidence-Based Medicine; Fluoxeti

2015
Systematic Review and Meta-Analysis: Dose-Response Relationship of Selective Serotonin Reuptake Inhibitors in Major Depressive Disorder.
    The American journal of psychiatry, 2016, Feb-01, Volume: 173, Issue:2

    Topics: Citalopram; Depressive Disorder, Major; Dose-Response Relationship, Drug; Fluoxetine; Fluvoxamine; H

2016
Statins for the treatment of depression: A meta-analysis of randomized, double-blind, placebo-controlled trials.
    Journal of affective disorders, 2016, Volume: 200

    Topics: Antidepressive Agents; Atorvastatin; Citalopram; Depressive Disorder, Major; Double-Blind Method; Fl

2016
Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis.
    Lancet (London, England), 2016, Aug-27, Volume: 388, Issue:10047

    Topics: Adolescent; Amitriptyline; Antidepressive Agents; Bayes Theorem; Child; Citalopram; Clomipramine; Co

2016
Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis.
    Lancet (London, England), 2016, Aug-27, Volume: 388, Issue:10047

    Topics: Adolescent; Amitriptyline; Antidepressive Agents; Bayes Theorem; Child; Citalopram; Clomipramine; Co

2016
Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis.
    Lancet (London, England), 2016, Aug-27, Volume: 388, Issue:10047

    Topics: Adolescent; Amitriptyline; Antidepressive Agents; Bayes Theorem; Child; Citalopram; Clomipramine; Co

2016
Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis.
    Lancet (London, England), 2016, Aug-27, Volume: 388, Issue:10047

    Topics: Adolescent; Amitriptyline; Antidepressive Agents; Bayes Theorem; Child; Citalopram; Clomipramine; Co

2016
Pharmacokinetic Pharmacogenetic Prescribing Guidelines for Antidepressants: A Template for Psychiatric Precision Medicine.
    Mayo Clinic proceedings, 2016, Volume: 91, Issue:7

    Topics: Antidepressive Agents, Second-Generation; Cytochrome P-450 CYP2D6; Cytochrome P-450 Enzyme Inhibitor

2016
Lamotrigine compared to placebo and other agents with antidepressant activity in patients with unipolar and bipolar depression: a comprehensive meta-analysis of efficacy and safety outcomes in short-term trials.
    CNS spectrums, 2016, Volume: 21, Issue:5

    Topics: Anticonvulsants; Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bip

2016
Pharmacological treatment of children and adolescents with depression.
    Expert opinion on pharmacotherapy, 2016, Volume: 17, Issue:17

    Topics: Adolescent; Antidepressive Agents; Child; Clinical Trials as Topic; Data Interpretation, Statistical

2016
New antidepressants for older people: a critical review of the evidence base.
    L'Encephale, 2008, Volume: 34 Suppl 2

    Topics: Aged; Antidepressive Agents; Cyclohexanols; Depressive Disorder, Major; Electroconvulsive Therapy; F

2008
Treatment of adolescent depression: what we have come to know.
    Depression and anxiety, 2009, Volume: 26, Issue:5

    Topics: Adolescent; Antidepressive Agents, Second-Generation; Cognitive Behavioral Therapy; Combined Modalit

2009
Fluoxetine and olanzapine combination therapy in treatment-resistant major depression: review of efficacy and safety data.
    Expert opinion on pharmacotherapy, 2009, Volume: 10, Issue:13

    Topics: Antidepressive Agents, Second-Generation; Antipsychotic Agents; Benzodiazepines; Depressive Disorder

2009
Venlafaxine XR therapy for major depression and anxiety disorders. The clinical implications that its advantages pose.
    Postgraduate medicine, 1999, Volume: 106, Issue:6 Suppl

    Topics: Adult; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Anxiety Disorders; Delayed-Act

1999
Clinical messages from the Treatment for Adolescents With Depression Study (TADS).
    The American journal of psychiatry, 2009, Volume: 166, Issue:10

    Topics: Adolescent; Adolescent Behavior; Cognitive Behavioral Therapy; Combined Modality Therapy; Depressive

2009
Pharmacotherapy of major depressive disorder in adolescents.
    Expert opinion on pharmacotherapy, 2010, Volume: 11, Issue:3

    Topics: Adolescent; Adolescent Behavior; Adult; Antidepressive Agents; Cognitive Behavioral Therapy; Combine

2010
Olanzapine/fluoxetine: a review of its use in patients with treatment-resistant major depressive disorder.
    CNS drugs, 2010, Volume: 24, Issue:3

    Topics: Benzodiazepines; Clinical Trials as Topic; Databases, Factual; Depressive Disorder, Major; Fluoxetin

2010
Are typical starting doses of the selective serotonin reuptake inhibitors sub-optimal? A meta-analysis of randomized, double-blind, placebo-controlled, dose-finding studies in major depressive disorder.
    The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, 2010, Volume: 11, Issue:2 Pt 2

    Topics: Citalopram; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-Blind Method; Fluox

2010
From TADS and SOFTADS to TORDIA and beyond: what's new in the treatment of adolescent depression?
    Current psychiatry reports, 2010, Volume: 12, Issue:2

    Topics: Adolescent; Antidepressive Agents; Clinical Trials as Topic; Cognitive Behavioral Therapy; Combined

2010
Remission with mirtazapine and selective serotonin reuptake inhibitors: a meta-analysis of individual patient data from 15 controlled trials of acute phase treatment of major depression.
    International clinical psychopharmacology, 2010, Volume: 25, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antidepressive Agents, Tricyclic; Citalopram; Depressive

2010
Suicidal thoughts and behavior with antidepressant treatment: reanalysis of the randomized placebo-controlled studies of fluoxetine and venlafaxine.
    Archives of general psychiatry, 2012, Volume: 69, Issue:6

    Topics: Cyclohexanols; Depressive Disorder, Major; Fluoxetine; Humans; Randomized Controlled Trials as Topic

2012
Benefits from antidepressants: synthesis of 6-week patient-level outcomes from double-blind placebo-controlled randomized trials of fluoxetine and venlafaxine.
    Archives of general psychiatry, 2012, Volume: 69, Issue:6

    Topics: Adolescent; Adult; Aged; Cyclohexanols; Depressive Disorder, Major; Fluoxetine; Humans; Randomized C

2012
Drug interactions in the treatment of depression in patients with ischemic heart disease.
    The Journal of clinical psychiatry, 2012, Volume: 73, Issue:12

    Topics: Aged; Antidepressive Agents; Aryl Hydrocarbon Hydroxylases; Aspirin; Clopidogrel; Comorbidity; Cytoc

2012
Vasopressin as a target for antidepressant development: an assessment of the available evidence.
    Journal of affective disorders, 2002, Volume: 72, Issue:2

    Topics: Adrenocorticotropic Hormone; Antidepressive Agents; Corticotropin-Releasing Hormone; Depressive Diso

2002
Achieving remission with venlafaxine and fluoxetine in major depression: its relationship to anxiety symptoms.
    Depression and anxiety, 2002, Volume: 16, Issue:1

    Topics: Adult; Antidepressive Agents; Anxiety Disorders; Comorbidity; Cyclohexanols; Depressive Disorder, Ma

2002
Common treatment of polycystic ovarian syndrome and major depressive disorder: case report and review.
    Current drug targets. Immune, endocrine and metabolic disorders, 2002, Volume: 2, Issue:1

    Topics: Adult; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Drug Therapy, Combinati

2002
Long-term treatment outcomes of depression with associated anxiety: efficacy of continuation treatment with fluoxetine.
    The Journal of clinical psychiatry, 2004, Volume: 65, Issue:3

    Topics: Adult; Anxiety; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; F

2004
A meta-analysis of randomized controlled trials of tianeptine versus SSRI in the short-term treatment of depression.
    European psychiatry : the journal of the Association of European Psychiatrists, 2002, Volume: 17 Suppl 3

    Topics: Antidepressive Agents, Tricyclic; Depressive Disorder, Major; Fluoxetine; Humans; Randomized Control

2002
Fluoxetine--do the benefits outweigh the risks in adolescent major depression?
    Expert opinion on pharmacotherapy, 2005, Volume: 6, Issue:1

    Topics: Adolescent; Depressive Disorder, Major; Fluoxetine; Humans; Risk Factors; Suicide

2005
Side-effect profile of fluoxetine in comparison with other SSRIs, tricyclic and newer antidepressants: a meta-analysis of clinical trial data.
    Pharmacopsychiatry, 2005, Volume: 38, Issue:2

    Topics: Antidepressive Agents, Tricyclic; Depressive Disorder, Major; Drug Tolerance; Fluoxetine; Gastrointe

2005
Acute phase and five-year follow-up study of fluoxetine in adolescents with major depression and a comorbid substance use disorder: a review.
    Addictive behaviors, 2005, Volume: 30, Issue:9

    Topics: Adolescent; Alcohol Drinking; Alcoholism; Antidepressive Agents, Second-Generation; Combined Modalit

2005
Major depressive disorder in children and adolescents: clinical trial design and antidepressant efficacy.
    The Journal of clinical psychiatry, 2005, Volume: 66 Suppl 7

    Topics: Adolescent; Age Factors; Age of Onset; Antidepressive Agents; Child; Controlled Clinical Trials as T

2005
Comparative efficacy of cognitive behavioral therapy, fluoxetine, and their combination in depressed adolescents: initial lessons from the treatment for adolescents with depression study.
    Current psychiatry reports, 2005, Volume: 7, Issue:6

    Topics: Adolescent; Adolescent Behavior; Clinical Trials as Topic; Cognitive Behavioral Therapy; Combined Mo

2005
Suicidality in pediatric patients treated with antidepressant drugs.
    Archives of general psychiatry, 2006, Volume: 63, Issue:3

    Topics: Adolescent; Age Factors; Antidepressive Agents; Child; Depressive Disorder, Major; Female; Fluoxetin

2006
Duloxetine compared with fluoxetine and venlafaxine: use of meta-regression analysis for indirect comparisons.
    BMC psychiatry, 2006, Jul-24, Volume: 6

    Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Cyclohexanols; Depressive Disorder,

2006
Pharmacotherapy of child and adolescent depression.
    Child and adolescent psychiatric clinics of North America, 2006, Volume: 15, Issue:4

    Topics: Adolescent; Antidepressive Agents; Child; Citalopram; Depressive Disorder, Major; Fluoxetine; Humans

2006
Comprehensive analysis of remission (COMPARE) with venlafaxine versus SSRIs.
    Biological psychiatry, 2008, Feb-15, Volume: 63, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Citalopram; Cyclohexanols; Depressive Disorder, Major; F

2008
Meta-analysis of aggression and/or hostility-related events in children and adolescents treated with fluoxetine compared with placebo.
    Journal of child and adolescent psychopharmacology, 2007, Volume: 17, Issue:5

    Topics: Adolescent; Aggression; Antidepressive Agents, Second-Generation; Child; Depressive Disorder, Major;

2007
Efficacy of duloxetine and selective serotonin reuptake inhibitors: comparisons as assessed by remission rates in patients with major depressive disorder.
    Journal of clinical psychopharmacology, 2007, Volume: 27, Issue:6

    Topics: Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Depressive Disorder, Major;

2007
Fluoxetine and adult suicidality revisited: an updated meta-analysis using expanded data sources from placebo-controlled trials.
    Journal of clinical psychopharmacology, 2007, Volume: 27, Issue:6

    Topics: Adverse Drug Reaction Reporting Systems; Data Collection; Depressive Disorder, Major; Dose-Response

2007
Perimenopausal depression.
    The American journal of psychiatry, 2008, Volume: 165, Issue:1

    Topics: Administration, Cutaneous; Combined Modality Therapy; Comorbidity; Depression, Postpartum; Depressiv

2008
Augmentation of antidepressants with atypical antipsychotics for treatment-resistant major depressive disorder.
    Acta psychiatrica Scandinavica, 2008, Volume: 117, Issue:4

    Topics: Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Depressive Disorder, Maj

2008
[Therapeutic action lag time and resistance to treatment].
    L'Encephale, 1999, Volume: 25 Spec No 2

    Topics: Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Cyclohexanols; Depressiv

1999
Reboxetine: tolerability and safety profile in patients with major depression.
    Acta psychiatrica Scandinavica. Supplementum, 2000, Volume: 402

    Topics: Adrenergic Uptake Inhibitors; Age Factors; Antidepressive Agents; Cytochrome P-450 Enzyme System; De

2000
Reboxetine: its effects as measured by the Social Adaptation Self-evaluation Scale.
    Acta psychiatrica Scandinavica. Supplementum, 2000, Volume: 402

    Topics: Adrenergic Uptake Inhibitors; Adult; Antidepressive Agents; Depressive Disorder, Major; Female; Fluo

2000
Pindolol augmentation of antidepressant treatment: recent contributions from brain imaging studies.
    Biological psychiatry, 2000, Oct-15, Volume: 48, Issue:8

    Topics: Animals; Brain; Cerebrovascular Circulation; Clinical Trials as Topic; Depressive Disorder, Major; D

2000
Adverse events and treatment discontinuations in clinical trials of fluoxetine in major depressive disorder: an updated meta-analysis.
    Clinical therapeutics, 2000, Volume: 22, Issue:11

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Antidepressive

2000
Venlafaxine extended-release: a review of its use in the management of major depression.
    CNS drugs, 2001, Volume: 15, Issue:8

    Topics: Antidepressive Agents, Second-Generation; Anxiety; Cyclohexanols; Delayed-Action Preparations; Depre

2001
Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo.
    The Journal of clinical psychiatry, 2001, Volume: 62, Issue:11

    Topics: Adult; Analysis of Variance; Antidepressive Agents, Second-Generation; Cyclohexanols; Depressive Dis

2001
Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo.
    The Journal of clinical psychiatry, 2001, Volume: 62, Issue:11

    Topics: Adult; Analysis of Variance; Antidepressive Agents, Second-Generation; Cyclohexanols; Depressive Dis

2001
Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo.
    The Journal of clinical psychiatry, 2001, Volume: 62, Issue:11

    Topics: Adult; Analysis of Variance; Antidepressive Agents, Second-Generation; Cyclohexanols; Depressive Dis

2001
Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo.
    The Journal of clinical psychiatry, 2001, Volume: 62, Issue:11

    Topics: Adult; Analysis of Variance; Antidepressive Agents, Second-Generation; Cyclohexanols; Depressive Dis

2001
[Serotonin syndrome: report of a fatal case and review of the literature].
    Revista clinica espanola, 2002, Volume: 202, Issue:4

    Topics: Aged; Antiparkinson Agents; Carbidopa; Depressive Disorder, Major; Drug Combinations; Drug Synergism

2002

Trials

326 trials available for fluoxetine and Depression, Involutional

ArticleYear
Functional outcomes with bright light in monotherapy and combined with fluoxetine in patients with major depressive disorder: Results from the LIFE-D trial.
    Journal of affective disorders, 2022, 01-15, Volume: 297

    Topics: Cognition; Depressive Disorder, Major; Double-Blind Method; Efficiency; Fluoxetine; Humans; Treatmen

2022
Vortioxetine for Major Depressive Disorder in Adolescents: 12-Week Randomized, Placebo-Controlled, Fluoxetine-Referenced, Fixed-Dose Study.
    Journal of the American Academy of Child and Adolescent Psychiatry, 2022, Volume: 61, Issue:9

    Topics: Adolescent; Adult; Child; Depressive Disorder, Major; Double-Blind Method; Fluoxetine; Humans; Piper

2022
Vortioxetine for Major Depressive Disorder in Adolescents: 12-Week Randomized, Placebo-Controlled, Fluoxetine-Referenced, Fixed-Dose Study.
    Journal of the American Academy of Child and Adolescent Psychiatry, 2022, Volume: 61, Issue:9

    Topics: Adolescent; Adult; Child; Depressive Disorder, Major; Double-Blind Method; Fluoxetine; Humans; Piper

2022
Vortioxetine for Major Depressive Disorder in Adolescents: 12-Week Randomized, Placebo-Controlled, Fluoxetine-Referenced, Fixed-Dose Study.
    Journal of the American Academy of Child and Adolescent Psychiatry, 2022, Volume: 61, Issue:9

    Topics: Adolescent; Adult; Child; Depressive Disorder, Major; Double-Blind Method; Fluoxetine; Humans; Piper

2022
Vortioxetine for Major Depressive Disorder in Adolescents: 12-Week Randomized, Placebo-Controlled, Fluoxetine-Referenced, Fixed-Dose Study.
    Journal of the American Academy of Child and Adolescent Psychiatry, 2022, Volume: 61, Issue:9

    Topics: Adolescent; Adult; Child; Depressive Disorder, Major; Double-Blind Method; Fluoxetine; Humans; Piper

2022
Acute neural effects of fluoxetine on emotional regulation in depressed adolescents.
    Psychological medicine, 2023, Volume: 53, Issue:10

    Topics: Adolescent; Brain; Brain Mapping; Depressive Disorder, Major; Emotional Regulation; Emotions; Fluoxe

2023
Predictors of response to pharmacotherapy in children and adolescents with psychiatric disorders: A combined post hoc analysis of four clinical trial data.
    Neuropsychopharmacology reports, 2022, Volume: 42, Issue:4

    Topics: Adolescent; Child; Depressive Disorder, Major; Female; Fluoxetine; Humans; Selective Serotonin Reupt

2022
Sequenced treatment alternatives to relieve adolescent depression (STAR-AD): a multicentre open-label randomized controlled trial protocol.
    BMC psychiatry, 2023, 10-27, Volume: 23, Issue:1

    Topics: Adolescent; Child; Cognitive Behavioral Therapy; Combined Modality Therapy; Depression; Depressive D

2023
Is sleep disturbance linked to short- and long-term outcomes following treatments for recurrent depression?
    Journal of affective disorders, 2020, 02-01, Volume: 262

    Topics: Adult; Antidepressive Agents; Cognitive Behavioral Therapy; Depressive Disorder, Major; Female; Fluo

2020
Implementation research for public sector mental health care scale-up (SMART-DAPPER): a sequential multiple, assignment randomized trial (SMART) of non-specialist-delivered psychotherapy and/or medication for major depressive disorder and posttraumatic st
    BMC psychiatry, 2019, 12-28, Volume: 19, Issue:1

    Topics: Adult; Ambulatory Care; Ambulatory Care Facilities; Antidepressive Agents, Second-Generation; Combin

2019
Symptom clusters in adolescent depression and differential response to treatment: a secondary analysis of the Treatment for Adolescents with Depression Study randomised trial.
    The lancet. Psychiatry, 2020, Volume: 7, Issue:4

    Topics: Adolescent; Bayes Theorem; Child; Cognitive Behavioral Therapy; Combined Modality Therapy; Depressiv

2020
A placebo prognostic index (PI) as a moderator of outcomes in the treatment of adolescent depression: Could it inform risk-stratification in treatment with cognitive-behavioral therapy, fluoxetine, or their combination?
    Psychotherapy research : journal of the Society for Psychotherapy Research, 2021, Volume: 31, Issue:1

    Topics: Adolescent; Cognitive Behavioral Therapy; Combined Modality Therapy; Depression; Depressive Disorder

2021
Quality of Life Impacts of Bright Light Treatment, Fluoxetine, and the Combination in Patients with Nonseasonal Major Depressive Disorder: A Randomized Clinical Trial.
    Canadian journal of psychiatry. Revue canadienne de psychiatrie, 2021, Volume: 66, Issue:3

    Topics: Antidepressive Agents; Depressive Disorder, Major; Fluoxetine; Humans; Quality of Life; Treatment Ou

2021
Quality of life after response to acute-phase cognitive therapy for recurrent depression.
    Journal of affective disorders, 2021, 01-01, Volume: 278

    Topics: Adult; Cognitive Behavioral Therapy; Depression; Depressive Disorder, Major; Fluoxetine; Follow-Up S

2021
Trajectories of change in depression symptoms and suicidal ideation over the course of evidence-based treatment for depression: Secondary analysis of a randomised controlled trial of cognitive behavioural therapy plus fluoxetine in young people.
    The Australian and New Zealand journal of psychiatry, 2021, Volume: 55, Issue:5

    Topics: Adolescent; Australia; Cognitive Behavioral Therapy; Depression; Depressive Disorder, Major; Fluoxet

2021
Venlafaxine vs. fluoxetine in postmenopausal women with major depressive disorder: an 8-week, randomized, single-blind, active-controlled study.
    BMC psychiatry, 2021, 05-19, Volume: 21, Issue:1

    Topics: Cyclohexanols; Depressive Disorder, Major; Double-Blind Method; Female; Fluoxetine; Humans; Postmeno

2021
Venlafaxine vs. fluoxetine in postmenopausal women with major depressive disorder: an 8-week, randomized, single-blind, active-controlled study.
    BMC psychiatry, 2021, 05-19, Volume: 21, Issue:1

    Topics: Cyclohexanols; Depressive Disorder, Major; Double-Blind Method; Female; Fluoxetine; Humans; Postmeno

2021
Venlafaxine vs. fluoxetine in postmenopausal women with major depressive disorder: an 8-week, randomized, single-blind, active-controlled study.
    BMC psychiatry, 2021, 05-19, Volume: 21, Issue:1

    Topics: Cyclohexanols; Depressive Disorder, Major; Double-Blind Method; Female; Fluoxetine; Humans; Postmeno

2021
Venlafaxine vs. fluoxetine in postmenopausal women with major depressive disorder: an 8-week, randomized, single-blind, active-controlled study.
    BMC psychiatry, 2021, 05-19, Volume: 21, Issue:1

    Topics: Cyclohexanols; Depressive Disorder, Major; Double-Blind Method; Female; Fluoxetine; Humans; Postmeno

2021
Initial Steps to inform selection of continuation cognitive therapy or fluoxetine for higher risk responders to cognitive therapy for recurrent major depressive disorder.
    Psychiatry research, 2017, Volume: 253

    Topics: Adult; Antidepressive Agents, Second-Generation; Cognitive Behavioral Therapy; Depressive Disorder,

2017
Effect of Agomelatine and Fluoxetine on HAM-D Score, Serum Brain-Derived Neurotrophic Factor, and Tumor Necrosis Factor-α Level in Patients With Major Depressive Disorder With Severe Depression.
    Journal of clinical pharmacology, 2017, Volume: 57, Issue:12

    Topics: Acetamides; Adult; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Depressive Disorder, Ma

2017
Factors related to the improvement in quality of life for depressed inpatients treated with fluoxetine.
    BMC psychiatry, 2017, 08-25, Volume: 17, Issue:1

    Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Female; Fluoxetine; Humans; Inpatients; Ma

2017
Desvenlafaxine Versus Placebo in a Fluoxetine-Referenced Study of Children and Adolescents with Major Depressive Disorder.
    Journal of child and adolescent psychopharmacology, 2018, Volume: 28, Issue:1

    Topics: Adolescent; Antidepressive Agents; Child; Depressive Disorder, Major; Desvenlafaxine Succinate; Dose

2018
Nitrous oxide (N
    Trials, 2017, Dec-22, Volume: 18, Issue:1

    Topics: Adolescent; Child; Data Interpretation, Statistical; Depressive Disorder, Major; Drug Therapy, Combi

2017
Appetitive Symptoms Differentially Predict Treatment Response to Fluoxetine, Light, and Placebo in Nonseasonal Major Depression.
    The Journal of clinical psychiatry, 2018, 07-24, Volume: 79, Issue:4

    Topics: Adult; Appetitive Behavior; Combined Modality Therapy; Depressive Disorder, Major; Female; Fluoxetin

2018
Using acute tryptophan depletion to investigate predictors of treatment response in adolescents with major depressive disorder: study protocol for a randomised controlled trial.
    Trials, 2018, Aug-10, Volume: 19, Issue:1

    Topics: Adolescent; Adolescent Behavior; Affect; Age Factors; Amino Acids; Antidepressive Agents, Second-Gen

2018
Treating a broader range of depressed adolescents with combined therapy.
    Journal of affective disorders, 2018, 12-01, Volume: 241

    Topics: Adolescent; Adolescent Behavior; Antidepressive Agents, Second-Generation; Child; Cognitive Behavior

2018
Changes in cognitive distortions and affectivity levels in adolescent depression after acute phase fluoxetine treatment.
    Cognitive neuropsychiatry, 2019, Volume: 24, Issue:1

    Topics: Adolescent; Affect; Cognitive Dissonance; Depressive Disorder, Major; Female; Fluoxetine; Follow-Up

2019
Intravenous administration of adenosine triphosphate and phosphocreatine combined with fluoxetine in major depressive disorder: protocol for a randomized, double-blind, placebo-controlled pilot study.
    Trials, 2019, Jan-09, Volume: 20, Issue:1

    Topics: Adenosine Triphosphate; Administration, Intravenous; Administration, Oral; Adolescent; Adult; Affect

2019
Inflammatory Profiles in Depressed Adolescents Treated with Fluoxetine: An 8-Week Follow-up Open Study.
    Mediators of inflammation, 2018, Volume: 2018

    Topics: Adolescent; Adult; Antidepressive Agents, Second-Generation; Cytokines; Depression; Depressive Disor

2018
Trajectories of Symptom Change in the Treatment for Adolescents With Depression Study.
    Journal of the American Academy of Child and Adolescent Psychiatry, 2019, Volume: 58, Issue:3

    Topics: Adolescent; Cognitive Behavioral Therapy; Combined Modality Therapy; Depressive Disorder, Major; Dia

2019
Estimating patient-specific treatment advantages in the 'Treatment for Adolescents with Depression Study'.
    Journal of psychiatric research, 2019, Volume: 112

    Topics: Adolescent; Antidepressive Agents, Second-Generation; Child; Cognitive Behavioral Therapy; Combined

2019
The long-term effect of trauma history on adolescent depression treatment.
    Psychological trauma : theory, research, practice and policy, 2019, Volume: 11, Issue:7

    Topics: Adolescent; Cognitive Behavioral Therapy; Combined Modality Therapy; Comorbidity; Depressive Disorde

2019
Latent Profiles of Cognitive and Interpersonal Risk Factors for Adolescent Depression and Implications for Personalized Treatment.
    Journal of abnormal child psychology, 2019, Volume: 47, Issue:12

    Topics: Adolescent; Antidepressive Agents, Second-Generation; Child; Cognitive Behavioral Therapy; Cognitive

2019
The addition of fluoxetine to cognitive behavioural therapy for youth depression (YoDA-C): a randomised, double-blind, placebo-controlled, multicentre clinical trial.
    The lancet. Psychiatry, 2019, Volume: 6, Issue:9

    Topics: Adolescent; Adult; Anxiety; Australia; Cognitive Behavioral Therapy; Combined Modality Therapy; Como

2019
A randomized double-blind comparison of fluoxetine augmentation by high and low dosage folic acid in patients with depressive episodes.
    Journal of affective disorders, 2013, Sep-05, Volume: 150, Issue:2

    Topics: Adult; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Double-Blind Method; Dr

2013
Efficacy of vitamin C as an adjunct to fluoxetine therapy in pediatric major depressive disorder: a randomized, double-blind, placebo-controlled pilot study.
    Nutrition journal, 2013, Mar-09, Volume: 12

    Topics: Adjuvants, Pharmaceutic; Antidepressive Agents; Ascorbic Acid; Child; Depressive Disorder, Major; Do

2013
Sexual functioning in patients with recurrent major depressive disorder enrolled in the PREVENT study.
    The Journal of nervous and mental disease, 2013, Volume: 201, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Cyclohexanols;

2013
Effects of zinc supplementation on efficacy of antidepressant therapy, inflammatory cytokines, and brain-derived neurotrophic factor in patients with major depression.
    Nutritional neuroscience, 2014, Volume: 17, Issue:2

    Topics: Adolescent; Adult; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Citalopram; Cytokines;

2014
The change of insulin levels after six weeks antidepressant use in drug-naïve major depressive patients.
    Journal of affective disorders, 2013, Sep-05, Volume: 150, Issue:2

    Topics: Adolescent; Adult; Aged; Antidepressive Agents; Antidepressive Agents, Second-Generation; Body Mass

2013
Efficacy and safety of curcumin in major depressive disorder: a randomized controlled trial.
    Phytotherapy research : PTR, 2014, Volume: 28, Issue:4

    Topics: Adult; Antidepressive Agents; Curcumin; Depressive Disorder, Major; Double-Blind Method; Drug Therap

2014
Health-related quality of life and symptom severity in Chinese patients with major depressive disorder.
    Asia-Pacific psychiatry : official journal of the Pacific Rim College of Psychiatrists, 2013, Volume: 5, Issue:4

    Topics: Adolescent; Adult; Aged; Antidepressive Agents; Anxiety; Asian People; China; Depressive Disorder, M

2013
Preventing depressive relapse and recurrence in higher-risk cognitive therapy responders: a randomized trial of continuation phase cognitive therapy, fluoxetine, or matched pill placebo.
    JAMA psychiatry, 2013, Volume: 70, Issue:11

    Topics: Adult; Cognitive Behavioral Therapy; Depressive Disorder, Major; Female; Fluoxetine; Humans; Male; P

2013
The structure of the Montgomery-Åsberg depression rating scale over the course of treatment for depression.
    International journal of methods in psychiatric research, 2013, Volume: 22, Issue:3

    Topics: Adolescent; Adult; Aged; Ambulatory Care; Cognitive Behavioral Therapy; Combined Modality Therapy; D

2013
Neurocognitive changes in depressed patients in psychodynamic psychotherapy, therapy with fluoxetine and combination therapy.
    Journal of affective disorders, 2013, Volume: 151, Issue:3

    Topics: Adult; Antidepressive Agents, Second-Generation; Cognition; Combined Modality Therapy; Depressive Di

2013
Augmentation of fluoxetine with lovastatin for treating major depressive disorder, a randomized double-blind placebo controlled-clinical trial.
    Depression and anxiety, 2013, Volume: 30, Issue:11

    Topics: Adult; Depressive Disorder, Major; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; F

2013
Increased prefrontal cortex activity during negative emotion regulation as a predictor of depression symptom severity trajectory over 6 months.
    JAMA psychiatry, 2013, Volume: 70, Issue:11

    Topics: Antidepressive Agents, Second-Generation; Cyclohexanols; Delayed-Action Preparations; Depression; De

2013
Influence of sex and menopausal status on response, remission, and recurrence in patients with recurrent major depressive disorder treated with venlafaxine extended release or fluoxetine: analysis of data from the PREVENT study.
    The Journal of clinical psychiatry, 2014, Volume: 75, Issue:1

    Topics: Adult; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder, Major; Double-Blind Method;

2014
Prediction of remission of depression with clinical variables, neuropsychological performance, and serotonergic/dopaminergic gene polymorphisms.
    Human psychopharmacology, 2012, Volume: 27, Issue:6

    Topics: Adult; Antidepressive Agents; Catechol O-Methyltransferase; Depressive Disorder, Major; Diagnostic a

2012
Comparable efficacy and safety of 8 weeks treatment with agomelatine 25-50mg or fluoxetine 20-40mg in Asian out-patients with major depressive disorder.
    Asian journal of psychiatry, 2014, Volume: 8

    Topics: Acetamides; Adolescent; Adult; Aged; Antidepressive Agents; Depressive Disorder, Major; Double-Blind

2014
Mental health service use among adolescents following participation in a randomized clinical trial for depression.
    Journal of clinical child and adolescent psychology : the official journal for the Society of Clinical Child and Adolescent Psychology, American Psychological Association, Division 53, 2015, Volume: 44, Issue:4

    Topics: Adolescent; Child; Cognitive Behavioral Therapy; Combined Modality Therapy; Depressive Disorder, Maj

2015
Plasma fluoxetine concentrations and clinical improvement in an adolescent sample diagnosed with major depressive disorder, obsessive-compulsive disorder, or generalized anxiety disorder.
    Journal of clinical psychopharmacology, 2014, Volume: 34, Issue:3

    Topics: Adolescent; Anxiety Disorders; Child; Depressive Disorder, Major; Dose-Response Relationship, Drug;

2014
Efficacy and safety of olanzapine/fluoxetine combination vs fluoxetine monotherapy following successful combination therapy of treatment-resistant major depressive disorder.
    Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2014, Volume: 39, Issue:11

    Topics: Adult; Antidepressive Agents; Benzodiazepines; Depressive Disorder, Major; Depressive Disorder, Trea

2014
A double-blind efficacy and safety study of duloxetine flexible dosing in children and adolescents with major depressive disorder.
    Journal of child and adolescent psychopharmacology, 2014, Volume: 24, Issue:4

    Topics: Adolescent; Antidepressive Agents; Child; Depressive Disorder, Major; Dose-Response Relationship, Dr

2014
A double-blind efficacy and safety study of duloxetine fixed doses in children and adolescents with major depressive disorder.
    Journal of child and adolescent psychopharmacology, 2014, Volume: 24, Issue:4

    Topics: Adolescent; Antidepressive Agents; Child; Depressive Disorder, Major; Dose-Response Relationship, Dr

2014
Sequential treatment with fluoxetine and relapse--prevention CBT to improve outcomes in pediatric depression.
    The American journal of psychiatry, 2014, Volume: 171, Issue:10

    Topics: Adolescent; Child; Cognitive Behavioral Therapy; Combined Modality Therapy; Depressive Disorder, Maj

2014
Stable remission and recovery after acute-phase cognitive therapy for recurrent major depressive disorder.
    Journal of consulting and clinical psychology, 2014, Volume: 82, Issue:6

    Topics: Acute Disease; Adult; Antidepressive Agents, Second-Generation; Cognitive Behavioral Therapy; Depres

2014
Effects of olanzapine-fluoxetine combination treatment of major depressive disorders on the quality of life during acute treatment period.
    Cell biochemistry and biophysics, 2014, Volume: 70, Issue:3

    Topics: Adult; Benzodiazepines; Depressive Disorder, Major; Drug Administration Schedule; Drug Combinations;

2014
Latent classes of nonresponders, rapid responders, and gradual responders in depressed outpatients receiving antidepressant medication and psychotherapy.
    Depression and anxiety, 2015, Volume: 32, Issue:3

    Topics: Adult; Aged; Antidepressive Agents; Bayes Theorem; Cognitive Behavioral Therapy; Combined Modality T

2015
Childhood depression subscales using repeated sessions on Children's Depression Rating Scale - revised (CDRS-R) scores.
    Journal of child and adolescent psychopharmacology, 2014, Volume: 24, Issue:6

    Topics: Adolescent; Child; Depressive Disorder, Major; Factor Analysis, Statistical; Female; Fluoxetine; Hum

2014
Clinical outcomes and genome-wide association for a brain methylation site in an antidepressant pharmacogenetics study in Mexican Americans.
    The American journal of psychiatry, 2014, Dec-01, Volume: 171, Issue:12

    Topics: Adrenergic Uptake Inhibitors; Adult; Aged; Antidepressive Agents; Antidepressive Agents, Second-Gene

2014
Comparison of physician-rating and self-rating scales for patients with major depressive disorder.
    Journal of clinical psychopharmacology, 2014, Volume: 34, Issue:6

    Topics: Adult; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Female; Fluoxetine; Hum

2014
The addition of fluoxetine to cognitive behavioural therapy for youth depression (YoDA-C): study protocol for a randomised control trial.
    Trials, 2014, Nov-04, Volume: 15

    Topics: Adolescent; Adolescent Behavior; Adult; Age Factors; Antidepressive Agents, Second-Generation; Clini

2014
Crocin, the main active saffron constituent, as an adjunctive treatment in major depressive disorder: a randomized, double-blind, placebo-controlled, pilot clinical trial.
    Journal of affective disorders, 2015, Mar-15, Volume: 174

    Topics: Adult; Carotenoids; Citalopram; Crocus; Depressive Disorder, Major; Double-Blind Method; Female; Flu

2015
Individualized homeopathic treatment and fluoxetine for moderate to severe depression in peri- and postmenopausal women (HOMDEP-MENOP study): a randomized, double-dummy, double-blind, placebo-controlled trial.
    PloS one, 2015, Volume: 10, Issue:3

    Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Double-Blind Method; Female; Fluoxeti

2015
A rest-activity biomarker to predict response to SSRIs in major depressive disorder.
    Journal of psychiatric research, 2015, Volume: 64

    Topics: Adolescent; Adult; Aged; Analysis of Variance; Biomarkers; Depressive Disorder, Major; Female; Fluox

2015
Simvastatin as an adjuvant therapy to fluoxetine in patients with moderate to severe major depression: A double-blind placebo-controlled trial.
    Journal of psychopharmacology (Oxford, England), 2015, Volume: 29, Issue:5

    Topics: Adult; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, Combination; Female; Fluoxetin

2015
Acute and longer-term safety results from a pooled analysis of duloxetine studies for the treatment of children and adolescents with major depressive disorder.
    Journal of child and adolescent psychopharmacology, 2015, Volume: 25, Issue:4

    Topics: Adolescent; Antidepressive Agents; Child; Depressive Disorder, Major; Double-Blind Method; Duloxetin

2015
Acute and longer-term safety results from a pooled analysis of duloxetine studies for the treatment of children and adolescents with major depressive disorder.
    Journal of child and adolescent psychopharmacology, 2015, Volume: 25, Issue:4

    Topics: Adolescent; Antidepressive Agents; Child; Depressive Disorder, Major; Double-Blind Method; Duloxetin

2015
Acute and longer-term safety results from a pooled analysis of duloxetine studies for the treatment of children and adolescents with major depressive disorder.
    Journal of child and adolescent psychopharmacology, 2015, Volume: 25, Issue:4

    Topics: Adolescent; Antidepressive Agents; Child; Depressive Disorder, Major; Double-Blind Method; Duloxetin

2015
Acute and longer-term safety results from a pooled analysis of duloxetine studies for the treatment of children and adolescents with major depressive disorder.
    Journal of child and adolescent psychopharmacology, 2015, Volume: 25, Issue:4

    Topics: Adolescent; Antidepressive Agents; Child; Depressive Disorder, Major; Double-Blind Method; Duloxetin

2015
Predictors of longitudinal outcomes after unstable response to acute-phase cognitive therapy for major depressive disorder.
    Psychotherapy (Chicago, Ill.), 2015, Volume: 52, Issue:2

    Topics: Adult; Age Factors; Antidepressive Agents, Second-Generation; Chronic Disease; Cognitive Behavioral

2015
Improved cognitive content endures for 2 years among unstable responders to acute-phase cognitive therapy for recurrent major depressive disorder.
    Psychological medicine, 2015, Volume: 45, Issue:15

    Topics: Adult; Attitude; Cognitive Behavioral Therapy; Depressive Disorder, Major; Female; Fluoxetine; Follo

2015
Assessing cognitive therapy skills comprehension, acquisition, and use by means of an independent observer version of the Skills of Cognitive Therapy (SoCT-IO).
    Psychological assessment, 2016, Volume: 28, Issue:2

    Topics: Antidepressive Agents, Second-Generation; Cognitive Behavioral Therapy; Comprehension; Depression; D

2016
Comparison of efficacy, safety and brain derived neurotrophic factor (BDNF) levels in patients of major depressive disorder, treated with fluoxetine and desvenlafaxine.
    Asian journal of psychiatry, 2015, Volume: 18

    Topics: Adult; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Depressive Disorder, Major; Desvenl

2015
Trajectories of Functioning Into Emerging Adulthood Following Treatment for Adolescent Depression.
    The Journal of adolescent health : official publication of the Society for Adolescent Medicine, 2016, Volume: 58, Issue:3

    Topics: Adolescent; Adolescent Development; Brief Psychiatric Rating Scale; Cognitive Behavioral Therapy; Co

2016
Efficacy of Bright Light Treatment, Fluoxetine, and the Combination in Patients With Nonseasonal Major Depressive Disorder: A Randomized Clinical Trial.
    JAMA psychiatry, 2016, Volume: 73, Issue:1

    Topics: Adult; Antidepressive Agents, Second-Generation; Combined Modality Therapy; Depressive Disorder, Maj

2016
Efficacy of Bright Light Treatment, Fluoxetine, and the Combination in Patients With Nonseasonal Major Depressive Disorder: A Randomized Clinical Trial.
    JAMA psychiatry, 2016, Volume: 73, Issue:1

    Topics: Adult; Antidepressive Agents, Second-Generation; Combined Modality Therapy; Depressive Disorder, Maj

2016
Efficacy of Bright Light Treatment, Fluoxetine, and the Combination in Patients With Nonseasonal Major Depressive Disorder: A Randomized Clinical Trial.
    JAMA psychiatry, 2016, Volume: 73, Issue:1

    Topics: Adult; Antidepressive Agents, Second-Generation; Combined Modality Therapy; Depressive Disorder, Maj

2016
Efficacy of Bright Light Treatment, Fluoxetine, and the Combination in Patients With Nonseasonal Major Depressive Disorder: A Randomized Clinical Trial.
    JAMA psychiatry, 2016, Volume: 73, Issue:1

    Topics: Adult; Antidepressive Agents, Second-Generation; Combined Modality Therapy; Depressive Disorder, Maj

2016
Efficacy of Bright Light Treatment, Fluoxetine, and the Combination in Patients With Nonseasonal Major Depressive Disorder: A Randomized Clinical Trial.
    JAMA psychiatry, 2016, Volume: 73, Issue:1

    Topics: Adult; Antidepressive Agents, Second-Generation; Combined Modality Therapy; Depressive Disorder, Maj

2016
Efficacy of Bright Light Treatment, Fluoxetine, and the Combination in Patients With Nonseasonal Major Depressive Disorder: A Randomized Clinical Trial.
    JAMA psychiatry, 2016, Volume: 73, Issue:1

    Topics: Adult; Antidepressive Agents, Second-Generation; Combined Modality Therapy; Depressive Disorder, Maj

2016
Efficacy of Bright Light Treatment, Fluoxetine, and the Combination in Patients With Nonseasonal Major Depressive Disorder: A Randomized Clinical Trial.
    JAMA psychiatry, 2016, Volume: 73, Issue:1

    Topics: Adult; Antidepressive Agents, Second-Generation; Combined Modality Therapy; Depressive Disorder, Maj

2016
Efficacy of Bright Light Treatment, Fluoxetine, and the Combination in Patients With Nonseasonal Major Depressive Disorder: A Randomized Clinical Trial.
    JAMA psychiatry, 2016, Volume: 73, Issue:1

    Topics: Adult; Antidepressive Agents, Second-Generation; Combined Modality Therapy; Depressive Disorder, Maj

2016
Efficacy of Bright Light Treatment, Fluoxetine, and the Combination in Patients With Nonseasonal Major Depressive Disorder: A Randomized Clinical Trial.
    JAMA psychiatry, 2016, Volume: 73, Issue:1

    Topics: Adult; Antidepressive Agents, Second-Generation; Combined Modality Therapy; Depressive Disorder, Maj

2016
Efficacy of Bright Light Treatment, Fluoxetine, and the Combination in Patients With Nonseasonal Major Depressive Disorder: A Randomized Clinical Trial.
    JAMA psychiatry, 2016, Volume: 73, Issue:1

    Topics: Adult; Antidepressive Agents, Second-Generation; Combined Modality Therapy; Depressive Disorder, Maj

2016
Efficacy of Bright Light Treatment, Fluoxetine, and the Combination in Patients With Nonseasonal Major Depressive Disorder: A Randomized Clinical Trial.
    JAMA psychiatry, 2016, Volume: 73, Issue:1

    Topics: Adult; Antidepressive Agents, Second-Generation; Combined Modality Therapy; Depressive Disorder, Maj

2016
Efficacy of Bright Light Treatment, Fluoxetine, and the Combination in Patients With Nonseasonal Major Depressive Disorder: A Randomized Clinical Trial.
    JAMA psychiatry, 2016, Volume: 73, Issue:1

    Topics: Adult; Antidepressive Agents, Second-Generation; Combined Modality Therapy; Depressive Disorder, Maj

2016
Efficacy of Bright Light Treatment, Fluoxetine, and the Combination in Patients With Nonseasonal Major Depressive Disorder: A Randomized Clinical Trial.
    JAMA psychiatry, 2016, Volume: 73, Issue:1

    Topics: Adult; Antidepressive Agents, Second-Generation; Combined Modality Therapy; Depressive Disorder, Maj

2016
Efficacy of Bright Light Treatment, Fluoxetine, and the Combination in Patients With Nonseasonal Major Depressive Disorder: A Randomized Clinical Trial.
    JAMA psychiatry, 2016, Volume: 73, Issue:1

    Topics: Adult; Antidepressive Agents, Second-Generation; Combined Modality Therapy; Depressive Disorder, Maj

2016
Efficacy of Bright Light Treatment, Fluoxetine, and the Combination in Patients With Nonseasonal Major Depressive Disorder: A Randomized Clinical Trial.
    JAMA psychiatry, 2016, Volume: 73, Issue:1

    Topics: Adult; Antidepressive Agents, Second-Generation; Combined Modality Therapy; Depressive Disorder, Maj

2016
Efficacy of Bright Light Treatment, Fluoxetine, and the Combination in Patients With Nonseasonal Major Depressive Disorder: A Randomized Clinical Trial.
    JAMA psychiatry, 2016, Volume: 73, Issue:1

    Topics: Adult; Antidepressive Agents, Second-Generation; Combined Modality Therapy; Depressive Disorder, Maj

2016
Continued Effectiveness of Relapse Prevention Cognitive-Behavioral Therapy Following Fluoxetine Treatment in Youth With Major Depressive Disorder.
    Journal of the American Academy of Child and Adolescent Psychiatry, 2015, Volume: 54, Issue:12

    Topics: Adolescent; Child; Cognition; Cognitive Behavioral Therapy; Combined Modality Therapy; Depressive Di

2015
Study the effects of saffron on depression and lipid profiles: A double blind comparative study.
    Asian journal of psychiatry, 2016, Volume: 22

    Topics: Adolescent; Adult; Crocus; Depressive Disorder, Major; Double-Blind Method; Female; Fluoxetine; Huma

2016
Quantifying and qualifying the preventive effects of acute-phase cognitive therapy: Pathways to personalizing care.
    Journal of consulting and clinical psychology, 2016, Volume: 84, Issue:4

    Topics: Acute Disease; Adult; Aged; Antidepressive Agents, Second-Generation; Cognitive Behavioral Therapy;

2016
Longitudinal social-interpersonal functioning among higher-risk responders to acute-phase cognitive therapy for recurrent major depressive disorder.
    Journal of affective disorders, 2016, Jul-15, Volume: 199

    Topics: Adult; Cognitive Behavioral Therapy; Depressive Disorder, Major; Female; Fluoxetine; Follow-Up Studi

2016
Influence of ACE gene on differential response to sertraline versus fluoxetine in patients with major depression: a randomized controlled trial.
    European journal of clinical pharmacology, 2016, Volume: 72, Issue:9

    Topics: Adolescent; Adult; Aged; Alleles; Antidepressive Agents; Depressive Disorder, Major; Female; Fluoxet

2016
Effects of Restricted Time in Bed on Antidepressant Treatment Response: A Randomized Controlled Trial.
    The Journal of clinical psychiatry, 2016, Volume: 77, Issue:10

    Topics: Actigraphy; Adult; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Female; Flu

2016
PURLs: Light therapy for nonseasonal major depressive disorder?
    The Journal of family practice, 2016, Volume: 65, Issue:7

    Topics: Adult; Antidepressive Agents; Combined Modality Therapy; Depressive Disorder, Major; Female; Fluoxet

2016
Defined symptom-change trajectories during acute-phase cognitive therapy for depression predict better longitudinal outcomes.
    Behaviour research and therapy, 2016, Volume: 87

    Topics: Adult; Antidepressive Agents, Second-Generation; Cognitive Behavioral Therapy; Combined Modality The

2016
Acupuncture treatment modulates the corticostriatal reward circuitry in major depressive disorder.
    Journal of psychiatric research, 2017, Volume: 84

    Topics: Acupuncture Therapy; Adult; Antidepressive Agents, Second-Generation; Cerebral Cortex; Combined Moda

2017
Repeated acupuncture treatments modulate amygdala resting state functional connectivity of depressive patients.
    NeuroImage. Clinical, 2016, Volume: 12

    Topics: Acupuncture Therapy; Adult; Amygdala; Antidepressive Agents, Second-Generation; Brain; Brain Mapping

2016
Trajectories of relapse in randomised, placebo-controlled trials of treatment discontinuation in major depressive disorder: an individual patient-level data meta-analysis.
    The lancet. Psychiatry, 2017, Volume: 4, Issue:3

    Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Duloxetine Hydrochloride; Female; Fluoxeti

2017
Relationships between circadian measures, depression, and response to antidepressant treatment: A preliminary investigation.
    Psychiatry research, 2017, Volume: 252

    Topics: Adult; Antidepressive Agents; Circadian Rhythm; Depressive Disorder, Major; Female; Fluoxetine; Huma

2017
Sexually dimorphic effect of catechol-O-methyltransferase val158met polymorphism on clinical response to fluoxetine in major depressive patients.
    Journal of affective disorders, 2009, Volume: 113, Issue:1-2

    Topics: Adult; Asian People; Catechol O-Methyltransferase; Depressive Disorder, Major; Diagnostic and Statis

2009
Effect of antidepressants on melatonin metabolite in depressed patients.
    Journal of psychopharmacology (Oxford, England), 2009, Volume: 23, Issue:3

    Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Duloxetine Hydrochloride; Female; Fluoxeti

2009
Personality disorders and perceived stress in major depressive disorder.
    Psychiatry research, 2008, Aug-15, Volume: 160, Issue:2

    Topics: Adolescent; Adult; Aged; Ambulatory Care; Comorbidity; Depressive Disorder, Major; Diagnostic and St

2008
Short-term psychodynamic psychotherapy and fluoxetine in major depressive disorder: a randomized comparative study.
    Psychotherapy and psychosomatics, 2008, Volume: 77, Issue:6

    Topics: Adult; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Drug Admin

2008
A randomized, double-blind, and placebo-controlled trial of quetiapine augmentation of fluoxetine in major depressive disorder.
    International clinical psychopharmacology, 2008, Volume: 23, Issue:5

    Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Depressive

2008
Effect of folic acid combined with fluoxetine in patients with major depression on plasma homocysteine and vitamin B12, and serotonin levels in lymphocytes.
    Neuroimmunomodulation, 2008, Volume: 15, Issue:3

    Topics: Adult; Chromatography, High Pressure Liquid; Depressive Disorder, Major; Down-Regulation; Drug Syner

2008
Psychic and somatic anxiety symptoms as predictors of response to fluoxetine in major depressive disorder.
    Psychiatry research, 2008, Oct-30, Volume: 161, Issue:1

    Topics: Adolescent; Adult; Antidepressive Agents, Second-Generation; Anxiety Disorders; Comorbidity; Depress

2008
The pharmacokinetics of standard antidepressants with aripiprazole as adjunctive therapy: studies in healthy subjects and in patients with major depressive disorder.
    Journal of psychopharmacology (Oxford, England), 2010, Volume: 24, Issue:4

    Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Citalopram; Cyclohexanols; Delayed

2010
The pharmacokinetics of standard antidepressants with aripiprazole as adjunctive therapy: studies in healthy subjects and in patients with major depressive disorder.
    Journal of psychopharmacology (Oxford, England), 2010, Volume: 24, Issue:4

    Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Citalopram; Cyclohexanols; Delayed

2010
The pharmacokinetics of standard antidepressants with aripiprazole as adjunctive therapy: studies in healthy subjects and in patients with major depressive disorder.
    Journal of psychopharmacology (Oxford, England), 2010, Volume: 24, Issue:4

    Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Citalopram; Cyclohexanols; Delayed

2010
The pharmacokinetics of standard antidepressants with aripiprazole as adjunctive therapy: studies in healthy subjects and in patients with major depressive disorder.
    Journal of psychopharmacology (Oxford, England), 2010, Volume: 24, Issue:4

    Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Citalopram; Cyclohexanols; Delayed

2010
The pharmacokinetics of standard antidepressants with aripiprazole as adjunctive therapy: studies in healthy subjects and in patients with major depressive disorder.
    Journal of psychopharmacology (Oxford, England), 2010, Volume: 24, Issue:4

    Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Citalopram; Cyclohexanols; Delayed

2010
The pharmacokinetics of standard antidepressants with aripiprazole as adjunctive therapy: studies in healthy subjects and in patients with major depressive disorder.
    Journal of psychopharmacology (Oxford, England), 2010, Volume: 24, Issue:4

    Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Citalopram; Cyclohexanols; Delayed

2010
The pharmacokinetics of standard antidepressants with aripiprazole as adjunctive therapy: studies in healthy subjects and in patients with major depressive disorder.
    Journal of psychopharmacology (Oxford, England), 2010, Volume: 24, Issue:4

    Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Citalopram; Cyclohexanols; Delayed

2010
The pharmacokinetics of standard antidepressants with aripiprazole as adjunctive therapy: studies in healthy subjects and in patients with major depressive disorder.
    Journal of psychopharmacology (Oxford, England), 2010, Volume: 24, Issue:4

    Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Citalopram; Cyclohexanols; Delayed

2010
The pharmacokinetics of standard antidepressants with aripiprazole as adjunctive therapy: studies in healthy subjects and in patients with major depressive disorder.
    Journal of psychopharmacology (Oxford, England), 2010, Volume: 24, Issue:4

    Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Citalopram; Cyclohexanols; Delayed

2010
The pharmacokinetics of standard antidepressants with aripiprazole as adjunctive therapy: studies in healthy subjects and in patients with major depressive disorder.
    Journal of psychopharmacology (Oxford, England), 2010, Volume: 24, Issue:4

    Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Citalopram; Cyclohexanols; Delayed

2010
The pharmacokinetics of standard antidepressants with aripiprazole as adjunctive therapy: studies in healthy subjects and in patients with major depressive disorder.
    Journal of psychopharmacology (Oxford, England), 2010, Volume: 24, Issue:4

    Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Citalopram; Cyclohexanols; Delayed

2010
The pharmacokinetics of standard antidepressants with aripiprazole as adjunctive therapy: studies in healthy subjects and in patients with major depressive disorder.
    Journal of psychopharmacology (Oxford, England), 2010, Volume: 24, Issue:4

    Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Citalopram; Cyclohexanols; Delayed

2010
The pharmacokinetics of standard antidepressants with aripiprazole as adjunctive therapy: studies in healthy subjects and in patients with major depressive disorder.
    Journal of psychopharmacology (Oxford, England), 2010, Volume: 24, Issue:4

    Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Citalopram; Cyclohexanols; Delayed

2010
The pharmacokinetics of standard antidepressants with aripiprazole as adjunctive therapy: studies in healthy subjects and in patients with major depressive disorder.
    Journal of psychopharmacology (Oxford, England), 2010, Volume: 24, Issue:4

    Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Citalopram; Cyclohexanols; Delayed

2010
The pharmacokinetics of standard antidepressants with aripiprazole as adjunctive therapy: studies in healthy subjects and in patients with major depressive disorder.
    Journal of psychopharmacology (Oxford, England), 2010, Volume: 24, Issue:4

    Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Citalopram; Cyclohexanols; Delayed

2010
The pharmacokinetics of standard antidepressants with aripiprazole as adjunctive therapy: studies in healthy subjects and in patients with major depressive disorder.
    Journal of psychopharmacology (Oxford, England), 2010, Volume: 24, Issue:4

    Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Citalopram; Cyclohexanols; Delayed

2010
Assessing the efficacy of 2 years of maintenance treatment with venlafaxine extended release 75-225 mg/day in patients with recurrent major depression: a secondary analysis of data from the PREVENT study.
    International clinical psychopharmacology, 2008, Volume: 23, Issue:6

    Topics: Adult; Antidepressive Agents, Second-Generation; Cyclohexanols; Delayed-Action Preparations; Depress

2008
Cognitive-behavioral therapy to prevent relapse in pediatric responders to pharmacotherapy for major depressive disorder.
    Journal of the American Academy of Child and Adolescent Psychiatry, 2008, Volume: 47, Issue:12

    Topics: Adolescent; Antidepressive Agents, Second-Generation; Child; Cognitive Behavioral Therapy; Combined

2008
Cost-effectiveness and cost-utility of cognitive therapy, rational emotive behavioral therapy, and fluoxetine (Prozac) in treating depression: a randomized clinical trial.
    Journal of clinical psychology, 2009, Volume: 65, Issue:1

    Topics: Adult; Analysis of Variance; Antidepressive Agents, Second-Generation; Behavior Therapy; Cognitive B

2009
Brain functional changes during placebo lead-in and changes in specific symptoms during pharmacotherapy for major depression.
    Acta psychiatrica Scandinavica, 2009, Volume: 119, Issue:4

    Topics: Brain; Cyclohexanols; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disord

2009
Remission and recovery in the Treatment for Adolescents with Depression Study (TADS): acute and long-term outcomes.
    Journal of the American Academy of Child and Adolescent Psychiatry, 2009, Volume: 48, Issue:2

    Topics: Adolescent; Cognitive Behavioral Therapy; Combined Modality Therapy; Depressive Disorder, Major; Fem

2009
Assessment of safety and long-term outcomes of initial treatment with placebo in TADS.
    The American journal of psychiatry, 2009, Volume: 166, Issue:3

    Topics: Adolescent; Child; Cognitive Behavioral Therapy; Combined Modality Therapy; Depressive Disorder, Maj

2009
Predictors of spontaneous and systematically assessed suicidal adverse events in the treatment of SSRI-resistant depression in adolescents (TORDIA) study.
    The American journal of psychiatry, 2009, Volume: 166, Issue:4

    Topics: Adolescent; Antidepressive Agents; Benzodiazepines; Citalopram; Cognitive Behavioral Therapy; Cross-

2009
Predictors of spontaneous and systematically assessed suicidal adverse events in the treatment of SSRI-resistant depression in adolescents (TORDIA) study.
    The American journal of psychiatry, 2009, Volume: 166, Issue:4

    Topics: Adolescent; Antidepressive Agents; Benzodiazepines; Citalopram; Cognitive Behavioral Therapy; Cross-

2009
Predictors of spontaneous and systematically assessed suicidal adverse events in the treatment of SSRI-resistant depression in adolescents (TORDIA) study.
    The American journal of psychiatry, 2009, Volume: 166, Issue:4

    Topics: Adolescent; Antidepressive Agents; Benzodiazepines; Citalopram; Cognitive Behavioral Therapy; Cross-

2009
Predictors of spontaneous and systematically assessed suicidal adverse events in the treatment of SSRI-resistant depression in adolescents (TORDIA) study.
    The American journal of psychiatry, 2009, Volume: 166, Issue:4

    Topics: Adolescent; Antidepressive Agents; Benzodiazepines; Citalopram; Cognitive Behavioral Therapy; Cross-

2009
Placebo-controlled inpatient comparison of venlafaxine and fluoxetine for the treatment of major depression with melancholic features.
    International clinical psychopharmacology, 2009, Volume: 24, Issue:2

    Topics: Adult; Antidepressive Agents; Blood Pressure; Constipation; Cyclohexanols; Depressive Disorder, Majo

2009
Double-blind placebo-controlled trial of fluoxetine in adolescents with comorbid major depression and an alcohol use disorder.
    Addictive behaviors, 2009, Volume: 34, Issue:10

    Topics: Adolescent; Adolescent Behavior; Alcohol-Related Disorders; Cognitive Behavioral Therapy; Comorbidit

2009
Predictors of hopelessness among clinically depressed youth.
    Behavioural and cognitive psychotherapy, 2009, Volume: 37, Issue:3

    Topics: Adolescent; Antidepressive Agents, Second-Generation; Cognitive Behavioral Therapy; Combined Modalit

2009
Orosomucoid influences the response to antidepressants in major depressive disorder.
    Journal of psychopharmacology (Oxford, England), 2010, Volume: 24, Issue:4

    Topics: Adult; Antidepressive Agents; Biomarkers; Depressive Disorder, Major; Female; Fluoxetine; Genotype;

2010
Novel sequence variations in the brain-derived neurotrophic factor gene and association with major depression and antidepressant treatment response.
    Archives of general psychiatry, 2009, Volume: 66, Issue:5

    Topics: Adult; Aged; Alleles; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Case-Control Studies

2009
Relative cost-effectiveness of treatments for adolescent depression: 36-week results from the TADS randomized trial.
    Journal of the American Academy of Child and Adolescent Psychiatry, 2009, Volume: 48, Issue:7

    Topics: Adolescent; Antidepressive Agents, Second-Generation; Child; Cognitive Behavioral Therapy; Combined

2009
Relative cost-effectiveness of treatments for adolescent depression: 36-week results from the TADS randomized trial.
    Journal of the American Academy of Child and Adolescent Psychiatry, 2009, Volume: 48, Issue:7

    Topics: Adolescent; Antidepressive Agents, Second-Generation; Child; Cognitive Behavioral Therapy; Combined

2009
Relative cost-effectiveness of treatments for adolescent depression: 36-week results from the TADS randomized trial.
    Journal of the American Academy of Child and Adolescent Psychiatry, 2009, Volume: 48, Issue:7

    Topics: Adolescent; Antidepressive Agents, Second-Generation; Child; Cognitive Behavioral Therapy; Combined

2009
Relative cost-effectiveness of treatments for adolescent depression: 36-week results from the TADS randomized trial.
    Journal of the American Academy of Child and Adolescent Psychiatry, 2009, Volume: 48, Issue:7

    Topics: Adolescent; Antidepressive Agents, Second-Generation; Child; Cognitive Behavioral Therapy; Combined

2009
The role of readiness to change in response to treatment of adolescent depression.
    Journal of consulting and clinical psychology, 2009, Volume: 77, Issue:3

    Topics: Adolescent; Antidepressive Agents, Second-Generation; Child; Cognitive Behavioral Therapy; Combined

2009
Does defense style or psychological mindedness predict treatement response in major depression?
    Depression and anxiety, 2009, Volume: 26, Issue:7

    Topics: Adult; Cognition; Defense Mechanisms; Depressive Disorder, Major; Female; Fluoxetine; Humans; Male;

2009
The response of psychotic-like symptoms to fluoxetine monotherapy in non-psychotic major depressive disorder.
    Nordic journal of psychiatry, 2009, Volume: 63, Issue:5

    Topics: Adolescent; Adult; Aged; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Dis

2009
Childhood neglect and abuse as predictors of antidepressant response in adult depression.
    Depression and anxiety, 2009, Volume: 26, Issue:8

    Topics: Adult; Age of Onset; Antidepressive Agents; Child; Child Abuse; Child Abuse, Sexual; Chronic Disease

2009
Suicidal events in the Treatment for Adolescents With Depression Study (TADS).
    The Journal of clinical psychiatry, 2009, Apr-21, Volume: 70, Issue:5

    Topics: Adolescent; Child; Cognitive Behavioral Therapy; Depressive Disorder, Major; Diagnostic and Statisti

2009
Type of residual symptom and risk of relapse during the continuation/maintenance phase treatment of major depressive disorder with the selective serotonin reuptake inhibitor fluoxetine.
    European archives of psychiatry and clinical neuroscience, 2010, Volume: 260, Issue:2

    Topics: Adolescent; Adult; Aged; Checklist; Depressive Disorder, Major; Double-Blind Method; Drug Administra

2010
Effects of selective serotonin reuptake inhibitors on thyroid function in depressed patients with primary hypothyroidism or normal thyroid function.
    Thyroid : official journal of the American Thyroid Association, 2009, Volume: 19, Issue:7

    Topics: Adult; Aged; Autoantibodies; Depressive Disorder, Major; Fluoxetine; Humans; Hypothyroidism; Iodide

2009
Antidepressant response trajectories and quantitative electroencephalography (QEEG) biomarkers in major depressive disorder.
    Journal of psychiatric research, 2010, Volume: 44, Issue:2

    Topics: Antidepressive Agents; Brain Mapping; Cyclohexanols; Depressive Disorder, Major; Double-Blind Method

2010
Haplotype analysis of single nucleotide polymorphisms in the vascular endothelial growth factor (VEGFA) gene and antidepressant treatment response in major depressive disorder.
    Psychiatry research, 2009, Sep-30, Volume: 169, Issue:2

    Topics: Adult; Antidepressive Agents; Citalopram; Depressive Disorder, Major; Female; Fluoxetine; Gene Frequ

2009
The Treatment for Adolescents With Depression Study (TADS): outcomes over 1 year of naturalistic follow-up.
    The American journal of psychiatry, 2009, Volume: 166, Issue:10

    Topics: Adolescent; Child; Cognitive Behavioral Therapy; Combined Modality Therapy; Depressive Disorder, Maj

2009
Imbalance between pro- and anti-inflammatory cytokines, and between Th1 and Th2 cytokines in depressed patients: the effect of electroacupuncture or fluoxetine treatment.
    Pharmacopsychiatry, 2009, Volume: 42, Issue:5

    Topics: Adult; Analysis of Variance; Antidepressive Agents, Second-Generation; Cytokines; Depressive Disorde

2009
Assessing rates and predictors of tachyphylaxis during the prevention of recurrent episodes of depression with venlafaxine ER for two years (PREVENT) study.
    Psychopharmacology bulletin, 2009, Volume: 42, Issue:3

    Topics: Adult; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder, Major; Double-Blind Method;

2009
Effects of venlafaxine and fluoxetine on lymphocyte subsets in patients with major depressive disorder: a flow cytometric analysis.
    Progress in neuro-psychopharmacology & biological psychiatry, 2010, Feb-01, Volume: 34, Issue:1

    Topics: Adult; Antidepressive Agents, Second-Generation; Antigens, CD; Cyclohexanols; Depressive Disorder, M

2010
Personality disorders improve in patients treated for major depression.
    Acta psychiatrica Scandinavica, 2010, Volume: 122, Issue:3

    Topics: Adult; Antidepressive Agents; Bipolar Disorder; Comorbidity; Depressive Disorder, Major; Dose-Respon

2010
Fluoxetine-clonazepam cotherapy for anxious depression: an exploratory, post-hoc analysis of a randomized, double blind study.
    International clinical psychopharmacology, 2010, Volume: 25, Issue:1

    Topics: Adult; Anti-Anxiety Agents; Antidepressive Agents; Anxiety; Clonazepam; Depressive Disorder, Major;

2010
Research letter: Psychotherapy increases brain serotonin 5-HT1A receptors in patients with major depressive disorder.
    Psychological medicine, 2010, Volume: 40, Issue:3

    Topics: Adult; Analysis of Variance; Antidepressive Agents, Second-Generation; Brain; Brain Chemistry; Depre

2010
Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study.
    The American journal of psychiatry, 2010, Volume: 167, Issue:3

    Topics: Adult; Antidepressive Agents; Bupropion; Cyclohexanols; Depressive Disorder, Major; Double-Blind Met

2010
Factor structure and psychometric properties of the Children's Negative Cognitive Error Questionnaire with a clinically depressed adolescent sample.
    Journal of clinical child and adolescent psychology : the official journal for the Society of Clinical Child and Adolescent Psychology, American Psychological Association, Division 53, 2009, Volume: 38, Issue:6

    Topics: Adolescent; Affect; Child; Cognition; Cognitive Behavioral Therapy; Depressive Disorder, Major; Fact

2009
Cognitive measures of adolescent depression: unique or unitary constructs?
    Journal of clinical child and adolescent psychology : the official journal for the Society of Clinical Child and Adolescent Psychology, American Psychological Association, Division 53, 2009, Volume: 38, Issue:6

    Topics: Adolescent; Child; Cognition Disorders; Cognitive Behavioral Therapy; Culture; Depressive Disorder,

2009
An exploratory analysis of the impact of family functioning on treatment for depression in adolescents.
    Journal of clinical child and adolescent psychology : the official journal for the Society of Clinical Child and Adolescent Psychology, American Psychological Association, Division 53, 2009, Volume: 38, Issue:6

    Topics: Adolescent; Child; Cognitive Behavioral Therapy; Depressive Disorder, Major; Double-Blind Method; Fa

2009
Association of BDNF Val66Met polymorphism with both baseline HRQOL scores and improvement in HRQOL scores in Chinese major depressive patients treated with fluoxetine.
    Human psychopharmacology, 2010, Volume: 25, Issue:2

    Topics: Adolescent; Adult; Aged; Amino Acid Substitution; Brain-Derived Neurotrophic Factor; China; Cohort S

2010
Correlation between patient and clinician assessments of depression severity in the PREVENT study.
    Psychiatry research, 2010, May-15, Volume: 177, Issue:1-2

    Topics: Antidepressive Agents; Cyclohexanols; Depressive Disorder, Major; Double-Blind Method; Female; Fluox

2010
Measures of temperament and character are differentially impacted on by depression severity.
    Journal of affective disorders, 2010, Volume: 126, Issue:1-2

    Topics: Adult; Affect; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Cognitive

2010
Brain functional changes (QEEG cordance) and worsening suicidal ideation and mood symptoms during antidepressant treatment.
    Acta psychiatrica Scandinavica, 2010, Volume: 122, Issue:6

    Topics: Adult; Analysis of Variance; Antidepressive Agents; Antidepressive Agents, Second-Generation; Brain;

2010
Anxious depression and early changes in the HAMD-17 anxiety-somatization factor items and antidepressant treatment outcome.
    International clinical psychopharmacology, 2010, Volume: 25, Issue:4

    Topics: Adult; Antidepressive Agents, Second-Generation; Anxiety; Depressive Disorder, Major; Female; Fluoxe

2010
Comparative efficacy and durability of continuation phase cognitive therapy for preventing recurrent depression: design of a double-blinded, fluoxetine- and pill placebo-controlled, randomized trial with 2-year follow-up.
    Contemporary clinical trials, 2010, Volume: 31, Issue:4

    Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Cognitive Behavioral Therapy; Dep

2010
Effects of eicosapentaenoic acid and fluoxetine on plasma cortisol, serum interleukin-1beta and interleukin-6 concentrations in patients with major depressive disorder.
    Psychiatry research, 2010, Jun-30, Volume: 178, Issue:1

    Topics: Adult; Analysis of Variance; Antidepressive Agents; Depressive Disorder, Major; Eicosapentaenoic Aci

2010
Efficacy and mood conversion rate of short-term fluoxetine monotherapy of bipolar II major depressive episode.
    Journal of clinical psychopharmacology, 2010, Volume: 30, Issue:3

    Topics: Adult; Affect; Aged; Aged, 80 and over; Bipolar Disorder; Depressive Disorder, Major; Female; Fluoxe

2010
Insomnia severity is an indicator of suicidal ideation during a depression clinical trial.
    Sleep medicine, 2010, Volume: 11, Issue:9

    Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Azabicyclo Compounds; Depressive

2010
Personality traits and recovery from major depressive disorder.
    Nordic journal of psychiatry, 2011, Volume: 65, Issue:1

    Topics: Adult; Antidepressive Agents, Second-Generation; Comparative Effectiveness Research; Cooperative Beh

2011
Economic outcomes of eszopiclone treatment in insomnia and comorbid major depressive disorder.
    The journal of mental health policy and economics, 2010, Volume: 13, Issue:1

    Topics: Absenteeism; Algorithms; Antidepressive Agents, Second-Generation; Azabicyclo Compounds; Cost of Ill

2010
Double-blind fluoxetine trial in comorbid MDD-CUD youth and young adults.
    Drug and alcohol dependence, 2010, Nov-01, Volume: 112, Issue:1-2

    Topics: Adolescent; Adult; Antidepressive Agents, Second-Generation; Cognitive Behavioral Therapy; Combined

2010
Disposition of chiral and racemic fluoxetine and norfluoxetine across childbearing.
    Journal of clinical psychopharmacology, 2010, Volume: 30, Issue:4

    Topics: Adult; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Female; Fluoxetine; Hum

2010
Brain derived neurotrophic factor gene polymorphism (Val66Met) and short-term antidepressant response in major depressive disorder.
    Journal of affective disorders, 2010, Volume: 126, Issue:3

    Topics: Adult; Alleles; Antidepressive Agents, Second-Generation; Cyclohexanols; Depressive Disorder, Major;

2010
Psychoticism and paranoid ideation in patients with nonpsychotic major depressive disorder: prevalence, response to treatment, and impact on short- and long-term treatment outcome.
    CNS spectrums, 2010, Volume: 15, Issue:8

    Topics: Depressive Disorder, Major; Double-Blind Method; Fluoxetine; Humans; Prevalence; Selective Serotonin

2010
Treatment of insomnia in depressed insomniacs: effects on health-related quality of life, objective and self-reported sleep, and depression.
    Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine, 2010, Aug-15, Volume: 6, Issue:4

    Topics: Activities of Daily Living; Affect; Antidepressive Agents, Second-Generation; Azabicyclo Compounds;

2010
Effects of antidepressant drug treatment and psychotherapy on striatal and thalamic dopamine D2/3 receptors in major depressive disorder studied with [11C]raclopride PET.
    Journal of psychopharmacology (Oxford, England), 2011, Volume: 25, Issue:10

    Topics: Adult; Antidepressive Agents, Second-Generation; Carbon Radioisotopes; Corpus Striatum; Depressive D

2011
Superior antidepressant efficacy results of agomelatine versus fluoxetine in severe MDD patients: a randomized, double-blind study.
    International clinical psychopharmacology, 2010, Volume: 25, Issue:6

    Topics: Acetamides; Adolescent; Adult; Aged; Antidepressive Agents; Depressive Disorder, Major; Diagnostic a

2010
TPH1 is associated with major depressive disorder but not with SSRI/SNRI response in Taiwanese patients.
    Psychopharmacology, 2011, Volume: 213, Issue:4

    Topics: Adult; Asian People; Case-Control Studies; Cyclohexanols; Depressive Disorder, Major; Female; Fluoxe

2011
A comparison of various methods of measuring antidepressant medication adherence among children and adolescents with major depressive disorder in a 12-week open trial of fluoxetine.
    Journal of child and adolescent psychopharmacology, 2010, Volume: 20, Issue:5

    Topics: Adolescent; Antidepressive Agents, Second-Generation; Child; Depressive Disorder, Major; Drug Monito

2010
A comparison of various methods of measuring antidepressant medication adherence among children and adolescents with major depressive disorder in a 12-week open trial of fluoxetine.
    Journal of child and adolescent psychopharmacology, 2010, Volume: 20, Issue:5

    Topics: Adolescent; Antidepressive Agents, Second-Generation; Child; Depressive Disorder, Major; Drug Monito

2010
A comparison of various methods of measuring antidepressant medication adherence among children and adolescents with major depressive disorder in a 12-week open trial of fluoxetine.
    Journal of child and adolescent psychopharmacology, 2010, Volume: 20, Issue:5

    Topics: Adolescent; Antidepressive Agents, Second-Generation; Child; Depressive Disorder, Major; Drug Monito

2010
A comparison of various methods of measuring antidepressant medication adherence among children and adolescents with major depressive disorder in a 12-week open trial of fluoxetine.
    Journal of child and adolescent psychopharmacology, 2010, Volume: 20, Issue:5

    Topics: Adolescent; Antidepressive Agents, Second-Generation; Child; Depressive Disorder, Major; Drug Monito

2010
Symptom improvement and residual symptoms during acute antidepressant treatment in pediatric major depressive disorder.
    Journal of child and adolescent psychopharmacology, 2010, Volume: 20, Issue:5

    Topics: Adolescent; Age Factors; Antidepressive Agents, Second-Generation; Child; Depressive Disorder, Major

2010
Recovery and recurrence following treatment for adolescent major depression.
    Archives of general psychiatry, 2011, Volume: 68, Issue:3

    Topics: Adolescent; Antidepressive Agents, Second-Generation; Cognitive Behavioral Therapy; Combined Modalit

2011
Impact of antidepressant treatment history on clinical outcomes in placebo and medication treatment of major depression.
    Journal of clinical psychopharmacology, 2010, Volume: 30, Issue:6

    Topics: Adult; Antidepressive Agents, Second-Generation; Cyclohexanols; Depressive Disorder, Major; Double-B

2010
Clinical studies on event-related potentials (ERPs) N400 and the related factors in patients with poststroke depression (PSD).
    International journal of psychiatry in medicine, 2010, Volume: 40, Issue:3

    Topics: Aged; Antidepressive Agents, Second-Generation; Blood Platelets; Cerebral Hemorrhage; Cerebral Infar

2010
Antidepressant exposure as a predictor of clinical outcomes in the Treatment of Resistant Depression in Adolescents (TORDIA) study.
    Journal of clinical psychopharmacology, 2011, Volume: 31, Issue:1

    Topics: Adolescent; Age Factors; Antidepressive Agents; Citalopram; Depressive Disorder, Major; Female; Fluo

2011
A post hoc analysis of the effect of nightly administration of eszopiclone and a selective serotonin reuptake inhibitor in patients with insomnia and anxious depression.
    The Journal of clinical psychiatry, 2011, Volume: 72, Issue:4

    Topics: Adult; Anxiety; Azabicyclo Compounds; Depressive Disorder, Major; Double-Blind Method; Drug Therapy,

2011
A post hoc analysis of the effect of nightly administration of eszopiclone and a selective serotonin reuptake inhibitor in patients with insomnia and anxious depression.
    The Journal of clinical psychiatry, 2011, Volume: 72, Issue:4

    Topics: Adult; Anxiety; Azabicyclo Compounds; Depressive Disorder, Major; Double-Blind Method; Drug Therapy,

2011
A post hoc analysis of the effect of nightly administration of eszopiclone and a selective serotonin reuptake inhibitor in patients with insomnia and anxious depression.
    The Journal of clinical psychiatry, 2011, Volume: 72, Issue:4

    Topics: Adult; Anxiety; Azabicyclo Compounds; Depressive Disorder, Major; Double-Blind Method; Drug Therapy,

2011
A post hoc analysis of the effect of nightly administration of eszopiclone and a selective serotonin reuptake inhibitor in patients with insomnia and anxious depression.
    The Journal of clinical psychiatry, 2011, Volume: 72, Issue:4

    Topics: Adult; Anxiety; Azabicyclo Compounds; Depressive Disorder, Major; Double-Blind Method; Drug Therapy,

2011
Residual symptoms after remission of major depressive disorder with fluoxetine and risk of relapse.
    Depression and anxiety, 2011, Volume: 28, Issue:2

    Topics: Acute Disease; Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Depressive Disorde

2011
Topiramate augmentation in patients with resistant major depressive disorder: a double-blind placebo-controlled clinical trial.
    Progress in neuro-psychopharmacology & biological psychiatry, 2011, Jun-01, Volume: 35, Issue:4

    Topics: Adult; Citalopram; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders

2011
Does personality disorder co-morbidity impact treatment outcome for patients with major depression? A multi-level analysis.
    Journal of personality disorders, 2011, Volume: 25, Issue:1

    Topics: Antidepressive Agents; Cognitive Behavioral Therapy; Depressive Disorder, Major; Female; Fluoxetine;

2011
Early prediction of fluoxetine response for Han Chinese inpatients with major depressive disorder.
    Journal of clinical psychopharmacology, 2011, Volume: 31, Issue:2

    Topics: Adult; Aged; Asian People; Depressive Disorder, Major; Female; Fluoxetine; Humans; Male; Middle Aged

2011
Double-blind randomized parallel-group clinical trial of efficacy of the combination fluoxetine plus modafinil versus fluoxetine plus placebo in the treatment of major depression.
    Depression and anxiety, 2011, Volume: 28, Issue:4

    Topics: Adult; Antidepressive Agents, Second-Generation; Benzhydryl Compounds; Central Nervous System Stimul

2011
Evaluation of cognitive behavioral therapy/motivational enhancement therapy (CBT/MET) in a treatment trial of comorbid MDD/AUD adolescents.
    Addictive behaviors, 2011, Volume: 36, Issue:8

    Topics: Adolescent; Alcohol-Related Disorders; Cognitive Behavioral Therapy; Combined Modality Therapy; Como

2011
Rostral anterior cingulate cortex activity and early symptom improvement during treatment for major depressive disorder.
    Psychiatry research, 2011, Jun-30, Volume: 192, Issue:3

    Topics: Adult; Analysis of Variance; Antidepressive Agents; Brain Mapping; Cyclohexanols; Depressive Disorde

2011
Response rates to fluoxetine in subjects who initially show no improvement.
    The Journal of clinical psychiatry, 2011, Volume: 72, Issue:7

    Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Female;

2011
Gallbladder emptying in patients with major depression: a case series.
    Pharmacopsychiatry, 2011, Volume: 44, Issue:5

    Topics: Adolescent; Adult; Aged; Amitriptyline; Antidepressive Agents; Case-Control Studies; Depressive Diso

2011
Open-label adjunctive creatine for female adolescents with SSRI-resistant major depressive disorder: a 31-phosphorus magnetic resonance spectroscopy study.
    Journal of affective disorders, 2011, Volume: 135, Issue:1-3

    Topics: Adolescent; Antidepressive Agents; Creatine; Depressive Disorder; Depressive Disorder, Major; Female

2011
Open-label adjunctive creatine for female adolescents with SSRI-resistant major depressive disorder: a 31-phosphorus magnetic resonance spectroscopy study.
    Journal of affective disorders, 2011, Volume: 135, Issue:1-3

    Topics: Adolescent; Antidepressive Agents; Creatine; Depressive Disorder; Depressive Disorder, Major; Female

2011
Open-label adjunctive creatine for female adolescents with SSRI-resistant major depressive disorder: a 31-phosphorus magnetic resonance spectroscopy study.
    Journal of affective disorders, 2011, Volume: 135, Issue:1-3

    Topics: Adolescent; Antidepressive Agents; Creatine; Depressive Disorder; Depressive Disorder, Major; Female

2011
Open-label adjunctive creatine for female adolescents with SSRI-resistant major depressive disorder: a 31-phosphorus magnetic resonance spectroscopy study.
    Journal of affective disorders, 2011, Volume: 135, Issue:1-3

    Topics: Adolescent; Antidepressive Agents; Creatine; Depressive Disorder; Depressive Disorder, Major; Female

2011
Open-label adjunctive creatine for female adolescents with SSRI-resistant major depressive disorder: a 31-phosphorus magnetic resonance spectroscopy study.
    Journal of affective disorders, 2011, Volume: 135, Issue:1-3

    Topics: Adolescent; Antidepressive Agents; Creatine; Depressive Disorder; Depressive Disorder, Major; Female

2011
Open-label adjunctive creatine for female adolescents with SSRI-resistant major depressive disorder: a 31-phosphorus magnetic resonance spectroscopy study.
    Journal of affective disorders, 2011, Volume: 135, Issue:1-3

    Topics: Adolescent; Antidepressive Agents; Creatine; Depressive Disorder; Depressive Disorder, Major; Female

2011
Open-label adjunctive creatine for female adolescents with SSRI-resistant major depressive disorder: a 31-phosphorus magnetic resonance spectroscopy study.
    Journal of affective disorders, 2011, Volume: 135, Issue:1-3

    Topics: Adolescent; Antidepressive Agents; Creatine; Depressive Disorder; Depressive Disorder, Major; Female

2011
Open-label adjunctive creatine for female adolescents with SSRI-resistant major depressive disorder: a 31-phosphorus magnetic resonance spectroscopy study.
    Journal of affective disorders, 2011, Volume: 135, Issue:1-3

    Topics: Adolescent; Antidepressive Agents; Creatine; Depressive Disorder; Depressive Disorder, Major; Female

2011
Open-label adjunctive creatine for female adolescents with SSRI-resistant major depressive disorder: a 31-phosphorus magnetic resonance spectroscopy study.
    Journal of affective disorders, 2011, Volume: 135, Issue:1-3

    Topics: Adolescent; Antidepressive Agents; Creatine; Depressive Disorder; Depressive Disorder, Major; Female

2011
Predictors of fluoxetine remission for hospitalized patients with major depressive disorder.
    Psychiatry and clinical neurosciences, 2011, Volume: 65, Issue:5

    Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Femal

2011
Effect of an aerobic training program as complementary therapy in patients with moderate depression.
    Perceptual and motor skills, 2011, Volume: 112, Issue:3

    Topics: Adult; Antidepressive Agents, Second-Generation; Combined Modality Therapy; Complementary Therapies;

2011
Reduced right ventrolateral prefrontal cortex activity while inhibiting positive affect is associated with improvement in hedonic capacity after 8 weeks of antidepressant treatment in major depressive disorder.
    Biological psychiatry, 2011, Nov-15, Volume: 70, Issue:10

    Topics: Adult; Anhedonia; Antidepressive Agents; Cyclohexanols; Depressive Disorder, Major; Double-Blind Met

2011
The antidepressant treatment response index and treatment outcomes in a placebo-controlled trial of fluoxetine.
    Journal of clinical neurophysiology : official publication of the American Electroencephalographic Society, 2011, Volume: 28, Issue:5

    Topics: Adult; Antidepressive Agents, Second-Generation; Chi-Square Distribution; Depressive Disorder, Major

2011
Preclinical and clinical characterization of the selective 5-HT(1A) receptor antagonist DU-125530 for antidepressant treatment.
    British journal of pharmacology, 2012, Volume: 167, Issue:5

    Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Adult; Animals; Antidepressive Agents; Brain; Depressive Dis

2012
Therapeutic drug monitoring of children and adolescents treated with fluoxetine.
    Pharmacopsychiatry, 2012, Volume: 45, Issue:2

    Topics: Adolescent; Age Factors; Child; Cohort Studies; Depressive Disorder, Major; Dose-Response Relationsh

2012
Dense cranial electroacupuncture stimulation for major depressive disorder--a single-blind, randomized, controlled study.
    PloS one, 2012, Volume: 7, Issue:1

    Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Combined Modality Therapy; Depressive Disorde

2012
Dense cranial electroacupuncture stimulation for major depressive disorder--a single-blind, randomized, controlled study.
    PloS one, 2012, Volume: 7, Issue:1

    Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Combined Modality Therapy; Depressive Disorde

2012
Dense cranial electroacupuncture stimulation for major depressive disorder--a single-blind, randomized, controlled study.
    PloS one, 2012, Volume: 7, Issue:1

    Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Combined Modality Therapy; Depressive Disorde

2012
Dense cranial electroacupuncture stimulation for major depressive disorder--a single-blind, randomized, controlled study.
    PloS one, 2012, Volume: 7, Issue:1

    Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Combined Modality Therapy; Depressive Disorde

2012
Dense cranial electroacupuncture stimulation for major depressive disorder--a single-blind, randomized, controlled study.
    PloS one, 2012, Volume: 7, Issue:1

    Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Combined Modality Therapy; Depressive Disorde

2012
Dense cranial electroacupuncture stimulation for major depressive disorder--a single-blind, randomized, controlled study.
    PloS one, 2012, Volume: 7, Issue:1

    Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Combined Modality Therapy; Depressive Disorde

2012
Dense cranial electroacupuncture stimulation for major depressive disorder--a single-blind, randomized, controlled study.
    PloS one, 2012, Volume: 7, Issue:1

    Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Combined Modality Therapy; Depressive Disorde

2012
Dense cranial electroacupuncture stimulation for major depressive disorder--a single-blind, randomized, controlled study.
    PloS one, 2012, Volume: 7, Issue:1

    Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Combined Modality Therapy; Depressive Disorde

2012
Dense cranial electroacupuncture stimulation for major depressive disorder--a single-blind, randomized, controlled study.
    PloS one, 2012, Volume: 7, Issue:1

    Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Combined Modality Therapy; Depressive Disorde

2012
Dense cranial electroacupuncture stimulation for major depressive disorder--a single-blind, randomized, controlled study.
    PloS one, 2012, Volume: 7, Issue:1

    Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Combined Modality Therapy; Depressive Disorde

2012
Dense cranial electroacupuncture stimulation for major depressive disorder--a single-blind, randomized, controlled study.
    PloS one, 2012, Volume: 7, Issue:1

    Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Combined Modality Therapy; Depressive Disorde

2012
Dense cranial electroacupuncture stimulation for major depressive disorder--a single-blind, randomized, controlled study.
    PloS one, 2012, Volume: 7, Issue:1

    Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Combined Modality Therapy; Depressive Disorde

2012
Dense cranial electroacupuncture stimulation for major depressive disorder--a single-blind, randomized, controlled study.
    PloS one, 2012, Volume: 7, Issue:1

    Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Combined Modality Therapy; Depressive Disorde

2012
Dense cranial electroacupuncture stimulation for major depressive disorder--a single-blind, randomized, controlled study.
    PloS one, 2012, Volume: 7, Issue:1

    Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Combined Modality Therapy; Depressive Disorde

2012
Dense cranial electroacupuncture stimulation for major depressive disorder--a single-blind, randomized, controlled study.
    PloS one, 2012, Volume: 7, Issue:1

    Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Combined Modality Therapy; Depressive Disorde

2012
Dense cranial electroacupuncture stimulation for major depressive disorder--a single-blind, randomized, controlled study.
    PloS one, 2012, Volume: 7, Issue:1

    Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Combined Modality Therapy; Depressive Disorde

2012
Onset of alcohol or substance use disorders following treatment for adolescent depression.
    Journal of consulting and clinical psychology, 2012, Volume: 80, Issue:2

    Topics: Adolescent; Antidepressive Agents; Cognitive Behavioral Therapy; Combined Modality Therapy; Depressi

2012
Adjunctive sleep medications and depression outcome in the treatment of serotonin-selective reuptake inhibitor resistant depression in adolescents study.
    Journal of child and adolescent psychopharmacology, 2012, Volume: 22, Issue:1

    Topics: Adolescent; Cognitive Behavioral Therapy; Combined Modality Therapy; Cyclohexanols; Cytochrome P-450

2012
Insomnia moderates outcome of serotonin-selective reuptake inhibitor treatment in depressed youth.
    Journal of child and adolescent psychopharmacology, 2012, Volume: 22, Issue:1

    Topics: Adolescent; Age Factors; Antidepressive Agents, Second-Generation; Child; Depressive Disorder, Major

2012
Brain activity in adolescent major depressive disorder before and after fluoxetine treatment.
    The American journal of psychiatry, 2012, Volume: 169, Issue:4

    Topics: Adolescent; Adolescent Behavior; Brain; Child; Depressive Disorder, Major; Facial Expression; Female

2012
Objective vs. subjective measurements of sleep in depressed insomniacs: first night effect or reverse first night effect?
    Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine, 2012, Feb-15, Volume: 8, Issue:1

    Topics: Actigraphy; Adult; Antidepressive Agents, Second-Generation; Azabicyclo Compounds; Depressive Disord

2012
Serum cortisol concentration in patients with major depression after treatment with fluoxetine.
    Psychiatry research, 2012, Aug-15, Volume: 198, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antidepressive Agents; Chromatography, High Pressure Liquid; Depress

2012
Does prior antidepressant treatment of major depression impact brain function during current treatment?
    European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2012, Volume: 22, Issue:10

    Topics: Adult; Antidepressive Agents; Cohort Studies; Cyclohexanols; Depressive Disorder, Major; Diagnostic

2012
Cognitive reactivity, dysfunctional attitudes, and depressive relapse and recurrence in cognitive therapy responders.
    Behaviour research and therapy, 2012, Volume: 50, Issue:5

    Topics: Adolescent; Adult; Affect; Aged; Antidepressive Agents, Second-Generation; Attitude; Cognitive Behav

2012
Effect of saffron on fluoxetine-induced sexual impairment in men: randomized double-blind placebo-controlled trial.
    Psychopharmacology, 2012, Volume: 223, Issue:4

    Topics: Adolescent; Adult; Crocus; Depressive Disorder, Major; Double-Blind Method; Erectile Dysfunction; Fl

2012
Therapeutic effects of vitamin D as adjunctive therapy to fluoxetine in patients with major depressive disorder.
    The Australian and New Zealand journal of psychiatry, 2013, Volume: 47, Issue:3

    Topics: Adolescent; Adult; Aged; Calcifediol; Cholecalciferol; Depressive Disorder, Major; Double-Blind Meth

2013
Relationships between changes in sustained fronto-striatal connectivity and positive affect in major depression resulting from antidepressant treatment.
    The American journal of psychiatry, 2013, Volume: 170, Issue:2

    Topics: Affect; Antidepressive Agents; Biological Availability; Brain Mapping; Cyclohexanols; Depressive Dis

2013
Saffron for treatment of fluoxetine-induced sexual dysfunction in women: randomized double-blind placebo-controlled study.
    Human psychopharmacology, 2013, Volume: 28, Issue:1

    Topics: Adolescent; Adult; Crocus; Depressive Disorder, Major; Double-Blind Method; Female; Fluoxetine; Huma

2013
Reboxetine, a new noradrenaline selective antidepressant, is at least as effective as fluoxetine in the treatment of depression.
    Journal of clinical psychopharmacology, 2002, Volume: 22, Issue:4

    Topics: Adrenergic Uptake Inhibitors; Adult; Analysis of Variance; Antidepressive Agents; Chi-Square Distrib

2002
Double-blind study of high-dose fluoxetine versus lithium or desipramine augmentation of fluoxetine in partial responders and nonresponders to fluoxetine.
    Journal of clinical psychopharmacology, 2002, Volume: 22, Issue:4

    Topics: Adult; Analysis of Variance; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyc

2002
The SSRIs drug Fluoxetine, but not the noradrenergic tricyclic drug Desipramine, improves memory performance during acute major depression.
    Brain research bulletin, 2002, Aug-15, Volume: 58, Issue:4

    Topics: Acute Disease; Adult; Analysis of Variance; Antidepressive Agents, Tricyclic; Depressive Disorder, M

2002
Effects of adding cognitive therapy to fluoxetine dose increase on risk of relapse and residual depressive symptoms in continuation treatment of major depressive disorder.
    Journal of clinical psychopharmacology, 2002, Volume: 22, Issue:5

    Topics: Adult; Antidepressive Agents, Second-Generation; Cognitive Behavioral Therapy; Combined Modality The

2002
Site variability in treatment outcome in antidepressant trials.
    Progress in neuro-psychopharmacology & biological psychiatry, 2002, Volume: 26, Issue:5

    Topics: Adolescent; Adult; Aged; Antidepressive Agents; Chi-Square Distribution; Controlled Clinical Trials

2002
Tianeptine and fluoxetine in major depression: a 6-week randomised double-blind study.
    Human psychopharmacology, 2002, Volume: 17, Issue:6

    Topics: Adolescent; Adult; Aged; Antidepressive Agents, Tricyclic; Depressive Disorder, Major; Double-Blind

2002
Cerebral blood volume and clinical changes on the third day of placebo substitution for SSRI treatment.
    Biological psychiatry, 2003, Jan-01, Volume: 53, Issue:1

    Topics: Adult; Caudate Nucleus; Depressive Disorder, Major; Double-Blind Method; Female; Fluoxetine; Humans;

2003
An open study of olanzapine and fluoxetine for psychotic major depressive disorder: interim analyses.
    The Journal of clinical psychiatry, 2002, Volume: 63, Issue:12

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Depressive Disord

2002
Effects of fluoxetine, indomethacine and placebo on 3 alpha, 5 alpha tetrahydroprogesterone (THP) plasma levels in uncomplicated alcohol withdrawal.
    The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, 2000, Volume: 1, Issue:2

    Topics: Adult; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Ethanol; F

2000
Treatment for Adolescents With Depression Study (TADS): rationale, design, and methods.
    Journal of the American Academy of Child and Adolescent Psychiatry, 2003, Volume: 42, Issue:5

    Topics: Adolescent; Child; Cognitive Behavioral Therapy; Combined Modality Therapy; Depressive Disorder, Maj

2003
Switching to bupropion in fluoxetine-resistant major depressive disorder.
    Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, 2003, Volume: 15, Issue:1

    Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Depressive Disorder, Major; Drug Resista

2003
Fluvoxamine versus fluoxetine in major depressive episode: a double-blind randomised comparison.
    Human psychopharmacology, 2003, Volume: 18, Issue:5

    Topics: Adolescent; Adult; Aged; Depressive Disorder, Major; Double-Blind Method; Female; Fluoxetine; Fluvox

2003
Algorithm-based treatment of major depression in an outpatient clinic: clinical correlates of response to a specific serotonin reuptake inhibitor and to triiodothyronine augmentation.
    The international journal of neuropsychopharmacology, 2003, Volume: 6, Issue:1

    Topics: Adult; Aged; Algorithms; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Synergis

2003
Switching to reboxetine: an efficacy and safety study in patients with major depressive disorder unresponsive to fluoxetine.
    Journal of clinical psychopharmacology, 2003, Volume: 23, Issue:4

    Topics: Adolescent; Adult; Aged; Antidepressive Agents; Depressive Disorder, Major; Drug Resistance; Female;

2003
Selective serotonin reuptake inhibitor discontinuation syndrome is associated with a rostral anterior cingulate choline metabolite decrease: a proton magnetic resonance spectroscopic imaging study.
    Biological psychiatry, 2003, Sep-01, Volume: 54, Issue:5

    Topics: Adult; Brain Mapping; Choline; Depressive Disorder, Major; Female; Fluoxetine; Gyrus Cinguli; Humans

2003
Age-dependent antidepressant pharmacogenomics: polymorphisms of the serotonin transporter and G protein beta3 subunit as predictors of response to fluoxetine and nortriptyline.
    The international journal of neuropsychopharmacology, 2003, Volume: 6, Issue:4

    Topics: Adult; Age Factors; Alleles; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyc

2003
Comparative effects of mirtazapine and fluoxetine on sleep physiology measures in patients with major depression and insomnia.
    The Journal of clinical psychiatry, 2003, Volume: 64, Issue:10

    Topics: Adult; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Depressive Disord

2003
Fluoxetine once every third day in the treatment of major depressive disorder.
    European archives of psychiatry and clinical neuroscience, 2003, Volume: 253, Issue:6

    Topics: Adult; Antidepressive Agents, Second-Generation; Demography; Depressive Disorder, Major; Dose-Respon

2003
No evidence of increased adverse drug reactions in cytochrome P450 CYP2D6 poor metabolizers treated with fluoxetine or nortriptyline.
    Human psychopharmacology, 2004, Volume: 19, Issue:1

    Topics: Adolescent; Adult; Antidepressive Agents; Cytochrome P-450 CYP2D6; Depressive Disorder, Major; Femal

2004
Pindolol augmentation in depressed patients resistant to selective serotonin reuptake inhibitors: a double-blind, randomized, controlled trial.
    The Journal of clinical psychiatry, 2004, Volume: 65, Issue:2

    Topics: Adrenergic beta-Antagonists; Adult; Aged; Connecticut; Cross-Over Studies; Depressive Disorder, Majo

2004
Addition of the alpha2-antagonist yohimbine to fluoxetine: effects on rate of antidepressant response.
    Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2004, Volume: 29, Issue:6

    Topics: Adolescent; Adrenergic alpha-Antagonists; Adult; Aged; Antidepressive Agents; Depressive Disorder, M

2004
Long-term treatment outcomes of depression with associated anxiety: efficacy of continuation treatment with fluoxetine.
    The Journal of clinical psychiatry, 2004, Volume: 65, Issue:3

    Topics: Adult; Anxiety; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; F

2004
Adjunctive modafinil at initiation of treatment with a selective serotonin reuptake inhibitor enhances the degree and onset of therapeutic effects in patients with major depressive disorder and fatigue.
    The Journal of clinical psychiatry, 2004, Volume: 65, Issue:3

    Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Central Nervous System Stimulants; Depressive Disorde

2004
Response to tryptophan depletion in major depression treated with either cognitive therapy or selective serotonin reuptake inhibitor antidepressants.
    Biological psychiatry, 2004, May-01, Volume: 55, Issue:9

    Topics: Cognitive Behavioral Therapy; Cross-Over Studies; Depressive Disorder, Major; Diagnostic and Statist

2004
Bipolar II disorder: personality and outcome in two clinical samples.
    The Australian and New Zealand journal of psychiatry, 2004, Volume: 38, Issue:6

    Topics: Adrenergic Uptake Inhibitors; Adult; Bipolar Disorder; Bulimia; Cognitive Behavioral Therapy; Depres

2004
HPA axis activation in major depression and response to fluoxetine: a pilot study.
    Psychoneuroendocrinology, 2004, Volume: 29, Issue:9

    Topics: Adolescent; Adrenocorticotropic Hormone; Adult; Antidepressive Agents, Second-Generation; Circadian

2004
A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features.
    Journal of clinical psychopharmacology, 2004, Volume: 24, Issue:4

    Topics: Adult; Analysis of Variance; Benzodiazepines; Chi-Square Distribution; Depressive Disorder, Major; D

2004
Comparing the effects of 8-week treatment with fluoxetine and imipramine on fasting blood glucose of patients with major depressive disorder.
    Journal of clinical psychopharmacology, 2004, Volume: 24, Issue:4

    Topics: Adolescent; Adult; Aged; Analysis of Variance; Blood Glucose; Depressive Disorder, Major; Double-Bli

2004
Serum cholesterol in the continuation phase of pharmacotherapy with fluoxetine in remitted major depressive disorder.
    Journal of clinical psychopharmacology, 2004, Volume: 24, Issue:4

    Topics: Adult; Cholesterol; Depressive Disorder, Major; Female; Fluoxetine; Humans; Male; Middle Aged

2004
Sex- and age-related differences in major depressive disorder with comorbid anxiety treated with fluoxetine.
    Archives of women's mental health, 2004, Volume: 7, Issue:3

    Topics: Adult; Age Factors; Aged; Antidepressive Agents, Second-Generation; Anxiety Disorders; Cohort Studie

2004
Pretreatment neurophysiological and clinical characteristics of placebo responders in treatment trials for major depression.
    Psychopharmacology, 2004, Volume: 177, Issue:1-2

    Topics: Adult; Brain; Depressive Disorder, Major; Double-Blind Method; Female; Fluoxetine; Humans; Male; Mid

2004
Continuation cognitive-behavioural therapy maintains attributional style improvement in depressed patients responding acutely to fluoxetine.
    Psychological medicine, 2004, Volume: 34, Issue:3

    Topics: Adult; Antidepressive Agents, Second-Generation; Cognitive Behavioral Therapy; Depressive Disorder,

2004
Predictors of improved mood over time in clinical trials for major depression.
    Psychiatry research, 2004, Jun-30, Volume: 127, Issue:1-2

    Topics: Adult; Affect; Cyclohexanols; Depressive Disorder, Major; Double-Blind Method; Electroencephalograph

2004
Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial.
    JAMA, 2004, Aug-18, Volume: 292, Issue:7

    Topics: Adolescent; Antidepressive Agents, Second-Generation; Cognitive Behavioral Therapy; Combined Modalit

2004
Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial.
    JAMA, 2004, Aug-18, Volume: 292, Issue:7

    Topics: Adolescent; Antidepressive Agents, Second-Generation; Cognitive Behavioral Therapy; Combined Modalit

2004
Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial.
    JAMA, 2004, Aug-18, Volume: 292, Issue:7

    Topics: Adolescent; Antidepressive Agents, Second-Generation; Cognitive Behavioral Therapy; Combined Modalit

2004
Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial.
    JAMA, 2004, Aug-18, Volume: 292, Issue:7

    Topics: Adolescent; Antidepressive Agents, Second-Generation; Cognitive Behavioral Therapy; Combined Modalit

2004
Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial.
    JAMA, 2004, Aug-18, Volume: 292, Issue:7

    Topics: Adolescent; Antidepressive Agents, Second-Generation; Cognitive Behavioral Therapy; Combined Modalit

2004
Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial.
    JAMA, 2004, Aug-18, Volume: 292, Issue:7

    Topics: Adolescent; Antidepressive Agents, Second-Generation; Cognitive Behavioral Therapy; Combined Modalit

2004
Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial.
    JAMA, 2004, Aug-18, Volume: 292, Issue:7

    Topics: Adolescent; Antidepressive Agents, Second-Generation; Cognitive Behavioral Therapy; Combined Modalit

2004
Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial.
    JAMA, 2004, Aug-18, Volume: 292, Issue:7

    Topics: Adolescent; Antidepressive Agents, Second-Generation; Cognitive Behavioral Therapy; Combined Modalit

2004
Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial.
    JAMA, 2004, Aug-18, Volume: 292, Issue:7

    Topics: Adolescent; Antidepressive Agents, Second-Generation; Cognitive Behavioral Therapy; Combined Modalit

2004
Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial.
    JAMA, 2004, Aug-18, Volume: 292, Issue:7

    Topics: Adolescent; Antidepressive Agents, Second-Generation; Cognitive Behavioral Therapy; Combined Modalit

2004
Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial.
    JAMA, 2004, Aug-18, Volume: 292, Issue:7

    Topics: Adolescent; Antidepressive Agents, Second-Generation; Cognitive Behavioral Therapy; Combined Modalit

2004
Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial.
    JAMA, 2004, Aug-18, Volume: 292, Issue:7

    Topics: Adolescent; Antidepressive Agents, Second-Generation; Cognitive Behavioral Therapy; Combined Modalit

2004
Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial.
    JAMA, 2004, Aug-18, Volume: 292, Issue:7

    Topics: Adolescent; Antidepressive Agents, Second-Generation; Cognitive Behavioral Therapy; Combined Modalit

2004
Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial.
    JAMA, 2004, Aug-18, Volume: 292, Issue:7

    Topics: Adolescent; Antidepressive Agents, Second-Generation; Cognitive Behavioral Therapy; Combined Modalit

2004
Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial.
    JAMA, 2004, Aug-18, Volume: 292, Issue:7

    Topics: Adolescent; Antidepressive Agents, Second-Generation; Cognitive Behavioral Therapy; Combined Modalit

2004
Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial.
    JAMA, 2004, Aug-18, Volume: 292, Issue:7

    Topics: Adolescent; Antidepressive Agents, Second-Generation; Cognitive Behavioral Therapy; Combined Modalit

2004
Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial.
    JAMA, 2004, Aug-18, Volume: 292, Issue:7

    Topics: Adolescent; Antidepressive Agents, Second-Generation; Cognitive Behavioral Therapy; Combined Modalit

2004
Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial.
    JAMA, 2004, Aug-18, Volume: 292, Issue:7

    Topics: Adolescent; Antidepressive Agents, Second-Generation; Cognitive Behavioral Therapy; Combined Modalit

2004
Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial.
    JAMA, 2004, Aug-18, Volume: 292, Issue:7

    Topics: Adolescent; Antidepressive Agents, Second-Generation; Cognitive Behavioral Therapy; Combined Modalit

2004
Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial.
    JAMA, 2004, Aug-18, Volume: 292, Issue:7

    Topics: Adolescent; Antidepressive Agents, Second-Generation; Cognitive Behavioral Therapy; Combined Modalit

2004
Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial.
    JAMA, 2004, Aug-18, Volume: 292, Issue:7

    Topics: Adolescent; Antidepressive Agents, Second-Generation; Cognitive Behavioral Therapy; Combined Modalit

2004
Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial.
    JAMA, 2004, Aug-18, Volume: 292, Issue:7

    Topics: Adolescent; Antidepressive Agents, Second-Generation; Cognitive Behavioral Therapy; Combined Modalit

2004
Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial.
    JAMA, 2004, Aug-18, Volume: 292, Issue:7

    Topics: Adolescent; Antidepressive Agents, Second-Generation; Cognitive Behavioral Therapy; Combined Modalit

2004
Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial.
    JAMA, 2004, Aug-18, Volume: 292, Issue:7

    Topics: Adolescent; Antidepressive Agents, Second-Generation; Cognitive Behavioral Therapy; Combined Modalit

2004
Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial.
    JAMA, 2004, Aug-18, Volume: 292, Issue:7

    Topics: Adolescent; Antidepressive Agents, Second-Generation; Cognitive Behavioral Therapy; Combined Modalit

2004
Psychosocial functioning during the treatment of major depressive disorder with fluoxetine.
    Journal of clinical psychopharmacology, 2004, Volume: 24, Issue:5

    Topics: Activities of Daily Living; Adult; Ambulatory Care; Antidepressive Agents, Second-Generation; Antima

2004
Reboxetine induces similar sleep-EEG changes like SSRI's in patients with depression.
    Pharmacopsychiatry, 2004, Volume: 37, Issue:5

    Topics: Adrenergic Uptake Inhibitors; Adult; Aged; Depressive Disorder, Major; Electroencephalography; Femal

2004
Obesity among outpatients with major depressive disorder.
    The international journal of neuropsychopharmacology, 2005, Volume: 8, Issue:1

    Topics: Adult; Ambulatory Care; Antidepressive Agents, Second-Generation; Body Mass Index; Body Weight; Depr

2005
Brain serotonin transporter availability predicts treatment response to selective serotonin reuptake inhibitors.
    Biological psychiatry, 2004, Oct-01, Volume: 56, Issue:7

    Topics: Adult; Analysis of Variance; Brain Mapping; Cocaine; Depressive Disorder, Major; Diencephalon; Femal

2004
Hypericum extract in patients with MDD and reversed vegetative signs: re-analysis from data of a double-blind, randomized trial of hypericum extract, fluoxetine, and placebo.
    The international journal of neuropsychopharmacology, 2005, Volume: 8, Issue:2

    Topics: Analysis of Variance; Depressive Disorder, Major; Double-Blind Method; Fluoxetine; Humans; Hypericum

2005
Incidence and duration of antidepressant-induced nausea: duloxetine compared with paroxetine and fluoxetine.
    Clinical therapeutics, 2004, Volume: 26, Issue:9

    Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antidepressive Agents; Antidepressive Agent

2004
Safety of subchronic treatment with fluoxetine for major depressive disorder in children and adolescents.
    Journal of child and adolescent psychopharmacology, 2004,Fall, Volume: 14, Issue:3

    Topics: Adolescent; Child; Depressive Disorder, Major; Double-Blind Method; Fluoxetine; Humans; Single-Blind

2004
Fluoxetine versus trimipramine in the treatment of depression in geriatric patients.
    Pharmacopsychiatry, 2005, Volume: 38, Issue:1

    Topics: Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic;

2005
The relationship between early changes in the HAMD-17 anxiety/somatization factor items and treatment outcome among depressed outpatients.
    International clinical psychopharmacology, 2005, Volume: 20, Issue:2

    Topics: Adolescent; Adult; Aged; Antidepressive Agents; Antidepressive Agents, Second-Generation; Anxiety; D

2005
Comparison of mirtazapine and fluoxetine in the treatment of major depressive disorder: a double-blind, randomized trial.
    Journal of clinical pharmacy and therapeutics, 2005, Volume: 30, Issue:2

    Topics: Adolescent; Adult; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders

2005
Dopaminergic mechanism of antidepressant action in depressed patients.
    Journal of affective disorders, 2005, Volume: 86, Issue:1

    Topics: Adult; Affect; Case-Control Studies; Citalopram; Depressive Disorder, Major; Dopamine Antagonists; F

2005
Dose-effect relations in time-limited combined psycho-pharmacological treatment for depression.
    Psychological medicine, 2005, Volume: 35, Issue:1

    Topics: Adolescent; Adult; Combined Modality Therapy; Depressive Disorder, Major; Diagnostic and Statistical

2005
Reversed diurnal variation in depression: associations with a differential antidepressant response, tryptophan: large neutral amino acid ratio and serotonin transporter polymorphisms.
    Psychological medicine, 2005, Volume: 35, Issue:4

    Topics: Adult; Affect; Alleles; Amino Acids; Antidepressive Agents; Bipolar Disorder; Circadian Rhythm; Depr

2005
The relationship between serum folate, vitamin B12, and homocysteine levels in major depressive disorder and the timing of improvement with fluoxetine.
    The international journal of neuropsychopharmacology, 2005, Volume: 8, Issue:4

    Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Femal

2005
Controlled double-blind trial of phenytoin vs. fluoxetine in major depressive disorder.
    The Journal of clinical psychiatry, 2005, Volume: 66, Issue:5

    Topics: Adult; Age of Onset; Anticonvulsants; Depressive Disorder, Major; Double-Blind Method; Drug Administ

2005
Effect of repetitive TMS and fluoxetine on cognitive function in patients with Parkinson's disease and concurrent depression.
    Movement disorders : official journal of the Movement Disorder Society, 2005, Volume: 20, Issue:9

    Topics: Aged; Antiparkinson Agents; Cognition Disorders; Depressive Disorder, Major; Double-Blind Method; Fe

2005
Venlafaxine XR demonstrates higher rates of sustained remission compared to fluoxetine, paroxetine or placebo.
    International clinical psychopharmacology, 2005, Volume: 20, Issue:4

    Topics: Antidepressive Agents, Second-Generation; Cyclohexanols; Delayed-Action Preparations; Depressive Dis

2005
Tryptophan and tyrosine availability and response to antidepressant treatment in major depression.
    Journal of affective disorders, 2005, Volume: 86, Issue:2-3

    Topics: Adrenergic Uptake Inhibitors; Adult; Amino Acids, Neutral; Antidepressive Agents, Tricyclic; Circadi

2005
Loudness dependence of the auditory evoked potential and response to antidepressants in Chinese patients with major depression.
    Journal of psychiatry & neuroscience : JPN, 2005, Volume: 30, Issue:3

    Topics: Acoustic Stimulation; Adult; Antidepressive Agents; Antidepressive Agents, Second-Generation; China;

2005
Remission rates with 3 consecutive antidepressant trials: effectiveness for depressed outpatients.
    The Journal of clinical psychiatry, 2005, Volume: 66, Issue:6

    Topics: Adult; Ambulatory Care; Antidepressive Agents; Clinical Protocols; Depressive Disorder, Major; Doubl

2005
Fluoxetine monotherapy of bipolar type II and bipolar NOS major depression: a double-blind, placebo-substitution, continuation study.
    International clinical psychopharmacology, 2005, Volume: 20, Issue:5

    Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Bipolar Disorder; Depressive Disorder, Major;

2005
A Double-blind, randomized trial of St John's wort, fluoxetine, and placebo in major depressive disorder.
    Journal of clinical psychopharmacology, 2005, Volume: 25, Issue:5

    Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Doubl

2005
Comparison of efficacy and safety of milnacipran and fluoxetine in Korean patients with major depression.
    Current medical research and opinion, 2005, Volume: 21, Issue:9

    Topics: Adult; Aged; Antidepressive Agents; Cyclopropanes; Depressive Disorder, Major; Female; Fluoxetine; H

2005
Escitalopram in the treatment of depressed elderly patients.
    The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, 2005, Volume: 13, Issue:10

    Topics: Aged; Aged, 80 and over; Citalopram; Depressive Disorder, Major; Double-Blind Method; Female; Fluoxe

2005
Antidepressant response and well-being in pre-, peri- and postmenopausal women with major depressive disorder treated with fluoxetine.
    Psychotherapy and psychosomatics, 2005, Volume: 74, Issue:6

    Topics: Adult; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Female; Fluoxetine; Hum

2005
Olanzapine/fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistance.
    The Journal of clinical psychiatry, 2005, Volume: 66, Issue:10

    Topics: Adult; Antipsychotic Agents; Benzodiazepines; Depressive Disorder, Major; Diagnostic and Statistical

2005
Long-term weight gain in patients treated with open-label olanzapine in combination with fluoxetine for major depressive disorder.
    The Journal of clinical psychiatry, 2005, Volume: 66, Issue:11

    Topics: Adult; Ambulatory Care; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Depressive Disorder,

2005
Association study of two serotonin 1A receptor gene polymorphisms and fluoxetine treatment response in Chinese major depressive disorders.
    European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2006, Volume: 16, Issue:7

    Topics: Adult; Asian People; Asparagine; Depressive Disorder, Major; Female; Fluoxetine; Glycine; Humans; Li

2006
Effectiveness and cost-effectiveness of antidepressant treatment in primary health care: a six-month randomised study comparing fluoxetine to imipramine.
    Journal of affective disorders, 2006, Volume: 91, Issue:2-3

    Topics: Adult; Antidepressive Agents, Tricyclic; Cost-Benefit Analysis; Depressive Disorder, Major; Double-B

2006
Genetic, developmental and personality correlates of self-mutilation in depressed patients.
    The Australian and New Zealand journal of psychiatry, 2006, Volume: 40, Issue:3

    Topics: Adolescent; Adult; Alleles; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricycl

2006
Genetic, developmental and personality correlates of self-mutilation in depressed patients.
    The Australian and New Zealand journal of psychiatry, 2006, Volume: 40, Issue:3

    Topics: Adolescent; Adult; Alleles; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricycl

2006
Genetic, developmental and personality correlates of self-mutilation in depressed patients.
    The Australian and New Zealand journal of psychiatry, 2006, Volume: 40, Issue:3

    Topics: Adolescent; Adult; Alleles; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricycl

2006
Genetic, developmental and personality correlates of self-mutilation in depressed patients.
    The Australian and New Zealand journal of psychiatry, 2006, Volume: 40, Issue:3

    Topics: Adolescent; Adult; Alleles; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricycl

2006
Memory impairment in patients with late-onset major depression: the effect of antidepressant therapy.
    Journal of affective disorders, 2006, Volume: 91, Issue:2-3

    Topics: Adolescent; Adult; Age of Onset; Depressive Disorder, Major; Female; Fluoxetine; Humans; Male; Memor

2006
Response of emotional unawareness after stroke to antidepressant treatment.
    The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, 2006, Volume: 14, Issue:3

    Topics: Activities of Daily Living; Affective Symptoms; Aged; Agnosia; Antidepressive Agents; Awareness; Cog

2006
A double-blind, placebo-controlled study of venlafaxine and fluoxetine in geriatric outpatients with major depression.
    The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, 2006, Volume: 14, Issue:4

    Topics: Aged; Ambulatory Care; Antidepressive Agents, Second-Generation; Cyclohexanols; Demography; Depressi

2006
Cytokines and serotonin transporter in patients with major depression.
    Progress in neuro-psychopharmacology & biological psychiatry, 2006, Volume: 30, Issue:5

    Topics: Adult; Cytokines; Depressive Disorder, Major; DNA Primers; Female; Fluoxetine; Humans; Male; Middle

2006
A comparison of effects of fluoxetine and nortriptyline on the symptoms of major depressive disorder.
    Journal of clinical psychopharmacology, 2006, Volume: 26, Issue:2

    Topics: Adrenergic Uptake Inhibitors; Adult; Depressive Disorder, Major; Female; Fluoxetine; Humans; Iran; M

2006
A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression.
    Depression and anxiety, 2006, Volume: 23, Issue:6

    Topics: Benzodiazepines; Brief Psychiatric Rating Scale; Cyclohexanols; Depressive Disorder, Major; Double-B

2006
The role of IL-12 and TGF-beta1 in the pathophysiology of major depressive disorder.
    International immunopharmacology, 2006, Volume: 6, Issue:8

    Topics: Adult; Antidepressive Agents, Second-Generation; Cyclohexanols; Depressive Disorder, Major; Female;

2006
Differences in cognitive factors between "true drug" versus "placebo pattern" response to fluoxetine as defined by pattern analysis.
    Human psychopharmacology, 2006, Volume: 21, Issue:4

    Topics: Adult; Cognition; Depressive Disorder, Major; Female; Fluoxetine; Humans; Male; Middle Aged; Placebo

2006
Phenytoin as an augmentation for SSRI failures: a small controlled study.
    Journal of affective disorders, 2006, Volume: 96, Issue:1-2

    Topics: Adult; Aged; Anticonvulsants; Depressive Disorder, Major; Double-Blind Method; Drug Resistance; Drug

2006
Combined treatment of major depression in patients with borderline personality disorder: a comparison with pharmacotherapy.
    Canadian journal of psychiatry. Revue canadienne de psychiatrie, 2006, Volume: 51, Issue:7

    Topics: Adult; Antidepressive Agents, Second-Generation; Borderline Personality Disorder; Combined Modality

2006
Problem-solving ability and comorbid personality disorders in depressed outpatients.
    Depression and anxiety, 2006, Volume: 23, Issue:8

    Topics: Adult; Antidepressive Agents, Second-Generation; Aptitude; Comorbidity; Depressive Disorder, Major;

2006
Serum prolactin levels among outpatients with major depressive disorder during the acute phase of treatment with fluoxetine.
    The Journal of clinical psychiatry, 2006, Volume: 67, Issue:6

    Topics: Adult; Depressive Disorder, Major; Female; Fluoxetine; Humans; Hyperprolactinemia; Male; Middle Aged

2006
Changes in brain function (quantitative EEG cordance) during placebo lead-in and treatment outcomes in clinical trials for major depression.
    The American journal of psychiatry, 2006, Volume: 163, Issue:8

    Topics: Adult; Biomarkers; Brain; Brain Mapping; Cyclohexanols; Depressive Disorder, Major; Double-Blind Met

2006
Changes in brain function (quantitative EEG cordance) during placebo lead-in and treatment outcomes in clinical trials for major depression.
    The American journal of psychiatry, 2006, Volume: 163, Issue:8

    Topics: Adult; Biomarkers; Brain; Brain Mapping; Cyclohexanols; Depressive Disorder, Major; Double-Blind Met

2006
Changes in brain function (quantitative EEG cordance) during placebo lead-in and treatment outcomes in clinical trials for major depression.
    The American journal of psychiatry, 2006, Volume: 163, Issue:8

    Topics: Adult; Biomarkers; Brain; Brain Mapping; Cyclohexanols; Depressive Disorder, Major; Double-Blind Met

2006
Changes in brain function (quantitative EEG cordance) during placebo lead-in and treatment outcomes in clinical trials for major depression.
    The American journal of psychiatry, 2006, Volume: 163, Issue:8

    Topics: Adult; Biomarkers; Brain; Brain Mapping; Cyclohexanols; Depressive Disorder, Major; Double-Blind Met

2006
Treatment benefits of duloxetine in major depressive disorder as assessed by number needed to treat.
    International clinical psychopharmacology, 2006, Volume: 21, Issue:5

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antidepressive Agents; Depressive Disorder, Major; Doubl

2006
Effects of electroacupuncture and fluoxetine on the density of GTP-binding-proteins in platelet membrane in patients with major depressive disorder.
    Journal of affective disorders, 2007, Volume: 98, Issue:3

    Topics: Adult; Antibodies; Combined Modality Therapy; Depressive Disorder, Major; Electroacupuncture; Female

2007
Predictors of relapse in a prospective study of fluoxetine treatment of major depression.
    The American journal of psychiatry, 2006, Volume: 163, Issue:9

    Topics: Adult; Chronic Disease; Depressive Disorder, Major; Double-Blind Method; Drug Resistance; Female; Fl

2006
Phosphodiesterase genes are associated with susceptibility to major depression and antidepressant treatment response.
    Proceedings of the National Academy of Sciences of the United States of America, 2006, Oct-10, Volume: 103, Issue:41

    Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Adult; Aged; Antidepressive Agents; Cyclic Nucleotide Phosphodi

2006
Dysfunctional attitudes and personality disorder comorbidity during long-term treatment of MDD.
    Depression and anxiety, 2007, Volume: 24, Issue:6

    Topics: Adult; Antidepressive Agents, Second-Generation; Attitude; Cognition Disorders; Cognitive Behavioral

2007
Dysregulation of endogenous opioid emotion regulation circuitry in major depression in women.
    Archives of general psychiatry, 2006, Volume: 63, Issue:11

    Topics: Adrenocorticotropic Hormone; Adult; Brain; Carbon Radioisotopes; Depressive Disorder, Major; Emotion

2006
The Treatment for Adolescents with Depression Study (TADS): methods and message at 12 weeks.
    Journal of the American Academy of Child and Adolescent Psychiatry, 2006, Volume: 45, Issue:12

    Topics: Adolescent; Cognitive Behavioral Therapy; Combined Modality Therapy; Depressive Disorder, Major; Dia

2006
Remission and residual symptoms after short-term treatment in the Treatment of Adolescents with Depression Study (TADS).
    Journal of the American Academy of Child and Adolescent Psychiatry, 2006, Volume: 45, Issue:12

    Topics: Adolescent; Cognitive Behavioral Therapy; Combined Modality Therapy; Demography; Depressive Disorder

2006
Acute time to response in the Treatment for Adolescents with Depression Study (TADS).
    Journal of the American Academy of Child and Adolescent Psychiatry, 2006, Volume: 45, Issue:12

    Topics: Adolescent; Child; Cognitive Behavioral Therapy; Combined Modality Therapy; Depressive Disorder, Maj

2006
Functioning and quality of life in the Treatment for Adolescents with Depression Study (TADS).
    Journal of the American Academy of Child and Adolescent Psychiatry, 2006, Volume: 45, Issue:12

    Topics: Adolescent; Cognitive Behavioral Therapy; Combined Modality Therapy; Depressive Disorder, Major; Dia

2006
Predictors and moderators of acute outcome in the Treatment for Adolescents with Depression Study (TADS).
    Journal of the American Academy of Child and Adolescent Psychiatry, 2006, Volume: 45, Issue:12

    Topics: Adolescent; Cognitive Behavioral Therapy; Combined Modality Therapy; Depressive Disorder, Major; Dia

2006
Treatment for Adolescents with Depression Study (TADS): safety results.
    Journal of the American Academy of Child and Adolescent Psychiatry, 2006, Volume: 45, Issue:12

    Topics: Adolescent; Algorithms; Child; Cognitive Behavioral Therapy; Combined Modality Therapy; Depressive D

2006
Escitalopram in major depressive disorder: a multicenter, randomized, double-blind, fixed-dose, parallel trial in a Chinese population.
    Depression and anxiety, 2008, Volume: 25, Issue:1

    Topics: Adolescent; Adult; Aged; Asian People; China; Citalopram; Depressive Disorder, Major; Diagnostic and

2008
Treatment-associated suicidal ideation and adverse effects in an open, multicenter trial of fluoxetine for major depressive episodes.
    Psychotherapy and psychosomatics, 2007, Volume: 76, Issue:1

    Topics: Adolescent; Adult; Aged; Ambulatory Care; Depressive Disorder, Major; Drug Administration Schedule;

2007
Fluoxetine-mirtazapine interaction may induce restless legs syndrome: report of 3 cases from a clinical trial.
    The Journal of clinical psychiatry, 2006, Volume: 67, Issue:11

    Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Drug Interactions; Drug Therapy, Combinati

2006
Effect of fluoxetine on circadian rhythm of melatonin in patients with major depressive disorder.
    Neuro endocrinology letters, 2007, Volume: 28, Issue:1

    Topics: Adult; Antidepressive Agents, Second-Generation; Circadian Rhythm; Depressive Disorder, Major; Femal

2007
Fluoxetine, smoking, and history of major depression: A randomized controlled trial.
    Journal of consulting and clinical psychology, 2007, Volume: 75, Issue:1

    Topics: Adolescent; Adult; Depressive Disorder, Major; Fluoxetine; Follow-Up Studies; Humans; Middle Aged; S

2007
Extreme response style in recurrent and chronically depressed patients: change with antidepressant administration and stability during continuation treatment.
    Journal of consulting and clinical psychology, 2007, Volume: 75, Issue:1

    Topics: Acute Disease; Adult; Chronic Disease; Cognitive Behavioral Therapy; Depressive Disorder, Major; Dos

2007
Comparisons of glucose-insulin homeostasis following maprotiline and fluoxetine treatment in depressed males.
    Journal of affective disorders, 2007, Volume: 103, Issue:1-3

    Topics: Adrenergic Uptake Inhibitors; Adult; Antidepressive Agents, Second-Generation; Blood Glucose; Body M

2007
A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder.
    The Journal of clinical psychiatry, 2007, Volume: 68, Issue:2

    Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Depressive Disorder, Major; Double-B

2007
Evaluation of eszopiclone discontinuation after cotherapy with fluoxetine for insomnia with coexisting depression.
    Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine, 2007, Feb-15, Volume: 3, Issue:1

    Topics: Adult; Azabicyclo Compounds; Comorbidity; Depressive Disorder, Major; Double-Blind Method; Drug Admi

2007
[Copper-zinc superoxide dismutase activity in platelets in patients with depressive disorder treated by fluoxetine--preliminary study].
    Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, 2007, Volume: 22, Issue:129

    Topics: Adult; Antidepressive Agents, Second-Generation; Blood Platelets; Depressive Disorder, Major; Female

2007
rTMS treatment for depression in Parkinson's disease increases BOLD responses in the left prefrontal cortex.
    The international journal of neuropsychopharmacology, 2008, Volume: 11, Issue:2

    Topics: Affect; Aged; Antidepressive Agents, Second-Generation; Brain Mapping; Combined Modality Therapy; De

2008
A psychometric evaluation of the CDRS and MADRS in assessing depressive symptoms in children.
    Journal of the American Academy of Child and Adolescent Psychiatry, 2007, Volume: 46, Issue:9

    Topics: Child; Depression; Depressive Disorder, Major; Female; Fluoxetine; Humans; Male; Psychometrics; Sele

2007
Empirically derived subtypes of adolescent depression: latent profile analysis of co-occurring symptoms in the Treatment for Adolescents with Depression Study (TADS).
    Journal of consulting and clinical psychology, 2007, Volume: 75, Issue:5

    Topics: Adolescent; Antidepressive Agents, Second-Generation; Attention Deficit Disorder with Hyperactivity;

2007
The Treatment for Adolescents With Depression Study (TADS): long-term effectiveness and safety outcomes.
    Archives of general psychiatry, 2007, Volume: 64, Issue:10

    Topics: Adolescent; Clinical Protocols; Cognitive Behavioral Therapy; Combined Modality Therapy; Depressive

2007
Perceived stress and cognitive vulnerability mediate the effects of personality disorder comorbidity on treatment outcome in major depressive disorder: a path analysis study.
    The Journal of nervous and mental disease, 2007, Volume: 195, Issue:9

    Topics: Acute Disease; Adolescent; Adult; Ambulatory Care; Cognition Disorders; Comorbidity; Depressive Diso

2007
Transcranial direct stimulation and fluoxetine for the treatment of depression.
    European psychiatry : the journal of the Association of European Psychiatrists, 2008, Volume: 23, Issue:1

    Topics: Depressive Disorder, Major; Double-Blind Method; Female; Fluoxetine; Humans; Male; Middle Aged; Pers

2008
Transcranial direct stimulation and fluoxetine for the treatment of depression.
    European psychiatry : the journal of the Association of European Psychiatrists, 2008, Volume: 23, Issue:1

    Topics: Depressive Disorder, Major; Double-Blind Method; Female; Fluoxetine; Humans; Male; Middle Aged; Pers

2008
Transcranial direct stimulation and fluoxetine for the treatment of depression.
    European psychiatry : the journal of the Association of European Psychiatrists, 2008, Volume: 23, Issue:1

    Topics: Depressive Disorder, Major; Double-Blind Method; Female; Fluoxetine; Humans; Male; Middle Aged; Pers

2008
Transcranial direct stimulation and fluoxetine for the treatment of depression.
    European psychiatry : the journal of the Association of European Psychiatrists, 2008, Volume: 23, Issue:1

    Topics: Depressive Disorder, Major; Double-Blind Method; Female; Fluoxetine; Humans; Male; Middle Aged; Pers

2008
Research knowledge among the participants in the Treatment for Adolescents With Depression Study (TADS).
    Journal of the American Academy of Child and Adolescent Psychiatry, 2007, Volume: 46, Issue:12

    Topics: Adolescent; Cognitive Behavioral Therapy; Depressive Disorder, Major; Diagnostic and Statistical Man

2007
Differential antidepressant symptom efficacy: placebo-controlled comparisons of duloxetine and SSRIs (fluoxetine, paroxetine, escitalopram).
    Neuropsychobiology, 2007, Volume: 56, Issue:2-3

    Topics: Adult; Antidepressive Agents; Citalopram; Depressive Disorder, Major; Dose-Response Relationship, Dr

2007
Dimensional personality traits and treatment outcome in patients with major depressive disorder.
    Journal of affective disorders, 2008, Volume: 108, Issue:3

    Topics: Adolescent; Adult; Aged; Cognitive Behavioral Therapy; Depressive Disorder, Major; Diagnostic and St

2008
Comparison of therapeutic effects of omega-3 fatty acid eicosapentaenoic acid and fluoxetine, separately and in combination, in major depressive disorder.
    The Australian and New Zealand journal of psychiatry, 2008, Volume: 42, Issue:3

    Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Diagnostic and Statistical Manual of Menta

2008
Timing of clinical improvement and symptom resolution in the treatment of major depressive disorder. A replication of findings with the use of a double-blind, placebo-controlled trial of Hypericum perforatum versus fluoxetine.
    Neuropsychobiology, 2007, Volume: 56, Issue:2-3

    Topics: Adult; Depressive Disorder, Major; Double-Blind Method; Female; Fluoxetine; Humans; Hypericum; Male;

2007
Fluoxetine versus placebo in preventing relapse of major depression in children and adolescents.
    The American journal of psychiatry, 2008, Volume: 165, Issue:4

    Topics: Adolescent; Age Factors; Child; Depressive Disorder, Major; Double-Blind Method; Drug Administration

2008
Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial.
    JAMA, 2008, Feb-27, Volume: 299, Issue:8

    Topics: Adolescent; Citalopram; Cognitive Behavioral Therapy; Combined Modality Therapy; Cyclohexanols; Depr

2008
Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial.
    JAMA, 2008, Feb-27, Volume: 299, Issue:8

    Topics: Adolescent; Citalopram; Cognitive Behavioral Therapy; Combined Modality Therapy; Cyclohexanols; Depr

2008
Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial.
    JAMA, 2008, Feb-27, Volume: 299, Issue:8

    Topics: Adolescent; Citalopram; Cognitive Behavioral Therapy; Combined Modality Therapy; Cyclohexanols; Depr

2008
Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial.
    JAMA, 2008, Feb-27, Volume: 299, Issue:8

    Topics: Adolescent; Citalopram; Cognitive Behavioral Therapy; Combined Modality Therapy; Cyclohexanols; Depr

2008
Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial.
    JAMA, 2008, Feb-27, Volume: 299, Issue:8

    Topics: Adolescent; Citalopram; Cognitive Behavioral Therapy; Combined Modality Therapy; Cyclohexanols; Depr

2008
Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial.
    JAMA, 2008, Feb-27, Volume: 299, Issue:8

    Topics: Adolescent; Citalopram; Cognitive Behavioral Therapy; Combined Modality Therapy; Cyclohexanols; Depr

2008
Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial.
    JAMA, 2008, Feb-27, Volume: 299, Issue:8

    Topics: Adolescent; Citalopram; Cognitive Behavioral Therapy; Combined Modality Therapy; Cyclohexanols; Depr

2008
Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial.
    JAMA, 2008, Feb-27, Volume: 299, Issue:8

    Topics: Adolescent; Citalopram; Cognitive Behavioral Therapy; Combined Modality Therapy; Cyclohexanols; Depr

2008
Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial.
    JAMA, 2008, Feb-27, Volume: 299, Issue:8

    Topics: Adolescent; Citalopram; Cognitive Behavioral Therapy; Combined Modality Therapy; Cyclohexanols; Depr

2008
Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial.
    JAMA, 2008, Feb-27, Volume: 299, Issue:8

    Topics: Adolescent; Citalopram; Cognitive Behavioral Therapy; Combined Modality Therapy; Cyclohexanols; Depr

2008
Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial.
    JAMA, 2008, Feb-27, Volume: 299, Issue:8

    Topics: Adolescent; Citalopram; Cognitive Behavioral Therapy; Combined Modality Therapy; Cyclohexanols; Depr

2008
Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial.
    JAMA, 2008, Feb-27, Volume: 299, Issue:8

    Topics: Adolescent; Citalopram; Cognitive Behavioral Therapy; Combined Modality Therapy; Cyclohexanols; Depr

2008
Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial.
    JAMA, 2008, Feb-27, Volume: 299, Issue:8

    Topics: Adolescent; Citalopram; Cognitive Behavioral Therapy; Combined Modality Therapy; Cyclohexanols; Depr

2008
Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial.
    JAMA, 2008, Feb-27, Volume: 299, Issue:8

    Topics: Adolescent; Citalopram; Cognitive Behavioral Therapy; Combined Modality Therapy; Cyclohexanols; Depr

2008
Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial.
    JAMA, 2008, Feb-27, Volume: 299, Issue:8

    Topics: Adolescent; Citalopram; Cognitive Behavioral Therapy; Combined Modality Therapy; Cyclohexanols; Depr

2008
Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial.
    JAMA, 2008, Feb-27, Volume: 299, Issue:8

    Topics: Adolescent; Citalopram; Cognitive Behavioral Therapy; Combined Modality Therapy; Cyclohexanols; Depr

2008
Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial.
    JAMA, 2008, Feb-27, Volume: 299, Issue:8

    Topics: Adolescent; Citalopram; Cognitive Behavioral Therapy; Combined Modality Therapy; Cyclohexanols; Depr

2008
Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial.
    JAMA, 2008, Feb-27, Volume: 299, Issue:8

    Topics: Adolescent; Citalopram; Cognitive Behavioral Therapy; Combined Modality Therapy; Cyclohexanols; Depr

2008
Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial.
    JAMA, 2008, Feb-27, Volume: 299, Issue:8

    Topics: Adolescent; Citalopram; Cognitive Behavioral Therapy; Combined Modality Therapy; Cyclohexanols; Depr

2008
Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial.
    JAMA, 2008, Feb-27, Volume: 299, Issue:8

    Topics: Adolescent; Citalopram; Cognitive Behavioral Therapy; Combined Modality Therapy; Cyclohexanols; Depr

2008
Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial.
    JAMA, 2008, Feb-27, Volume: 299, Issue:8

    Topics: Adolescent; Citalopram; Cognitive Behavioral Therapy; Combined Modality Therapy; Cyclohexanols; Depr

2008
Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial.
    JAMA, 2008, Feb-27, Volume: 299, Issue:8

    Topics: Adolescent; Citalopram; Cognitive Behavioral Therapy; Combined Modality Therapy; Cyclohexanols; Depr

2008
Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial.
    JAMA, 2008, Feb-27, Volume: 299, Issue:8

    Topics: Adolescent; Citalopram; Cognitive Behavioral Therapy; Combined Modality Therapy; Cyclohexanols; Depr

2008
Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial.
    JAMA, 2008, Feb-27, Volume: 299, Issue:8

    Topics: Adolescent; Citalopram; Cognitive Behavioral Therapy; Combined Modality Therapy; Cyclohexanols; Depr

2008
Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial.
    JAMA, 2008, Feb-27, Volume: 299, Issue:8

    Topics: Adolescent; Citalopram; Cognitive Behavioral Therapy; Combined Modality Therapy; Cyclohexanols; Depr

2008
The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study.
    Journal of clinical psychopharmacology, 2008, Volume: 28, Issue:2

    Topics: Adult; Akathisia, Drug-Induced; Antidepressive Agents; Aripiprazole; Citalopram; Cyclohexanols; Depr

2008
The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study.
    Journal of clinical psychopharmacology, 2008, Volume: 28, Issue:2

    Topics: Adult; Akathisia, Drug-Induced; Antidepressive Agents; Aripiprazole; Citalopram; Cyclohexanols; Depr

2008
The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study.
    Journal of clinical psychopharmacology, 2008, Volume: 28, Issue:2

    Topics: Adult; Akathisia, Drug-Induced; Antidepressive Agents; Aripiprazole; Citalopram; Cyclohexanols; Depr

2008
The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study.
    Journal of clinical psychopharmacology, 2008, Volume: 28, Issue:2

    Topics: Adult; Akathisia, Drug-Induced; Antidepressive Agents; Aripiprazole; Citalopram; Cyclohexanols; Depr

2008
Achievement and maintenance of sustained response during the Treatment for Adolescents With Depression Study continuation and maintenance therapy.
    Archives of general psychiatry, 2008, Volume: 65, Issue:4

    Topics: Achievement; Adolescent; Antidepressive Agents, Second-Generation; Child; Cognitive Behavioral Thera

2008
Combined therapy of major depression with concomitant borderline personality disorder: comparison of interpersonal and cognitive psychotherapy.
    Canadian journal of psychiatry. Revue canadienne de psychiatrie, 2007, Volume: 52, Issue:11

    Topics: Anxiety Disorders; Borderline Personality Disorder; Cognitive Behavioral Therapy; Combined Modality

2007
Cost-effectiveness of treatments for adolescent depression: results from TADS.
    The American journal of psychiatry, 2008, Volume: 165, Issue:5

    Topics: Adolescent; Child; Combined Modality Therapy; Cost-Benefit Analysis; Depressive Disorder, Major; Dru

2008
Maternal depressive symptoms in pediatric major depressive disorder: relationship to acute treatment outcome.
    Journal of the American Academy of Child and Adolescent Psychiatry, 2008, Volume: 47, Issue:6

    Topics: Acute Disease; Adolescent; Antidepressive Agents, Second-Generation; Child; Child of Impaired Parent

2008
A randomised controlled trial of cognitive behaviour therapy in adolescents with major depression treated by selective serotonin reuptake inhibitors. The ADAPT trial.
    Health technology assessment (Winchester, England), 2008, Volume: 12, Issue:14

    Topics: Adolescent; Antidepressive Agents, Second-Generation; Child; Cognitive Behavioral Therapy; Combined

2008
Serotonin transporter is differentially localized in subpopulations of lymphocytes of major depression patients. Effect of fluoxetine on proliferation.
    Journal of neuroimmunology, 2008, May-30, Volume: 196, Issue:1-2

    Topics: Adolescent; Adult; Antidepressive Agents, Second-Generation; Antigens, CD; CD4-Positive T-Lymphocyte

2008
Effects of trazodone and fluoxetine in the treatment of major depression: therapeutic pharmacokinetic and pharmacodynamic interactions through formation of meta-chlorophenylpiperazine.
    Journal of clinical psychopharmacology, 1997, Volume: 17, Issue:5

    Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Dose-Response Rel

1997
Fluoxetine in medically stable, depressed geriatric patients: effects on weight.
    Journal of clinical psychopharmacology, 1997, Volume: 17, Issue:5

    Topics: Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Body Mass Index; Depressive Disor

1997
Fluoxetine in depressed patients on dialysis.
    International journal of psychiatry in medicine, 1997, Volume: 27, Issue:1

    Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Double-Blind Meth

1997
Serum levels of excitatory amino acids, serine, glycine, histidine, threonine, taurine, alanine and arginine in treatment-resistant depression: modulation by treatment with antidepressants and prediction of clinical responsivity.
    Acta psychiatrica Scandinavica, 1998, Volume: 97, Issue:4

    Topics: Adult; Aged; Alanine; Antidepressive Agents; Antidepressive Agents, Tricyclic; Arginine; Asparagine;

1998
A Canadian multicenter, double-blind study of paroxetine and fluoxetine in major depressive disorder.
    Journal of affective disorders, 1999, Volume: 54, Issue:1-2

    Topics: Adult; Anxiety; Depressive Disorder, Major; Dose-Response Relationship, Drug; Female; Fluoxetine; Hu

1999
Tryptophan-depletion challenge in depressed patients treated with desipramine or fluoxetine: implications for the role of serotonin in the mechanism of antidepressant action.
    Biological psychiatry, 1999, Jul-15, Volume: 46, Issue:2

    Topics: Adult; Aged; Amino Acids; Analysis of Variance; Antidepressive Agents, Second-Generation; Antidepres

1999
Comparative efficacy of sertraline vs. fluoxetine in patients age 70 or over with major depression.
    The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, 1999,Summer, Volume: 7, Issue:3

    Topics: Aged; Aged, 80 and over; Antidepressive Agents; Cognition; Depressive Disorder, Major; Double-Blind

1999
A double-blind comparison of sertraline and fluoxetine in the treatment of major depressive episode in outpatients.
    European psychiatry : the journal of the Association of European Psychiatrists, 1999, Volume: 14, Issue:1

    Topics: Adolescent; Adult; Aged; Ambulatory Care; Depressive Disorder, Major; Double-Blind Method; Drug Tole

1999
Serotonin and the prediction of response time to fluoxetine in patients with mild depression.
    Psychiatry research, 1999, Nov-08, Volume: 88, Issue:2

    Topics: Adult; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Double-Blind Method; Fe

1999
A quantitative magnetic resonance imaging study of caudate and lenticular nucleus gray matter volume in primary unipolar major depression: relationship to treatment response and clinical severity.
    Psychiatry research, 1998, Dec-14, Volume: 84, Issue:2-3

    Topics: Adult; Antidepressive Agents, Second-Generation; Caudate Nucleus; Corpus Striatum; Depressive Disord

1998
Lymphocyte proliferation among major depressive and dysthymic patients with typical or atypical features.
    Journal of affective disorders, 2000, Volume: 58, Issue:1

    Topics: Adult; Antidepressive Agents, Second-Generation; Cyclohexanols; Depressive Disorder, Major; Dysthymi

2000
Comparison of pramipexole, fluoxetine, and placebo in patients with major depression.
    Depression and anxiety, 2000, Volume: 11, Issue:2

    Topics: Adult; Benzothiazoles; Depressive Disorder, Major; Dopamine Agonists; Dose-Response Relationship, Dr

2000
Executive dysfunction predicts nonresponse to fluoxetine in major depression.
    Journal of affective disorders, 2000, Volume: 60, Issue:1

    Topics: Adult; Cognition Disorders; Depressive Disorder, Major; Double-Blind Method; Female; Fluoxetine; Hum

2000
Executive dysfunction predicts nonresponse to fluoxetine in major depression.
    Journal of affective disorders, 2000, Volume: 60, Issue:1

    Topics: Adult; Cognition Disorders; Depressive Disorder, Major; Double-Blind Method; Female; Fluoxetine; Hum

2000
Executive dysfunction predicts nonresponse to fluoxetine in major depression.
    Journal of affective disorders, 2000, Volume: 60, Issue:1

    Topics: Adult; Cognition Disorders; Depressive Disorder, Major; Double-Blind Method; Female; Fluoxetine; Hum

2000
Executive dysfunction predicts nonresponse to fluoxetine in major depression.
    Journal of affective disorders, 2000, Volume: 60, Issue:1

    Topics: Adult; Cognition Disorders; Depressive Disorder, Major; Double-Blind Method; Female; Fluoxetine; Hum

2000
Enhancement of the antidepressant action of fluoxetine by folic acid: a randomised, placebo controlled trial.
    Journal of affective disorders, 2000, Volume: 60, Issue:2

    Topics: Adult; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Double-Blind Method; Dr

2000
Preliminary randomized double-blind placebo-controlled trial of tryptophan combined with fluoxetine to treat major depressive disorder: antidepressant and hypnotic effects.
    Journal of psychiatry & neuroscience : JPN, 2000, Volume: 25, Issue:4

    Topics: Adolescent; Adult; Aged; Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Dru

2000
Short-term cotherapy with clonazepam and fluoxetine: anxiety, sleep disturbance and core symptoms of depression.
    Journal of affective disorders, 2000, Volume: 61, Issue:1-2

    Topics: Adult; Aged; Anxiety; Clonazepam; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug

2000
Anemia and macrocytosis in the prediction of serum folate and vitamin B12 status, and treatment outcome in major depression.
    Journal of psychosomatic research, 2000, Volume: 49, Issue:3

    Topics: Adult; Anemia, Macrocytic; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Dru

2000
Augmentation of fluoxetine's antidepressant action by pindolol: analysis of clinical, pharmacokinetic, and methodologic factors.
    Journal of clinical psychopharmacology, 2001, Volume: 21, Issue:1

    Topics: Adrenergic beta-Antagonists; Adult; Antidepressive Agents; Depressive Disorder, Major; Double-Blind

2001
Benefits from mianserin augmentation of fluoxetine in patients with major depression non-responders to fluoxetine alone.
    Acta psychiatrica Scandinavica, 2001, Volume: 103, Issue:1

    Topics: Adult; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Double-Blind Method; Dr

2001
A feasibility study of antidepressant drug therapy in depressed elderly patients with chronic obstructive pulmonary disease.
    International journal of geriatric psychiatry, 2001, Volume: 16, Issue:5

    Topics: Activities of Daily Living; Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Depre

2001
Coadministration of melatonin and fluoxetine does not improve the 3-month outcome following ECT.
    The journal of ECT, 2001, Volume: 17, Issue:2

    Topics: Aged; Bipolar Disorder; Combined Modality Therapy; Depressive Disorder, Major; Dose-Response Relatio

2001
Fluoxetine treatment of cocaine-dependent patients with major depressive disorder.
    Drug and alcohol dependence, 2001, Aug-01, Volume: 63, Issue:3

    Topics: Adolescent; Adult; Analysis of Variance; Cocaine-Related Disorders; Depressive Disorder, Major; Diag

2001
Association study of the 5-HT(6) receptor polymorphism (C267T) and symptomatology and antidepressant response in major depressive disorders.
    Neuropsychobiology, 2001, Volume: 44, Issue:4

    Topics: Adult; Antidepressive Agents, Second-Generation; Cyclohexanols; Delayed-Action Preparations; Depress

2001
Changes in brain function of depressed subjects during treatment with placebo.
    The American journal of psychiatry, 2002, Volume: 159, Issue:1

    Topics: Adult; Cerebral Cortex; Cyclohexanols; Depressive Disorder, Major; Double-Blind Method; Electroencep

2002
Changes in brain function of depressed subjects during treatment with placebo.
    The American journal of psychiatry, 2002, Volume: 159, Issue:1

    Topics: Adult; Cerebral Cortex; Cyclohexanols; Depressive Disorder, Major; Double-Blind Method; Electroencep

2002
Changes in brain function of depressed subjects during treatment with placebo.
    The American journal of psychiatry, 2002, Volume: 159, Issue:1

    Topics: Adult; Cerebral Cortex; Cyclohexanols; Depressive Disorder, Major; Double-Blind Method; Electroencep

2002
Changes in brain function of depressed subjects during treatment with placebo.
    The American journal of psychiatry, 2002, Volume: 159, Issue:1

    Topics: Adult; Cerebral Cortex; Cyclohexanols; Depressive Disorder, Major; Double-Blind Method; Electroencep

2002
NEO-FFI factor scores as predictors of clinical response to fluoxetine in depressed outpatients.
    Psychiatry research, 2002, Jan-31, Volume: 109, Issue:1

    Topics: Adolescent; Adult; Aged; Ambulatory Care; Depressive Disorder, Major; Dose-Response Relationship, Dr

2002
Acute efficacy of fluoxetine versus sertraline and paroxetine in major depressive disorder including effects of baseline insomnia.
    Journal of clinical psychopharmacology, 2002, Volume: 22, Issue:2

    Topics: Acute Disease; Adverse Drug Reaction Reporting Systems; Antidepressive Agents; Depressive Disorder,

2002
Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial.
    The Journal of clinical psychiatry, 2002, Volume: 63, Issue:3

    Topics: Adrenergic Uptake Inhibitors; Adult; Antidepressive Agents; Blood Pressure; Body Weight; Depressive

2002
Switching patients from daily citalopram, paroxetine, or sertraline to once-weekly fluoxetine in the maintenance of response for depression.
    The Journal of clinical psychiatry, 2002, Volume: 63, Issue:3

    Topics: Adult; Antidepressive Agents, Second-Generation; Citalopram; Depressive Disorder, Major; Drug Admini

2002
Fluoxetine alone in the treatment of first episode anxious-depression: an open clinical trial.
    Journal of clinical psychopharmacology, 2002, Volume: 22, Issue:3

    Topics: Adult; Aged; Analysis of Variance; Anxiety; Comorbidity; Depressive Disorder, Major; Fluoxetine; Hum

2002
Early changes in prefrontal activity characterize clinical responders to antidepressants.
    Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2002, Volume: 27, Issue:1

    Topics: Adult; Analysis of Variance; Antidepressive Agents; Chi-Square Distribution; Cyclohexanols; Depressi

2002
Early changes in prefrontal activity characterize clinical responders to antidepressants.
    Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2002, Volume: 27, Issue:1

    Topics: Adult; Analysis of Variance; Antidepressive Agents; Chi-Square Distribution; Cyclohexanols; Depressi

2002
Early changes in prefrontal activity characterize clinical responders to antidepressants.
    Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2002, Volume: 27, Issue:1

    Topics: Adult; Analysis of Variance; Antidepressive Agents; Chi-Square Distribution; Cyclohexanols; Depressi

2002
Early changes in prefrontal activity characterize clinical responders to antidepressants.
    Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2002, Volume: 27, Issue:1

    Topics: Adult; Analysis of Variance; Antidepressive Agents; Chi-Square Distribution; Cyclohexanols; Depressi

2002
Fluoxetine and norfluoxetine plasma concentrations during relapse-prevention treatment.
    Journal of affective disorders, 2002, Volume: 68, Issue:2-3

    Topics: Adolescent; Adult; Aged; Depressive Disorder, Major; Double-Blind Method; Drug Administration Schedu

2002

Other Studies

311 other studies available for fluoxetine and Depression, Involutional

ArticleYear
Discovery of Novel and Potent
    Journal of medicinal chemistry, 2021, 05-13, Volume: 64, Issue:9

    Topics: Action Potentials; Allosteric Regulation; Animals; Antidepressive Agents; Binding Sites; Cell Surviv

2021
Impact of CYP2D6 Polymorphism on Equilibrium Concentration of Fluoxetine in Patients Diagnosed With Major Depressive Disorder and Comorbid Alcohol Use Disorders.
    Journal of psychiatric practice, 2021, 09-16, Volume: 27, Issue:5

    Topics: Adult; Alcoholism; Cytochrome P-450 CYP2D6; Depressive Disorder, Major; Fluoxetine; Humans; Middle A

2021
Fluoxetine-induced hepatic lipid accumulation is mediated by prostaglandin endoperoxide synthase 1 and is linked to elevated 15-deoxy-Δ
    Journal of applied toxicology : JAT, 2022, Volume: 42, Issue:6

    Topics: Cyclooxygenase 2; Depressive Disorder, Major; Fluoxetine; Humans; Non-alcoholic Fatty Liver Disease;

2022
Fluoxetine inhibited the activation of A1 reactive astrocyte in a mouse model of major depressive disorder through astrocytic 5-HT
    Journal of neuroinflammation, 2022, Jan-29, Volume: 19, Issue:1

    Topics: Animals; Astrocytes; beta-Arrestin 2; Depressive Disorder, Major; Fluoxetine; Mice; Serotonin

2022
Evidence for machine learning guided early prediction of acute outcomes in the treatment of depressed children and adolescents with antidepressants.
    Journal of child psychology and psychiatry, and allied disciplines, 2022, Volume: 63, Issue:11

    Topics: Adolescent; Antidepressive Agents; Artificial Intelligence; Child; Depressive Disorder, Major; Doubl

2022
Oridonin relieves depressive-like behaviors by inhibiting neuroinflammation and autophagy impairment in rats subjected to chronic unpredictable mild stress.
    Phytotherapy research : PTR, 2022, Volume: 36, Issue:8

    Topics: Animals; Antidepressive Agents; Autophagy; Autophagy-Related Proteins; Cytokines; Depression; Depres

2022
Octopamine mediates sugar relief from a chronic-stress-induced depression-like state in Drosophila.
    Current biology : CB, 2022, 09-26, Volume: 32, Issue:18

    Topics: 5-Hydroxytryptophan; Animals; Depression; Depressive Disorder, Major; Dopaminergic Neurons; Drosophi

2022
Chronic Fluoxetine Treatment of Socially Isolated Rats Modulates Prefrontal Cortex Proteome.
    Neuroscience, 2022, 10-01, Volume: 501

    Topics: Animals; Antidepressive Agents; Calcium; Calcium-Binding Proteins; Cytochromes c; Depression; Depres

2022
Fluoxetine Decreases Phagocytic Function via REV-ERBα in Microglia.
    Neurochemical research, 2023, Volume: 48, Issue:1

    Topics: ARNTL Transcription Factors; Circadian Rhythm; Depressive Disorder, Major; Fluoxetine; Humans; Infla

2023
Physical exercise prevents behavioral alterations in a reserpine-treated zebrafish: A putative depression model.
    Pharmacology, biochemistry, and behavior, 2022, Volume: 220

    Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antidepressive Agents; Behavior, Animal; COVID-19; Depressi

2022
Multispectral and Molecular Docking Studies Reveal Potential Effectiveness of Antidepressant Fluoxetine by Forming π-Acceptor Complexes.
    Molecules (Basel, Switzerland), 2022, Sep-10, Volume: 27, Issue:18

    Topics: Adolescent; Antidepressive Agents; Benzoic Acid; Child; Depressive Disorder, Major; Dinitrobenzenes;

2022
Delineation of biomarkers and molecular pathways of residual effects of fluoxetine treatment in juvenile rhesus monkeys by proteomic profiling.
    Zoological research, 2023, Jan-18, Volume: 44, Issue:1

    Topics: Animals; Biomarkers; Depressive Disorder, Major; Fluoxetine; Macaca mulatta; Proteomics; Selective S

2023
Fluoxetine Enhances Synaptic Vesicle Trafficking and Energy Metabolism in the Hippocampus of Socially Isolated Rats.
    International journal of molecular sciences, 2022, Dec-05, Volume: 23, Issue:23

    Topics: Animals; Depressive Disorder, Major; Energy Metabolism; Fluoxetine; Hippocampus; Proteomics; Rats; S

2022
Fluoxetine Enhances Synaptic Vesicle Trafficking and Energy Metabolism in the Hippocampus of Socially Isolated Rats.
    International journal of molecular sciences, 2022, Dec-05, Volume: 23, Issue:23

    Topics: Animals; Depressive Disorder, Major; Energy Metabolism; Fluoxetine; Hippocampus; Proteomics; Rats; S

2022
Fluoxetine Enhances Synaptic Vesicle Trafficking and Energy Metabolism in the Hippocampus of Socially Isolated Rats.
    International journal of molecular sciences, 2022, Dec-05, Volume: 23, Issue:23

    Topics: Animals; Depressive Disorder, Major; Energy Metabolism; Fluoxetine; Hippocampus; Proteomics; Rats; S

2022
Fluoxetine Enhances Synaptic Vesicle Trafficking and Energy Metabolism in the Hippocampus of Socially Isolated Rats.
    International journal of molecular sciences, 2022, Dec-05, Volume: 23, Issue:23

    Topics: Animals; Depressive Disorder, Major; Energy Metabolism; Fluoxetine; Hippocampus; Proteomics; Rats; S

2022
Synergistic anti-depressive effect of combination treatment of Brexpiprazole and selective serotonin reuptake inhibitors on forced swimming test in mice.
    Neuropsychopharmacology reports, 2023, Volume: 43, Issue:1

    Topics: Animals; Antidepressive Agents; Depressive Disorder, Major; Escitalopram; Fluoxetine; Mice; Paroxeti

2023
Case Report: Performing a Medication Safety Review Assisted by Pharmacogenomics to Explain a Prescribing Cascade Resulting in a Patient Fall.
    Medicina (Kaunas, Lithuania), 2023, Jan-06, Volume: 59, Issue:1

    Topics: Antidepressive Agents; Depressive Disorder, Major; Fluoxetine; Humans; Hydrocodone; Pharmacogenetics

2023
Selective Serotonin Reuptake Inhibitors within Cells: Temporal Resolution in Cytoplasm, Endoplasmic Reticulum, and Membrane.
    The Journal of neuroscience : the official journal of the Society for Neuroscience, 2023, 03-29, Volume: 43, Issue:13

    Topics: Animals; Citalopram; Depressive Disorder, Major; Endoplasmic Reticulum; Escitalopram; Fluoxetine; Hu

2023
Inflammatory Factors Predicted the Resilient Phenotype in Social Defeat-induced Depression of Male Mouse.
    Neuroscience, 2023, 05-21, Volume: 519

    Topics: Animals; Depressive Disorder, Major; Fluoxetine; Male; Mice; Mice, Inbred C57BL; Minocycline; Phenot

2023
Right-side frontal-central cortical hyperactivation before the treatment predicts outcomes of antidepressant and electroconvulsive therapy responsivity in major depressive disorder.
    Journal of psychiatric research, 2023, Volume: 161

    Topics: Antidepressive Agents; Depressive Disorder, Major; Electroconvulsive Therapy; Fluoxetine; Frontal Lo

2023
Intrahippocampal injection of a selective blocker of NMDA receptors containing the GluN2B subunit, Ro25-6981, increases glutamate neurotransmission and induces antidepressant-like effects.
    Fundamental & clinical pharmacology, 2023, Volume: 37, Issue:6

    Topics: Animals; Antidepressive Agents; Depressive Disorder, Major; Excitatory Amino Acid Antagonists; Fluox

2023
Chronic fluoxetine treatment in socially-isolated rats modulates the prefrontal cortex synaptoproteome.
    Journal of proteomics, 2023, 06-30, Volume: 282

    Topics: Adenosine Triphosphatases; Animals; Antidepressive Agents; Cation Transport Proteins; Cell Adhesion

2023
Antidepressant effects of novel positive allosteric modulators of Trk-receptor mediated signaling - a potential therapeutic concept?
    Psychopharmacology, 2023, Volume: 240, Issue:8

    Topics: Animals; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Depressive Disorder, Major; Fluox

2023
Organic cation transporter 2 contributes to SSRI antidepressant efficacy by controlling tryptophan availability in the brain.
    Translational psychiatry, 2023, 09-29, Volume: 13, Issue:1

    Topics: Anhedonia; Animals; Antidepressive Agents; Brain; Corticosterone; Depressive Disorder, Major; Fluoxe

2023
Role of Tyrosine Nitrosylation in Stress-Induced Major Depressive Disorder: Mechanisms and Implications.
    International journal of molecular sciences, 2023, Sep-27, Volume: 24, Issue:19

    Topics: Animals; Antidepressive Agents; Depressive Disorder, Major; Fluoxetine; Glucocorticoids; Hippocampus

2023
Developmental fluoxetine exposure affects adolescent and adult bone depending on the dose and period of exposure in mice.
    Physiological reports, 2023, Volume: 11, Issue:23

    Topics: Animals; Bone and Bones; Depressive Disorder, Major; Female; Fluoxetine; Humans; Mice; Prenatal Expo

2023
Time-to-effect of fluoxetine in children with depression.
    Canadian family physician Medecin de famille canadien, 2019, Volume: 65, Issue:8

    Topics: Adolescent; Child; Depressive Disorder, Major; Fluoxetine; Humans; Practice Guidelines as Topic; Ris

2019
Activating newborn neurons suppresses depression and anxiety-like behaviors.
    Nature communications, 2019, 08-21, Volume: 10, Issue:1

    Topics: Animals; Antidepressive Agents; Anxiety; Behavior, Animal; Dentate Gyrus; Depression; Depressive Dis

2019
Applying the inclusion/exclusion criteria in placebo-controlled studies to a clinical sample: A comparison of medications.
    Journal of affective disorders, 2020, 01-01, Volume: 260

    Topics: Adult; Antidepressive Agents; Controlled Clinical Trials as Topic; Depressive Disorder, Major; Femal

2020
Alterations in the Levels of Growth Factors in Adolescents with Major Depressive Disorder: A Longitudinal Study during the Treatment with Fluoxetine.
    Mediators of inflammation, 2019, Volume: 2019

    Topics: Adolescent; Adult; Depressive Disorder, Major; Female; Fibroblast Growth Factor 2; Fluoxetine; Granu

2019
Increased circulatory IL-6 during 8-week fluoxetine treatment is a risk factor for suicidal behaviors in youth.
    Brain, behavior, and immunity, 2020, Volume: 87

    Topics: Adolescent; Child; Depressive Disorder, Major; Female; Fluoxetine; Humans; Interleukin-6; Male; Risk

2020
Simultaneous determination of fluoxetine, venlafaxine, vortioxetine and their active metabolites in human plasma by LC-MS/MS using one-step sample preparation procedure.
    Journal of pharmaceutical and biomedical analysis, 2020, Mar-20, Volume: 181

    Topics: Adolescent; Adult; Aged; Antidepressive Agents; Child; Chromatography, High Pressure Liquid; Depress

2020
Antidepressant treatment strategy with an early onset of action improves the clinical outcome in patients with major depressive disorder and high anxiety: a multicenter and 6-week follow-up study.
    Chinese medical journal, 2020, Mar-20, Issue:6

    Topics: Antidepressive Agents; Anxiety; Citalopram; Depressive Disorder, Major; Fluoxetine; Fluvoxamine; Fol

2020
Electroconvulsive Therapy Versus Fluoxetine in Suicidal Resolution for Patients With Major Depressive Disorder.
    The journal of ECT, 2020, Volume: 36, Issue:4

    Topics: Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Electroconvulsive Therapy; Fem

2020
Higher dose weekly fluoxetine in hemodialysis patients: A case series report.
    International journal of psychiatry in medicine, 2021, Volume: 56, Issue:1

    Topics: Antidepressive Agents; Depressive Disorder, Major; Female; Fluoxetine; Humans; Psychiatric Status Ra

2021
The impact of repetitive transcranial magnetic stimulation and fluoxetine on the brain lipidome in a rat model of chronic unpredictable stress.
    Progress in neuro-psychopharmacology & biological psychiatry, 2020, 08-30, Volume: 102

    Topics: Animals; Antidepressive Agents; Behavior, Animal; Brain Chemistry; Chronic Disease; Depressive Disor

2020
Long-term use of fluoxetine accelerates bone loss through the disruption of sphingolipids metabolism in bone marrow adipose tissue.
    Translational psychiatry, 2020, 05-12, Volume: 10, Issue:1

    Topics: Adipose Tissue; Animals; Bone Marrow; Depressive Disorder, Major; Fluoxetine; Mice; Sphingolipids

2020
Key role of the 5-HT1A receptor addressing protein Yif1B in serotonin neurotransmission and SSRI treatment.
    Journal of psychiatry & neuroscience : JPN, 2020, 09-01, Volume: 45, Issue:5

    Topics: Animals; Autopsy; Behavior, Animal; Depressive Disorder, Major; Disease Models, Animal; Female; Fluo

2020
What next? A Bayesian hierarchical modeling re-examination of treatments for adolescents with selective serotonin reuptake inhibitor-resistant depression.
    Depression and anxiety, 2020, Volume: 37, Issue:9

    Topics: Adolescent; Bayes Theorem; Cyclohexanols; Depression; Depressive Disorder, Major; Fluoxetine; Humans

2020
An increase in IL-6 levels at 6-month follow-up visit is associated with SSRI-emergent suicidality in high-risk children and adolescents treated with fluoxetine.
    European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2020, Volume: 40

    Topics: Adolescent; Anxiety Disorders; Child; Depressive Disorder, Major; Female; Fluoxetine; Follow-Up Stud

2020
Do Cognitive Therapy Skills Neutralize Lifetime Stress to Improve Treatment Outcomes in Recurrent Depression?
    Behavior therapy, 2020, Volume: 51, Issue:5

    Topics: Cognitive Behavioral Therapy; Depression; Depressive Disorder, Major; Fluoxetine; Humans; Recurrence

2020
Developing a data-driven algorithm for guiding selection between cognitive behavioral therapy, fluoxetine, and combination treatment for adolescent depression.
    Translational psychiatry, 2020, 09-21, Volume: 10, Issue:1

    Topics: Adolescent; Algorithms; Child; Cognitive Behavioral Therapy; Combined Modality Therapy; Depression;

2020
Neural effects of a single dose of fluoxetine on resting-state functional connectivity in adolescent depression.
    Journal of psychopharmacology (Oxford, England), 2020, Volume: 34, Issue:12

    Topics: Adolescent; Cerebral Cortex; Connectome; Default Mode Network; Depressive Disorder, Major; Female; F

2020
Can the Risk of Severe Depression-Related Outcomes Be Reduced by Tailoring the Antidepressant Therapy to Patient Characteristics?
    American journal of epidemiology, 2021, 07-01, Volume: 190, Issue:7

    Topics: Adult; Aged; Antidepressive Agents; Citalopram; Cohort Studies; Databases, Factual; Depressive Disor

2021
Ketamine treatment protects against oxidative damage and the immunological response induced by electroconvulsive therapy.
    Pharmacological reports : PR, 2021, Volume: 73, Issue:2

    Topics: Animals; Antidepressive Agents; Bupropion; Combined Modality Therapy; Depressive Disorder, Major; El

2021
Joy Journal: A Behavioral Activation Technique Used in the Treatment of Late-Life Depression Associated With Hopelessness During the COVID-19 Pandemic.
    The primary care companion for CNS disorders, 2021, 01-07, Volume: 23, Issue:1

    Topics: Aged; Antidepressive Agents; Aripiprazole; Cognitive Behavioral Therapy; COVID-19; Depressive Disord

2021
Dentate gyrus activin signaling mediates the antidepressant response.
    Translational psychiatry, 2021, 01-07, Volume: 11, Issue:1

    Topics: Activins; Animals; Antidepressive Agents; Dentate Gyrus; Depressive Disorder, Major; Fluoxetine; Hum

2021
Standardised ginseng extract G115® potentiates the antidepressant-like properties of fluoxetine in the forced swim test.
    Acta neuropsychiatrica, 2021, Volume: 33, Issue:3

    Topics: Animals; Anxiety; Autopsy; Behavior, Animal; Brain-Derived Neurotrophic Factor; Depressive Disorder,

2021
Stress Resilience is Associated with Hippocampal Synaptoprotection in the Female Rat Learned Helplessness Paradigm.
    Neuroscience, 2021, 04-01, Volume: 459

    Topics: Animals; Depressive Disorder, Major; Disease Models, Animal; Female; Fluoxetine; Helplessness, Learn

2021
Moderators and Predictors of Response After 36 Weeks of Treatment in the Treatment for Adolescents with Depression Study (TADS).
    Research on child and adolescent psychopathology, 2021, Volume: 49, Issue:11

    Topics: Adolescent; Child; Cognitive Behavioral Therapy; Combined Modality Therapy; Depression; Depressive D

2021
Postpartum corticosterone and fluoxetine shift the tryptophan-kynurenine pathway in dams.
    Psychoneuroendocrinology, 2021, Volume: 130

    Topics: Animals; Corticosterone; Depression, Postpartum; Depressive Disorder, Major; Female; Fluoxetine; Hum

2021
Sex-Based Impact of Creatine Supplementation on Depressive Symptoms, Brain Serotonin and SSRI Efficacy in an Animal Model of Treatment-Resistant Depression.
    International journal of molecular sciences, 2021, Jul-30, Volume: 22, Issue:15

    Topics: Animals; Brain; Creatine; Depressive Disorder, Major; Dietary Supplements; Drug Synergism; Energy Me

2021
Prenatal fluoxetine modifies the behavioral and hormonal responses to stress in male mice: role for glucocorticoid insensitivity.
    Behavioural pharmacology, 2017, Volume: 28, Issue:5

    Topics: Animals; Antidepressive Agents; Anxiety; Anxiety Disorders; Behavior, Animal; Corticosterone; Depres

2017
Fluoxetine induces paradoxical effects in C57BL6/J mice: comparison with BALB/c mice.
    Behavioural pharmacology, 2017, Volume: 28, Issue:6

    Topics: Animals; Antidepressive Agents; Behavior, Animal; Depression; Depressive Disorder, Major; Disease Mo

2017
A Case of Fluoxetine-Induced Lower Extremity Ecchymosis.
    The primary care companion for CNS disorders, 2017, Jun-15, Volume: 19, Issue:3

    Topics: Adult; Antidepressive Agents, Second-Generation; Cytochrome P-450 CYP2D6 Inhibitors; Depressive Diso

2017
Glucocorticoid Receptor Genetic Variants and Response to Fluoxetine in Major Depressive Disorder.
    The Journal of neuropsychiatry and clinical neurosciences, 2018,Winter, Volume: 30, Issue:1

    Topics: Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Femal

2018
Alterations in amino acid levels in mouse brain regions after adjunctive treatment of brexpiprazole with fluoxetine: comparison with (R)-ketamine.
    Psychopharmacology, 2017, Volume: 234, Issue:21

    Topics: Administration, Oral; Amino Acids; Animals; Antidepressive Agents; Brain; Depressive Disorder, Major

2017
Heterogeneous stock rats: a model to study the genetics of despair-like behavior in adolescence.
    Genes, brain, and behavior, 2018, Volume: 17, Issue:2

    Topics: Animals; Antidepressive Agents; Behavior, Animal; Depressive Disorder, Major; Disease Models, Animal

2018
Patients' comprehension and skill usage as a putative mediator of change or an engaged target in cognitive therapy: Preliminary findings.
    Journal of affective disorders, 2018, 01-15, Volume: 226

    Topics: Adult; Cognitive Behavioral Therapy; Comprehension; Depression; Depressive Disorder, Major; Female;

2018
Behavioural and computational methods reveal differential effects for how delayed and rapid onset antidepressants effect decision making in rats.
    European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2017, Volume: 27, Issue:12

    Topics: Acoustic Stimulation; Amphetamine; Analgesics; Animals; Antidepressive Agents; Association Learning;

2017
ECT Has Greater Efficacy Than Fluoxetine in Alleviating the Burden of Illness for Patients with Major Depressive Disorder: A Taiwanese Pooled Analysis.
    The international journal of neuropsychopharmacology, 2018, 01-01, Volume: 21, Issue:1

    Topics: Adult; Age Factors; Antidepressive Agents, Second-Generation; Cost of Illness; Depressive Disorder,

2018
FGF21 Is Associated with Metabolic Effects and Treatment Response in Depressed Bipolar II Disorder Patients Treated with Valproate.
    The international journal of neuropsychopharmacology, 2018, 04-01, Volume: 21, Issue:4

    Topics: Adult; Antimanic Agents; Bipolar Disorder; Body Weight; Depressive Disorder, Major; Drug Therapy, Co

2018
Desvenlafaxine Versus Placebo in a Fluoxetine-Referenced Study of Children and Adolescents with Major Depressive Disorder: Design, Definitions, and Ongoing Challenges for Child and Adolescent Psychopharmacology Research.
    Journal of child and adolescent psychopharmacology, 2018, Volume: 28, Issue:5

    Topics: Adolescent; Antidepressive Agents; Child; Depressive Disorder, Major; Desvenlafaxine Succinate; Fluo

2018
Effects of vortioxetine and fluoxetine on the level of Brain Derived Neurotrophic Factors (BDNF) in the hippocampus of chronic unpredictable mild stress-induced depressive rats.
    Brain research bulletin, 2018, Volume: 142

    Topics: Anhedonia; Animals; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Depressive Disorder, M

2018
Translational control of depression-like behavior via phosphorylation of eukaryotic translation initiation factor 4E.
    Nature communications, 2018, 06-25, Volume: 9, Issue:1

    Topics: Animals; Antidepressive Agents; Anxiety; Behavior, Animal; Benzofurans; Citalopram; Depression; Depr

2018
Further Support for the Involvement of Genetic Variants Related to the Serotonergic Pathway in the Antidepressant Response in Children and Adolescents After a 12-Month Follow-Up: Impact of the
    Journal of child and adolescent psychopharmacology, 2018, Volume: 28, Issue:10

    Topics: Adolescent; Antidepressive Agents; Child; Depressive Disorder, Major; Female; Fluoxetine; Genetic Va

2018
Do comorbid social and other anxiety disorders predict outcomes during and after cognitive therapy for depression?
    Journal of affective disorders, 2019, 01-01, Volume: 242

    Topics: Adult; Antidepressive Agents, Second-Generation; Cognitive Behavioral Therapy; Comorbidity; Depressi

2019
Preliminary evidence of an association between increased cortical inhibition and reduced suicidal ideation in adolescents treated for major depression.
    Journal of affective disorders, 2019, 02-01, Volume: 244

    Topics: Adolescent; Adolescent Behavior; Antidepressive Agents, Second-Generation; Bupropion; Citalopram; De

2019
Major depression model induced by repeated and intermittent lipopolysaccharide administration: Long-lasting behavioral, neuroimmune and neuroprogressive alterations.
    Journal of psychiatric research, 2018, Volume: 107

    Topics: Animals; Behavior, Animal; Depressive Disorder, Major; Disease Models, Animal; Female; Fluoxetine; L

2018
Early improvement in HAMD-17 and HAMD-6 scores predicts ultimate response and remission for depressed patients treated with fluoxetine or ECT.
    Journal of affective disorders, 2019, 02-15, Volume: 245

    Topics: Adult; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Electroconvulsive Thera

2019
Do baseline WAIS-III subtests predict treatment outcomes for depressed inpatients receiving fluoxetine?
    Psychiatry research, 2019, Volume: 271

    Topics: Adult; Aged; Depressive Disorder, Major; Female; Fluoxetine; Humans; Inpatients; Male; Middle Aged;

2019
Precuneus and psychiatric manifestations: Novel neurobiological formulations through lesion based connectivity mapping of psychopathology.
    Asian journal of psychiatry, 2019, Volume: 39

    Topics: Anticonvulsants; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Brain Mapping; Brai

2019
A single dose of fluoxetine reduces neural limbic responses to anger in depressed adolescents.
    Translational psychiatry, 2019, 01-21, Volume: 9, Issue:1

    Topics: Adolescent; Amygdala; Anger; Brain Mapping; Depressive Disorder, Major; Facial Expression; Female; F

2019
Adolescent fluoxetine history impairs spatial memory in adult male, but not female, C57BL/6 mice.
    Journal of affective disorders, 2019, Apr-15, Volume: 249

    Topics: Animals; Antidepressive Agents, Second-Generation; Behavior, Animal; Depressive Disorder, Major; Dos

2019
Switching Selective Serotonin Reuptake Inhibitors in Adolescents with Selective Serotonin Reuptake Inhibitor-Resistant Major Depressive Disorder: Balancing Tolerability and Efficacy.
    Journal of child and adolescent psychopharmacology, 2019, Volume: 29, Issue:4

    Topics: Adolescent; Citalopram; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Fluoxe

2019
Re: "Desvenlafaxine Versus Placebo in a Fluoxetine-Referenced Study of Children and Adolescents with Major Depressive Disorder: Design, Definitions, and Ongoing Challenges for Child and Adolescent Psychopharmacology Research" by Strawn JR and Croarkin PE
    Journal of child and adolescent psychopharmacology, 2019, Volume: 29, Issue:3

    Topics: Adolescent; Antidepressive Agents; Child; Depressive Disorder, Major; Desvenlafaxine Succinate; Fluo

2019
A functional variant in the serotonin receptor 7 gene (HTR7), rs7905446, is associated with good response to SSRIs in bipolar and unipolar depression.
    Molecular psychiatry, 2020, Volume: 25, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Animals; Citalopram; Depressive Disorder, Major; Female; Fluoxetine;

2020
A Case Report of Serotonin Syndrome in a Patient on Selective Serotonin Reuptake Inhibitor (SSRI) Monotherapy.
    Journal of pharmacy practice, 2020, Volume: 33, Issue:2

    Topics: Anxiety; Depressive Disorder, Major; Female; Fluoxetine; Humans; Hydroxyzine; Paroxetine; Selective

2020
Early improvement in HAMD-17 and HAMD-7 scores predict response and remission in depressed patients treated with fluoxetine or electroconvulsive therapy.
    Journal of affective disorders, 2019, 06-15, Volume: 253

    Topics: Adult; Antidepressive Agents, Second-Generation; Clinical Trials as Topic; Combined Modality Therapy

2019
Could Treatment Matching Patients' Beliefs About Depression Improve Outcomes?
    Behavior therapy, 2019, Volume: 50, Issue:4

    Topics: Adult; Chronic Disease; Cognitive Behavioral Therapy; Depression; Depressive Disorder, Major; Female

2019
Chronic unpredictable mild stress-induced behavioral changes are coupled with dopaminergic hyperfunction and serotonergic hypofunction in mouse models of depression.
    Behavioural brain research, 2019, 10-17, Volume: 372

    Topics: Animals; Aripiprazole; Behavior, Animal; Depression; Depressive Disorder, Major; Disease Models, Ani

2019
Influence of baseline severity on the effects of SSRIs in depression: an item-based, patient-level post-hoc analysis.
    The lancet. Psychiatry, 2019, Volume: 6, Issue:9

    Topics: Antidepressive Agents; Citalopram; Clinical Trials as Topic; Depression; Depressive Disorder, Major;

2019
A pooled analysis of six month comparative efficacy and tolerability in four randomized clinical trials: agomelatine versus escitalopram, fluoxetine, and sertraline.
    CNS spectrums, 2013, Volume: 18, Issue:3

    Topics: Acetamides; Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Citalopram; Depressiv

2013
Antidepressant treatment outcome depends on the quality of the living environment: a pre-clinical investigation in mice.
    PloS one, 2013, Volume: 8, Issue:4

    Topics: Anhedonia; Animals; Antidepressive Agents; Behavior, Animal; Brain; Brain-Derived Neurotrophic Facto

2013
Comparing effects of citalopram with fluoxetine on sleep quality in patients with major depressive disorder.
    European review for medical and pharmacological sciences, 2013, Volume: 17, Issue:9

    Topics: Adolescent; Adult; Citalopram; Depressive Disorder, Major; Diagnostic and Statistical Manual of Ment

2013
Prediction of the time-course pattern of remission in depression by using clinical, neuropsychological, and genetic variables.
    Journal of affective disorders, 2013, Sep-25, Volume: 150, Issue:3

    Topics: Adult; Alleles; Amino Acid Substitution; Antidepressive Agents; Catechol O-Methyltransferase; Depres

2013
An adolescent with nonsuicidal self-injury: a case and discussion of neurobiological research on emotion regulation.
    The American journal of psychiatry, 2013, Volume: 170, Issue:8

    Topics: Adaptation, Psychological; Adolescent; Allosteric Regulation; Antidepressive Agents; Autonomic Nervo

2013
Neural response to emotional stimuli associated with successful antidepressant treatment and behavioral activation.
    Journal of affective disorders, 2013, Volume: 151, Issue:2

    Topics: Adult; Affect; Antidepressive Agents; Behavioral Symptoms; Benzodiazepines; Depressive Disorder, Maj

2013
Relief of depression and pain improves daily functioning and quality of life in patients with major depressive disorder.
    Progress in neuro-psychopharmacology & biological psychiatry, 2013, Dec-02, Volume: 47

    Topics: Adult; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Female; Fluoxetine; Hum

2013
When depression doesn't lead with depression.
    JAMA psychiatry, 2013, Volume: 70, Issue:11

    Topics: Anger; Bipolar Disorder; Cyclohexanols; Depression; Depressive Disorder, Major; Emotions; Female; Fl

2013
Angioedema probably related to fluoxetine in a preadolescent being followed up for major depressive disorder.
    Journal of child and adolescent psychopharmacology, 2013, Volume: 23, Issue:10

    Topics: Angioedema; Child; Depressive Disorder, Major; Fluoxetine; Follow-Up Studies; Humans; Male; Selectiv

2013
Frontal-subcortical volumetric deficits in single episode, medication-naïve depressed patients and the effects of 8 weeks fluoxetine treatment: a VBM-DARTEL study.
    PloS one, 2014, Volume: 9, Issue:1

    Topics: Adolescent; Adult; Antidepressive Agents, Second-Generation; Brain; Case-Control Studies; Cerebral C

2014
Lower cortical serotonin 2A receptors in major depressive disorder, suicide and in rats after administration of imipramine.
    The international journal of neuropsychopharmacology, 2014, Volume: 17, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Animals; Antidepressive Agents; Antipsychotic Agents; Bipolar Disord

2014
Continuation-phase cognitive therapy and fluoxetine are effective in reducing the risk of relapse/recurrence in major depression after incomplete remission.
    Evidence-based mental health, 2014, Volume: 17, Issue:2

    Topics: Cognitive Behavioral Therapy; Depressive Disorder, Major; Female; Fluoxetine; Humans; Male; Secondar

2014
Both body weight and BMI predicts improvement in symptom and functioning for patients with major depressive disorder.
    Journal of affective disorders, 2014, Volume: 161

    Topics: Adult; Antidepressive Agents, Second-Generation; Body Mass Index; Body Weight; Depressive Disorder,

2014
The 25th anniversary of the launch of Prozac gives pause for thought: where did we go wrong?
    The British journal of psychiatry : the journal of mental science, 2014, Volume: 204

    Topics: Antidepressive Agents; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disor

2014
"The ickiness factor:" case study of an unconventional psychotherapeutic approach to pediatric OCD.
    American journal of psychotherapy, 2014, Volume: 68, Issue:1

    Topics: Child; Cognitive Behavioral Therapy; Combined Modality Therapy; Defense Mechanisms; Depressive Disor

2014
An aripiprazole discontinuation syndrome.
    Rhode Island medical journal (2013), 2013, Volume: 96, Issue:2

    Topics: Adult; Akathisia, Drug-Induced; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Depressiv

2013
The role of patient expectancy in placebo and nocebo effects in antidepressant trials.
    The Journal of clinical psychiatry, 2014, Volume: 75, Issue:10

    Topics: Adult; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Drug Administration Sch

2014
Fluoxetine-induced pancreatic beta cell dysfunction: New insight into the benefits of folic acid in the treatment of depression.
    Journal of affective disorders, 2014, Volume: 166

    Topics: Animals; Cell Line; Depressive Disorder, Major; Female; Fluoxetine; Folic Acid; Humans; Insulin-Secr

2014
Relationship of cortisol levels and genetic polymorphisms to antidepressant response to placebo and fluoxetine in patients with major depressive disorder: a prospective study.
    BMC psychiatry, 2014, Aug-03, Volume: 14

    Topics: Adolescent; Adult; Antidepressive Agents, Second-Generation; Arginine Vasopressin; Depressive Disord

2014
Improving remission and preventing relapse in youths with major depression.
    The American journal of psychiatry, 2014, Volume: 171, Issue:10

    Topics: Cognitive Behavioral Therapy; Depressive Disorder, Major; Female; Fluoxetine; Humans; Male

2014
Glutamate transporter 1-mediated antidepressant-like effect in a rat model of chronic unpredictable stress.
    Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban, 2014, Volume: 34, Issue:6

    Topics: Animals; Antidepressive Agents, Second-Generation; Behavior, Animal; Brain; Chronic Disease; Depress

2014
Impact of antidepressant therapy on cognitive aspects of work, condom use, and psychosocial well-being among HIV clients in Uganda.
    International journal of psychiatry in medicine, 2014, Volume: 48, Issue:3

    Topics: Adult; Antidepressive Agents; Cognition Disorders; Condoms; Depressive Disorder, Major; Developing C

2014
Prophylactic efficacy of fluoxetine, escitalopram, sertraline, paroxetine, and concomitant psychotherapy in major depressive disorder: outcome after long-term follow-up.
    Psychiatry research, 2015, Feb-28, Volume: 225, Issue:3

    Topics: Adult; Citalopram; Cognitive Behavioral Therapy; Cohort Studies; Combined Modality Therapy; Depressi

2015
Effects of remission speed and improvement of cognitive functions of depressed patients.
    Psychiatry research, 2015, Mar-30, Volume: 226, Issue:1

    Topics: Adult; Antidepressive Agents; Cognition; Depressive Disorder, Major; Executive Function; Female; Flu

2015
Detecting treatment-covariate interactions using permutation methods.
    Statistics in medicine, 2015, May-30, Volume: 34, Issue:12

    Topics: Adolescent; Analysis of Variance; Antidepressive Agents, Second-Generation; Bias; Clinical Decision-

2015
Real-world outcomes in patients with depression treated with duloxetine or a selective serotonin reuptake inhibitor in East Asia.
    Asia-Pacific psychiatry : official journal of the Pacific Rim College of Psychiatrists, 2016, Volume: 8, Issue:1

    Topics: Adult; Asia, Eastern; Citalopram; Depressive Disorder, Major; Duloxetine Hydrochloride; Female; Fluo

2016
Fluoxetine associated with thrombocytopenia and treatment with reboxetine: 3 cases.
    Journal of clinical psychopharmacology, 2015, Volume: 35, Issue:3

    Topics: Adult; Antidepressive Agents; Antidepressive Agents, Second-Generation; Depressive Disorder, Major;

2015
Association of a brain methylation site with clinical outcomes in depression does not replicate across populations.
    The American journal of psychiatry, 2015, Volume: 172, Issue:4

    Topics: Antidepressive Agents; Brain-Derived Neurotrophic Factor; Depressive Disorder, Major; Desipramine; F

2015
Response to Uher et al.
    The American journal of psychiatry, 2015, Volume: 172, Issue:4

    Topics: Antidepressive Agents; Brain-Derived Neurotrophic Factor; Depressive Disorder, Major; Desipramine; F

2015
Persistent decrease in alpha current density in fully remitted subjects with major depressive disorder treated with fluoxetine: A prospective electric tomography study.
    International journal of psychophysiology : official journal of the International Organization of Psychophysiology, 2015, Volume: 96, Issue:3

    Topics: Adolescent; Adult; Alpha Rhythm; Antidepressive Agents, Second-Generation; Brain Mapping; Chi-Square

2015
Relative efficacy of psychological and pharmacological treatments for social anxiety disorder.
    Evidence-based mental health, 2015, Volume: 18, Issue:2

    Topics: Cognitive Behavioral Therapy; Depressive Disorder, Major; Female; Fluoxetine; Humans; Male

2015
Improving outcome of paediatric depression with cognitive-behavioural therapy (CBT) after initial improvement on antidepressant medication.
    Evidence-based mental health, 2015, Volume: 18, Issue:2

    Topics: Cognitive Behavioral Therapy; Depressive Disorder, Major; Female; Fluoxetine; Humans; Male

2015
Dose equivalents of antidepressants: Evidence-based recommendations from randomized controlled trials.
    Journal of affective disorders, 2015, Jul-15, Volume: 180

    Topics: Adult; Amitriptyline; Antidepressive Agents; Bupropion; Citalopram; Depressive Disorder, Major; Dose

2015
The role of 5-HT1A receptors in mediating acute negative effects of antidepressants: implications in pediatric depression.
    Translational psychiatry, 2015, May-05, Volume: 5

    Topics: Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents; Anxiety; Behavior, Animal; Child; Depr

2015
The relationship between symptom relief and functional improvement during acute fluoxetine treatment for patients with major depressive disorder.
    Journal of affective disorders, 2015, Aug-15, Volume: 182

    Topics: Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Female; Fluoxetine; Humans; Ma

2015
The positive effect on ketamine as a priming adjuvant in antidepressant treatment.
    Translational psychiatry, 2015, May-26, Volume: 5

    Topics: Animals; Antidepressive Agents; Anxiety; Aspartic Acid; Behavior, Animal; Brain; Depression; Depress

2015
What's in a delayed bathyphase?
    Journal of psychiatric research, 2015, Volume: 68

    Topics: Depressive Disorder, Major; Female; Fluoxetine; Humans; Male; Rest; Selective Serotonin Reuptake Inh

2015
MiR-335 is involved in major depression disorder and antidepressant treatment through targeting GRM4.
    Neuroscience letters, 2015, Oct-08, Volume: 606

    Topics: Adolescent; Antidepressive Agents; Case-Control Studies; Child; Citalopram; Depressive Disorder, Maj

2015
Changes in Muscarinic M2 Receptor Levels in the Cortex of Subjects with Bipolar Disorder and Major Depressive Disorder and in Rats after Treatment with Mood Stabilisers and Antidepressants.
    The international journal of neuropsychopharmacology, 2016, Volume: 19, Issue:4

    Topics: Animals; Antidepressive Agents; Antimanic Agents; Bipolar Disorder; Cerebral Cortex; Depressive Diso

2016
Pain Affects Clinical Patterns and Treatment Outcomes for Patients With Major Depressive Disorder Taking Fluoxetine.
    Journal of clinical psychopharmacology, 2015, Volume: 35, Issue:6

    Topics: Adult; Antidepressive Agents, Second-Generation; Comorbidity; Depressive Disorder, Major; Female; Fl

2015
Lower [3H]LY341495 binding to mGlu2/3 receptors in the anterior cingulate of subjects with major depressive disorder but not bipolar disorder or schizophrenia.
    Journal of affective disorders, 2016, Jan-15, Volume: 190

    Topics: Amino Acids; Animals; Antidepressive Agents; Bipolar Disorder; Brain; Depressive Disorder, Major; Ex

2016
Fluoxetine effects on molecular, cellular and behavioral endophenotypes of depression are driven by the living environment.
    Molecular psychiatry, 2017, Volume: 22, Issue:4

    Topics: Affect; Animals; Behavior, Animal; Brain; Brain-Derived Neurotrophic Factor; CA1 Region, Hippocampal

2017
Genetic dysfunction of serotonin 2A receptor hampers response to antidepressant drugs: A translational approach.
    Neuropharmacology, 2016, Volume: 105

    Topics: Adolescent; Adult; Aged; Animals; Antidepressive Agents; Cell Survival; Citalopram; Depressive Disor

2016
The Relationship Between Plasma Cytokine Levels and Response to Selective Serotonin Reuptake Inhibitor Treatment in Children and Adolescents with Depression and/or Anxiety Disorders.
    Journal of child and adolescent psychopharmacology, 2016, Volume: 26, Issue:8

    Topics: Adolescent; Anxiety Disorders; Child; Cytokines; Depressive Disorder, Major; Enzyme-Linked Immunosor

2016
Staying Up at Night: Overlapping Bipolar and Obsessive-Compulsive Disorder Symptoms in an Adolescent with Autism Spectrum Disorder.
    Journal of child and adolescent psychopharmacology, 2016, Volume: 26, Issue:1

    Topics: Adolescent; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Autism Spectrum Disorder

2016
Melancholic features in inpatients with major depressive disorder associate with differential clinical characteristics and treatment outcomes.
    Psychiatry research, 2016, Apr-30, Volume: 238

    Topics: Adult; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Diagnostic and Statisti

2016
Neurocognitive Changes in Selective Serotonin Reuptake Inhibitors-Treated Adolescents with Depression.
    Journal of child and adolescent psychopharmacology, 2016, Volume: 26, Issue:8

    Topics: Adolescent; Attention; Case-Control Studies; Child; Cognition; Depressive Disorder, Major; Executive

2016
The symptom trajectories to clinical remission in Chinese patients with unipolar major depressive disorder.
    Asia-Pacific psychiatry : official journal of the Pacific Rim College of Psychiatrists, 2016, Volume: 8, Issue:4

    Topics: Adult; Depressive Disorder, Major; Female; Fluoxetine; Humans; Male; Middle Aged; Outcome Assessment

2016
Evaluation of interleukin-6 and serotonin as biomarkers to predict response to fluoxetine.
    Human psychopharmacology, 2016, Volume: 31, Issue:3

    Topics: Adolescent; Adult; Aged; Biomarkers; Case-Control Studies; Chromatography, Liquid; Depressive Disord

2016
Selective corticotropin-releasing factor 1 receptor antagonist E2508 has potent antidepressant-like and anxiolytic-like properties in rodent models.
    Behavioural brain research, 2016, 10-01, Volume: 312

    Topics: Acetylcholine; Administration, Oral; Animals; Anti-Anxiety Agents; Antidepressive Agents; Anxiety Di

2016
One-Year Follow-up of Children and Adolescents with Major Depressive Disorder: Relationship between Clinical Variables and Abcb1 Gene Polymorphisms.
    Pharmacopsychiatry, 2016, Volume: 49, Issue:6

    Topics: Adolescent; ATP Binding Cassette Transporter, Subfamily B, Member 1; Depressive Disorder, Major; Fem

2016
Serotonin transporter gene (SLC6A4) polymorphisms are associated with response to fluoxetine in south Indian major depressive disorder patients.
    European journal of clinical pharmacology, 2016, Volume: 72, Issue:10

    Topics: Adult; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Female; Fluoxetine; Gen

2016
Chronic Fluoxetine Treatment Upregulates the Activity of the ERK1/2-NF-κB Signaling Pathway in the Hippocampus and Prefrontal Cortex of Rats Exposed to Forced-Swimming Stress.
    Medical principles and practice : international journal of the Kuwait University, Health Science Centre, 2016, Volume: 25, Issue:6

    Topics: Analysis of Variance; Animals; Antidepressive Agents, Second-Generation; Behavior, Animal; Blotting,

2016
TNFAIP3, a negative regulator of the TLR signaling pathway, is a potential predictive biomarker of response to antidepressant treatment in major depressive disorder.
    Brain, behavior, and immunity, 2017, Volume: 59

    Topics: Adult; Animals; Antidepressive Agents; Biomarkers; Cell Line; Depressive Disorder, Major; Female; Fl

2017
Antidepressant Prescription in the Geriatric Population: A Teachable Moment.
    JAMA internal medicine, 2016, 11-01, Volume: 176, Issue:11

    Topics: Aged; Antidepressive Agents; Depressive Disorder, Major; Diagnosis, Differential; Female; Fluoxetine

2016
Which SSRIs most effectively treat depression in adolescents?
    The Journal of family practice, 2016, Volume: 65, Issue:9

    Topics: Adolescent; Adolescent Behavior; Antidepressive Agents; Behavior Therapy; Citalopram; Depressive Dis

2016
Alternative splicing of SMPD1 coding for acid sphingomyelinase in major depression.
    Journal of affective disorders, 2017, Volume: 209

    Topics: Adult; Aged; Alternative Splicing; Antidepressive Agents; Biomarkers; Depressive Disorder, Major; Fe

2017
Adjunctive treatment of brexpiprazole with fluoxetine shows a rapid antidepressant effect in social defeat stress model: Role of BDNF-TrkB signaling.
    Scientific reports, 2016, 12-19, Volume: 6

    Topics: Animals; Antidepressive Agents; Azepines; Behavior, Animal; Benzamides; Brain-Derived Neurotrophic F

2016
Epigenetic and genetic variants in the HTR1B gene and clinical improvement in children and adolescents treated with fluoxetine.
    Progress in neuro-psychopharmacology & biological psychiatry, 2017, 04-03, Volume: 75

    Topics: Adolescent; Antidepressive Agents, Second-Generation; Anxiety Disorders; Child; Depressive Disorder,

2017
Fluoxetine-Induced Severe Oral Ulceration in a 13-Year-Old Girl.
    Journal of child and adolescent psychopharmacology, 2017, Volume: 27, Issue:5

    Topics: Adolescent; Depressive Disorder, Major; Female; Fluoxetine; Humans; Oral Ulcer; Selective Serotonin

2017
Antidepressant-associated mania: soon after switch from fluoxetine to mirtazapine in an elderly woman with mixed depressive features.
    Journal of psychopharmacology (Oxford, England), 2009, Volume: 23, Issue:2

    Topics: Adrenergic alpha-Antagonists; Aged; Bipolar Disorder; Depressive Disorder, Major; Dose-Response Rela

2009
Neuropsychological characteristics as predictors of SSRI treatment response in depressed subjects.
    Journal of neural transmission (Vienna, Austria : 1996), 2008, Volume: 115, Issue:8

    Topics: Adult; Depressive Disorder, Major; Female; Fluoxetine; Humans; Intelligence Tests; Male; Memory, Sho

2008
Flat dose-response curves for efficacy: what do they mean to the clinician?
    Journal of psychiatric practice, 2008, Volume: 14, Issue:4

    Topics: Attitude of Health Personnel; Cyclohexanols; Depressive Disorder, Major; Desvenlafaxine Succinate; D

2008
[A place for SSRIs in the treatment of severely depressed children and adolescents].
    Nederlands tijdschrift voor geneeskunde, 2008, Aug-02, Volume: 152, Issue:31

    Topics: Adolescent; Antidepressive Agents, Second-Generation; Child; Cyclohexanols; Depressive Disorder, Maj

2008
Plasminogen activator inhibitor-1 gene is associated with major depression and antidepressant treatment response.
    Pharmacogenetics and genomics, 2008, Volume: 18, Issue:10

    Topics: Adult; Antidepressive Agents; Case-Control Studies; Citalopram; Depressive Disorder, Major; Female;

2008
Platelet serotonin uptake in drug-naïve depressive patients before and after treatment with citalopram.
    Psychiatry research, 2008, Nov-30, Volume: 161, Issue:2

    Topics: Adult; Blood Platelets; Citalopram; Depressive Disorder, Major; Female; Fluoxetine; Follow-Up Studie

2008
The treatment of major depressive disorders (MDD) in Thailand using escitalopram compared to fluoxetine and venlafaxine: a pharmacoeconomic evaluation.
    Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2008, Volume: 91, Issue:7

    Topics: Antidepressive Agents, Second-Generation; Citalopram; Cost-Benefit Analysis; Cyclohexanols; Decision

2008
Dysfunctional attitudes and perceived stress predict depressive symptoms severity following antidepressant treatment in patients with chronic depression.
    Psychiatry research, 2008, Dec-15, Volume: 161, Issue:3

    Topics: Adult; Antidepressive Agents, Second-Generation; Attitude; Depressive Disorder, Major; Female; Fluox

2008
[A place for SSRIs in the treatment of severely depressed children and adolescents].
    Nederlands tijdschrift voor geneeskunde, 2008, Oct-25, Volume: 152, Issue:43

    Topics: Adolescent; Antidepressive Agents, Second-Generation; Child; Depressive Disorder, Major; Fluoxetine;

2008
Early prediction of acute antidepressant treatment response and remission in pediatric major depressive disorder.
    Journal of the American Academy of Child and Adolescent Psychiatry, 2009, Volume: 48, Issue:1

    Topics: Acute Disease; Adolescent; Antidepressive Agents, Second-Generation; Child; Depressive Disorder, Maj

2009
Cost effectiveness of venlafaxine compared with generic fluoxetine or generic amitriptyline in major depressive disorder in the UK.
    Clinical drug investigation, 2009, Volume: 29, Issue:3

    Topics: Amitriptyline; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Cost-Bene

2009
Tryptophan hydroxylase 2 gene is associated with major depression and antidepressant treatment response.
    Progress in neuro-psychopharmacology & biological psychiatry, 2009, Jun-15, Volume: 33, Issue:4

    Topics: Adult; Antidepressive Agents; Citalopram; Depressive Disorder, Major; Female; Fluoxetine; Gene Frequ

2009
An integrated analysis of olanzapine/fluoxetine combination in clinical trials of treatment-resistant depression.
    The Journal of clinical psychiatry, 2009, Volume: 70, Issue:3

    Topics: Adult; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Benzodiazepines; Cyclohexanol

2009
Oxidative stress parameters after combined fluoxetine and acetylsalicylic acid therapy in depressive patients.
    Human psychopharmacology, 2009, Volume: 24, Issue:4

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antidepressive Agents, Second-Generation; Antioxidan

2009
Trismus induced by fluoxetine.
    Journal of clinical psychopharmacology, 2009, Volume: 29, Issue:3

    Topics: Anxiety Disorders; Depressive Disorder, Major; Fluoxetine; Humans; Male; Middle Aged; Selective Sero

2009
Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial.
    Depression and anxiety, 2009, Volume: 26, Issue:7

    Topics: Adult; Celecoxib; Cyclooxygenase 2 Inhibitors; Depressive Disorder, Major; Diagnostic and Statistica

2009
Efficacy of SSRIs on cognition of Alzheimer's disease patients treated with cholinesterase inhibitors.
    International psychogeriatrics, 2010, Volume: 22, Issue:1

    Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Citalopram; Cognition; Cognition Disorders; Depr

2010
5-HTR1A, 5-HTR2A, 5-HTR6, TPH1 and TPH2 polymorphisms and major depression.
    Neuroreport, 2009, Aug-05, Volume: 20, Issue:12

    Topics: Adolescent; Adult; Aged; Citalopram; Depressive Disorder, Major; Fluoxetine; Humans; Middle Aged; Pa

2009
SSRI antidepressants do not confound single photon emission computed tomography (SPECT) imaging studies using the alpha4beta2 nicotinic acetylcholine receptor [123I]5-I-A85380 ligand: in vivo and in vitro evidence.
    Synapse (New York, N.Y.), 2010, Volume: 64, Issue:2

    Topics: Adult; Antidepressive Agents, Second-Generation; Autoradiography; Azetidines; Brain; Citalopram; Dep

2010
The treatment of SSRI-resistant depression in adolescents (TORDIA): in search of the best next step.
    Depression and anxiety, 2009, Volume: 26, Issue:10

    Topics: Adolescent; Antidepressive Agents; Citalopram; Cognitive Behavioral Therapy; Combined Modality Thera

2009
Treatment response in depressed adolescents with and without co-morbid attention-deficit/hyperactivity disorder in the Treatment for Adolescents with Depression Study.
    Journal of child and adolescent psychopharmacology, 2009, Volume: 19, Issue:5

    Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Child; Cognitive Behavioral Therapy; Comb

2009
Olanzapine/fluoxetine combination for the treatment of mixed depression in bipolar I disorder: a post hoc analysis.
    The Journal of clinical psychiatry, 2009, Volume: 70, Issue:10

    Topics: Adult; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Benzodiazepines; Bipolar Diso

2009
Elevated level of metabotropic glutamate receptor 2/3 in the prefrontal cortex in major depression.
    Progress in neuro-psychopharmacology & biological psychiatry, 2010, Mar-17, Volume: 34, Issue:2

    Topics: Adult; Aged; Animals; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Female;

2010
[Further evidence of the efficacy of the antidepressant Valdoxan (agomelatine) compared with conventional antidepressive drugs (from the ECNP held in Istanbul, 15 September 2009)].
    L'Encephale, 2009, Volume: 35, Issue:6

    Topics: Acetamides; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Flu

2009
Association of brain-derived neurotrophic factor genetic Val66Met polymorphism with severity of depression, efficacy of fluoxetine and its side effects in Chinese major depressive patients.
    Neuropsychobiology, 2010, Volume: 61, Issue:2

    Topics: Adult; Antidepressive Agents, Second-Generation; Asian People; Brain-Derived Neurotrophic Factor; De

2010
Altered function of the serotonin 1A autoreceptor and the antidepressant response.
    Neuron, 2010, Jan-14, Volume: 65, Issue:1

    Topics: Animals; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Fluoxetine; Humans; M

2010
Severe laryngeal dystonia in a patient receiving zuclopenthixol "Acuphase" and fluoxetine.
    Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists, 2010, Volume: 18, Issue:2

    Topics: Adult; Antipsychotic Agents; Clopenthixol; Depressive Disorder, Major; Drug Interactions; Drug Thera

2010
Combining antidepressant medications: a good idea?
    The American journal of psychiatry, 2010, Volume: 167, Issue:3

    Topics: Antidepressive Agents; Bupropion; Cyclohexanols; Depressive Disorder, Major; Double-Blind Method; Dr

2010
Impact of childhood trauma on treatment outcome in the Treatment for Adolescents with Depression Study (TADS).
    Journal of the American Academy of Child and Adolescent Psychiatry, 2010, Volume: 49, Issue:2

    Topics: Adolescent; Antidepressive Agents, Second-Generation; Child; Child Abuse; Child Abuse, Sexual; Cogni

2010
Cognitive-behavioral therapy added to fluoxetine in major depressive disorder after 4 weeks of fluoxetine-treatment: 16-week open label study.
    Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2010, Volume: 93, Issue:3

    Topics: Adult; Cognitive Behavioral Therapy; Combined Modality Therapy; Depressive Disorder, Major; Female;

2010
Anxiety as a predictor of treatment outcome in children and adolescents with depression.
    Journal of child and adolescent psychopharmacology, 2010, Volume: 20, Issue:3

    Topics: Adolescent; Antidepressive Agents, Second-Generation; Anxiety Disorders; Child; Depressive Disorder,

2010
The role of clinical variables, neuropsychological performance and SLC6A4 and COMT gene polymorphisms on the prediction of early response to fluoxetine in major depressive disorder.
    Journal of affective disorders, 2010, Volume: 127, Issue:1-3

    Topics: Adult; Alleles; Antidepressive Agents, Second-Generation; Anxiety Disorders; Attention; Comorbidity;

2010
Early improvements in anxiety, depression, and anger/hostility symptoms and response to antidepressant treatment.
    Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, 2010, Volume: 22, Issue:3

    Topics: Adult; Anger; Antidepressive Agents, Second-Generation; Anxiety Disorders; Depressive Disorder, Majo

2010
Adherence to antidepressant therapy for major depressive patients in a psychiatric hospital in Thailand.
    BMC psychiatry, 2010, Aug-22, Volume: 10

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antidepressive Agents; Depressive Disorder, Major; Femal

2010
Comparing venlafaxine extended release and fluoxetine for preventing the recurrence of major depression: results from the PREVENT study.
    Journal of psychiatric research, 2011, Volume: 45, Issue:3

    Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Cyclohexanols; Depressive Disorder, Major; Di

2011
A structural mean model to allow for noncompliance in a randomized trial comparing 2 active treatments.
    Biostatistics (Oxford, England), 2011, Volume: 12, Issue:2

    Topics: Algorithms; Bias; Computer Simulation; Depressive Disorder, Major; Double-Blind Method; Fluoxetine;

2011
Habenula volume in bipolar disorder and major depressive disorder: a high-resolution magnetic resonance imaging study.
    Biological psychiatry, 2011, Feb-15, Volume: 69, Issue:4

    Topics: Adult; Analysis of Variance; Antidepressive Agents; Antimanic Agents; Bipolar Disorder; Brain Mappin

2011
Daily emotional dynamics in depressed youth: a cell phone ecological momentary assessment study.
    Journal of experimental child psychology, 2011, Volume: 110, Issue:2

    Topics: Adolescent; Affect; Age Factors; Antidepressive Agents, Second-Generation; Anxiety Disorders; Cell P

2011
Daily emotional dynamics in depressed youth: a cell phone ecological momentary assessment study.
    Journal of experimental child psychology, 2011, Volume: 110, Issue:2

    Topics: Adolescent; Affect; Age Factors; Antidepressive Agents, Second-Generation; Anxiety Disorders; Cell P

2011
Daily emotional dynamics in depressed youth: a cell phone ecological momentary assessment study.
    Journal of experimental child psychology, 2011, Volume: 110, Issue:2

    Topics: Adolescent; Affect; Age Factors; Antidepressive Agents, Second-Generation; Anxiety Disorders; Cell P

2011
Daily emotional dynamics in depressed youth: a cell phone ecological momentary assessment study.
    Journal of experimental child psychology, 2011, Volume: 110, Issue:2

    Topics: Adolescent; Affect; Age Factors; Antidepressive Agents, Second-Generation; Anxiety Disorders; Cell P

2011
Psychometric properties of the Children's Depression Rating Scale-Revised in adolescents.
    Journal of child and adolescent psychopharmacology, 2010, Volume: 20, Issue:6

    Topics: Adolescent; Depressive Disorder; Depressive Disorder, Major; Female; Fluoxetine; Follow-Up Studies;

2010
Do early changes in the HAM-D-17 anxiety/somatization factor items affect the treatment outcome among depressed outpatients? Comparison of two controlled trials of St John's wort (Hypericum perforatum) versus a SSRI.
    International clinical psychopharmacology, 2011, Volume: 26, Issue:4

    Topics: Depressive Disorder, Major; Fluoxetine; Humans; Hypericum; Logistic Models; Outpatients; Phytotherap

2011
Fluoxetine regulates the expression of neurotrophic/growth factors and glucose metabolism in astrocytes.
    Psychopharmacology, 2011, Volume: 216, Issue:1

    Topics: Animals; Animals, Newborn; Astrocytes; Brain-Derived Neurotrophic Factor; Cells, Cultured; Depressiv

2011
Female sexual dysfunction in patients treated with antidepressant-comparison between escitalopram and fluoxetine.
    The journal of sexual medicine, 2012, Volume: 9, Issue:5

    Topics: Adult; Citalopram; Cross-Sectional Studies; Depressive Disorder, Major; Dose-Response Relationship,

2012
Mother-infant antidepressant concentrations, maternal depression, and perinatal events.
    The Journal of clinical psychiatry, 2011, Volume: 72, Issue:7

    Topics: Adult; Antidepressive Agents; Antidepressive Agents, Tricyclic; Depressive Disorder, Major; Dose-Res

2011
Hypoactive sexual desire among depressed female patients treated with selective serotonin reuptake inhibitors: a comparison between escitalopram and fluoxetine.
    International journal of psychiatry in clinical practice, 2012, Volume: 16, Issue:1

    Topics: Adolescent; Adult; Aged; Citalopram; Cross-Sectional Studies; Depressive Disorder, Major; Dose-Respo

2012
Fluoxetine effect on aortic nitric oxide-dependent vasorelaxation in the unpredictable chronic mild stress model of depression in mice.
    Psychosomatic medicine, 2012, Volume: 74, Issue:1

    Topics: Acetylcholine; Animals; Aorta; Atherosclerosis; Biological Factors; Depressive Disorder, Major; Dise

2012
Antidepressant-suicide link in children questioned.
    Lancet (London, England), 2012, Mar-03, Volume: 379, Issue:9818

    Topics: Adolescent; Antidepressive Agents; Child; Depression; Depressive Disorder, Major; Drug Prescriptions

2012
Imaging adolescent depression treatment.
    The American journal of psychiatry, 2012, Volume: 169, Issue:4

    Topics: Adolescent Behavior; Brain; Depressive Disorder, Major; Female; Fluoxetine; Humans; Magnetic Resonan

2012
Repetitive transcranial magnetic stimulation in depressed adolescents: experience, knowledge, and attitudes of recipients and their parents.
    The journal of ECT, 2012, Volume: 28, Issue:2

    Topics: Adolescent; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Female; Fluoxetine

2012
Cost-effectiveness of adjunctive therapy with atypical antipsychotics for acute treatment of major depressive disorder.
    The Annals of pharmacotherapy, 2012, Volume: 46, Issue:5

    Topics: Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Cost-Benefit Analysis; D

2012
On the interpretation of odds ratios.
    The Clinical journal of pain, 2012, Volume: 28, Issue:5

    Topics: Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Female; Fluoxetine; Humans; In

2012
Chronic effects of corticosterone on GIRK1-3 subunits and 5-HT1A receptor expression in rat brain and their reversal by concurrent fluoxetine treatment.
    European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2013, Volume: 23, Issue:3

    Topics: Animals; Autoradiography; Corticosterone; Dentate Gyrus; Depressive Disorder, Major; Fluoxetine; G P

2013
Convergent evidence from mouse and human studies suggests the involvement of zinc finger protein 326 gene in antidepressant treatment response.
    PloS one, 2012, Volume: 7, Issue:5

    Topics: Adult; Aged; Animals; Antidepressive Agents; Behavior, Animal; Brain; Case-Control Studies; Depressi

2012
CYP2D6 ultrarapid metabolism and early dropout from fluoxetine or amitriptyline monotherapy treatment in major depressive patients.
    Molecular psychiatry, 2013, Volume: 18, Issue:1

    Topics: Amitriptyline; Antidepressive Agents; Cytochrome P-450 CYP2D6; Depressive Disorder, Major; Dose-Resp

2013
Prevalence of MTHFR C677T and MS A2756G polymorphisms in major depressive disorder, and their impact on response to fluoxetine treatment.
    CNS spectrums, 2012, Volume: 17, Issue:2

    Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Femal

2012
Raphe-mediated signals control the hippocampal response to SRI antidepressants via miR-16.
    Translational psychiatry, 2011, Nov-22, Volume: 1

    Topics: Adult; Animals; Behavior, Animal; Depressive Disorder, Major; Female; Fluoxetine; Hippocampus; Human

2011
Serotonin transporter genotype and function in relation to antidepressant response in Koreans.
    Psychopharmacology, 2013, Volume: 225, Issue:2

    Topics: Adult; Aged; Asian People; Blood Platelets; Case-Control Studies; Depressive Disorder, Major; Female

2013
Sexual arousal difficulties in women treated with antidepressants: a comparison between escitalopram and fluoxetine.
    International journal of psychiatry in medicine, 2012, Volume: 43, Issue:4

    Topics: Adult; Antidepressive Agents; Citalopram; Cross-Sectional Studies; Depressive Disorder, Major; Dose-

2012
Hypomania associated with adjunctive aripiprazole in an elder female with recurrent major depressive disorder: dose-related phenomenon?
    Journal of clinical psychopharmacology, 2012, Volume: 32, Issue:6

    Topics: Aripiprazole; Bipolar Disorder; Clonazepam; Depressive Disorder, Major; Dose-Response Relationship,

2012
Inappropriate data and measures lead to questionable conclusions.
    JAMA psychiatry, 2013, Volume: 70, Issue:1

    Topics: Cyclohexanols; Depressive Disorder, Major; Fluoxetine; Humans; Randomized Controlled Trials as Topic

2013
Inappropriate data and measures lead to questionable conclusions--reply.
    JAMA psychiatry, 2013, Volume: 70, Issue:1

    Topics: Cyclohexanols; Depressive Disorder, Major; Fluoxetine; Humans; Randomized Controlled Trials as Topic

2013
Suicide risk and efficacy of antidepressant drugs.
    JAMA psychiatry, 2013, Volume: 70, Issue:1

    Topics: Cyclohexanols; Depressive Disorder, Major; Fluoxetine; Humans; Randomized Controlled Trials as Topic

2013
Suicide risk and efficacy of antidepressant drugs--reply.
    JAMA psychiatry, 2013, Volume: 70, Issue:1

    Topics: Cyclohexanols; Depressive Disorder, Major; Fluoxetine; Humans; Randomized Controlled Trials as Topic

2013
Chronic SSRI treatment exacerbates serotonin deficiency in humanized Tph2 mutant mice.
    ACS chemical neuroscience, 2013, Jan-16, Volume: 4, Issue:1

    Topics: Animals; Depressive Disorder, Major; Fluoxetine; Humans; Mice; Mice, Mutant Strains; Polymorphism, G

2013
A typological model for estimation of drug and placebo effects in depression.
    Journal of clinical psychopharmacology, 2002, Volume: 22, Issue:4

    Topics: Antidepressive Agents; Clinical Trials as Topic; Depressive Disorder, Major; Fluoxetine; Humans; Imi

2002
Fluoxetine treatment of depressed patients with comorbid anxiety disorders.
    Journal of psychopharmacology (Oxford, England), 2002, Volume: 16, Issue:3

    Topics: Adult; Antidepressive Agents, Second-Generation; Anxiety Disorders; Comorbidity; Depressive Disorder

2002
[Dextromethorphane intoxication under co-medication with cytochrome P450-inhibitor fluoxetin: prolonged and accentuated signs of intoxication].
    Psychiatrische Praxis, 2002, Volume: 29, Issue:6

    Topics: Adult; Antitussive Agents; Cytochrome P-450 Enzyme Inhibitors; Depressive Disorder, Major; Dextromet

2002
Fluoxetine response in children with autistic spectrum disorders: correlation with familial major affective disorder and intellectual achievement.
    Developmental medicine and child neurology, 2002, Volume: 44, Issue:10

    Topics: Autistic Disorder; Bipolar Disorder; Child; Child, Preschool; Cluster Analysis; Depressive Disorder,

2002
The brain tells: early signs of depression recovery.
    The Harvard mental health letter, 2002, Volume: 19, Issue:5

    Topics: Antidepressive Agents, Second-Generation; Cyclohexanols; Depressive Disorder, Major; Female; Fluoxet

2002
A retrospective analysis of the revocation of prior authorization restrictions and the use of antidepressant medications for treating major depressive disorder.
    Clinical therapeutics, 2002, Volume: 24, Issue:11

    Topics: Adult; California; Depressive Disorder, Major; Drug Costs; Drug Utilization Review; Female; Fluoxeti

2002
Serotonin transporter modulation in blood lymphocytes from patients with major depression.
    Cellular and molecular neurobiology, 2002, Volume: 22, Issue:5-6

    Topics: Adrenergic alpha-Antagonists; Adult; Antidepressive Agents, Second-Generation; Brain; Carrier Protei

2002
Association analysis for neuronal nitric oxide synthase gene polymorphism with major depression and fluoxetine response.
    Neuropsychobiology, 2003, Volume: 47, Issue:3

    Topics: Adult; Antipsychotic Agents; Depressive Disorder, Major; Female; Fluoxetine; Gene Expression; Gene F

2003
Glia as a putative target for antidepressant treatments.
    Journal of affective disorders, 2003, Volume: 75, Issue:1

    Topics: Animals; Depressive Disorder, Major; Fluorescent Antibody Technique; Fluoxetine; Hippocampus; Male;

2003
Sertraline versus fluoxetine in the treatment of major depression: a combined analysis of five double-blind comparator studies.
    International clinical psychopharmacology, 2003, Volume: 18, Issue:4

    Topics: Adult; Antidepressive Agents, Second-Generation; Anxiety Disorders; Depressive Disorder, Major; Doub

2003
Fluoxetine augmentation with olanzapine for treatment of chronic resistant depression in an elderly patient: a case report.
    The Journal of clinical psychiatry, 2003, Volume: 64, Issue:7

    Topics: Aged; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Depressive Disorder, Major; Dose-Respo

2003
Psychopharmacological treatment of major depressive disorder in children and adolescents.
    JAMA, 2003, Aug-27, Volume: 290, Issue:8

    Topics: Adolescent; Antidepressive Agents; Child; Depressive Disorder, Major; Fluoxetine; Humans; Paroxetine

2003
Serotonin transporter polymorphisms and adverse effects with fluoxetine treatment.
    Biological psychiatry, 2003, Nov-01, Volume: 54, Issue:9

    Topics: Adult; Alleles; Antidepressive Agents, Second-Generation; Carrier Proteins; Depressive Disorder, Maj

2003
Association study of a brain-derived neurotrophic-factor genetic polymorphism and major depressive disorders, symptomatology, and antidepressant response.
    American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics, 2003, Nov-15, Volume: 123B, Issue:1

    Topics: Adult; Aged; Alleles; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Chromosomes, Human,

2003
Economic impact of olanzapine plus fluoxetine combination therapy among patients treated for depression: a pilot study.
    Psychopharmacology bulletin, 2003,Summer, Volume: 37, Issue:3

    Topics: Adolescent; Adult; Aged; Benzodiazepines; Cost-Benefit Analysis; Depressive Disorder, Major; Drug Th

2003
Temperament, childhood environment and psychopathology as risk factors for avoidant and borderline personality disorders.
    The Australian and New Zealand journal of psychiatry, 2003, Volume: 37, Issue:6

    Topics: Adolescent; Adult; Borderline Personality Disorder; Child; Demography; Depressive Disorder, Major; F

2003
The impact of medical comorbidity on acute treatment in major depressive disorder.
    The American journal of psychiatry, 2003, Volume: 160, Issue:12

    Topics: Adult; Antidepressive Agents, Second-Generation; Chronic Disease; Comorbidity; Cost of Illness; Depr

2003
Effect of bupropion on sexual dysfunction induced by fluoxetine: a case report of hypersexuality.
    The Journal of clinical psychiatry, 2003, Volume: 64, Issue:10

    Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Depressive Disorder, Major; Drug Interac

2003
Long-term sequestration of fluorinated compounds in tissues after fluvoxamine or fluoxetine treatment: a fluorine magnetic resonance spectroscopy study in vivo.
    Magma (New York, N.Y.), 2004, Volume: 16, Issue:6

    Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Bone Marrow; Brain; Chromatography, High Pres

2004
Fluoxetine in depressed AUD adolescents: a 1-year follow-up evaluation.
    Journal of child and adolescent psychopharmacology, 2004,Spring, Volume: 14, Issue:1

    Topics: Adolescent; Adult; Alcohol-Related Disorders; Depressive Disorder, Major; Diagnosis, Dual (Psychiatr

2004
Anxiety and somatic symptoms as predictors of treatment-related adverse events in major depressive disorder.
    Psychiatry research, 2004, May-30, Volume: 126, Issue:3

    Topics: Adult; Anxiety; Depressive Disorder, Major; Female; Fluoxetine; Humans; Male; Prospective Studies; S

2004
Fluoxetine-induced mania in an Asian patient.
    Psychiatry and clinical neurosciences, 2004, Volume: 58, Issue:4

    Topics: Adult; Antidepressive Agents, Second-Generation; Bipolar Disorder; Depressive Disorder, Major; Diagn

2004
Treatment of adolescents with major depression: contributions of a major trial.
    JAMA, 2004, Aug-18, Volume: 292, Issue:7

    Topics: Adolescent; Antidepressive Agents, Second-Generation; Cognitive Behavioral Therapy; Depressive Disor

2004
Cost and effectiveness of venlafaxine extended-release and selective serotonin reuptake inhibitors in the acute phase of outpatient treatment for major depressive disorder.
    Journal of clinical psychopharmacology, 2004, Volume: 24, Issue:5

    Topics: Activities of Daily Living; Acute Disease; Ambulatory Care; Cost-Benefit Analysis; Cyclohexanols; De

2004
Fluoxetine-induced memory impairment in four family members.
    International journal of psychiatry in medicine, 2004, Volume: 34, Issue:2

    Topics: Adult; Antidepressive Agents, Second-Generation; Depressive Disorder; Depressive Disorder, Major; Fe

2004
SSRIs: are the accusations justified?
    The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, 2004, Volume: 5, Issue:4

    Topics: Adolescent Psychiatry; Child Psychiatry; Depressive Disorder, Major; Fluoxetine; Humans; Selective S

2004
Adolescents with depression.
    JAMA, 2004, Dec-01, Volume: 292, Issue:21

    Topics: Adolescent; Antidepressive Agents, Second-Generation; Cognitive Behavioral Therapy; Depressive Disor

2004
Adolescents with depression.
    JAMA, 2004, Dec-01, Volume: 292, Issue:21

    Topics: Adolescent; Antidepressive Agents, Second-Generation; Cognitive Behavioral Therapy; Depressive Disor

2004
Adolescents with depression.
    JAMA, 2004, Dec-01, Volume: 292, Issue:21

    Topics: Adolescent; Antidepressive Agents, Second-Generation; Cognitive Behavioral Therapy; Depressive Disor

2004
Adolescents with depression.
    JAMA, 2004, Dec-01, Volume: 292, Issue:21

    Topics: Adolescent; Antidepressive Agents, Second-Generation; Cognitive Behavioral Therapy; Depressive Disor

2004
Pharmacological management of treatment-resistant pediatric depression.
    Journal of the American Academy of Child and Adolescent Psychiatry, 2005, Volume: 44, Issue:2

    Topics: Child; Cognitive Behavioral Therapy; Combined Modality Therapy; Depressive Disorder, Major; Drug Res

2005
Plasma catecholamine levels after fluoxetine treatment in depressive patients.
    Neuropsychobiology, 2005, Volume: 51, Issue:2

    Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Catecholamines; Depressive Disord

2005
Interferon-alpha-induced modulation of glucocorticoid and serotonin receptors as a mechanism of depression.
    Journal of hepatology, 2005, Volume: 42, Issue:6

    Topics: Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Antiviral Agents; Cell C

2005
Association study of a monoamine oxidase a gene promoter polymorphism with major depressive disorder and antidepressant response.
    Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2005, Volume: 30, Issue:9

    Topics: Adolescent; Adult; Aged; Alleles; Antidepressive Agents; Depressive Disorder, Major; Female; Fluoxet

2005
Turning darkness into light. A new landmark study on the treatment of adolescent depression. Comments on the TADS study.
    European child & adolescent psychiatry, 2005, Volume: 14, Issue:3

    Topics: Adolescent; Cognitive Behavioral Therapy; Combined Modality Therapy; Depressive Disorder, Major; Dru

2005
Interpersonal psychotherapy for depression with panic spectrum symptoms: a pilot study.
    Depression and anxiety, 2005, Volume: 21, Issue:3

    Topics: Anxiety Disorders; Citalopram; Depressive Disorder, Major; Female; Fluoxetine; Humans; Interpersonal

2005
What happens with adverse events during 6 months of treatment with selective serotonin reuptake inhibitors?
    The Journal of clinical psychiatry, 2005, Volume: 66, Issue:7

    Topics: Adult; Adverse Drug Reaction Reporting Systems; Data Interpretation, Statistical; Depressive Disorde

2005
Fluoxetine for depression relapse prevention.
    Journal of the American Academy of Child and Adolescent Psychiatry, 2005, Volume: 44, Issue:10

    Topics: Adolescent; Child; Depressive Disorder, Major; Fluoxetine; Humans; Secondary Prevention; Selective S

2005
Noradrenaline transporter and its turnover rate are decreased in blood lymphocytes of patients with major depression.
    Journal of neuroimmunology, 2005, Dec-30, Volume: 170, Issue:1-2

    Topics: Adult; Blood Platelets; Cell Membrane; Depressive Disorder, Major; Female; Fluoxetine; Humans; Hydro

2005
Depressed youth, suicidality and antidepressants.
    The Medical journal of Australia, 2005, Sep-05, Volume: 183, Issue:5

    Topics: Adolescent; Child; Depressive Disorder, Major; Drug Evaluation; Fluoxetine; Humans; Selective Seroto

2005
Stimulation of neurogenesis in the hippocampus of the adult rat by fluoxetine requires rhythmic change in corticosterone.
    Biological psychiatry, 2006, Apr-01, Volume: 59, Issue:7

    Topics: Age Factors; Aging; Animals; Cell Proliferation; Corticosterone; Dentate Gyrus; Depressive Disorder,

2006
Psychomotor slowing as a predictor of fluoxetine nonresponse in depressed outpatients.
    The American journal of psychiatry, 2006, Volume: 163, Issue:1

    Topics: Adolescent; Adult; Aged; Ambulatory Care; Depressive Disorder, Major; Dopamine; Female; Fluoxetine;

2006
Psychomotor slowing as a predictor of fluoxetine nonresponse in depressed outpatients.
    The American journal of psychiatry, 2006, Volume: 163, Issue:1

    Topics: Adolescent; Adult; Aged; Ambulatory Care; Depressive Disorder, Major; Dopamine; Female; Fluoxetine;

2006
Psychomotor slowing as a predictor of fluoxetine nonresponse in depressed outpatients.
    The American journal of psychiatry, 2006, Volume: 163, Issue:1

    Topics: Adolescent; Adult; Aged; Ambulatory Care; Depressive Disorder, Major; Dopamine; Female; Fluoxetine;

2006
Psychomotor slowing as a predictor of fluoxetine nonresponse in depressed outpatients.
    The American journal of psychiatry, 2006, Volume: 163, Issue:1

    Topics: Adolescent; Adult; Aged; Ambulatory Care; Depressive Disorder, Major; Dopamine; Female; Fluoxetine;

2006
Stereoselective disposition of fluoxetine and norfluoxetine during pregnancy and breast-feeding.
    British journal of clinical pharmacology, 2006, Volume: 61, Issue:2

    Topics: Adult; Aging; Antidepressive Agents, Second-Generation; Breast Feeding; Depressive Disorder, Major;

2006
Determining the duration of antidepressant treatment: application of signal detection methodology and the need for duration adaptive designs (DAD).
    Biological psychiatry, 2006, Mar-15, Volume: 59, Issue:6

    Topics: Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Dose-Response Relationship, Dr

2006
Increased BDNF serum concentration in fibromyalgia with or without depression or antidepressants.
    Journal of psychiatric research, 2007, Volume: 41, Issue:7

    Topics: Amitriptyline; Antidepressive Agents; Brain; Brain-Derived Neurotrophic Factor; Depressive Disorder,

2007
Antidepressant therapy and C-reactive protein levels.
    The British journal of psychiatry : the journal of mental science, 2006, Volume: 188

    Topics: Adult; Aged; C-Reactive Protein; Depressive Disorder, Major; Female; Fluoxetine; Humans; Male; Middl

2006
The resistance to depressive relapse in menopausal women undergoing tryptophan depletion: preliminary findings.
    Journal of psychopharmacology (Oxford, England), 2007, Volume: 21, Issue:4

    Topics: Adult; Affect; Cognition; Depressive Disorder, Major; Drug Therapy, Combination; Estradiol; Female;

2007
Should selective serotonin reuptake inhibitors be prescribed for children with major depressive and anxiety disorders?
    Pediatrics, 2006, Volume: 118, Issue:3

    Topics: Adolescent; Age Factors; Anxiety Disorders; Child; Clinical Trials as Topic; Depressive Disorder, Ma

2006
[Psychomotor retardation in depression assessed by visuomotor tasks. Overview and achievements of ten years' research].
    Tijdschrift voor psychiatrie, 2006, Volume: 48, Issue:2

    Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Female; Fluoxetin

2006
An exploratory factor analysis of the children's depression rating scale-revised.
    Journal of child and adolescent psychopharmacology, 2006, Volume: 16, Issue:4

    Topics: Adolescent; Age Factors; Analysis of Variance; Antidepressive Agents, Second-Generation; Child; Clin

2006
Monoamine transporter gene polymorphisms and antidepressant response in koreans with late-life depression.
    JAMA, 2006, Oct-04, Volume: 296, Issue:13

    Topics: Adult; Aged; Antidepressive Agents; Asian People; Depressive Disorder, Major; Female; Fluoxetine; Hu

2006
Lymphocyte subsets and viral load in male AIDS patients with major depression: naturalistic study.
    Psychiatry and clinical neurosciences, 2006, Volume: 60, Issue:6

    Topics: Acquired Immunodeficiency Syndrome; Adult; Antidepressive Agents, Second-Generation; Antiretroviral

2006
After TADS, can we measure up, catch up, and ante up?
    Journal of the American Academy of Child and Adolescent Psychiatry, 2006, Volume: 45, Issue:12

    Topics: Adolescent; Cognitive Behavioral Therapy; Combined Modality Therapy; Depressive Disorder, Major; Flu

2006
Glad for what TADS adds, but many TADS grads still sad.
    Journal of the American Academy of Child and Adolescent Psychiatry, 2006, Volume: 45, Issue:12

    Topics: Adolescent; Cognitive Behavioral Therapy; Combined Modality Therapy; Depressive Disorder, Major; Flu

2006
Timing of clinical improvement and symptom resolution in the treatment of major depressive disorder.
    Psychiatry research, 2007, Jan-15, Volume: 149, Issue:1-3

    Topics: Adolescent; Adult; Aged; Anger; Anxiety Disorders; Depressive Disorder, Major; Diagnostic and Statis

2007
Effects of antidepressant treatment on neural correlates of emotional and neutral declarative verbal memory in depression.
    Journal of affective disorders, 2007, Volume: 101, Issue:1-3

    Topics: Adult; Antidepressive Agents, Second-Generation; Cyclohexanols; Depressive Disorder, Major; Dose-Res

2007
Generic fluoxetine and choice of antidepressant medication.
    Psychiatric services (Washington, D.C.), 2007, Volume: 58, Issue:1

    Topics: Choice Behavior; Depressive Disorder, Major; Drugs, Generic; Fluoxetine; Humans; Selective Serotonin

2007
Suicidality scores during double-blind fluoxetine and desipramine treatment in Mexican Americans.
    Journal of clinical psychopharmacology, 2007, Volume: 27, Issue:1

    Topics: Antidepressive Agents, Tricyclic; Depressive Disorder, Major; Desipramine; Double-Blind Method; Fluo

2007
Association study of corticotropin-releasing hormone receptor1 gene polymorphisms and antidepressant response in major depressive disorders.
    Neuroscience letters, 2007, Mar-06, Volume: 414, Issue:2

    Topics: Adult; Antidepressive Agents; Brain; China; Corticotropin-Releasing Hormone; Depressive Disorder, Ma

2007
Do children and adolescents have differential response rates in placebo-controlled trials of fluoxetine?
    CNS spectrums, 2007, Volume: 12, Issue:2

    Topics: Adolescent; Age Factors; Antidepressive Agents, Second-Generation; Child; Depressive Disorder, Major

2007
Early symptomatic worsening during treatment with fluoxetine in major depressive disorder: prevalence and implications.
    The Journal of clinical psychiatry, 2007, Volume: 68, Issue:1

    Topics: Adult; Clinical Trials as Topic; Depressive Disorder, Major; Disease Progression; Female; Fluoxetine

2007
L-thyroxine augmentation of serotonergic antidepressants in female patients with refractory depression.
    Journal of affective disorders, 2007, Volume: 103, Issue:1-3

    Topics: Adult; Bipolar Disorder; Clomipramine; Depressive Disorder, Major; Drug Resistance; Drug Therapy, Co

2007
Dopaminergic function in depressed patients with affective flattening or with impulsivity: [18F]fluoro-L-dopa positron emission tomography study with voxel-based analysis.
    Psychiatry research, 2007, Feb-28, Volume: 154, Issue:2

    Topics: Adult; Affect; Biogenic Monoamines; Brain Stem; Caudate Nucleus; Cyclohexanols; Depressive Disorder,

2007
Autonomic reactivity to induced emotion as potential predictor of response to antidepressant treatment.
    Psychiatry research, 2007, May-30, Volume: 151, Issue:1-2

    Topics: Adult; Antidepressive Agents; Arousal; Autonomic Nervous System; Blood Pressure; Depressive Disorder

2007
Neural responses to happy facial expressions in major depression following antidepressant treatment.
    The American journal of psychiatry, 2007, Volume: 164, Issue:4

    Topics: Antidepressive Agents; Brain; Brain Mapping; Depressive Disorder, Major; Facial Expression; Fluoxeti

2007
Ecchymoses as an adverse effect of fluoxetine treatment.
    Psychiatry research, 2007, Jul-30, Volume: 152, Issue:1

    Topics: Adult; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Ecchymosis; Female; Flu

2007
An abbreviated version of the Connor-Davidson Resilience Scale (CD-RISC), the CD-RISC2: psychometric properties and applications in psychopharmacological trials.
    Psychiatry research, 2007, Aug-30, Volume: 152, Issue:2-3

    Topics: Antidepressive Agents; Anxiety Disorders; Clinical Trials as Topic; Cyclohexanols; Depressive Disord

2007
Simple options for improving signal detection in antidepressant clinical trials.
    Psychopharmacology bulletin, 2007, Volume: 40, Issue:2

    Topics: Antidepressive Agents; Citalopram; Clinical Trials as Topic; Databases, Factual; Depressive Disorder

2007
Does early response predict outcome in psychotherapy and combined therapy for major depression?
    Journal of affective disorders, 2008, Volume: 105, Issue:1-3

    Topics: Adult; Antidepressive Agents; Combined Modality Therapy; Depressive Disorder, Major; Diagnostic and

2008
[Comparison of different antidepression therapy in perimenopausal and postmenopausal women with depression].
    Zhonghua fu chan ke za zhi, 2007, Volume: 42, Issue:3

    Topics: Adult; Depressive Disorder, Major; Estrogen Replacement Therapy; Female; Fluoxetine; Follow-Up Studi

2007
A longitudinal functional magnetic resonance imaging study of verbal working memory in depression after antidepressant therapy.
    Biological psychiatry, 2007, Dec-01, Volume: 62, Issue:11

    Topics: Adult; Antidepressive Agents; Antidepressive Agents, Second-Generation; Caudate Nucleus; Cerebral Co

2007
Benefits and harms of pediatric antidepressant medications.
    JAMA, 2007, Aug-08, Volume: 298, Issue:6

    Topics: Adolescent; Antidepressive Agents, Second-Generation; Child; Depressive Disorder, Major; Fluoxetine;

2007
Circadian rhythm of salivary serotonin in patients with major depressive disorder.
    Neuro endocrinology letters, 2007, Volume: 28, Issue:4

    Topics: Adult; Case-Control Studies; Circadian Rhythm; Depressive Disorder, Major; Female; Fluoxetine; Human

2007
Tics, anxiety, and possible PANDAS in an adolescent.
    Journal of child and adolescent psychopharmacology, 2007, Volume: 17, Issue:4

    Topics: Adolescent; Adrenergic alpha-Agonists; Antidepressive Agents, Second-Generation; Anxiety; Autoimmune

2007
Regionally specific regulation of ERK MAP kinase in a model of antidepressant-sensitive chronic depression.
    Biological psychiatry, 2008, Feb-15, Volume: 63, Issue:4

    Topics: Amitriptyline; Animals; Anti-Inflammatory Agents; Antidepressive Agents, Tricyclic; Chronic Disease;

2008
A case of unexpected and selective remission of a 20-year history of ephedrine dependence following treatment with low-dose aripiprazole.
    The Journal of clinical psychiatry, 2007, Volume: 68, Issue:10

    Topics: Adult; Antipsychotic Agents; Aripiprazole; Depressive Disorder, Major; Drug Administration Schedule;

2007
Functional coupling of the amygdala in depressed patients treated with antidepressant medication.
    Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2008, Volume: 33, Issue:8

    Topics: Adult; Amygdala; Analysis of Variance; Antidepressive Agents, Second-Generation; Brain Mapping; Depr

2008
Sertraline and tic: case report.
    Pharmacopsychiatry, 2007, Volume: 40, Issue:6

    Topics: Adult; Depressive Disorder, Major; Eyelids; Female; Fluoxetine; Humans; Obsessive-Compulsive Disorde

2007
Toxic epidermal necrolysis and fluoxetine: a case report.
    Journal of clinical psychopharmacology, 2008, Volume: 28, Issue:1

    Topics: Adult; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Female; Fluoxetine; Hum

2008
Time to rehospitalization in patients with major depressive disorder taking venlafaxine or fluoxetine.
    The Journal of clinical psychiatry, 2008, Volume: 69, Issue:1

    Topics: Adult; Combined Modality Therapy; Comorbidity; Cyclohexanols; Depressive Disorder, Major; Diagnostic

2008
Cannabis withdrawal is common among treatment-seeking adolescents with cannabis dependence and major depression, and is associated with rapid relapse to dependence.
    Addictive behaviors, 2008, Volume: 33, Issue:11

    Topics: Adolescent; Cannabinoids; Controlled Clinical Trials as Topic; Depressive Disorder, Major; Diagnosti

2008
A depressed adolescent at high risk of suicidal behavior.
    The American journal of psychiatry, 2008, Volume: 165, Issue:3

    Topics: Acetaminophen; Adolescent; Antidepressive Agents; Cognitive Behavioral Therapy; Combined Modality Th

2008
Continuation treatment with antidepressants in child and adolescent major depression.
    The American journal of psychiatry, 2008, Volume: 165, Issue:4

    Topics: Adolescent; Age Factors; Antidepressive Agents; Child; Depressive Disorder, Major; Fluoxetine; Human

2008
Cost-effectiveness of depression treatment for adolescents.
    The American journal of psychiatry, 2008, Volume: 165, Issue:5

    Topics: Adolescent; Cognitive Behavioral Therapy; Combined Modality Therapy; Cost-Benefit Analysis; Depressi

2008
Antidepressant treatment, posttraumatic stress disorder, survivor guilt, and spiritual awakening.
    Journal of traumatic stress, 1997, Volume: 10, Issue:4

    Topics: Alcoholism; Antidepressive Agents, Second-Generation; Awareness; Combat Disorders; Combined Modality

1997
Increase in the cerebrospinal fluid content of neurosteroids in patients with unipolar major depression who are receiving fluoxetine or fluvoxamine.
    Proceedings of the National Academy of Sciences of the United States of America, 1998, Mar-17, Volume: 95, Issue:6

    Topics: Adult; Depressive Disorder, Major; Female; Fluoxetine; Fluvoxamine; Humans; Male; Middle Aged; Pregn

1998
Divided attention in major depression.
    Psychiatry research, 1998, Dec-14, Volume: 81, Issue:3

    Topics: Adult; Antidepressive Agents, Second-Generation; Attention; Decision Making; Depressive Disorder, Ma

1998
Relationships between low red blood cell count and clinical response to fluoxetine in depressed elderly patients.
    Psychiatry research, 1998, Dec-14, Volume: 81, Issue:3

    Topics: Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Blood Platelets; Carrier Proteins

1998
Venlafaxine: new preparation. Just another antidepressant.
    Prescrire international, 1998, Volume: 7, Issue:36

    Topics: Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Cyclohexanols; Depressiv

1998
A case of sequential anti-stress medication in a patient with major depression resistant to amine-reuptake inhibitors.
    Acta psychiatrica Scandinavica, 1999, Volume: 100, Issue:1

    Topics: Amines; Antidepressive Agents; Anxiety Disorders; Dehydroepiandrosterone; Depressive Disorder, Major

1999
Dopamine D2 receptor binding before and after treatment of major depression measured by [123I]IBZM SPECT.
    Psychiatry research, 1999, Apr-26, Volume: 90, Issue:2

    Topics: Adult; Aged; Anti-Anxiety Agents; Benzamides; Benzodiazepines; Case-Control Studies; Contrast Media;

1999
Fluoxetine efficacy in menopausal women with and without estrogen replacement.
    Journal of affective disorders, 1999, Volume: 55, Issue:1

    Topics: Antidepressive Agents, Second-Generation; Climacteric; Depressive Disorder, Major; Drug Therapy, Com

1999
Retardation in depression: assessment by means of simple motor tasks.
    Journal of affective disorders, 1999, Volume: 55, Issue:1

    Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic;

1999
Defense mechanisms and personality in depression.
    Depression and anxiety, 1999, Volume: 10, Issue:4

    Topics: Adult; Antidepressive Agents; Cyclohexanols; Defense Mechanisms; Depressive Disorder, Major; Female;

1999
Maintenance treatment for recurrent depression in late life. A four-year outcome study.
    The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, 2000,Spring, Volume: 8, Issue:2

    Topics: Aged; Antidepressive Agents; Combined Modality Therapy; Depressive Disorder, Major; Drug Therapy, Co

2000
Dose of selective serotonin uptake inhibitors across pregnancy: clinical implications.
    Depression and anxiety, 2000, Volume: 11, Issue:2

    Topics: Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Administration Schedule; Female;

2000
Simultaneous determination of human plasma levels of four selective serotonin reuptake inhibitors by high-performance liquid chromatography.
    Therapeutic drug monitoring, 2000, Volume: 22, Issue:3

    Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Chromatography, High Pressure Liquid; Depress

2000
Brain pharmacokinetics and tissue distribution in vivo of fluvoxamine and fluoxetine by fluorine magnetic resonance spectroscopy.
    Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2000, Volume: 23, Issue:4

    Topics: Adult; Aged; Brain; Depressive Disorder, Major; Female; Fluorine Radioisotopes; Fluoxetine; Fluvoxam

2000
Treatment of depression with associated anxiety: comparisons of tricyclic antidepressants and selective serotonin reuptake inhibitors.
    Acta psychiatrica Scandinavica. Supplementum, 2000, Volume: 403

    Topics: Antidepressive Agents, Tricyclic; Anxiety Disorders; Clomipramine; Depressive Disorder, Major; Fluox

2000
Regional metabolic effects of fluoxetine in major depression: serial changes and relationship to clinical response.
    Biological psychiatry, 2000, Oct-15, Volume: 48, Issue:8

    Topics: Brain; Depressive Disorder, Major; Drug Administration Schedule; Fluoxetine; Glucose; Humans; Limbic

2000
Changes in energy during treatment of depression: an analysis of fluoxetine in double-blind, placebo-controlled trials.
    Journal of clinical psychopharmacology, 2000, Volume: 20, Issue:6

    Topics: Adult; Aged; Analysis of Variance; Controlled Clinical Trials as Topic; Depressive Disorder, Major;

2000
Urinary retention with reboxetine-fluoxetine combination in a young man.
    Canadian journal of psychiatry. Revue canadienne de psychiatrie, 2000, Volume: 45, Issue:10

    Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Drug Therapy, Combination; Fluoxetine; Hum

2000
Prefrontal changes and treatment response prediction in depression.
    Seminars in clinical neuropsychiatry, 2001, Volume: 6, Issue:2

    Topics: Adult; Antidepressive Agents; Cyclohexanols; Depression; Depressive Disorder, Major; Electroencephal

2001
Mood disorders in children and adolescents: psychopharmacological treatment.
    Biological psychiatry, 2001, Jun-15, Volume: 49, Issue:12

    Topics: Adolescent; Antidepressive Agents, Tricyclic; Child; Depressive Disorder, Major; Drug Therapy, Combi

2001
Ethical dilemmas in prescribing antidepressants.
    Archives of general psychiatry, 2001, Volume: 58, Issue:11

    Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Drug Prescriptions; Ethics, Clinical; Fema

2001
Multinuclear magnetic resonance spectroscopy studies of brain purines in major depression.
    The American journal of psychiatry, 2001, Volume: 158, Issue:12

    Topics: Adenosine Triphosphate; Adult; Basal Ganglia; Depressive Disorder, Major; Energy Metabolism; Female;

2001
Fluoxetine and olanzapine for resistant depression.
    The American journal of psychiatry, 2002, Volume: 159, Issue:1

    Topics: Benzodiazepines; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, Combination; Fluoxet

2002
Serotonin and fluoxetine levels in plasma and platelets after fluoxetine treatment in depressive patients.
    Journal of clinical psychopharmacology, 2002, Volume: 22, Issue:2

    Topics: Adolescent; Adult; Aged; Blood Platelets; Depressive Disorder, Major; Dose-Response Relationship, Dr

2002